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ABSTRACT
Inborn errors of metabolism (IEM) affect 1 in 500 newborns causing significant disease-burden and
mortality throughout childhood. However, despite extensive genetic and biochemical investigations
the cause of disease remains unknown in up to 50% of patients with neurological symptoms;
so-called neurometabolic disorders (NMD). The overarching aim of this thesis was to determine
the cellular and molecular aetiologies for the clinical phenotypes seen in patients with undiagnosed
NMD.
In order to improve the diagnosis of these disorders in clinical practice, a comprehensive
targeted gene panel of 614 genes known to cause IEM was designed and a cohort of 44 patients
was analysed. A definitive or probable genetic diagnosis was achieved in 53% of patients without
a prior genetic diagnosis. Method optimisation and validation, comparison to other diagnostic
strategies and the advantages and disadvantages of targeted sequencing are reviewed. Case
reports, novel mutations/phenotypes and their contribution to the expansion of the literature are
described.
Whole exome sequencing and functional characterisation was also undertaken for patients who
had been extensively clinically investigated previously. Five patients identified with mutations
in the mitochondrial glutamate transporter, SLC25A22, presenting with novel biochemical
phenotypes are described and novel transporter functions are postulated. One patient diagnosed
with a potassium channelopathy with biochemical abnormalities and anticonvulsant responses
suggestive of an inborn error of vitmain B6 metabolism is documented and the mechanisms
underlying the generalised anticonvulsant effects of vitamin B6 are postulated. Characterisation
of a possible novel inborn error of lysine metabolism in a patient presenting with hyperlysinaemia
and motor neuron disease is also discussed.
These studies also demonstrate the complexity of unravelling the relationship between genotype
and phenotype and highlight the need for novel functional assays to assess the pathogenicity of
sequence variants. Mass spectrometry-based assays were developed to enable characterisation
of disorders affecting vitamin B6 homeostasis, including pyridox(am)ine 5’-phosphate oxidase
(PNPO), antiquitin and PROSC deficiency, the latter being a novel disorder. The differences
between pyridoxine- and pyridoxal phosphate-responsive PNPO deficiency and fibroblast vitamer
profiles in all patients were all investigated. Finally, multiple methodologies were employed with
the aim of understanding the biological function of PROSC.
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GSH Reduced glutathione
GSSG Oxidised glutathione disulphide
HFBA Heptafluorobutyric acid
HPI Hyperprolinaemia type I
HPII Hyperprolinaemia type II
HPLC High-performance liquid chromatography
HPO Human Phenotype Ontology
HVA Homovanillic acid
IEM Inborn error of metabolism
IVT In vitro translation
KA Kynurenic acid
KAC α-keto--aminocaproate
KCNQ2 Potassium voltage-gated channel subfamily Q member 2
KN Kynurenine
LAMP2 Lysosome-associated membrane protein 2
LC-MS/MS Liquid chromatography coupled to tandem mass spectrometry
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m/z Mass-to-charge ratio
MA Malonic acid
MgCl2 Magnesium chloride
miRNA MicroRNA
MLPA Multiplex ligation-dependent probe amplification
MMA Methylmalonic acid
MRI Magnetic resonance imaging
MRM Multiple reaction monitoring
mRNA Messenger RNA
MS/MS Tandem mass spectrometry
mTORC1 Mammalian target of rapamycin complex 1
NAD+ Nicotinamide adenine dinucleotide
NADH Reduced nicotinamide adenine dinucleotide
NADP+ Nicotinamide adenine dinucleotide phosphate
NADPH Reduced nicotinamide adenine dinucleotide phosphate
NEE Neonatal epileptic encephalopathy
NGS Next-generation sequencing
NMD Neurometabolic disorders
NMDA N-methyl-D-aspartate receptor
o-AB o-aminobenzaldehyde
OAT Ornithine δ-aminotransferase
OMIM Online Mendelian Inheritance in Man
P2C L-∆1-piperideine-2-carboxylate
P5C L-∆1-pyrroline-5-carboxylic acid
p62 Nucleoporin 62
P6C L-∆1-piperideine-6-carboxylic acid
PA 4-pyridoxic acid
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDE Pyridoxine dependent epilepsy
PK Pyridoxal kinase
PL Pyridoxal
PLP Pyridoxal 5’-phosphate
PM Pyridoxamine
PMP Pyridoxamine 5’-phosphate
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PN Pyridoxine
PNH Peripheral nerve hyperexcitability
PNP Pyridoxine 5’-phosphate
PNPO Pyridox(am)ine 5’-phosphate oxidase
PolyPhen-2 Polymorphism Phenotyping version 2
PPADS Pyridoxal phosphate-6-azophenyl-2-4-disulfonic acid
PPNDS Pyridoxal-5’-phosphate-6-(2’-naphthylazo-6’-nitro-4’,8’-disulfonate)
PROSC Proline synthetase co-transcribed [bacterial homolog]
qRT-PCR Quantitative real-time polymerase chain reaction
RNA Ribonucleic acid
ROS Reactive oxygen species
SIFT Sorting Intolerant from Tolerant
SLC25A22 Solute carrier family 25 member 22
SSIEM Society for the Study of Inborn Errors of Metabolism
Tm Melting temperature
TBE Tris-Borate-EDTA
TBST Tris-buffered saline and Tween 20
TCA Tricarboxylic acid
TCA Trichloroacetic acid
TFA Trifluoroacetic acid
UDP Uridine diphosphate
UDP-GalNAc UDP-N-acetylglucosamine
UDP-GlcNAc UDP-N-acetylgalactosamine
UPLC Ultra-performance liquid chromatography
UPLC-MS/MS Ultra-performance liquid chromatography coupled to tandem mass spec-
trometry
UTR Untranslated region
VCF Variant call file
VEP Visual evoked potential
WES Whole exome sequencing
WGS Whole genome sequencing
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
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INTRODUCTION
1.1 inborn errors of metabolism (iem)
1.1.1 First description of IEM
The concept of inborn errors of metabolism (IEM) was introduced at the beginning of the
twentieth century by Sir Archibald Garrod (Garrod, 1908). Despite the existence of only very
rudimentary analytical techniques and before the discovery of DNA, he proposed the existence
of innumerable minor differences in biochemistry that make an individual unique. He also
highlighted the fact that the anabolism and catabolism of all molecules including proteins,
carbohydrates, fats and sugars, are catalysed by enzymes specific to each reaction, despite very
limited evidence to support this hypothesis. Using the examples of albinism, alkaptonuria,
cystinuria and pentosuria, Garrod assembled evidence to suggest that these disorders could be
explained by a block in normal metabolic pathways due to a congenital deficiency of a specific
enzyme. Indeed, he viewed metabolism as a continuous step-wise flux through intermediary
molecules, each of which only has a transient existence. Unfortunately, Garrod’s work was
mostly ignored (particularly amongst his medical colleagues) for fifty years until La Du et al.
(1958) demonstrated the absence of an enzyme, homogentisate 1,2-dioxygenase, in the liver of
a patient with alkaptonuria. Integral to this progression within the field were technological
advances including the advent of electrophoresis and chromatography, as well as the rediscovery
and growing acceptance of Mendel’s laws of inheritance. Indeed, the era of molecular medicine
truly begun in 1949 when Pauling et al. demonstrated that genetic mutations could alter the
structure of wild-type proteins. In his study of patients with sickle cell anaemia, he showed that
the "sickling" of the red blood cells in affected patients was due to an altered conformation and
charge of the haemoglobin molecules within. The next leap forward in the understanding of
the pathogenesis of monogenic disorders came when it was shown that the altered properties of
haemoglobin in patients with sickle cell anaemia is due to a single amino acid alteration within
the polypeptide sequence (Ingram, 1956, 1957). However, this concept was soon extended beyond
a select few disorders and in 1969 the assertion that genetic factors are involved in all diseases
was made (McKusick, 1969), pre-dating the sequencing of the human genome by more than thirty
years. Indeed, the vast genetic variation uncovered through the DNA sequencing revolution has
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simply confirmed the remarkable insights made by Garrod almost 100 years previously; people
are "chemically individual" (Garrod, 1908).
1.1.2 Pathogenic mechanisms underlying IEM
Since the recognition of alkaptonuria as the first IEM, more than 600 disorders have been
described (Hamosh et al., 2005). Indeed, what was once thought to be a few benign ("sport")
medical conditions (Garrod, 1908), has been expanded to include a range of disorders that
cumulatively affect up to 1 in 500 newborns and account for a significant proportion of morbidity
and mortality both in childhood and the neonatal period (Chiaratti de Oliveira et al., 2001).
Collectively they are a diverse class of genetic disorders which are markedly heterogeneous, both
clinically and genetically with disease involving almost any organ or system. The majority of IEM
are caused by single-gene defects in pathways involved in the synthesis, metabolism, transport
and/or storage of metabolites or larger molecules and result in insufficient, absent or abnormal
conversion of substrates into products. These disorders typically follow an autosomal recessive
mode of inheritance and can arise as a result of missense and nonsense mutations, insertions,
deletions or genomic rearrangements. These mutations can occur in coding regions, intron-exon
boundaries so as to affect correct gene splicing, regulatory regions, or intronic regions through the
introduction of cryptic splice sites or the disruption of splicing enhancer sites. Due to the highly
inerconnected nature of metabolism, mutations in different genes can affect the same pathway
causing similar or even identical phenotypes. In most cases, the adverse biological effects of these
mutations are propagated by five main mechanisms: toxic accumulation of substrates upstream
of the pathway block, reduction of essential compounds downstream, activation of alternative
pathways, diversion of metabolic flux to abnormal secondary pathways or secondary deficiencies
of essential metabolites due to uncontrolled or inappropriate chemical reactions (Figure 1.1.1).
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Figure 1.1.1: Pathogenesis of inborn errors of metabolism. Adapted from Lanpher et al.
(2006).
1.1.3 Classes of IEM
In 1963, the Society for the Study of Inborn Errors of Metabolism (SSIEM) was founded to foster
the exchange of ideas between professionals in different disciplines with an interest in inherited
metabolic disease. The SSIEM later formulated a hierarchical classification which formed the
basis of the designation of inborn errors of metabolism in the 11th international classification of
diseases (ICD11). Metabolic defects that affect the same or interconnected biochemical pathways,
or indeed the appropriate metabolism of related molecules, often present with similar clinical
features in patients. They are also typically diagnosed and monitored using the same routine or
specialised assays and subject to comparable acute and long-term treatments. Therefore, this
classification groups the > 600 disorders into 15 broad classes according to their dysfunctional
biochemical pathway, disease group and pathophysiological mechanisms. These classes are listed
in Table 1.1.1, alongside examples of disorders within each class, the normal functions of these
enzymes and the clinical and biochemical findings that may suggest one of these disorders.
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Importantly, this summary also illustrates the vast intra- and inter-class clinical heterogeneity
that complicates the diagnosis of these disorders.
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Table 1.1.1: Classes of inborn errors of metabolism, examples of disorders and associated clinical and biochemical features.
Disorder class Examples of disorders within this class Normal function of enzymes within this class Phenotypic and biochemical indicators that would
suggest a disorder within this class
Amino acid and peptide
metabolism
Urea cycle disorders, organic acidurias,
phenylketonuria, maple syrup urine
disease, alkaptonuria,
hyperprolinaemia, hyperlysinaemia.
These enzymes catalyse the metabolism of amino acids and related molecules in the
body. Their dysfunction results in abnormal levels of these and metabolically
connected molecules. The urea cycle also functions to remove ammonia from the
bloodstream and produce urea for excretion. Defects affecting this process or the
provision of its substrates results in severe hyperammonaemia.
Hyperammonaemia (including acute crisis), avoidance
of high-protein foods, vomiting, lethargy,
neurodevelopmental abnormalities, seizures, abnormal
organic acids in biofluids, abnormal amino acid
concentrations in biofluids.
Carbohydrate metabolism Glycogen storage disorders,
galactosaemia, hereditary fructose
intolerance, glucose transporter
deficiency.
Carbohydrates are sugars ranging in size from monosaccharides (e.g. galactose and
glucose) to polysaccharides (e.g. glycogen which is used for energy storage). The
main function of carbohydrates is to be catabolised to produce cellular energy.
Defects in the interconversion of carbohydrates and related molecules can cause
abnormal storage of polysaccharides impairing normal function or accumulation of
toxic sugar-derivatives.
Hypoglycaemia, hepatomegaly, hyperlipidaemia,
growth retardation, exercise intolerance, renal failure,
vomiting, neurodevelopmental abnormalities, seizures,
abnormal storage material visible in tissue samples
under electron microscopy.
Fatty acid and ketone body
metabolism
Disorders of mitochondrial fatty acid
oxidation, medium-chain acyl-CoA
dehydrogenase (MCAD) deficiency,
carnitine deficiency.
The oxidation of fatty acids by β-oxidation and the citric acid cycle is a major source
of cellular ATP. Fatty acids are the major storage form of energy in humans which
are normally broken down and utilised when glucose is unavailable. However,
dysfunction of enzymes within these pathways means that this fat source cannot be
metabolised to form energy, halting bodily processes.
Non-ketotic hypoglycaemia, cardiomyopathy,
rhabdomyolysis, liver dysfunction, poor appetite,
abnormal acylcarnitine profile.
Energy metabolism Mitochondrial respiratory chain
disorders (mutations in mitochondrial
and nuclear DNA), mitochondrial
membrane transport disorders,
disorders of creatine metabolism.
Mitochondria are cellular organelles that generate ATP through oxidative
phosphorylation carried out by the respiratory chain. Disease can result in defective
energy production (isolated or multiple complex dysfunction), defects in the
maintenance of mitochondrial DNA, mitochondrial protein synthesis or importation.
Multi-systemic disorder, proximal myopathy,
cardiomyopathy, encephalopathy, seizures,
neurodevelopmental abnormalities, characteristic MRI
abnormalities (basal ganglia changes), elevated lactate
in biofluids, reduced mitochondrial respiratory chain
complex activity in muscle biopsy, abnormal copy
number of mitochondrial DNA.
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Metabolism of purines,
pyrimidines and nucleotides
Aicardi-Goutieres syndrome, orotic
aciduria.
Purines and pyrimidines are the building blocks of DNA and RNA, as well as playing
a role in the regulation of cell metabolism (NADH), energy transport (ATP), cell
signalling (cyclic AMP), formation of coenzymes (coenzyme A) and intermediates of
phospholipid and carbohydrate metabolism.
Immunodeficiency, failure to thrive, seizures,
neurodevelopmental abnormalities, renal
abnormalities, anaemia, acute drug toxicity, abnormal
organic acid concentrations in biofluids, abnormal uric
acid concentrations in biofluids.
Metabolism of sterols Disorders of bile acid biosynthesis,
metabolism and transport,
Smith-Lemli-Opitz syndrome.
Sterols are steroid alcohols. The most common is cholesterol which forms part of
cellular membranes and is a precursor for bile acids (digestion, liver function,
absorption of fat soluble vitamins), steroids (hormones) and hedgehog proteins
(developmental signalling).
Cholestasis, fat-soluble vitamin malabsorption, liver
disease, neurodevelopmental abnormalities,
dysmorphic features/structural abnormalities, skin
abnormalities, abnormal concentrations/isoforms of
bile acids in biofluids, abnormal sterol analysis in
biofluids.
Porphyrin and haem
metabolism
Erythropoietic porphyria, X-linked
sideroblastic anaemia.
Porphyrins are heterocyclic macrocycle organic compounds. Haem is most well
known as the pigment in erythrocytes and cofactor of haemoglobin; it is synthesised
from porphyrin precursors. It is the accumulation of these precursors caused by a
deficiency in one of the enzymes in the metabolic pathway, that are toxic to the
tissues.
Acute abdominal pain, vomiting, hypertension,
tachycardia, motor neuropathy, photosensitivity, skin
disease.
Lipid and lipoprotein
metabolism
Familial hypercholesterolaemia,
Sjogren-Larsson syndrome, Tangier
disease.
Lipids function to store energy, act as signalling molecules and as structural
components of cell membranes. Lipoproteins serve to emulsify lipid molecules,
allowing them to move through aqueous environments (e.g. high- and low-density
lipoproteins enable fats to be carried in the bloodstream).
Neurodevelopmental abnormalities, skin
discolouration/abnormalities, cardiovascular disease,
neuropathy, ocular abnormalities, abnormal
cholesterol levels in biofluids, abnormal triglyceride
levels in biofluids, alterations in the levels/ratios of
lipoproteins in biofluids.
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Congenital disorders of
glycosylation and other
disorders of protein
modification
Disorders of N- and O-linked
glycosylation, disorders of
glycosphingolipid and
glycosylphosphatidylinositol anchor
glycosylation.
Glycosylation is the enzymatic attachment of a carbohydrate to another molecule,
including proteins and lipids. This modification (occurring in 50% of proteins)
enables correct protein folding and stability, cell-cell adhesion, antigen recognition,
cell surface receptors and protein-protein interactions. Due to the variety of tissue
proteins and lipids that are affected by defective glycosylation, dysfunction of these
processes result in multi-systemic disorder.
Multi-systemic disorder, neurodevelopmental
abnormalities, dysmorphic features/structural
abnormalities, seizures, ocular abnormalities, failure
to thrive, coagulopathy, hypoglycaemia, liver
abnormalities, hyperphosphatasia, abnormal
transferrin isoelectric focussing pattern, abnormal
glycan analysis.
Lysosomal disorders Mucopolysaccharidoses,
oligosaccharidoses, sphingolipidoses,
neuronal ceroid lipofuscinoses.
Lysosomes are cellular membrane-bound organelles that contain hydrolytic enzymes
that degrade biomolecules (e.g. proteins, lipids, carbohydrates and nucleic acids).
The dysfunction of these hydrolytic enzymes or proteins can impact on the transport
of lysosome/lysosomal substrates, resulting in the toxic accumulation of waste
products within cells.
Neurodevelopmental abnormalities, movement
disorders, seizures, deafness, blindness,
hepatosplenomegaly, cardiac abnormalities, abnormal
lysosomal enzyme screen, abnormal storage material
visible in tissue samples under electron microscopy.
Peroxisomal disorders Zellweger spectrum disorder, defects of
peroxisomal alpha-, beta- and
omega-oxidation, peroxisomal
biogenesis disorders.
Peroxisomes are cellular organelles, the main functions of which are catabolism of
very long chain fatty acids (VLCFAs) and the biosynthesis of plasmologens.
Dysfunction of the latter process causes profound abnormalities in the myelination of
nerve cells. Impaired catabolism of VLCFAs results in a deficiency of substrates for
the mitochondrial respiratory chain.
Neurodevelopmental abnormalities, dysmorphism,
seizures, liver dysfunction, bone abnormalities,
deafness, ocular abnormalities, abnormal very long
chain fatty acid concentrations, abnormal plasmalogen
concentrations in biofluids, abnormal bile acid
concentrations in biofluids.
Neurotransmitter metabolism Aromatic L-amino acid decarboxylase
(AADC) deficiency, tyrosine
hydroxylase deficiency, GABA
transaminase deficiency.
Neurotransmitters transmit signals across a chemical synapse between neurons. They
can be excitatory, inhibitory or a mixture of the two. Many are synthesised from
amino acids through a small number of enzymatic conversions. Dysfunction of these
enzymes causes imbalances of neurotransmitter concentrations and altered neuronal
function/excitability.
Neurodevelopmental abnormalities, movement
disorders, autonomic nervous system dysfunction,
abnormal muscle tone and movements, seizures,
oculogyric crises, abnormal neurotransmitter
concentrations in biofluids.
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Metabolism of vitamins and
non-protein cofactors
Pyridox(am)ine 5’-phosphate oxidase
(PNPO) deficiency,
pyridoxine-dependent epilepsy, vitamin
B12-responsive methylmalonic
aciduria, hereditary folate
malabsorption.
Vitamins are essential cofactors for more than 200 enzymes in the human body.
Consequently, a deficiency of the active cofactor caused by dysfunction of an enzyme
critical for its metabolism, can have widespread effects. E.g. the active form of
vitamin B6 is a cofactor for > 140 enzymes, many of which are involved in
neurotransmitter metabolism.
Neurodevelopmental abnormalities, movement
disorders, seizures, lethargy, vomiting, renal
abnormalities, hepatomegaly, anaemia, abnormal
neurotransmitter concentrations in biofluids, abnormal
vitamin concentrations in biofluids.
Metabolism of trace elements
and metals
Wilson disease, hypermanganesaemia,
hereditary haemochromatosis.
Similarly to vitamins, trace elements are essential cofactors for enzyme activity and
to maintain tertiary structures of proteins. Some have only a few functions (e.g.
cobalt in the structure of vitamin B12 and iodine in the synthesis of thyroid hormone)
but others are cofactors for many enzymatic reactions and thus their deficiency has
widespread effects (e.g. iron, zinc, copper, manganese and selenium).
Neurodevelopmental abnormalities, liver dysfunction,
movement disorders, abnormal blood cells, abnormal
concentrations of trace elements in biofluids.
Metabolism of xenobiotics Trimethylaminuria,
dimethylglycinuria.
Xenobiotics are molecules not naturally produced by the body, not expected to be
present within it or present in much higher concentrations than normal. The two
metabolic disorders within this class result from dysfunction of enzymes which
usually break down and then excrete molecules that are ingested in food. Instead,
these accumulated chemicals are released in body fluids.
Unusual body odour.
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1.1.4 The importance of early diagnosis
Timely diagnosis of IEM is crucial, especially for those disorders that are treatable or manageable.
However, diagnosis can be complicated not only by the inordinate clinical variability and lack of
genotype-phenotype correlations, but also by the fact that environmental factors can be central
to determining each patient’s phenotype (Dipple and McCabe, 2000; Scriver and Waters, 1999).
These factors, alongside genetic variation/polymorphisms in other genes, explain the variable
presentations within families sharing identical pathogenic mutations. Indeed, these interactions
are thought to underlie the fact that a patient’s genotype cannot typically predict the severity of
disease, prognosis or treatment response. Once a diagnosis has been established, there are eight
generic forms of treatment that can typically be undertaken:
1. Restriction of the accumulating upstream metabolites. If pathogenesis is being
propagated by the accumulation of toxic metabolites upstream of the dysfunctional enzyme,
dietary restriction of these compounds can be an effective treatment. One example is maple
syrup urine disease, a disorder caused by a deficiency of the branched-chain α-oxoacid
dehydrogenase complex which leads to a toxic accumulation of the branched chain amino
acids and their keto-acids. Restriction of these branched chain amino acids (leucine, valine
and isoleucine) from the diet followed by strict life-long adherence to a specially formulated
diet can prevent the neurological damage associated with the disorder (Morton et al.,
2002). Indeed, similar preservation of neurological function and intellect can be observed in
patients with phenylketonuria when phenylalanine is restricted from the diet; this finding
lay the foundation for newborn screening for IEM (Guthrie and Susi, 1963).
2. Removal of toxic substrates. For some disorders, unlike those described above, more
rapid removal of toxic compounds than can be achieved by dietary alteration is required
to prevent severe neurological damage. One example can be seen in patients with urea
cycle disorders. In normal individuals, the metabolism of protein results in the production
of nitrogen which is then removed from the blood and converted to urea for urinary
excretion. In patients affected by a deficiency of one of the six enzymes that together are
responsible for the removal of ammonia from the blood, severe hyperammonaemia can occur
which if untreated can result in respiratory distress, coma and death. Life-long dietary
protein restriction is necessary to prevent excessive ammonia formation; however acute
hyperammonaemic crises can still occur, especially within the neonatal period, after high-
protein meals or periods of viral illness (Leonard and Morris, 2002). In severe cases including
patients presenting with acute encephalopathy, haemodialysis or haemofiltration to remove
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the ammonia may be required (Häberle et al., 2012). Outside of acutely life-threatening
scenarios, other compounds such as sodium benzoate can be used as adjunctive treatments
to promote the excretion of nitrogenated molecules, thereby rapidly reducing ammonia
accumulation (Leonard and Morris, 2002). Similar molecular scavenging treatments are
used in a variety of other IEM including isovaleric aciduria and other organic acidaemias
(Naglak et al., 1988).
3. Supplementation of the deficient downstream metabolites. Where the pathogenic
effects of a disorder are caused by low levels of essential metabolites downstream of
the dysfunctional enzyme, supplementation of these products can ameliorate symptoms.
Pyridox(am)ine 5’-phosphate oxidase deficiency is a primary defect in the synthesis of
the form of vitamin B6 that is a critical cofactor for more than 140 different enzymes in
humans, many of which are involved in neurotransmitter metabolism. Hence, the addition
of a supplement containing this vitamin to the diet of these patients causes the cessation of
their seizure disorder and improves their neurological outcome (Mills et al., 2014).
4. Supplementation with competing metabolites. Dietary supplementation is not lim-
ited to the replacement of deficient metabolites within the affected pathway; in some
cases, treatment with metabolites that competitively inhibit enzyme activity or compete
with the accumulating substrates for transport can be effective. One example is Wilson’s
disease, which is caused by defective excretion of carrier protein-bound copper into the
bloodstream and secretion of excess concentrations of this metal into the bile. Therefore,
copper accumulates in the liver causing chronic hepatitis, fibrosis and cirrhosis. Free copper
also accumulates in the kidneys, eyes and brain causing neuropsychiatric symptoms (Bie
et al., 2007). Instead of being treated with chelation therapy, the majority of patients are
now given zinc supplementation as it competes with copper for the same transporter at the
gut mucosa, resulting in its excretion (Hoogenraad, 2006).
5. Stimulation of residual enzyme activity. As mentioned in Table 1.1.1, many enzymes
depend on vitamins or trace metals for catalytic activity. In patients with mutations in
these enzymes that do not completely abolish function, supplementation with these essential
cofactors can increase the residual flux through the pathway and ameliorate symptoms. An
example is methylmalonyl-coA mutase deficiency; the function of this enzyme is to catalyse
the isomerisation of methylmalonyl-coA to succinyl-coA and requires vitamin B12 as a
coenzyme. Affected patients can present with feeding problems, failure to thrive, hypotonia,
developmental delay and acute metabolic decompensation. In a small proportion of patients,
supplementation with vitamin B12 results in a marked decrease in the concentration of
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methylmalonic acid in biofluids accompanied by a reduction in the severity of symptoms
(de Baulny et al., 2005). Supplementation with vitamin B6 can be similarly effective in
patients with cystathionine β-synthase deficiency (Clayton, 2006).
6. Direct replacement of the dysfunctional enzyme. In the case of many defects
underlying IEM, the above treatment strategies are not possible because defects do not
simply affect the interconversion of two metabolites. One such class of diseases are the
lysosomal storage disorders, the majority of which are caused by dysfunctional enzymes
which break down macromolecules within lysosomes. In recent years, enzyme-replacement
therapy (typically in the form of intravenous or intrathecal administration of a recombinant
form of the wild-type form of the deficient/defective enzyme) has been developed for
the treatment of some IEM. Lysosomal enzymes have been particularly targeted due to
the fact that some can be secreted and taken up by other cells, meaning that systemic
administration can be efficacious. Clinical benefits of enzyme replacement therapy have
been demonstrated in patients with early-stage Fabry disease, with favourable effects on
heart and kidney function, decreased pain and increased quality of life (Lidove et al.,
2010). Similar prevention of progressive blood cell abnormalities, organomegaly and bone
pathologies have been reported in patients with type I Gaucher disease (Weinreb et al.,
2002). However, one of the most significant limitations of these treatments is the fact
that the recombinant enzymes cannot cross the blood-brain barrier or penetrate the bones.
Therefore, the progression of bone and neurological disease is not affected in patients.
However, work is ongoing to overcome these issues (Urayama, 2013).
7. Replacement of the defective gene inside patient cells. A complementary therapeu-
tic technique which, similarly to enzyme replacement therapy, relies on the ability of cells to
take up functional enzymes from another source is organ transplantation. The donor organ,
or cells in the case of a haematopoietic stem cell transplant, contain the wild-type gene and
therefore secrete the functional enzyme which can compensate for the systemic deficiency.
Hurler syndrome is caused by a deficiency of α-L-iduronidase which functions to degrade
heparan and dermatan sulphate within lysosomes. Patients are affected by progressive
hepatic, cardiac, neurological and bone disease often leading to death before ten years of
age (Pastores et al., 2007). Treatment with a haematopoietic stem cell transplant from
a heterozygous or unrelated donor is recommended in these patients as, unlike enzyme
replacement therapy, functional enzymes can target the central nervous system (Aldenhoven
et al., 2015). Indeed, following a successful transplant a substantial clinical improvement
is often seen, including the resolution of hepatosplenomegaly, improvements in cardiac,
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pulmonary and hearing function, decreased coarseness of facial features and stabilisation
of neuropsychological function (Souillet et al., 2003). Similarly, liver transplantation in
patients with urea cycle disorders can eradicate hyperammonaemia and result in improved
neurodevelopmental outcomes (Kim et al., 2013).
In contrast to delivering wild-type copies of the defective gene within the cells of a donor,
direct insertion of DNA into patient cells can be achieved using gene therapy. This is
typically accomplished by packaging the DNA in viral vectors, which takes advantage
of the natural ability of viruses to introduce their DNA into host cells to enable their
replication and the production of viral proteins. To date, gene therapy has been shown to be
efficacious in multiple IEM including lysosomal storage disorders, urea cycle disorders and
organic acidurias. One example can be seen in patients with Canavan disease, a hereditary
leukodystrophy caused by inadequate catabolism of N-acetylaspartate in the brain. This
results in the aberrant myelination of neurons and associated morphological changes in
the brain that cause intellectual disability, loss of skills, seizures, macrocephaly and death
in the third decade of life. Therapy using an adeno-associated viral vector delivered
via intraparenchymal infusions resulted in normalisation of cerebral N-acetylaspartate
concentrations as well as a stabilisation of brain atrophy and some reduction in seizure
frequency (Leone et al., 2012). Regardless of the disease and route of wild-type gene
administration, children who are transplanted/treated at a younger age will invariably have
a better clinical outcome as established organ damage is not typically reversible (Wynn,
2011; Ginocchio and Brunetti-Pierri, 2016).
8. Symptom management. Despite the multiple treatment options described above that
are available for patients with certain IEM, many disorders remain for which treatment is
essentially symptomatic or palliative. This can include anti-epileptic drug treatment for
seizures, cochlear implants for sensorineural hearing loss, organ transplantation in situations
of single-organ failure, enteral feeding to optimise nutritional intake, intravenous fluid
administration at times of intercurrent illness and physiotherapy to maintain muscle tone
and physical abilities (Parikh et al., 2009).
A shared theme amongst the therapeutic options described above is the fact that early
initiation of treatment invariably results in improved outcomes. Therefore, making diagnoses
in patients in whom an IEM is suspected is critical to ensure that appropriate therapy can
commence before permanent, particularly neurological, damage occurs.
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1.2 neurometabolic disorders (nmd)
As is evident in Table 1.1.1, neurological symptoms are the most common feature of IEM with
global developmental delay often being the intial presenting feature. These IEM that include
neurological dysfunction as a prominent manifestation are known as neurometabolic disorders
(NMD). Clinical features may include epilepsy, movement disorders, neuro-cognitive deficits,
behavioural abnormalities and psychiatric disorders (Karimzadeh, 2015). Indeed, there are
more than 90 NMD in which this dysfunction may be treatable (Tarailo-Graovac et al., 2016).
Neurological signs can become apparent at any age between the newborn period and adulthood.
Whilst in some cases disorders can cause abnormal brain development in utero resulting in
gross structural abnormalities (Klouwer et al., 2015), in most cases symptoms are caused by
progressive destruction of mental, motor and perceptual functions due to the accumulation of
toxic molecules. This can be evident as a non-specific neurodevelopmental delay, be acutely
precipitated by environmental stresses such as infection or vaccination, or have a latent period
whereby a number of years of seemingly normal development are followed by the regression of
skills once cellular damage has reached a certain threshold (van Karnebeek and Stockler, 2012;
Filiano, 2006). Whilst the vast majority of reported NMD/IEM cases have presented during
childhood (≤ 16 years), it is becoming increasingly recognised that this likely reflects the more
severe and easily diagnosed spectrum of these conditions and that phenotypically milder forms of
these disorders do not manifest until later in adulthood, typically with psychiatric signs, dementia,
mood or behavioural disorders (Sedel et al., 2007). Indeed, a recent publication suggests that
NMD are likely to account for a significant proportion of neurodegenerative diseases secondary
to a genetic cause, with prevalence data ranging between 1 - 13% (Shevell et al., 2003; Masri and
Wahsh, 2014).
In addition to the presence of one or more of the neurological features described above,
in order to invoke a clinical suspicion of an underlying NMD in a patient other indications
suggesting a metabolic abnormality should be present. These can be in the form of clearly
abnormal biochemical parameters including levels of amino acids, organic acids, acylcarnitines
or lactate, an abnormal pattern of transferrin glycoforms or aberrant mitochondrial respiratory
chain activity. However, episodes of acute metabolic decompensation, unusual dietary habits,
multi-systemic involvement, dysmorphism, liver dysfunction (particularly hepatosplenomegaly)
and failure to thrive are also suggestive features. Characteristic electroencephalography (EEG) or
neuroimaging findings may also be present. Despite NMD not being a common cause of epilepsy,
seizures are a frequent symptom of NMD. These seizures are often refractory to treatment with
conventional anti-epileptic drugs but may have a good response to supplementation with vitamins,
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cofactors or dietary manipulation (Papetti et al., 2013). Although many different seizure types
may occur including epileptic encephalopathy, status epilepticus, infantile spasms, generalised
tonic-clonic and myoclonic seizures, an EEG showing burst-suppression or hypsarrhythmia may
point towards an NMD (Youssef-Turki et al., 2011). Similarly, the existence of white matter or
basal ganglia abnormalities, a leukodystrophy, or atypical metabolite peaks upon examination
using magnetic resonance spectroscopy are highly suggestive of an NMD.
The challenges when diagnosing these pathologies are largely attributable to the clinical
and genetic heterogeneity (including often non-specific or atypical presentations early on in the
disease course) and lack of clinical awareness of rare entities. Indeed, patients with suspected
NMD are frequently referred to specialist centres and undergo extensive and often invasive
diagnostic testing. Despite this, diagnostic delays or difficulties establishing a definitive diagnosis
are commonly encountered, with many such patients attending secondary and tertiary neurology
clinics remaining undiagnosed (Verity et al., 2010).
1.3 current methods for the diagnosis of iem/nmd
Just as the advent of novel technologies have been critical in the discovery and understanding of
the pathogenic mechanisms underlying IEM (Section 1.1.1), these same techniques have been
utilised to revolutionise the diagnosis of these disorders in a clinical setting.
1.3.1 Profiling of analytes in biofluids
The primary method for the diagnosis, monitoring and investigation of IEM is through the
analysis of metabolites. These assays are based on the fundamental principle underlying IEM,
that dysfunction of an enzyme causes a block in a metabolic pathway that results in the
accumulation of molecules upstream and the deficiency of molecules downstream of the block. A
classic example is phenylketonuria, in which a deficiency of phenylalanine hydroxylase results in
impaired conversion of phenylalanine to tyrosine. Hence, the analysis of amino acid concentrations
in biological fluids from an affected patient will reveal high levels of phenylalanine and low levels
of tyrosine (Vockley et al., 2014). Indeed, many classes of metabolites may be analysed in
this way, with particular patterns of abnormalities being diagnostic of a specific disorder or
indicative of a wider sub-group of IEM. Relatively small groups of molecules sharing similar
physicochemical properties and involved in related biological pathways are typically analysed
concurrently; examples include organic acids, acylcarnitines, neurotransmitter amine metabolites,
fatty acids and vitamins.
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Many of these assays use mass spectrometry to quantify the concentrations of each analyte.
Mass spectrometry is an analytical technique which allows the concurrent measurement of
multiple analytes that are present at low concentrations in biological fluids including dried blood
spots, whole blood, plasma, urine and cerebrospinal fluid (Figure 1.3.1). For some analytes
such as acylcarnitines, tandem mass spectrometry (MS/MS) analysis is performed without
prior chromatographic separation (Rinaldo et al., 2008). When operated in scan mode, this
technique facilitates the evaluation of the whole metabolite profile, as well as the detection of
common drug artefacts and interfering compounds. However, greater analytical specificity can be
achieved through the coupling of liquid chromatography separation to tandem mass spectrometry.
This is typically performed using either high-performance (HPLC) or ultra-performance liquid
chromatography (UPLC). The latter makes use of smaller stationary phase particles and can
operate at higher pressures, resulting in superior analyte resolution and faster analysis when
compared to HPLC. In contrast to MS/MS, HPLC-MS/MS and UPLC-MS/MS provide three
levels of identification for each molecule, resulting in higher specificity and a superior ability
to analyse complex mixtures. Firstly, HPLC/UPLC is used to separate compounds based on
their physicochemical properties. The chromatographic system typically consists of a non-polar
silica-based stationary phase and an eluting mobile phase; the composition of the mobile phase is
then gradually altered to elute the analytes according to their polarity. Alteration of a number
of parameters including the composition, gradient and flow rate of the mobile phase can change
the ability to separate particular classes of molecules. Thus, the retention time of each molecule
on the liquid chromatography column forms the first level of analyte identification.
Following chromatographic separation, the compounds sequentially enter the mass spectrome-
ter and are ionised to form charged gas-phase ions. Electrospray ionisation is the most widely
used technique as it is particularly suited to the analysis of polar molecules within a liquid
matrix, as is commonly required for the analysis of biological fluids. Firstly, the liquid sample
is pumped at high pressure through a fine capillary which is maintained at a high temperature
and voltage to form a fine aerosol of highly charged droplets (Dass, 2007). Aided by a flow of
heated nitrogen gas, the solvent within these droplets then evaporates to generate gas-phase ions
(precursor ions). Depending on the physicochemical properties of the molecules to be measured,
a positive or negative charge can be imparted to the ions which enables optimal sensitivity for
the particular ion of interest. Following ionisation, the precursor ions enter the first quadrupole.
This consists of four cylindrical metal rods aligned parallel to each other and through which a
variable radiofrequency voltage can be applied (Pitt, 2009). This voltage can be tuned to allow
the passage of ions with a specific mass-to-charge ratio (m/z) corresponding to that expected from
the precursor ion of the analyte of interest. This selection constitutes the second level of analyte
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identification. However, in a complex biological sample it is likely that multiple metabolites
will produce an ion with a particular m/z. Therefore, the majority of mass spectrometry-based
assays used within the clinical setting and this thesis use a triple quadrupole mass analyser.
In this system, once selected precursor ions have passed through the first quadrupole they are
bombarded with argon gas within a collision cell which fragments each species to form a product
ion (Pitt, 2009).
Figure 1.3.1: The diagnosis of IEM using mass spectrometry coupled to liquid chro-
matography. (a) Metabolites are typically quantified in biofluids which can
include dried blood spots, whole blood, plasma, urine and cerebrospinal fluid.
(b) When preparing each sample, one or more internal standards are added to
enable quantitation of each analyte. (c) Samples may also be subject to further
processing steps including precipitation to remove contaminating proteins. (d)
Each sample is then injected into a HPLC or UPLC system which separates
the complex mixture based on the physicochemical properties of each molecule.
Following this, they enter the mass spectrometer and are ionised to form precursor
ions. Each precursor ion of interest is then selected and fragmented through
collision with argon gas to form a number of smaller product ions. (e) These
analytes are then identified based on their retention time and the mass-to-charge
ratio (m/z) of their corresponding ions, and quantified by comparison of the
signal to that of a known concentration of internal standard.
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In an identical fashion to the first quadrupole, the second selects only product ions with the
predicted m/z of the analyte of interest; this is the third level of identification. By combining the
retention time and the m/z values of both the precursor and product ions metabolites can be
identified and quantified.
There are many advantages to these types of assays to measure the concentrations of various
metabolites in biofluids, particularly within a clinical laboratory setting. These include high
sample throughput, the ability to analyse multiple molecules of interest within a single assay
and reduced cost compared to traditional radio-immunoassays. Therefore, the adoption and
growth in the use of LC-MS/MS in these environments has been rapid (Grebe and Singh, 2011),
with the majority of hospitals within the UK having at least one LC-MS/MS instrument and
tertiary referral centres having dedicated departments housing multiple platforms. However, one
limitation of these methodologies for the diagnosis of IEM is that findings may be non-specific and
indicate a multitude of possible disorders. One example is an elevated concentration of alanine in
plasma which can be indicative of long-term pyruvate accumulation, with concentrations above
450 µmol/L being used as a diagnostic factor for mitochondrial disorders (Wolf and Smeitink,
2002). However, the sensitivity of hyperalaninaemia for mitochondrial dysfunction is low as it
may only be present in certain genetic defects or at times of physiological stress. In addition, mild
abnormalities revealed by these classes of analyses can be overlooked or misinterpreted as being
due to environmental factors. For example, non-specific aminoacdiuria can be a consequence of
recent ingestion of a carbohydrate- or protein-rich meal or renal tubular dysfunction (Haas et al.,
2008).
1.3.2 Specialised biochemical tests
In contrast to the measurement of certain groups of metabolites in biofluids which is standard
practice in the majority of hospitals for the diagnosis and monitoring of many IEM, there are
a multitude of assays which are only available in specialist centres. This is usually because
the required reagents are expensive, the assay is labour-intensive or the disorder for which
the assay is used to diagnose is very rare. Examples of tests in this class include transferrin
isoelectric focussing for congenital disorders of glycosylation (Figure 1.3.2), glycosaminoglycan
analysis for mucopolysaccharidoses, measurement of globotriasylceramide for Fabry disease and
α-aminoadipic semialdehyde quantitation for pyridoxine-dependent epilepsy.
Alternatively, the activity of certain enzymes can be assessed directly. These assays rely on the
fundamental principle of IEM that dysfunction of an enzyme results in impaired conversion of the
substrate to the corresponding product. It is the quantification of this activity that is measured
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Figure 1.3.2: Transferrin isoelectric focussing patterns. The transferrin polypeptide has
two N-linked polysaccharide chains which are branched with sialic acid residues
(orange). Due to the fact that sialic acid has a negative charge, the differently
glycosylated forms can be separated on a gel over a pH gradient. In normal
individuals the most common oligosaccharide is that with four polysaccharide
chains terminating in sialic acid residues. CDG type I (CDG-I) involves impaired
synthesis of the lipid-linked oligosaccharide precursor or its transfer to the protein.
CDG type II (CDG-II) is caused by dysfunctional processing of the protein-bound
oligosaccharide chain.
in patient biofluids or tissue samples. One such group of diagnostic tests are the lysosomal
enzyme screens which quantify the activity of between 7 and 11 enzymes in the leukocytes of
patients presenting with suggestive features (e.g. neurodegeneration, hepatosplenomegaly or a
cherry red spot on the macula of the eye). However, the majority of methods only examine the
activity of a single enzyme at one time such as phosphomannomutase, arginase or galactokinase.
These assays can be performed using substrates that are isotopically- or fluorescently-labelled and
that can be detected using mass spectrometry and spectrofluorimetry, respectively (Blanchard
et al., 2008). Alternatively, colourmetric chemical reactions can be utilised and measured using a
spectrophotometer (Bisswanger, 2014).
These specialised biochemical tests are beneficial as they allow the detailed examination of a
specific disorder or small sub-group of disorders. In addition, enzyme assays provide a conclusive
functional demonstration of the specific enzyme defect. Moreover, due to their availability only at
a limited number of specialist centres, these tests are usually expensive and require a high degree
of clinical suspicion to be requested. Whilst a positive result is diagnostic in an affected patient
and the degree of residual enzyme activity may give some indication of prognosis (Koprivica
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et al., 2000), identification of the pathogenic mutation(s) is desirable for pre-natal testing of
future pregnancies within affected families.
1.3.3 Single-gene Sanger sequencing
The traditional approach for genetic diagnosis involves the amplification of all exons and intron-
exon boundaries of a candidate gene using polymerase chain reaction (PCR) prior to Sanger
sequencing. This method, also known as the "chain termination" or "dideoxy" sequencing, was
first described by Sanger et al. (1977). Firstly, the DNA of interest is isolated and denatured to
form single-stranded DNA. An oligonucleotide primer then binds to its complementary template
sequence and free nucleotides are incorporated by DNA polymerase to facilitate de novo synthesis
of a new DNA strand. However, in addition to normal deoxynucleotides (dNTPs), the reaction
mix also contains di-deoxynucleotides (ddNTPs) which lack a 3’-hydroxyl group required for the
formation of the phosphodiester bond between two adjacent nucleotides. These ddNTPs are also
fluorescently labelled. The repetition of this process therefore results in the formation of multiple
DNA fragments of differing lengths, each of which terminates in one of the four labelled ddNTPs.
In order to determine the sequence of each DNA strand, these fragments must then be aligned
in order of size. In the vast majority of clinical laboratories, this analysis is performed by capillary
electrophoresis. Each sample is loaded into a glass capillary and the migration of each fragment
is initiated by an electric field. DNA has a backbone of negatively charged phosphate groups,
thus the charge of a particular DNA fragment and the speed of its electrophoretic migration is
determined by the number of nucleotides within it. The identity of the terminating amino acid is
determined through laser excitation of each fragment when it reaches the end of the capillary,
as the label of each ddNTP (A, T, G and C) emits light at a specific wavelength. The DNA
sequence in the patient can then be aligned and compared to that of the wild-type sequence to
detect any base alterations that may result in disease.
Sanger sequencing has been a mainstay of geneticists for over 30 years and remains the
"gold-standard" DNA sequencing technique. With advances in automation, this methodology can
be used to read continuous sequences of up to 1000 bp in length with a base-calling accuracy
of up to 99.999% at a cost in the order of £0.35 per kilobase (Shendure and Ji, 2008). It
can be used to identify the vast majority of mutations causing IEM including missense and
nonsense mutations, insertions and deletions. However some pathogenic variants can be missed
unless they are specifically searched for. These can include deep intronic splice variants as
in leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation
(van Berge et al., 2014) or whole gene deletions and duplications as in Pelizaeus-Merzbacher
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disease (Lee et al., 2006). The latter can be identified using alternative methods for analysing
copy number variants (CNVs) such as array comparative genomic hybridisation (aCGH) or
multiplex ligation-dependent probe amplification (MLPA) and indeed, these investigations are
often requested alongside standard sequencing. However, Sanger sequencing is accompanied by
the obvious draw-back of requiring candidate genes for sequencing, which in turn often requires
specialist clinical knowledge of the group of disorders in question and their genotype-phenotype
correlations. Even if a specific disorder is suspected, clinical-grade single-gene sequencing is
only available for a small subset of genes which often vary between centres. Indeed, advances in
chemistry and bioinformatics, alongside the advent of "next-generation" sequencing methodologies
have supplanted Sanger sequencing in many cases, especially for the analysis of large numbers of
genes. These technologies will be described in Sections 1.3.4 and 1.3.5.
1.3.4 Gene panels targeting multiple disease genes
In 2001, Lander et al. published the sequence of the first human genome. This extraordinary
collaborative effort took 15 years and cost almost 3 billion dollars to complete. In the fifteen
years since this accomplishment, the demand for low-cost sequencing has driven the development
of next-generation sequencing (NGS) technologies, facilitated by advances in microscopy, surface
and nucleotide chemistry, computation and data storage (Shendure and Ji, 2008). This has
occurred to such an extent that the latest platforms are capable of sequencing more than 45
human genomes in a single day for approximately $1000 each, with the data output for NGS
applications more than doubling each year (Stein, 2010).
Although many NGS technologies exist, each making use of different biochemistry and
detection methodologies, the Illumina sequencing platforms have emerged as the most widely-
used choice in both clinical and research settings (Buermans and den Dunnen, 2014). Accordingly,
the Illumina MiSeq and HiSeq 2500 platforms have been utilised throughout this thesis. The
concept behind this technology is similar to Sanger sequencing in that DNA polymerase catalyses
the sequential incorporation of fluorescently labelled dNTPs into a DNA template and each
nucleotide is identified through laser excitation. The difference is that instead of sequencing
only a single DNA fragment at one time, NGS performs this process concurrently across millions
of small DNA fragments. Firstly, the sequencing library is prepared; this procedure depends
on the capture methodology being used and is generally achieved using random fragmentation
or enzymatic digestion. After isolating the desired genomic regions and fragmenting the DNA
into strands of approximately 150 bp in length, adapters are annealed to the 3’ and 5’ end and
the fragments are PCR amplified. These adapters contain (i) binding sites for the forward and
43
reverse sequencing primers, (ii) indexes to enable multiplexing of samples and the subsequent
de-coding of data and (iii) regions complementary to oligos anchored to the flow cell (a glass
slide containing small fluidic channels through which reagents can be pumped) to enable the
immmobilisation of each DNA fragment on the solid sequencing platform. The library is then
loaded into the sequencing flow cell and the DNA fragments are captured on the lawn of oligos
which are complementary to either the 3’ or 5’ adapters. Each fragment is then amplified through
bridge-amplification to generate distinct clonal clusters (Figure 1.3.3).
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Figure 1.3.3: Cluster generation using bridge-amplification utilised by Illumina technologies. (a) The forward DNA strands bind to the comple-
mentary oligos on the flow cell surface. (b) DNA polymerase synthesises the complementary reverse strand. (c) The double-stranded molecule is
denatured and the original forward template is washed away. (d) The strand folds over and the adapter region hybridises to the second type
of oligo imbolised on the surface of the flow cell. (e) DNA polymerases again synthesise the complementary strand forming a double-stranded
bridge. (f) The bridge is then denatured, resulting in two single-stranded copies of the DNA fragment that are tethered to the flow cell. (g)
This process is then repeated multiple times and occurs simultaneously for millions of clusters, resulting in clonal amplification of all the DNA
fragments. (h) The reverse strands are then cleaved and washed off leaving only the forward strands. Finally, the 3’ ends are blocked to prevent
unwanted priming. Adapted from www.illumina.com.
45
Sequencing then begins with the binding of the first sequencing primer to the immobilised
DNA fragments and their extension to produce the first read. The four nucleotides (A, T, G and
C) utilised in this method have been modified in two ways: each is reversibly attached to (i) a
fluorescent label with a unique emission wavelength and (ii) a terminator group. With each cycle,
the four nucleotides compete for addition to the growing DNA strand (Figure 1.3.4a). Only one
is incorporated based on the sequence of the template. After the addition of each nucleotide, the
clusters are excited by a laser and a characteristic fluorescent signal is emitted (Figure 1.3.4b).
Both the fluorescent label and the terminator group are then cleaved and washed away (Figure
1.3.4c). The number of cycles determines the length of the read, whereas the emission wavelength
along with the signal intensity determines each base call. For a given cluster, all identical strands
are read simultaneously and millions of clusters are sequenced in a massively-parallel process
(Figure 1.3.4d). The indexes of each DNA fragment are also sequenced in the same way which
allows for the computational determination of which sequences belong to each patient when
multiple samples have been multiplexed in the same run. Finally, each read (forward and reverse)
is aligned to the reference genome for variant identification.
Figure 1.3.4: Sequencing-by-synthesis methodology on which Illumina technologies
are based. (a) The reversibly terminated nucleotides and DNA polymerase
are added. (b) Each complementary nucleotide is incorporated and excited
sequentially to produce a fluorescent emission which is detected. (c) Both the
label and terminator are cleaved and (d) the process is repeated to achieve
massively-parallel sequencing.
This NGS technology has lead to a substantial increase in the identification of new disease-
causing genes and the expansion of genotype-phenotype relationships. Indeed, increased reliability,
robustness and the advent of novel capture techniques have facilitated its introduction into routine
genetic diagnostics in the clinical setting. This has been particular useful for groups of disorders
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characterised by great phenotypic and genetic heterogeneity such as intellectual disability (Vissers
et al., 2016) and epilepsy (Møller et al., 2015) that require the analysis of many candidate
genes. Generally, there are three ways to implement NGS for the diagnosis of disorders such as
IEM/NMD: (i) targeted gene panel sequencing of a subset of genes, (ii) whole exome sequencing
and (iii) whole genome sequencing. All share the ability to perform untargeted screening of
multiple genes, which bypasses the need for specialist knowledge of individual candidate defects.
Targeted gene panel sequencing involves selecting a subset of protein-coding genes for analysis,
typically those in which mutations are already known to cause a disorder within the group of
interest. This approach has been increasing in prevalence over the past five years and is now
broadly available in clinical genetics services of many healthcare systems worldwide including
the National Health Service (www.ukgtn.nhs.uk). Whilst many panels exist targeting small
subsets of genes often associated with specific phenotypic features such as inflammatory bowel
disease, deafness or epilepsy (Kammermeier et al., 2014; Tekin et al., 2016; Lemke et al., 2012;
Trump et al., 2016), currently panels for IEM are limited and focus on small subgroups of
disease including congenital disorders of glycosylation and mitochondrial disorders (Jones et al.,
2013; DaRe et al., 2013). Given the degree of phenotypic heterogeneity and overlap that is
commonly seen within and between subgroups of IEM, an extended gene panel approach may be
advantageous in this population.
Gene panel approaches have several advantages compared to whole exome or genome se-
quencing, including greater average sequencing depth (i.e. the number of reads in which any
given nucleotide of a target sequence is represented) due to a reduction in the number of target
regions. This parameter is critical for the identification of heterozygous variants and in the
diagnosis of IEM, where many children born to non-consanguineous parents would be expected
to harbour compound heterozygous mutations. Further advantages also include lowered cost per
sample due to greater multiplexing capability and reduced time required for data processing.
The clinical implications of any identified variants are also easier to interpret as only genes
previously associated with a disease phenotype are sequenced. Indeed, this restriction reduces the
identification of incidental findings and variants of uncertain significance (Table 1.3.1). However,
these factors can also be disadvantageous as diagnostic success will only be achieved if the
pathogenic gene is included in the panel design.
1.3.5 Whole exome (WES) and genome (WGS) sequencing
On a research basis, whole exome sequencing (WES) is the most widely used targeted sequencing
method. The exome is defined as the part of the genome which when transcribed, remains within
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the RNA after intron splicing and therefore constitutes the protein-coding regions. These regions
represent less than 2% of the human genome but harbour the majority of known pathogenic
variants. Thus, sequencing of these regions is a cost-effective alternative to whole genome
sequencing (WGS) which is defined as the determination of the complete DNA sequence of an
individual. Both techniques make use of the same NGS technologies as for gene panel sequencing,
with Illumina platforms being the most popular due to their superior capacity for data output.
Many recent studies have successfully shown that WES or WGS can be used in a research
environment to identify the genetic basis of rare disorders including IEM/NMD (Tarailo-Graovac
et al., 2016). Whilst WES, and to a much lesser extent WGS, are being adopted in many clinical
centres internationally (Rabbani et al., 2014), currently in the UK this approach is only offered by
private companies or as part of a research study. In the case of screening offered by commercial
companies, the prices of these investigations are often variable and turn-around times for research
studies can range between three months and in excess of one year. However, three years ago
Genomics England (funded by the UK Department of Health) launched the 100,000 Genomes
Project which aims to perform WGS for NHS patients with rare diseases and those with cancer.
This initiative is ongoing and to-date the genomes of 11,000 individuals have been sequenced (as
of July 2016). Both WES and WGS have advantages compared to gene panel sequencing (Table
1.3.1), the most obvious of which is the ability to detect variants in novel disease-causing genes
and therefore not relying on the prior identification of a likely disease class. However, this can
also be a disadvantage as determining the significance of variants within genes that have not
previously been associated with a disease in humans may not be possible, especially within a
clinical diagnostic setting where further functional studies would be impractical.
Table 1.3.1: Comparison between targeted gene panel, whole exome (WES) and
whole genome sequencing (WGS). -, no; X, yes. Adapted from Sun et al.
(2015).
Targeted gene panel WES WGS
Relative cost compared with WES Depends on size of gene
panel
1 ∼ 3
Coverage of target regions Up to 100% when
complemented with in-filling
of inadequate regions using
Sanger sequencing
97.5% >97.5%
Analysis of novel disease genes - X X
Intronic variants (> 30 bp from splice site) - - X
Incidental findings - X X
One limitation of both gene panel sequencing and WES is that because they both target only
exonic regions, any pathogenic mutations in intronic or regulatory regions will not be identified
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(Table 1.3.1). In addition, due to NGS technologies being based on sequencing short (∼150
bp) DNA fragments, if copy number variants (duplications, insertional transpositions, deletions
or complex genomic rearrangements) are present that span more than one read or when the
breakpoints are intronic they will not be detected. An advantage of WGS is that these types of
potentially pathogenic structural changes can be detected as the coverage not only encompasses
the entirety of each copy number variation, but also is more even across the genome (Gilissen
et al., 2014). The methods that exist to enable the detection of these variations are described
in Section 3.3.3. However, whilst the advent of WES and WGS has revolutionised the field of
molecular medicine, further guidelines regarding the reporting of medically actionable findings
that are unrelated to the original indication for the test (e.g. BRCA1 and BRCA2 mutations)
and advances in bioinformatic pipelines and data storage are required prior to the establishment
of these technologies in routine clinical practice.
1.4 the importance of functional confirmation and characterisation of
identified variants
As already discussed, the interpretation of the significance of the millions of variants being
identified through WES or WGS presents a challenge in both a research and clinical setting (Stein,
2010). Indeed, the clinical significance of any sequence variant lies along a gradient, ranging from
those in which the variant is almost certainly pathogenic to those that are almost certainly benign.
Current guidelines suggest using a combination of in silico tools to determine the conservation of
the mutated amino acid position across species and the frequency of each variant within healthy
human populations; as well as incorporating functional consequence predictions, gene-specific
information in the literature (e.g. annotation of critical protein domains and mutation hot-spots)
and the phenotypic correlation between the patient being investigated and those previously
reported with mutations in the same gene, to classify the potential pathogenicity of sequence
variants (Richards et al., 2015). Genetic testing of additional family members is also recommended
where samples are available to confirm co-segregation of the variant with disease.
However, despite these recommendations, it has been reported that up to 27% of mutations
cited in the medical literature as pathogenic have been misannotated and are in fact common
polymorphisms (Bell et al., 2011). These false assignments of pathogenicity can then have severely
detrimental consequences on patient care as incorrect prognostic, therapeutic and reproductive
advice may be given (MacArthur et al., 2014). Indeed, the only way to conclusively support
pathogenicity is through functional demonstration of the defect in patient-derived samples and
this should be carried out whenever possible. However, each type of functional assay differs in
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their ability to recapitulate the in vivo environment within each patient and therefore accurately
determine any functional impairment. For example, determination of enzyme activity in a
patient-derived skin biopsy or an animal disease model provides stronger evidence than the same
experiment carried out using a protein generated through in vitro overexpression.
Unfortunately, functional assays are only established to assess the pathogenicity of variants in
a minority of genes (Sections 1.3.1 and 1.3.2). Thus, novel biochemical methods are required
not only to complement and support NGS findings, but also to further the understanding of the
pathogenesis of novel disorders and the genotype-phenotype relationships that often complicate
the treatment of patients with IEM. It is the development and application of such novel techniques,
alongside the utilisation of next-generation sequencing technologies that will form the basis of
my thesis.
1.5 aims of this thesis
The overarching aim of this thesis is to determine the cellular and molecular aetiologies for
the clinical phenotypes observed in patients with undiagnosed neurometabolic disorders. This
includes:
1. Developing and validating a targeted gene panel sequencing approach incorporating all
genes known to cause inborn errors of metabolism to improve the diagnosis of these patients
in clinical practice.
2. Using whole exome sequencing for the diagnosis of patients in which extensive genetic and
biochemical testing has not identified a diagnosis.
3. Examining the heterogeneity of response to vitamin B6 supplementation in patients with
pyridox(am)ine 5’-phosphate oxidase deficiency in order to optimise treatment.
4. Utilising functional assays to characterise a novel inborn error of vitamin B6 metabolism.
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MATERIALS AND METHODS
2.1 materials
The following were purchased from Sigma Alrich (Poole, UK):
2-oxobutyrate, 2-oxoglutarate, acetic acid, acetonitrile, adenosine triphosphate (ATP), amido-
sulphobetanine-14 (ASB-14), ammonium acetate, ammonium bicarbonate, ampicillin, bacteri-
ological agar, betaine, β-mercaptoethanol, borate buffer, calcium acetate, catalase, D-amino
acid oxidase from porcine kidney, dimethyl sulphoxide (DMSO), dithioerythritol, D-lysine, flavin
adenine dinucleotide, flavin mononucleotide (FMN), fluorenylmethyloxycarbonyl chloride (FMOC-
Cl), formic acid, glycerol, heptafluorobutyric acid, hydrogen peroxide, iodoacetamide, kanamycin,
kynurenic acid, kynurenic acid D5 [>98% atom %D], kynurenine, L-lysine, magnesium chloride
(MgCl2), methanol, Miller LB broth, mouse β-actin primary antibody, napthol AS-BI phosphate,
ninhydrin, Nuclear Fast Red, o-aminobenzaldehyde, oxaloacetate, pararosaniline hydrochloride,
perchloric acid, poly-D-lysine, potassium phosphate buffer, PROSC primary antibody, pyri-
doxal (PL), pyridoxal methyl D3 hydrochloride [>98% atom %D], pyridoxal 5’-phosphate (PLP),
pyridoxamine (PM), pyridoxamine methyl D3 hydrochloride [>98% atom %D], pyridoxic acid
(PA), pyridoxine (PN), pyridoxine 5’-phosphate (PNP), pyrophosphate buffer, pyruvate, Rainbow
Marker, sheep serum, skim milk powder, sodium acetate, sodium hydroxide, sodium nitrate,
sodium phosphate, thiourea, trichloroacetic acid, trifluoroacetic acid, Tris-HCl buffer, Triton
X-100, urea.
The following were purchased from Thermo Fisher (Loughborough, UK):
1-Step Human Coupled IVT Kit (containing HeLa cell lysate, accessory proteins, reaction mix,
nuclease-free water), CyroTube Vials, MicroAmp Fast Optical 96-well Reaction Plates, Alexa Fluor
610 secondary antibody, non-DEPC-treated nuclease-free water, Novex ECL Chemiluminescent
Substrate Reagent Kit, NuPAGE Antioxidant, NuPAGE LDS Buffer, NuPAGE MOPS SDS
Running Buffer, NuPAGE Novex 4-12% Bis-Tris Protein Gels, NuPAGE Sample Reducing
Agent, Pierce BCA Protein Assay Kit, Pierce Bovine Serum Albumin Standard (Pre-diluted
Set), protease inhibitor cocktail, pT7CFE1 vector, Qubit dsDNA Broad Range (BR) Assay Kit,
Qubit dsDNA High Sensitivity (HS) Assay Kit, RIPA buffer, RNase H, RNase-free water (dH2O),
sequencing primers, SuperScript III First-Strand Synthesis System for RT-PCR, TaqMan Gene
Expression Assay, TaqMan Gene Expression Master Mix, Tempus Blood RNA Tube, Tempus
Spin RNA Isolation Kit.
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The following were purchased from VWR (Lutterworth, UK):
Acetone, dimethylformamide, ethanol, hydrochloric acid, isopropanol, Oil Red O, paraformalde-
hyde, sterile glass coverslips, Sudan Black, Superfrost Plus Micro Slides.
The following were purchased from Invitrogen (Carlsbad, CA):
1 kilobase pair ladder, 100 base pair ladder, orange loading dye, SOC Medium, TOP10
chemically competent cells, TOPO TA Cloning Kit (containing TOPO vector, salt solution),
Tris-Borate-EDTA (TBE) buffer, UltraPure agarose.
The following were purchased from New England Biolabs (Ipswich, MA):
ApaI, Buffer 4, calf intestinal phosphatase, EcoRI, EcoRI buffer, Exonuclease I, NdeI, Phusion
High-Fidelity DNA polymerase kit (containing Phusion GC buffer, dNTPs, DMSO, Phusion
DNA polymerase), SAP dilution buffer, shrimp alkaline phosphatase (SAP), T4 DNA ligase, T4
DNA ligase buffer.
The following were purchased from Agilent Technologies (Cedar Creek, TX):
Agilent High Sensitivity DNA Assay, Agilent SureSelect v4 (51Mb) kit, Custom HaloPlex
Target Enrichment Kit, DpnI, Herculase II Fusion DNA Polymerase Kit (including Herculase II
reaction buffer, dNTPs, primer 1 and 2, Herculase DNA polymerase), PfuUltra High-Fidelity
DNA polymerase, QuikChange II XL Site-Directed Mutagenesis Kit (containing reaction buffer,
dNTP mix, QuikSolution), TBST buffer, XL-1 Blue competent cells.
The following were purchased from Illumina (San Diego, CA):
HiSeq cartridge, Hybidization buffer (HT1), MiSeq cartridge, MiSeq v2 Reagent (300 cycles)
Kit, PhiX virus library, Rapid SBS (3 x 50 cycle) Kit, Tris-HCl (pH 8.5) [0.1% Tween 20].
The following were purchased from Life Technologies (Paisley, UK):
Dulbecco’s phosphate buffered saline (PBS), fetal bovine serum (FBS), HAMS F-10 media,
penicillin, streptomycin, trypsin-EDTA.
The following were purchased from Agar Scientific (Stansted, UK):
Agar 100 Resin, alcoholic uranyl acetate, benzyldimethylamine, cacodylate buffer, copper
grids, dodecenyl succinic anhydride, glutaraldehyde, methyl nadic andydride, osmium tetroxide,
propylene oxide, Reynold’s lead citrate.
The following were purchased from Qiagen (Hilden, Germany):
DNeasy Blood & Tissue Kit, DNeasy mini spin columns, QIAprep Spin Miniprep Kit, QIAquik
Gel Extraction Kit, QIAshredder spin columns, Rnase A, RNeasy Mini Kit.
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The following were purchased from Leica Biosystems (Newcastle, UK):
Bond Epitope Retrieval Solution 2, Bond primary antibody diluent, Bond Wash Solution,
Eosin, Harris haematoxylin, Mayers haematoxylin, Mixed DAB Refine Solution, Post Primary
Solution.
The following were purchased from Promega (Madison, WI):
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) in 2% N, N-dimethyl formamide,
Mass Spectrometry Grade Trypsin Gold, Tris-EDTA (TE) buffer.
The following were purchased from Waters (Manchester, UK):
[glu1]-fibrinopeptide B, enolase peptides standard, TruView LCMS Certified, Total Recovery
Vials.
The following were purchased from Bioline (London, UK):
BIOTAQ DNA polymerase kit (including PCR reaction buffer, MgCl2, Taq DNA polymerase),
dNTP mixture.
The following were purchased from Applied Biosystems (Waltham, MA):
Big Dye sequencing buffer, Big Dye Terminator version 1.1.
The following were purchased from Bio-Rad (Hemel Hempstead, UK):
Dual-chambered cell couting slides, trypan blue.
C18 solid phase extraction columns were purchased from Biotage (Ystrad Mynach, UK),
formaldehyde was purchased from Acquascience (Uckfield, UK), propylene glycol was purchased
from Amresco (Solon, OH), Luxol Fast Blue Stain Kit was purchased from Atom Scientific
(Hyde, UK), Vectashield aqueous mounting medium was purchased from Vector Laboratories
(Peterborough, UK), AMPure XP beads were purchased from Beckman Coulter (High Wycombe,
UK), donkey anti-rabbit IgG-HRP was purchased from Santa Cruz Biotechnology (Heidelberg,
Germany), goat anti-mouse IgG-HRP was purchased from DAKO (Ely, UK), LAMP-2 anti-
body was purchased from Abcam (Cambridge, UK), p62 antibody was purchased from BD
Biosciences (Oxford, UK). Pyridoxine D2 hydrochloride (5-hydroxymethyl-D2) [>98% atom %D]
and α-aminoadipic acid D2 [>98% atom %D] were purchased from CDN Isotopes (Thaxted,
UK), 4-pyridoxic acid D2 [>98% atom %D] was purchased from Buchem BV (Apeldoorn, The
Netherlands), DL-proline D7 [>98% atom %D] was purchased from CK Isotopes (Leicester, UK).
Pyridoxal 5’-phosphate D2 was kindly supplied as a gift by Professor Coburn, Department of
Chemistry, Indiana University, Purdue University, Forte Wayne.
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2.2 ethics statement
All patient-derived samples were obtained following the approval of the study (REC Ref.
13/LO/0168) by the ethics committee of Great Ormond Street Hospital for Children (GOSH),
London, UK.
2.3 dna extraction and sanger sequencing
2.3.0.1 Automated DNA extraction
Genomic DNA was extracted from EDTA blood using an AutoGenFlex STAR automated system
(AutoGen, Holliston, MA) according to the manufacturer’s protocol at the NE Thames Regional
Genetics Service Laboratories, GOSH, London.
2.3.0.2 Manual DNA extraction
Genomic DNA was extracted from EDTA blood using the DNeasy Blood & Tissue Kit as
described by the manufacturer. 20 µL of proteinase K, 100 µL of blood and 100 µL of phosphate
buffered saline (PBS) were mixed. 4 µL of RNase A (100 mg/ml) was added and incubated for
2 minutes at room temperature to remove contaminating RNA. 200 µL of Buffer AL was then
added and samples were immediately vortexed and incubated at 56◦C for 10 minutes. 200 µL of
100% ethanol was added and mixed to yield a homogeneous solution. The mixture was transferred
to a DNeasy mini spin column, centrifuged at 6000 x g for 1 minute and the flow-through was
discarded. 500 µL of Buffer AW1 was then added, centrifuged at 6000 x g for 1 minute and
the flow-through was discarded. 500 µL of Buffer AW2 was added and centrifuged at 20,000 x
g for 3 minutes to dry the DNeasy membrane as any residual ethanol can inhibit downstream
reactions. The flow-through and collection tube was discarded. Columns were placed in clean
microcentrifuge tubes and 200 µL of Buffer AE was applied directly to the column membrane.
Columns were incubated at room temperature for 1 minute and centrifuged at 6000 x g for 1
minute to elute the DNA. DNA samples were stored long-term at -20◦C.
2.3.1 Primer design
In order to design intronic primers for amplification of patient DNA by Polymerase Chain
Reaction (PCR), genomic sequences of the gene of interest annotated with all known variants
were downloaded from Ensembl (www.ensembl.org) and the region of interest (usually one or
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more exons) and approximately 200 bp of flanking sequence was imported into Primer3 version
4.0.0 (www.primer3.ut.ee). Primers were picked using default settings. These included selecting
primers between 18-23 bp in length, a G/C content between 30% - 70% and a predicted melting
temperature (Tm) between 57 and 62◦C. Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-
blast) was subsequently used to ensure that primers were specific for the gene of interest by
comparing the chosen sequences to the human genome. Primers were redesigned if both forward
and reverse primers were complementary not only to the region of interest, but also additional
regions.
In the case of cDNA or plasmid sequencing, primers were designed in the same way as above
with the exception that primers were designed to “walk” across the length of the sequence by
generating overlapping PCR products to enable complete target coverage. All primer sequences
and PCR conditions are detailed in the Appendices.
2.3.2 Amplification of target genes from genomic DNA using Polymerase Chain Reaction (PCR)
2.3.2.1 PCR conditions
Typical PCR reactions were carried out in a total volume of 25 µL using the conditions outlined
in Table 2.3.1. When non-specific amplification was present, the volume of nuclease-free water
could be reduced and PCR enhancing agents were added, alongside the optimisation of other
reaction parameters (see Section 2.3.2.2). Negative controls were prepared for each reaction
containing nuclease-free water instead of genomic DNA to check for any contamination. All
samples were prepared and kept on ice until amplification.
Table 2.3.1: Typical PCR reaction mix.
Reagent Volume (µL)
Nuclease-free water 15.55
10X PCR reaction buffer 2.5
MgCl2 (25 mM) 0.75
dNTP mixture (10 mM) 2.5
Forward primer (10 µM) 1.25
Reverse primer (10 µM) 1.25
Taq DNA polymerase (5 U/µL) 0.2
Genomic DNA (100 ng) 1
Amplification was carried out using a Veriti 96-well Thermal Cycler (Thermo Fisher, Lough-
borough, UK). Typical cycling conditions are outlined in Table 2.3.2.
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Table 2.3.2: Typical PCR cycling conditions. Amplification occurs in three stages: denat-
uration of the double-stranded DNA, annealing of primers to the complementary
DNA at a variable temperature and extension of the DNA template copy by the
5’ → 3’ activity of Taq DNA polymerase. Tm; melting temperature (details of
optimised Tm for each set of primers are detailed in the Appendices).
Step Conditions
1 96◦C for 5 mins
2 96◦C for 30 secs
3 Tm ◦C for 30 secs
4 72◦C for 30 secs
5 Repeat steps 2-4 34 times for a total of 35 cycles
6 72◦C for 10 mins
2.3.2.2 Visualisation of PCR products by agarose gel electrophoresis
PCR products were analysed by agarose gel electrophoresis to determine both the specificity of
amplification and the size of the products. Gels were prepared at different percentages depending
on the requirements of downstream applications. Typically 1% (w/v) agarose gels were prepared
using 1 g of UltraPure Agarose in 100 mL of 1X Tris-Borate-EDTA (TBE) buffer [containing 45
mM of Tris-HCL, 45 mM of boric acid and 10 mM of EDTA (pH 8.0)]. The gel was poured into
a tray containing a comb and allowed to set at room temperature for 30 minutes. The gel was
then placed into an electrophoresis tank containing 1X TBE buffer.
Differing amounts of PCR products were loaded into the agarose gel wells depending on
the initial DNA concentration, PCR conditions and requirements of downstream applications.
Typically, 5 µL of PCR product was mixed with 3 µL of orange loading dye and loaded into
the agarose gel wells. 5 µL of 100 base pair or 1 kilobase pair ladder (1 µg/µL) was loaded
into the first lane in order to estimate PCR product size. Electrophoresis was typically carried
out at 95 V for between 30-60 minutes depending on the size of the PCR product. Bands were
visualised using a ChemiDoc MP System (Bio-Rad, Hemel Hempstead, UK) coupled to Image
Lab Software. If, after analysis, a distinct band was not produced then the reaction conditions
were varied to optimise the PCR reaction. This included changing the annealing temperature,
MgCl2 concentration and the addition of 1.25 µL of 100% dimethyl sulphoxide (DMSO) and/or
2.5 µL of 5 M betaine.
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2.3.3 Sanger sequencing
2.3.3.1 Purification of PCR products using ExoSAP
10 µL of PCR product was added to 0.75 µL of dH2O, 0.5 µL of exonuclease I, 1 µL of shrimp
alkaline phosphatase (SAP) and 0.25 µL of SAP dilution buffer. Reactions were mixed then
incubated at 37◦C for 15 minutes followed by 80◦C for 15 minutes in a Veriti 96-well Thermal
Cycler (Thermo Fisher). Samples were stored on ice until Sanger sequencing.
2.3.3.2 Sanger sequencing
3 µL of PCR product that had been cleaned according to the protocol above was added to with
0.5 µL of Big Dye Terminator version 1.1, 1.5 µL of 5X Sequencing Buffer, 4 µL dH2O and 1 µL
(5 pmol/µL) of forward or reverse primer. Each reaction was then cycled using the parameters
outlined in Table 2.3.3.
Table 2.3.3: Sanger sequencing thermal cycling parameters.
Step Conditions
1 95◦C for 2 mins
2 95◦C for 20 secs
3 50◦C for 10 secs
4 60◦C for 3 minutes
5 Repeat steps 2-4 34 times for a total of 35 cycles
2.3.3.3 DNA precipitation
2 µL of 3 M sodium acetate and 50 µL of 100% ethanol was added to each sequencing product and
incubated for 20 minutes at room temperature after vortexing. Samples were then centrifuged
at 12,000 x g for 40 minutes and the supernatant was discarded. An additional 50 µL of 70%
ethanol was added to wash the DNA, samples were centrifuged at 12,000 x g for 10 minutes
and the supernatant was discarded. Finally, the samples were centrifuged at 1000 x g upside
down for 1 minute to remove residual ethanol. DNA was resuspended in 0.1X Tris-EDTA buffer
and sequenced on an ABI DNA Sequencer (Life Technologies, Paisley, UK) at the NE Thames
Regional Genetics Service Laboratories, GOSH, London. Sequence data was analysed using
Sequencher 4.10.1 software (Gene Codes, Ann Arbor, MI) and compared to reference sequences
downloaded from Ensembl (www.ensembl.org).
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2.4 gene panel sequencing
2.4.1 Qubit quantitation
DNA was extracted as described in Section 2.3. DNA concentration was quantified prior to
target capture using the Qubit dsDNA Broad Range (BR) Assay Kit according to manufacturer’s
instructions. Samples were quantified by mixing 2 µL of DNA and 198 µL of master mix
[containing 1 µL of BR reagent and 199 µL of BR buffer per sample] and incubated for two
minutes at room temperature. DNA concentration was then calculated using a Qubit 2.0
fluorometer (Thermo Fisher) and samples were diluted to a final concentration of 5 ng/µL with
non-DEPC-treated nuclease-free water to a final volume of 45 µL.
2.4.2 Target capture
Library construction and capture hybridisation was performed using a Custom HaloPlex Target
Enrichment Kit according to the manufacturer’s protocol. DNA was processed in batches of 12
samples including one Enrichment Control DNA (ECD) sample to enable assessment of sample
processing quality at two time points during the protocol. The 11 pre-diluted genomic DNA
samples and 45 µL of ECD were digested in 8 different reactions by 16 restriction enzymes.
Restriction enzyme master mixes were assembled in 0.2 mL 8-well strip tubes (Figure 2.4.1a). 476
µL of restriction enzyme buffer and 11.9 µL of bovine serum albumin solution were mixed and 56
µL of mixture was aliquoted into each well of an 8-well tube. 7 µL of the appropriate restriction
enzymes from both the Green and Red Enzyme Strips were added to the master mixes (Figure
2.4.1a). The solutions were kept on ice throughout handling and mixed by gentle vortexing. 5 µL
of restriction enzyme master mix was aliquoted row-wise into each well of a 96-well plate (Figure
2.4.1b). 5 µL of each genomic DNA sample was then aliquoted column-wise into each well of
the 96-well plate (Figure 2.4.1c). The plate was sealed with adhesive plastic film, vortexed and
briefly centrifuged. Each column then corresponds to one DNA sample digested in eight different
restriction reactions.
The restriction digest plate was then placed in a thermal cycler and incubated at 37◦C for
30 minutes followed by a low-temperature hold step at 8◦C until restriction digestion validation
could be carried out.
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Figure 2.4.1: HaloPlex restriction enzyme digestion. A) Preparation of the restriction
enzyme master mix strip for the 12-sample run. B) Aliquoting the restriction
enzyme master mixes into the rows of a 96-well plate. Each row thus contains 5
µL per well of the same restriction enzyme combination. C) Aliquoting 5 µL of
the 11 genomic DNA samples and the ECD sample column-wise into each well of
the reaction plate.
2.4.3 Restriction digestion validation
Correct restriction enzyme digestion of the DNA was assessed using the Agilent High Sensitivity
DNA Assay according to manufacturer’s instructions. 4 µL of each of the eight Enrichment
Control DNA (ECD) digestion reactions (Section 2.4.2) were transferred to 0.2 mL PCR tubes
and incubated at 80◦C for 5 minutes in a thermal cycler to inactivate the restriction enzymes.
The eight digested ECD samples were processed and loaded onto a microfluidic chip (Agilent
Technologies) and analysed within five minutes using an Agilent 2100 Bioanalyzer (Agilent
Technologies) according to manufacturer’s instructions. The ECD sample contains genomic DNA
mixed with an 800 bp PCR product containing restriction sites for all the enzymes used in the
digestion protocol. The presence of three prominent fragments (125 bp, 225 bp and 450 bp)
over a smear of restriction DNA fragments between 100 and 2500 bp indicated correct sample
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digestion. The undigested control showed genomic DNA bands larger that 2.5 kbp in size and a
PCR product of 800 bp.
2.4.4 Target enrichment and sample indexing
Upon validation of correct restriction enzyme digestion, genomic DNA fragments were hybridised
to the custom HaloPlex probe capture library. A hybridisation master mix was prepared by
combining 650 µL of hybridisation solution and 260 µL of HaloPlex probes. 70 µL of master mix
was then aliquoted into 12 0.2 mL PCR tubes. 10 µL of one specific indexing primer cassette
was added to each tube containing master mix, using different indexes for each sample to be
multiplexed. The identity of each Indexing Primer Cassette was noted for later sequence analysis.
All 8 digestion reactions for each DNA sample were transferred to the appropriate hybridisation
reaction tube and gently mixed to ensure inactivation of the enzymes. For the ECD sample, 32
µL of non-DEPC-treated nuclease-free water was also added in addition to the digested DNA
samples to compensate for the volume removed for digest validation. The hybridisation reaction
tubes were then incubated in a thermal cycler at 95◦C for 10 minutes followed by 54◦C for 16
hours overnight.
2.4.5 Target DNA capture, ligation and elution
Following target enrichment, the circularised target DNA-HaloPlex probe hybrids containing
biotin, were captured using streptavidin beads. 520 µL of HaloPlex magnetic bead solution was
transferred to a microcentrifuge tube and placed in a DynaMag-2 Magnet (Thermo Fisher) for 5
minutes. After the solution had cleared the supernatant was removed and 520 µL of capture
solution was added to resuspend the beads. The hybridisation reactions were then removed
from the thermal cycler and 40 µL of bead suspension was added to each reaction. The capture
reactions were mixed thoroughly by pipetting up and down 15 times before incubating at room
temperature for 15 minutes. Tubes were then transferred to an Agencourt SPRIPlate Super
Magnet magnetic plate (Beckman Coulter, High Wycombe, UK) and the supernatant was allowed
to clear for 30 seconds. The supernatant was removed, 100 µL of Wash Solution was added
and the beads were resuspended by pipetting up and down 10 times. The tubes were then
incubated at 46◦C for 10 minutes in a thermal cycler and transferred again to the Agencourt
SPRIPlate Super Magnet magnetic plate. The solution was allowed to clear and the supernatant
was carefully discarded, taking care to remove any residual liquid.
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Once the DNA had been captured, nicks in the circularised target DNA-HaloPlex probe
hybrids were closed using DNA ligase. A DNA ligase master mix was prepared by adding 617.5
µL of ligation solution to 32.5 µL of DNA ligase. 50 µL of this master mix was then added
to the beads in each DNA capture reaction tube. The beads were thoroughly resuspended by
pipetting the mixture up and down 15 times. Subsequently the mixes were incubated at 55◦C
for 10 minutes in a thermal cycler. The tubes were then transferred to the magnetic plate, the
solution was allowed to clear and the supernatant was carefully discarded. 100 µL of SSC Buffer
was added to each tube and the beads were resuspended by pipetting up and down 10 times.
The tubes were then returned to the Agencourt SPRIPlate Super Magnet magnetic plate, the
solution was allowed to clear and the SSC Buffer was removed, making sure that no residual
liquid remained. The beads were then resuspended in 25 µL of freshly prepared 50 mM sodium
hydroxide and incubated at room temperature for 1 minute to elute the captured DNA.
2.4.6 PCR amplification of target libraries
Following DNA elution, the tubes were transferred to the Agencourt SPRIPlate Super Magnet
magnetic plate and 20 µL of cleared supernatant from each tube was added to a PCR master
mix tube (Table 2.4.1) kept on ice. The reactions were mixed by gentle vortexing and amplified
using the cycling conditions outlined in Table 2.4.2.
Table 2.4.1: PCR reaction mix for amplification of HaloPlex target libraries. A
Herculase II Fusion DNA Polymerase Kit (containing 100 mM dNTPs) was used
for amplification.
Reagent Volume (µL)
Nuclease-free water 16.1
5X Herculase II Reaction Buffer 10
dNTPs (25 mM each) 0.4
Primer 1 (25 µM) 1
Primer 2 (25 µM) 1
2 M acetic acid 0.5
Herculase II Fusion DNA Polymerase 1
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Table 2.4.2: HaloPlex PCR cycling conditions.
Step Conditions
1 98◦C for 2 mins
2 98◦C for 30 secs
3 60◦C for 30 secs
4 72◦C for 1 min
5 Repeat steps 2-4 16 times for a total of 17 cycles
6 72◦C for 10 mins
7 8◦C hold until purification step
2.4.7 Purification of target libraries
In this step, the amplified target DNA were purified using AMPure XP beads that have been
allowed to come to room temperature for at least 30 minutes. 40 µL of each PCR reaction
was transferred to a fresh 0.2 mL tube and the remaining volume was stored at -20◦C for
troubleshooting. The AMPure XP bead suspension was mixed well until the suspension appeared
homogeneous. 100 µL of AMPure XP bead suspension and 40 µL of nuclease-free water was
added to each 40 µL of PCR reaction and vortexed thoroughly. The samples were then incubated
at room temperature for 5 minutes with shaking, then placed in the Agencourt SPRIPlate Super
Magnet magnetic plate for 5 minutes to allow the solution to clear. The cleared solution was
removed and discarded, taking care to avoid touching the beads. Keeping the tubes in the
Agencourt SPRIPlate Super Magnet magnetic plate, 200 µL of 70% ethanol was added and
any disturbed beads were allowed to settle for 30 seconds. The ethanol was then removed and
an additional ethanol wash was performed. The tubes were air-dried with open lids at room
temperature until the residual ethanol completely evaporated. The beads were resuspended in
40 µL of 10 mM Tris-HCl buffer (pH 8.0) and incubated at room temperature for 2 minutes to
elute the DNA. The tubes were transferred to the Agencourt SPRIPlate Super Magnet magnetic
plate for a final time and the solution was allowed to clear for 2 minutes. Finally, the cleared
supernatant (approximately 40 µL) was transferred to a fresh tube and the beads were discarded.
2.4.8 Validation of DNA enrichment
Prior to sample pooling and sequencing, sample enrichment was validated using the Agilent
High Sensitivity DNA Assay on the Agilent 2100 Bioanalyzer platform. Analysis was performed
according to the manufacturer’s instructions using 1 µL of each enriched sample library. Each
amplicon of the libraries contains one target insert between 50-500 bp surrounded by 125 bp
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of sequence motifs required for multiplexed sequencing using the Illumina platform. Therefore,
microfluidic analysis showing amplicons ranging from 175-625 bp indicated correct library
preparation. Smear analysis of amplicons in the range of 175-625 bp was used to determine the
mean size of each library. DNA concentration was then quantified using the Qubit dsDNA High
Sensitivity (HS) Assay Kit according to manufacturer’s instructions.
2.4.9 Library preparation for sequencing
Each library to be sequenced was diluted in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0) to a
final concentration of 10 nM. The libraries were then pooled equally and the library mix was
diluted to a concentration of 2 nM with TE buffer. The pooled libraries were re-quantified using
the Qubit dsDNA HS Assay Kit (Section 2.4.1) and the concentration was adjusted to 2 nM.
10 µL of freshly prepared 0.2 N sodium hydroxide was then mixed with 10 µL of 2 nM pooled
library DNA before being incubated at room temperature for 5 minutes to denature the DNA.
The denatured DNA was subsequently diluted to 20 pM by the addition of 980 µL of pre-chilled
Hybridization Buffer (HT1). Finally, 400 µL of 20 pM denatured DNA library was mixed with
600 µL of pre-chilled HT1, inverted several times to mix and the resulting 8 pM solution was
kept on ice.
The internal sequencing control was prepared by mixing 2 µL of 10 nM PhiX virus library,
8 µL of 10 mM Tris-HCl, pH 8.5 containing 0.1% Tween 20 and 10 µL of freshly prepared 0.2
N sodium hydroxide. The solution was vortexed briefly and incubated at room temperature
for 5 minutes to denature the DNA. The solution was then diluted to 8 pM as described above.
Finally, 10 µL of 8 pM PhiX control was mixed with 990 µL of 8 pM denatured sample libraries
and kept on ice until the samples were loaded onto the MiSeq or HiSeq cartridge.
2.4.10 Next-generation sequencing
Next-generation sequencing was performed on either the Illumina MiSeq or HiSeq 2500 platform
(Illumina, San Diego, CA) according to manufacturer’s instructions. In the case of the MiSeq
platform, sequencing was performed using the reagents provided in the MiSeq v2 Reagent (300
cycles) Kit using 2 x 150 bp paired-end chemistry. In the case of the HiSeq 2500 platform,
sequencing was performed using the reagents provided in the Rapid SBS (3 x 50 cycle) Kit in
rapid run mode using 2 x 150 bp paired-end chemistry.
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2.4.11 Data analysis
Sequencing reads were imported from FASTQ files and HaloPlex adaptors were trimmed using
Cutadapt version 1.3 (Martin, 2011). Reads were aligned to the hg19 reference genome using
the Burrows-Wheeler Alignment (BWA) (Li and Durbin, 2009) with default settings. Variants
were then called using VarScan version 2.3 (Koboldt et al., 2012) within our genomic regions of
interest (coding exons plus 14bp of upstream and 6bp of downstream sequence) using a BED file
generated using the UCSC Table Browser (Karolchik et al., 2004). Variants were called according
to a minimum of 30X coverage with five alternate reads, a Phred base quality of 20, and without
strand bias. Copy number variants on the processed BAM files were called using an in-house
read depth pipeline. Results were exported in VCF format for downstream analysis.
Variants were annotated based on Ensembl gene transcripts. Variants listed in the Ensembl
(African, American or European population frequencies) (www.ensembl.org) or 1000 genomes
database (www.browser.1000genomes.org/index.html) with a minor allele frequency of greater
than 2% were filtered out. Prioritisation of the remaining variants was carried out based on the
following criteria: selection of candidate genes based on patient’s phenotype, predicted effect on
gene function, conservation of amino acid position, and frequency of the variant in the publicly
available databases. Selection of candidate genes based on patient’s phenotype was carried
out using Phenomizer (www.compbio.charite.de/phenomizer/), a resource based on the Human
Phenotype Ontology, filtering by disease class or through manual literature searching. Details of
other criteria used to prioritise non-synonymous variants can be found in Section 2.6.
2.5 whole exome sequencing (wes)
Whole exome sequencing (WES) was performed in generous collaboration with GOSgene at The
Centre for Translational Genomics, UCL Institute of Child Health, London.
Whole exome sequencing was outsourced to BGI Genomics Hong Kong (www.genomics.cn).
DNA was captured using the Agilent SureSelect v4 (51Mb) kit followed by sequencing using the
Illumina HiSeq 2000 platform (Illumina, San Diego, CA). Three samples were mutliplexed per
flowcell lane using 2 x 150bp paired-end chemistry to give an overall coverage of 100 times.
Processing of raw data files was carried out by Dr Chela James at GOSgene. Sequencing reads
were processed using the Genome Analysis Toolkit (GATK) (McKenna et al., 2010) recommended
best practice of alignment to the reference human genome (human_g1k_v37) using the Burrows-
Wheeler Aligner (Li and Durbin, 2009) with default settings. The alignment was then refined
using Picard tools, GATK data processing tools, base quality score recalibration and indel
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realignment. Single nucleotide polymorphism and insertion/deletion discovery and genotyping
was performed using the GATK variant discovery pipeline including variant calling using Unified
Genotyper followed by variant quality score recalibration (DePristo et al., 2011). The resultant
VCF files were filtered using Ingenuity Variant Analysis software (Ingenuity, Redwood City,
CA) using differing parameters depending on the patient/family being investigated. Following
this filtering the remaining variants were individually assessed to ensure they were not located
within a segmental duplication, and finally BAM files were inspected using Integrative Genomics
Viewer (IGV) software (Robinson et al., 2011) to confirm the quality of the call. Non-synonymous
variants were also prioritised and further investigation using the tools detailed in Section 2.6.
2.6 biological interpretation using bioinformatics tools
When a potentially pathogenic variant was identified, sequence conservation was assessed by
importing the protein sequence of the mutated gene in a range of species into Clustal Omega
(www.ebi.ac.uk/Tools/msa/clustalo). Where possible, species were chosen that represented a
large distance in evolutionary time such as Escherichia coli and/or Saccharomyces cerevisiae.
Sequences were aligned using default settings.
In the case of amino acid substitutions, the effect on protein function was predicted using online
tools such as SIFT (www.sift.bii.a-star.edu.sg/) and PolyPhen-2 (www.genetics.bwh.harvard.edu/
pph2/). SIFT and PolyPhen-2 scores were determined for potentially pathogenic variants either
through Ensembl (www.ensembl.org/) or direct input to the prediction tools.
In order to assess the frequency at which potentially pathogenic variants are present in the gen-
eral population, multiple databases containing variant population statistics were searched including
Ensembl (www.ensembl.org/), Exome Aggregation Consortium (www.exac.broadinstitute.org/)
and 1000 Genomes (www.1000genomes.org/). If the minor allele of a variant was present at a
frequency greater than 2%, especially in the ethnic sub-population of the affected patient, it was
discarded.
2.7 cell culture
2.7.1 Fibroblast cell culture conditions
Fibroblasts were cultured in sterile 75 cm2 flasks at 37◦C in 5% CO2 in 8 mL HAMS F-10
media supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin
(100 µg/ml). Once cells were between 70 - 90% confluent the media was removed. Cells were
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washed with 8 mL of Dulbecco’s phosphate buffered saline (PBS) and detached using 3 mL 0.25%
trypsin-EDTA for one minute. Trypsin was inactivated by addition of 13 mL of media and the
resulting 16 mL of cell suspension was split equally between two 75 cm2 flasks.
To harvest cells, the media was removed once cells were confluent and cells were trypsinised
as above. Trypsin was inactivated by addition of 10 mL of media and then transferred to a 15
mL falcon tube. Cells were pelleted at 4500 x g for 5 minutes, the supernatant was removed
and the cells were thoroughly washed and pelleted twice with 3 mL PBS. The remaining pellet
was stored in 10 µL of PBS at -80◦C to prevent degradation of proteins and metabolites before
experimental use.
2.7.2 Counting cells
10 µL of cell suspension (Section 2.7.1) was mixed with 10 µL of 0.4% trypan blue in 0.81%
sodium chloride and 0.06% potassium phosphate dibasic solution. 10 µL of mixture was loaded
into dual-chambered slides and counted using a TC10 Automated Cell Counter. Cells were then
diluted to the desired concentration in media, prior to harvesting or seeding (Section 2.7.1).
2.7.3 Fibroblast cell storage
Cells were harvested as above (Section 2.7.1) and the resulting pellet was resuspended in 900 µL
of media. The cell suspension was added to 100 µL of 100% dimethyl sulphoxide in a CryoTube
Vial and stored in a Mr. Frosty Freezing Container (Thermo Scientific) overnight. Vials were
subsequently stored long-term at -196◦C in liquid nitrogen.
2.7.4 Protein assay
Cellular protein concentration was determined using the Pierce BCA Protein Assay Kit according
to manufacturer’s instructions. BCA Working Reagent was prepared by mixing 50 parts of BCA
Reagent A with 1 part of BCA Reagent B. All standards and samples were assembled in 96-well
plates. 10 µL of each Pierce Bovine Serum Albumin Standard (Pre-Diluted Set) was added to
the first 10 wells of the 96-well plate. 5 µL of each cell lysate was diluted with 5 µL of dH2O
in the following wells. 200 µL of BCA working reagent was then added to each standard and
diluted cell lysate. The plate was mixed thoroughly on a plate shaker for 30 seconds before
the plate was covered and incubated at 37◦C for 30 minutes. The absorbance of each sample
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was then measured at 555 nm using a Tecan Infinite 200 Microplate Reader (Tecan, Mannedorf,
Switzerland).
The absorbance measurement of the blank standard was subtracted from all other standards
and samples. The corrected absorbance of each standard was plotted against the concentration
of each standard to yield a standard curve, from which the concentation of each lysate was
determined.
2.8 cdna analysis
2.8.1 Isolation and purification of total RNA from fibroblasts
Total RNA was purified from patient fibroblasts using the RNeasy Mini Kit. Fibroblasts were
harvested as described in Section 2.7.1 and had been stored in DNase and RNase free falcon tubes
at -80◦C. Cells were resuspended in the residual 10 µL of PBS that the pellets were stored in and
transferred to microcentrifuge tubes. Cells were then centrifuged for 5 minutes at 300 x g and the
supernatant was removed. 600 µL of Buffer RLT was added to disrupt the cells and lysates were
added to QIAshredder spin columns and centrifuged at 8000 x g for 2 minutes. 600 µL of 70%
ethanol was added to the resulting homogenised lysate and mixed well. Samples were transferred
to an RNeasy spin column, centrifuged for 15 seconds at 8000 x g and the flow-through was
discarded. Columns were washed by addition of 700 µL of Buffer RW1, centrifuging for 15 seconds
at 8000 x g and the flow-through was discarded. 500 µL of Buffer RPE was added, centrifuged for
2 minutes at 8000 x g and the flow-through was discarded. This latter centrifugation ensures that
no ethanol is carried over during RNA elution as residual ethanol may interfere with downstream
reactions. Spin columns were placed in clean microcentrifuge tubes and 50 µL of RNase-free
water was added to the spin column membrane prior to centrifugation for 1 minute at 8000 x g
to elute the RNA.
2.8.2 Isolation and purification of total RNA from blood
Total RNA was purified from whole blood using the Tempus Spin RNA Isolation Kit. 3 mL of
blood was drawn directly into a Tempus Blood RNA Tube and immediately vigorously shaken
for 10 seconds to ensure uniform contact with the Applied Biosystems Stabilizing Reagent. The
mixture was then transferred to a 50 mL sterile falcon tube and 3 mL of PBS was added. The
solution was then vortexed thoroughly for 30 seconds and centrifuged at 3,000 x g for 30 minutes
at 4◦C. After removing the supernatant, the pellet containing the RNA was resuspended in 400
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µL of RNA purification resuspension solution before being stored on ice. Each sample was then
purified using an RNA purification filter. The filters were primed initially by the addition of 100
µL of Wash Solution 1 followed by 400 µL of resuspended RNA. Samples were centrifuged at
16,000 x g for 30 seconds and the flowthrough was discarded. An additional 500 µL of Wash
Solution 1 was then added, before centrifuging at 16,000 x g for 30 seconds and discarding the
flowthrough. Samples were then washed with 500 µL of Wash Solution 2, centrifuged at 16,000
x g for 30 seconds and the flowthrough was discarded. This wash was then repeated. Samples
were centrifuged again for 30 seconds at 16,000 x g to dry the membrane. To elute the RNA, 100
µL of Elution Solution was added and samples were incubated at 70◦C for 2 minutes. Samples
were centrifuged at 16,000 x g for 30 seconds and the resulting solution was re-applied to the
filters before being centrifuged a second time for two minutes. Finally, 90 µL of RNA eluate was
transferred to a clean microcentrifuge tube, taking care not to disturb any pelleted particulates
from the column.
2.8.3 cDNA synthesis
cDNA synthesis was carried out using the SuperScript III First-Strand Synthesis System for
RT-PCR. 8 µL of RNA, 1 µL of 50 µM oligo[dT]20 and 1 µL of 10 mM dNTP mix were combined
and incubated at 65◦C for 5 minutes, then placed on ice for 1 minute. cDNA synthesis mix was
made up containing 2 µL of 10X RT buffer, 4 µL of 25 mM MgCl2, 2 µL of 0.1 M DTT, 1 µL of
RNaseOUT (40 U/µL) and 1 µL of SuperScript II RT (200 U/µL). 10 µL of cDNA synthesis mix
was added to each RNA/oligo[DT]20 mixture and incubated for 50 minutes at 50◦C. Reactions
were then terminated at 85◦C for 5 minutes and chilled on ice. 1 µL of RNase H was added and
reactions were incubated for 20 minutes at 37◦C. Resulting products containing RNA-free cDNA
were stored at -20◦C.
2.8.4 PCR conditions
The amplification of each whole cDNA sequence was carried out as described in (Table 2.8.1).
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Table 2.8.1: Primers and conditions used to amplify and sequence whole cDNA.
* 5% DMSO and 0.5 mM betaine were also added.
Gene Sequence 5’ → 3’ Tm
(◦C)
Polymerase MgCl2
(mM)
Product
size (bp)
NDUFS1 F CGAGGCCGCCATATTGAATA 58 Phusion 0 2537
NDUFS1 R TCGTCACAAAGGTTATCAATGCT
PROSC F GGGGATGTGGAGAGCTGG 56 Taq 1.5* 846
PROSC R CAGTATTCCCTGGCTCAGTG
2.9 quantitative polymerase chain reaction (qrt-pcr)
Total RNA was purified from patient and control fibroblasts using the RNeasy Mini Kit as
described in Section 2.8.1. The RNA concentration of each sample was determined using a
NanoDrop 1000 (Thermo Scientific) and the RNA was stored at -80◦C prior to cDNA synthesis.
RNA samples were diluted to a final concentration of 500 ng RNA in 8 µL of RNase-free water
before using the SuperScript III First-Strand Synthesis System to synthesise cDNA (Section
2.8.3).
Each qRT-PCR experiment was assembled in a MicroAmp Fast Optical 96-well Reaction Plate.
As much as possible, reagents and plates were kept in the dark as the fluorescent-labelled probes
are light-sensitive. Seven samples could be analysed in each assay; 4 µL of each patient’s cDNA
was aliquoted into each well of one row (12 wells). Three reaction master mixes were assembled
consisting of 10 µL of 2X TaqMan Gene Expression Master Mix, 5 µL of RNase-free water and 1
µL of 20X TaqMan Gene Expression Assay per well. For each gene to be analysed a different
TaqMan Gene Expression Assay was used: PROSC (Hs00200497_m1), β-actin (4333762T) and
GAPDH (hs02758991_g1). For each cDNA sample, the expression of the three genes was analysed
in four replicates. Thus, 16 µL of each master mix was added to four wells corresponding to each
sample. Finally, 16 µL of each master mix was added to one well containing 4 µL of RNase-free
water to act as a negative control. The plate was then sealed using adhesive film and centrifuged
briefly to collect the contents of each well.
Each qRT-PCR reaction was cycled using the Applied Biosystems StepOne Real-Time PCR
System using Standard Run Mode. Thermal cycling conditions were as follows: 50◦C for 2
minutes, 95◦C for 10 minutes, followed by 40 cycles of 95◦C for 15 seconds and 60◦C for 1 minute.
The instrument was operated in Comparative CT (∆∆CT ) mode using the same control sample
in each assay and both β-actin and GAPDH as endogenous controls. After all assays were run,
the threshold cycles (CT ) for each gene were averaged and all parameters were then re-analysed
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using these standardised thresholds. Relative quantitation was carried out using the comparative
CT method (2−∆∆CT method) according to Schmittgen and Livak (2008).
2.10 western blotting
Fibroblasts were cultured to confluence in 175 cm2 flasks before being trypsinised and pelleted
(Section 2.7.1). Cell pellets were washed three times with 3 mL of PBS and kept on ice until
lysis. Cells were lysed through addition of 200 µL of lysis buffer [containing 40 µL of 5X RIPA
buffer and 2 µL 100X protease inhibitor cocktail] and pipetted up and down to resuspend the
pellet. Samples were incubated on ice for 10 minutes, centrifuged at 8600 x g for 5 minutes
and the supernatant was collected. Protein concentration was determined using the Pierce BCA
Protein Assay Kit (Section 2.7.4). Lysates were diluted in lysis buffer to yield 20 µg of protein
in a final volume of 20 µL. To each diluted cell lysate, 5 µL of NuPAGE LDS Buffer and 2 µL
of NuPAGE Sample Reducing Agent were added. Samples were mixed, heated at 90◦C for 10
minutes and immediately returned to ice. Electrophoresis was carried out using a NuPAGE
Novex 4-12% Bis-Tris Protein Gel. Gel wells were washed with 1X NuPAGE MOPS SDS Running
Buffer to displace air bubbles and gel cassettes were assembled in an XCell SureLock Mini-Cell
Electrophoresis System (Thermo Fisher). The Upper Buffer Chamber was filled with 200 mL
of 1X NuPAGE MOPS SDS Running Buffer and 0.5 mL of NuPAGE Antioxidant. 10 µL of
Rainbow Marker was loaded into the first well and samples were loaded into each of the following
wells. The Lower Buffer Chamber was filled with 600 mL of 1X NuPAGE MOPS SDS Running
Buffer and electrophoresis was carried out at a constant voltage of 180 V for 1 hour. The gel
was removed from the cassette and the bottom foot and top fringes of the gel were removed
using a clean scalpel. Gel transfer was carried out using an iBlot Dry Blotting System (Thermo
Fisher) using the P3 setting for 13 minutes according to the manufacturer’s instructions. The
membrane was transferred to 50 mL of 5% skimmed milk powder in 1 X TBST [containing 50
mmol/L Tris-HCl, 300 mmol/L NaCl, 0.1% Tween 20 (pH 7.6)] and incubated for 1 hour at room
temperature with gentle agitation to block the membrane. The milk was then discarded and
replaced with 1.5 mL of PROSC primary antibody (1:100 in 5% TBST milk; HPA023646). The
membrane was then incubated overnight at 4◦C with gentle agitation. The following morning,
the primary antibody solution was removed and the membrane was washed three times with 10
mL of 1X TBST. Each wash consisted of a 10 minute incubation with gentle agitation before
replacing with clean 1X TBST. Once the washing of the membrane was complete, the TBST was
replaced with 5 mL of donkey anti-rabbit IgG-HRP (sc-2317) diluted 1:5000 with 5% TBST milk.
The membrane was then incubated for 1 hour at room temperature with gentle agitation. The
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secondary antibody solution was then removed and the membrane was washed again three times
with 10 mL of 1X TBST. The membrane was developed using the Novex ECL Chemiluminescent
Substrate Reagent Kit. 500 µL of Reagent A and 500 µL of Reagent B were mixed and the
membrane was subsequently washed in this solution for 5 minutes, taking care not to let the
membrane dry out. The membrane was then imaged using a ChemiDoc MP System (Bio-Rad)
coupled to ImageLab 4.1 software.
The membrane was again washed three times in 1X TBST, before being incubated with 10
mL of mouse beta-actin primary antibody (A1978) diluted 1:40,000 in 1X TBST for 1 hour at
room temperature with gentle agitation. The primary antibody solution was then removed and
the membrane was washed again three times in 1X TBST. The membrane was then incubated
with 6 mL of goat anti-mouse IgG-HRP (P0447) diluted 1:3000 with 1X TBST for 1 hour at
room temperature with gentle agitation. Finally, the membrane was washed three times in 1X
TBST and developed and imaged following the same protocol as for the PROSC antibody. The
membrane was then stored at 4◦C in 1X TBST in case further imaging was required.
2.11 measurement of b6 vitamers and 4-pyridoxic acid using ultra-per-
formance liquid chromatography tandem mass-spectrometry (uplc-
ms/ms)
The method described in this thesis for the quantitation of the B6 vitamers in fibroblasts is based
on those previously published from the department for the analysis of plasma (Footitt et al.,
2013).
2.11.1 Fibroblast sample preparation
Prior to mass spectrometry analysis fibroblast pellets were removed from storage at -80◦C,
resuspended in 50 µL of dH2O and vortexed. Cells were then subjected to five freeze-thaw
cycles in a methanol-dry ice mix and a 37◦C water bath in order to lyse them. The lysates were
then pelleted at 4500 x g for 5 minutes at 4◦C and the resulting supernatant collected. Protein
concentration was determined using the Pierce BCA Protein Assay Kit (Section 2.7.4). Proteins
were precipitated by mixing 10 µL of cell lysate supernatant with 110 µL of master mix [containing
40 µL of dH2O, 60 µL of 0.3N trichloroacetic acid (TCA) and 2 µL of each deuterated internal
standard (concentrations detailed in Section 2.11.3)]. The sample was vortexed thoroughly for 30
seconds, left on ice in the dark for 60 minutes and centrifuged to pellet the precipitated protein.
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The resulting supernatant, containing the B6 vitamers, was transferred to a HPLC vial and
placed in an autosampler, protected from light and kept at 4◦C until sample injection.
2.11.2 CSF sample preparation
50 µL of CSF was added to 70 µL of master mix [containing 60 µL of 0.3N TCA and 2 µL of each
deuterated internal standard (concentrations detailed in Section 2.11.3)]. Samples were vortexed
thoroughly for 30 seconds, left on ice in the dark for 60 minutes and centrifuged to pellet the
precipitated protein. The resulting supernatant, containing the B6 vitamers, was transferred to
a HPLC vial and placed in an autosampler, protected from light and kept at 4◦C until sample
injection.
2.11.3 Quantification of B6 vitamers and 4-pyridoxic acid
Stock solutions of all the B6 vitamers, PA and deuterated internal standards were made up using
dH2O and stored at -80◦C to prevent degredation. During laboratory handling, all standards
were kept on ice and protected from light. Quantification of the analytes in fibroblasts was
achieved by spiking 2 µL of a known concentration [d2-PLP; 100 nM, d2-PA, d3-PM, and d2-PN;
10 nM, d3-PL; 50 nM] of each internal standard into each sample. Calibration curves were
constructed using different concentrations of the undeuterated vitamers (except PNP which is
not commercially available) and the known concentrations of deuterated standards. The amounts
of each endogenous analyte was then determined by ratioing the analyte signal area to that of its
corresponding standard Table 2.11.1.
Table 2.11.1: B6 vitamers and their corresponding internal standards used for quan-
titation.
Analyte Deuterated standard Deuterated standard
concentration (nmol/L)
Analyte concentration
expressed as:
PL d3-PL 50 nmol/L
PM d3-PM 10 nmol/L
PN d2-PN 10 nmol/L
PA d2-PA 10 nmol/L
PLP d2-PLP 100 nmol/L
PMP d2-PLP 100 nmol/L
PNP d2-PLP 100 "concentration units"
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Stable isotopes of PMP and PNP were not commercially available at the time this assay was
set-up, therefore these two vitamers were quantitated by ratioing to d2-PLP. PNP was also not
commercially available and thus calibration curves could not be generated. Although PNP and
PLP should behave similarly due to their chemical similarity and difference of only one functional
group, we cannot assume that their response within the mass spectrometer would be identical.
Therefore, concentrations of PNP are expressed as "concentration units" instead of nmol/L. All
results are corrected for cellular protein concentration using the Pierce BCA Protein Assay Kit
according to manufacturer’s instructions (Section 2.7.4).
2.11.4 Identification of B6 vitamers and 4-pyridoxic acid
LC-MS/MS was performed using an Acquity Ultra Performance LC system linked to a triple
quadrupole Xevo TQ-S instrument (Waters, Manchester, UK). Samples were separated on an
Acquity UPLC HSS T3 column (1.8 µm x 2.1 mm x 50 mm) fitted with a HSS T3 VanGuard
guard column (Waters) using the gradient described in Table 2.11.2. The flow rate was maintained
at 0.4 mL/min.
Table 2.11.2: Mobile phase gradient profile for separation of B6 vitamers in fibrob-
lasts. HFBA; heptafluorobutyric acid.
Time (minutes) A (3.7% acetic acid +
0.01% HFBA)
B (100% methanol) Curve
0.00 97.5 2.5 0
0.40 97.5 2.5 6
3.75 50.0 50.0 6
3.76 0.1 99.9 11
4.26 97.5 2.5 1
5.00 97.5 2.5 1
Transitions for each analyte were determined by direct infusion into the mass spectrometer
and subsequently detected using multiple reaction monitoring (MRM) in positive ion mode. All
B6 vitamers and their excretion product 4-pyridoxic acid (PA) could be uniquely identified based
on their retention time and the m/z ratios of their corresponding parent and daughter ions Table
2.11.3. From these parent and daughter ions for each analyte we were able to then calculate
their respective fragmentation patterns. These suggested losses of H2O for PL; NH3 and H2O
for PM; two molecules of H2O for PN and PA; HPO3 and H2O for PLP; and H2O, HPO3 and
NH3 for PMP. As PNP was not available for direct infusion into the mass spectrometer to allow
experimental determination of any transitions, an additional transition was added to the MRM
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using a predicted fragmentation pattern based on that of PLP and PN (i.e. a loss of phosphate
and H2O). A 15 µL volume of spiked sample mixture was injected on to the mass spectrometer
every 5 minutes and the data was acquired using MassLynx software (Waters, Manchester,
UK). Once the method parameters were fully investigated and validated, data processing was
subsequently completed using QuanLynx to reduce variability in results due to human error.
Table 2.11.3: Molecular weights, mass transitions, cone voltages, collision energies
and retention times of the different B6 vitamers and internal standards.
All analytes were detected using a Xevo TQ-S mass spectrometer in positive ion
mode using MRM.
Analyte Molecular
weight
(g/mol)
Parent
ion (m/z)
Daughter
ion (m/z)
Cone
voltage
(V)
Collision
energy
(V)
Retention
time
(mins)
Pyridoxal 167.16 168.10 150.05 21 12 0.93
d3-pyridoxal 170.16 171.10 153.05 21 12 0.93
Pyridoxamine 168.19 169.12 134.04 22 20 0.95
d3-pyridoxamine 171.19 172.12 137.04 22 20 0.95
Pyridoxine 169.18 170.09 134.04 27 19 1.01
d2-pyridoxine 171.18 172.09 136.04 27 19 1.01
Pyridoxic acid 183.16 184.06 147.99 18 18 0.85
d2-pyridoxic acid 185.16 186.06 149.99 18 18 0.85
Pyridoxal
phosphate
247.14 248.00 150.01 27 16 0.81
d2-pyridoxal
phosphate
249.14 250.00 152.01 27 16 0.81
Pyridoxamine
phosphate
248.17 249.04 134.05 27 22 0.69
Pyridoxine
phosphate
249.16 250.04 134.04 27 16 1.42
2.12 measurement of plp-cysteine conjugates using uplc-ms/ms
PLP can react with cysteine to form a thiazolidine complex (Ponticelli et al., 1983; Terzuoli et al.,
1998) with a predicted molecular weight of 350 g/mol.
2.12.1 Sample preparation
Prior to mass spectrometry analysis fibroblast pellets were removed from -80◦C storage, re-
suspended in 60 µL of dH2O and vortexed. Mixtures were freeze-thawed, pelleted and the
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supernatant was collected as above (Section 2.11.1). Protein concentration was determined using
the Pierce BCA Protein Assay Kit (Section 2.7.4). Proteins were precipitated by mixing 45 µL
of cell lysate supernatant with 90 µL of ice-cold 100% methanol. The samples were incubated on
ice in the dark for ten minutes and centrifuged to pellet the precipitated protein. The resulting
supernatant was transferred to a HPLC vial and placed in an autosampler, protected from light
and kept at 4◦C until sample injection.
2.12.2 Identification of PLP-cysteine conjugate
LC-MS/MS was performed using a Waters Alliance 2795 LC system linked to a triple quadrupole
Micro Quattro instrument (MicroMass, Waters, UK). Samples were separated on a HS F5 column
(3 µm x 10 cm x 2.1 mm) fitted with a HS F5 guard column (Supelco, Sigma Aldrich) using the
gradient described in Table 2.12.1. The flow rate was maintained at 0.2 mL/min.
Table 2.12.1: Mobile phase gradient profile for the detection of PLP-cysteine in
fibroblasts.
Time (minutes) A (100% methanol) B (3.7% acetic acid) Curve
0.00 2.5 97.5 1
2.00 2.5 97.5 6
10.00 50.0 50.0 6
12.00 2.5 97.5 11
14.00 2.5 97.5 11
The mass spectrometer was operated in positive ion MRM mode and PLP-cysteine was
identified using a parent ion of 350.98 m/z, a daughter ion of 219.03 m/z, a cone voltage of 27 V
and a collision voltage of 19 V.
2.13 quantification of pnpo enzyme activity using uplc-ms/ms
2.13.1 Sample preparation
The cell pellets were removed from -80◦C storage, resuspended in 50 µL of dH2O and vortexed.
Mixtures were then subjected to three freeze-thaw cycles in a methanol-dry ice mix and a 37◦C
water bath to gently lyse cells. The lysates were then pelleted at 4500 x g for 5 minutes at
4◦C. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Section
2.7.4) and the supernatants were diluted with dH2O to an equal starting concentration. 10 µL
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of diluted supernatant was then transferred into five labelled eppendorfs corresponding to the
five time-points used to measure the enzyme activity [0, 0.5, 1, 2 and 3 hours]. 110 µL of buffer
[containing 60 µL of 40 mM potassium phosphate buffer (pH 7.6), 12 µL of 3mM ATP, 12 µL of
3 mM MgCl2, 12 µL of 15 µM FMN, 4 µL of 3 µM d2-PN and 10 µL dH2O] was added and the
reaction tubes were covered in foil to protect the vitamers from light.
The 0 hour reaction was stopped by adding 120 µL of 0.3N TCA [containing 4 µL of 3 µM
d3-PLP and 4 µL of 3 µM d3-PL] and vortexing thoroughly for 30 seconds. The remaining tubes
were incubated with shaking at 37◦C for the appropriate times, and subsequently stopped with
120 µL of 0.3N TCA containing the deuterated vitamers. After stopping each time-point reaction,
each tube was left on ice in the dark for 45 minutes to allow any Schiff bonds to be broken and
protein to precipitate, before centrifuging at 17,900 x g for 10 minutes to pellet the proteins
present in the reaction mixture. The resulting supernatant, which contains the B6 vitamers, was
transferred to a HPLC vial and placed in an autosampler, protected from light and kept at 4◦C
until sample injection.
LC-MS/MS quantitation of the relevant vitamers was carried out using the method described
previously in Section 2.11.4, with the addition of one transition. This corresponds to the predicted
fragmentation of d2-pyridoxine phosphate (i.e. a loss of HPO3 and H2O) to allow the measurement
of the conversion of d2-PN to d2-PNP and d2-PLP by pyridoxal kinase (PK) and pyridox(am)ine
phosphate oxidase (PNPO), respectively (Table 2.13.1).
Calibration curves were constructed using different concentrations of the analytes d2-PLP
and d2-PN and known concentrations of other deuterated standards (Table 2.13.2). d2-PNP
is not commercially available, thus this analyte was quantitated using the standard curve for
d2-PLP and results were expressed as "concentration units".
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Table 2.13.1: Molecular weights, mass transitions, cone voltages, collision energies
and retention times of the analytes quantified in the PNPO/PK en-
zyme assay. All analytes were detected using a Xevo TQ-S mass spectrometer
in positive ion mode using MRM.
Analyte Molecular
weight
(g/mol)
Parent
ion (m/z)
Daughter
ion (m/z)
Cone
voltage
(V)
Collision
energy
(V)
Retention
time
(mins)
Pyridoxal 167.16 168.1 150.05 21 12 0.93
Pyridoxamine 168.19 169.12 134.04 22 20 0.95
Pyridoxine 169.18 170.09 134.04 27 19 1.01
d2-pyridoxine 171.18 172.09 136.04 27 19 1.01
Pyridoxic acid 183.16 184.06 147.99 18 18 0.85
Pyridoxal
phosphate
247.14 248.00 150.01 27 16 0.81
d2-pyridoxal
phosphate
249.14 250.00 152.01 27 16 0.81
Pyridoxamine
phosphate
248.17 249.04 134.05 27 22 0.69
Pyridoxine
phosphate
249.16 250.04 134.04 27 16 1.42
d2-pyridoxine
phosphate
251.16 252.04 136.04 27 16 1.42
Table 2.13.2: Internal standards used to quantitate analytes and construct calibra-
tion curves for the PK/PNPO enzyme assay.
Analyte Deuterated
standard
Deuterated standard
concentration (nmol/L)
Analyte concentration
expressed as:
d2-PN d3-PL 100 nmol/L
d2-PNP d3-PLP 100 "concentration units"
d2PLP d2-PLP 100 nmol/L
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2.14 tinctoral staining, immunofluorescence and electron microscopy
of patient fibroblasts
2.14.1 Tinctoral staining and immunohistochemistry
2.14.1.1 Cell immobilisation
Once confluent, fibroblasts were detached from 75 cm2 flasks (as described in Section 2.7.1)
and resuspended in 2 mL of Ham’s F10 medium. Cells were immobilised as a monolayer onto
Superfrost Plus Micro Slides by aliquoting 300 µL of suspension into six sample chambers of a
Thermo Scientific Cytospin 4 and spinning at 450 rpm for 10 minutes. Slides were allowed to
air-dry for 5 minutes prior to fixation and staining.
2.14.1.2 Haematoxylin and Eosin to examine cell morphology
Slides were fixed in 95% ethanol for 5 minutes and rinsed in running water. Slides were stained
with Harris haematoxylin for 30 seconds under gentle agitation. Haematoxylin staining was
differentiated briefly in a solution of 1% hydrochloric acid in 70% ethanol and nuclear staining
intensity was checked macroscopically. Slides were run under warm tap water to convert nuclear
colouration from red/purple to blue and counterstained in 1% eosin for 10 seconds.
2.14.1.3 Oil Red O to stain neutral lipids
Oil Red O working solution was made by dissolving 1 g Oil Red O in 5 mL acetone and mixing
with 100 mL 70% ethanol. The solution was allowed to settle for 24 hours before filtration and
use. Slides were stained in Oil Red O working solution for one hour then rinsed in 70% ethanol
followed by water. Nuclei were stained in Mayers haematoxylin for one minute and washed in
running water until nuclei appeared blue.
2.14.1.4 Sudan Black to stain phospholipids
Sudan Black working solution was made by dissolving 1 g Sudan Black in 100 mL propylene
glycol in a boiling water bath, before cooling and filtering. Slides were fixed in 4% formal calcium
[100 mL of 40% w/w formaldehyde, 20 g of calcium acetate and 900 mL of dH2O] and stained in
Sudan Black working solution for two hours. Sudan Black was flooded off with 85% propylene
glycol and staining was differentiated by washing two further times with 85% propylene glycol.
Slides were subsequently washed well in 50% propylene glycol followed by running water. Slides
were counterstained with Nuclear Fast Red and washed again in water.
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2.14.1.5 Luxol Fast Blue to stain myelin/sphingomyelin
Slides were fixed in 95% ethanol for 5 minutes. Staining was carried out using the Luxol Fast
Blue Stain Kit with some modifications. 0.1% Luxol Fast Blue in Acidified Methanol was filtered
and placed in a thick glass staining trough at 60◦C. Slides were incubated in the pre-heated
solution for 2 hours at 60◦C, then washed in 70% Denatured Ethanol and rinsed in tap water.
Subsequently, slides were differentiated in 0.05% Lithium Carbonate Solution, briefly rinsed in
95% alcohol and washed in tap water. Slides were stained in Cresyl Violet Solution for 10-12
minutes, washed in tap water and differentiated in Cresyl Violet Differentiator for 4 seconds with
gentle agitation and washed again in water.
2.14.1.6 Lysosome-associated membrane protein 2 (LAMP2)
Immunohistochemical staining was performed using a Leica Bond-Max autostainer (Leica Mi-
crosystems, Milton Keynes, UK). Firstly, slide details were entered onto the Bond-Max computer
system, each slide was labelled with unique barcoded labels and reagents were uploaded onto the
machine. Slides were placed in a Bond-Max slide tray, each slide was covered with a Bond-Max
slide cover and inserted into the autostainer. LAMP-2 [H4B4] primary antibody was diluted
1:100 in Bond primary antibody diluent. Antibody detection was carried out with the Bond
Polymer Refine Detection using Protocol F according to the manufacturer’s protocol. 150 µL of
each reagent was dispensed for all steps of the protocol. Slides were washed in alcohol and washed
in Bond Wash Solution at room temperature for 5 minutes. Heat-induced epitope retrieval using
Bond Epitope Retrieval Solution 2 (pH 7.0) was carried out for 20 minutes. Slides were washed
in Bond Wash Solution at 35◦C for 3 minutes after antigen retrieval. Slides were then blocked
with 3-4% hydrogen peroxide at room temperature for 10 minutes and then incubated with the
LAMP-2 primary antibody at room temperature for 15 minutes. Slides were washed in Bond
Wash Solution and incubated with Post Primary Solution at room temperature for 8 minutes.
Slides were washed in Bond Wash Solution and incubated in Mixed DAB Refine Solution at room
temperature for 10 minutes. Slides were washed in dH2O prior to counterstaining with Mayer’s
haematoxylin for 5 minutes at room temperature.
2.14.1.7 Dehydration, clearing and mounting
After staining, slides were dehydrated and cleared by sequential washing through a series of
alcohol (70%, 90%, 100% and 100%) followed by two washes in xylene. Finally, slides were
coverslipped using a Leica Multistainer and Coverslipper (Leica Microsystems).
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2.14.1.8 Visualisation and image capture
Cells were visualised using a Nikon Optiphot microscope and images were captured using a Leica
DMD108 Digital Microimaging Device.
2.14.2 Electron microscopy
Sample processing was carried out by Elizabeth Latimer-Bowman and electron microscopy
imaging was carried out by Glenn Anderson (Histopathology Department, GOSH, London).
One confluent 75 cm2 flask of fibroblasts per patient was pelleted as described in Section
2.7.1. Pellets were then fixed in 5 mL of 2.5% glutaraldehyde buffered with 100 mM cacodylate
buffer (pH 7.2) for 24 hours at room temperature. Samples were placed on a sample rotator for
5 minutes, the buffered glutaraldehyde was removed and replaced with 5 mL of fresh 100 mM
cacodylate buffer (pH 7.2). Samples were placed on a sample rotator for 5 minutes, the buffer
solution was removed and replaced with 5 mL of 1% osmium tetroxide. Samples were incubated
on a sample rotator for 1 hour at room temperature to allow for the secondary fixation of lipids
with the samples. The osmium solution was then removed, discarded and washed twice with
5 mL of fresh 100 mM cacodylate buffer (pH 7.2) for 5 minutes. Once the buffer solution was
removed, samples were dehydrated through graded alcohol washes (70%, 90% and two washes
of 100%), incubating the samples for 10 minutes on a sample rotator at each step. The final
100% alcohol wash was removed, replaced with reagent grade propylene oxide and incubated for
10 minutes on a sample rotator. This was subsequently replaced with fresh propylene oxide for
a second 10 minute wash. The propylene oxide was removed and replaced with 1 mL of fresh
propylene oxide and 1 mL of freshly-made resin [12 g of Agar 100 Resin, 8 g of dodecenyl succinic
anhydride, 5 g of methyl nadic anhydride and 0.38 g of benzyldimethylamine]. Samples were
then incubated for 1 hour at room temperature on a sample rotator to allow resin infiltration.
The solution was removed and 1 mL of fresh resin was added. Any residual propylene oxide was
allowed to evaporate before the samples were again incubated for 1 hour on a sample rotator.
Finally, the solution was replaced with fresh resin and incubated overnight at room temperature
on a sample rotator. Samples were then transferred to embedding moulds and the resin was
polymerised overnight at 60◦C.
Ultrathin 90 nm sections were cut with a diamond knife on a Leica Ultracut UCT Ultramicro-
tome, placed on copper grids and stained with alcoholic uranyl acetate for 5 minutes. Sections
were then rinsed in 50% ethanol followed by dH2O and allowed to dry for 5 minutes. Finally,
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sections were stained with Reynold’s lead citrate for 15 minutes before being rinsed in dH2O.
Examination was carried out using a JEOL 1400 transmission electron microscope.
2.14.3 Nucleoporin p62 (p62) immunofluorescence
Immunofluorescence was carried out using the method of Yasin et al. (2013). Sterile glass coverslips
were covered with 1 N hydrochloric acid and shaken for 1 hour at room temperature. Coverslips
were removed from the acid, laid on Whatman filter paper in a glass dish and autoclaved for 20
minutes at 120◦C. Treated coverslips were transferred into wells of a 24-well plate using sterile
forceps. 500 µL of 5 µg/mL poly-D-lysine was added to each well and the plate was incubated at
37◦C for 1 hour. Coverslips were washed in PBS three times for 5 minutes and the 24-well plate
was left to dry at room temperature for 1 hour.
Fibroblasts were trypsinised, pelleted and resuspended in media as previously (Section 2.7.1).
Fibroblasts were seeded on the coverslips at a density of 5 x 104 cells per coverslip and incubated
at 37◦C for 6 hours to allow the cells to adhere. 500 µL of media was added to each well and
incubated overnight at 37◦C to culture the cells to confluence. The following morning, the media
was aspirated and 400 µL of 4% paraformaldehyde was added for 15 minutes at room temperature
to fix the cells. 300 µL of paraformaldehyde was removed, 400 µL of PBS was added and the
plate was stored at 4◦C prior to staining.
PBS was removed from the wells and 400 µL of blocking solution [containing 0.1% Triton
X-100, 10% Sheep serum in PBS] was added. The plate was incubated at room temperature for 1
hour with shaking and the blocking solution was then removed. Autophagosomes were stained by
incubating cells with 200 µL of p62 primary antibody (1:50) at 4◦C overnight. After removing the
primary antibody, cells were washed twice with 500 µL of PBS for 10 minutes. PBS was removed
and cells were then incubated in 200 µL of Alexa Fluor 610 secondary antibody (1:240) in the dark
for 1 hour at room temperature. The secondary antibody was removed and cells were again washed
with 500 µL of PBS for 10 minutes. Slides were washed twice in PBS and mounted in Vectashield
aqueous mounting medium containing 4’,6-diamidino-2-phenylindole/DAPI. Fibroblasts were
visualised and images captured using a Leica DMLB fluorescent microscope.
CellProfiler 2.1.1 (Carpenter et al., 2006) was used to analyse the immunofluorescence images
obtained. CellProfiler uses analysis pipelines to complete counting tasks which contain configurable
modules that can be optimised to suit a specific task. Representative images with different cell
densities and staining intensities were selected to determine the most accurate settings for the
analysis pipeline. Cells were counted by quantitation of nuclear DAPI staining using minimum
and maximum diameter settings of 70 and 300 pixels, respectively. The threshold correction
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factor was set to 1 using the Otsu Global thresholding method in two-class mode. Staining of
p62 punctae was also counted using a diameter range of 1 to 30 pixels and a threshold correction
factor of 2.2. The Otsu Global thresholding method in three-class mode was used with the middle
intensity assigned to the background to avoid counting background as cells. All other pipeline
settings were kept as default.
2.15 measurement of glutamate-γ -semialdehyde using uplc-ms/ms
Glutamate-γ-semialdehyde is structurally similar to α-aminoadipic semialdehyde which is routinely
measured in our laboratory by HPLC-MS/MS of FMOC derivatives of each molecule (Mills et al.,
2006).
2.15.1 Fibroblast sample preparation
Prior to mass spectrometry analysis fibroblast pellets were lysed in 50 µL of dH2O as previously
(Section 2.11.1). 10 µL of cell lysate was then mixed in a HPLC vial with 10 µL of 0.1 mM
d3-aminoadipic acid, 40 µL of dH2O, 125 µL of 0.1 M borate buffer (pH 10.4) and 125 µL of
6 mM fluorenylmethyloxycarbonyl chloride (FMOC-Cl) in acetone. Care was taken to add the
FMOC-Cl to the vials last and to immediately cap and vortex the samples as the FMOC-Cl is
water sensitive. Vials were placed in an autosampler, protected from light and kept at 4◦C until
sample injection.
2.15.2 Identification and semi-quantification of glutamate-γ-semialdehyde
LC-MS/MS was performed using the method used in our laboratory to measure α-aminoadipic
semialdehyde for the diagnosis of pyridoxine-dependent epilepsy (Mills et al., 2006). The Micro
Quattro instrument was operated in positive ion MRM mode and glutamate-γ-semialdehyde
(GSA) was identified using a parent ion of 352.30 m/z, a daughter ion of 130.10 m/z, a cone
voltage of 10 V and a collision voltage of 8 V. A 10 µL volume of cell lysate mixture was injected
on to the mass spectrometer every 5 minutes and the data was acquired using MassLynx software
(Waters). Data processing was completed using QuanLynx (Waters). Analysis of the amount
of GSA in fibroblasts was achieved by spiking 10 µL of 0.1 mM d3-aminoadipic acid into each
sample (Section 2.15.1). The amount of GSA was determined by ratioing the signal area to that
of the 15N-aminoadipic acid. GSA is not commercially available, therefore calibration curves
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could not be generated. Thus, concentrations of GSA are expressed as "concentration units". All
results are corrected for cellular protein concentration using the Pierce BCA Protein Assay Kit
according to manufacturer’s instructions.
2.16 molecular cloning of cysteine conjugate-β lyase (ccbl1)
2.16.1 cDNA clone information
A full length cDNA clone of CCBL1 in the vector pME18SFL3 (Accession No. AK314427) was
purchased from the Biological Resource Center, National Institute of Technology and Evaluation,
Japan. Upon arrival, the clone was resuspended in 200 µL 0.1X Tris-EDTA buffer prior to
transformation into XL-1 Blue cells (Section 2.16.3.1).
2.16.2 Molecular biology media
2.16.2.1 Solid LB medium
Solid LB medium was made by mixing 8 g of Miller LB Broth and 6 g of bacteriological agar
in 400 mL of dH2O before autoclaving for 20 minutes at 120◦C. The medium was allowed to
cool to 55◦C and ampicillin or kanamycin antibiotic (stock concentration 50 mg/mL) was then
added to a final concentration of 50 µg/mL. 40 mL aliquots were then poured into sterile petri
dishes and left to set for 30 minutes at room temperature. If blue-white screening was required
then 32 µL of 50 mg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) in 2% N,
N-dimethyl formamide was evenly spread on each plate and incubated at 37◦C for 30 minutes
prior to bacterial plating.
2.16.2.2 Liquid LB broth
Liquid LB broth was made by mixing 3 g of Miller LB Broth in 150 mL of dH2O before autoclaving
for 20 minutes at 120◦C. The broth was allowed to cool to room temperature and ampicillin or
kanamycin antibiotic (stock concentration 50 mg/mL) was then added to a final concentration of
50 µg/mL.
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2.16.3 Bacterial transformation of E. coli cells
2.16.3.1 XL-1 Blue Cells
XL-1 Blue competent cells and β-mercaptoethanol were thawed on ice. 40 µL of cells was added
to 0.68 µL of β-mercaptoethanol in a pre-chilled 1.5 mL eppendorf, then left on ice for 10 minutes,
swirling every two minutes. 1 µL of resuspended plasmid was added to the cells and gently mixed
prior to incubation on ice for 30 minutes. Cells were then heat shocked at 42◦C for 45 seconds
in a water bath, then placed on ice for two minutes. 500 µL of SOC Medium that had been
pre-warmed to 37◦C was added and the mixture incubated at 37◦C for one hour with shaking.
Cells were streaked on LB agar plates containing 50 µg/mL of ampicillin at different densities
(10, 50, 100 and 200 µL). Plates were allowed to dry for five minutes and incubated at 37◦C
overnight, upside down to prevent condensation from falling onto the agar.
2.16.3.2 TOP10 Chemically Competent Cells
One vial containing 50 µL of TOP10 chemically competent cells per transformation were thawed
on ice. 2 µL of TOPO cloning reaction was then added to the cells, gently mixed and incubated
on ice for 30 minutes. Cells were then heat shocked at 42◦C for 30 seconds, then placed on ice.
500 µL of SOC Medium that had been pre-warmed to 37◦C was added and the mixture incubated
at 37◦C for one hour with shaking (200 rpm). LB agar plates containing 50 µg/mL of kanamycin
and coated with X-Gal for blue-white screening, were pre-warmed at 37◦C for 30 minutes. Cells
were then streaked at different densities (10, 30, 80 and 150 µL). Plates were allowed to dry for
five minutes and incubated at 37◦C overnight, upside down to prevent condensation from falling
onto the agar.
2.16.4 Liquid culture of E. coli transformants and preparation of glycerol stocks
Single isolated E. coli colonies were picked using sterile inoculation loops following overnight
growth on agar plates and incubated in 5 mL of LB liquid media (Section 2.16.2.2) containing 50
µg/mL of ampicillin or kanamycin at 37◦C overnight with shaking. Where blue-white screening
was used, only white colonies were picked. Glycerol stocks were prepared by mixing 850 µL of
each liquid culture with 150 µL 100% sterile glycerol. Stocks were stored at -80◦C for future use.
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2.16.5 Preparation of plasmid DNA
The remaining 4.15 mL of liquid culture was centrifuged at 16,000 x g for one minute to pellet
the E. coli cells. The supernatant was removed and the pellet resuspended in the 20 µL that
remained. Plasmid DNA was then extracted using the QIAprep Spin Miniprep Kit according to
manufacturer’s instructions. 250 µL of Buffer P1 containing 100 µg/ml RNase A was used to
resuspend the pellet until no cell clumps were visible. Cells were then lysed by addition of 250 µL
of Buffer P2 followed by gentle inversion of the mixture 4-6 times. 350 µL of Buffer N3 was then
added and each tube was immediately inverted 4-6 times to avoid localised precipitation. Samples
were then centrifuged at 16,000 x g for 10 minutes to form a compact white pellet. Supernatants
were applied to QIAprep spin columns by pipetting and the columns were centrifuged at 16,000 x
g for 60 seconds. The flow-through was discarded and the columns were washed by the addition of
500 µL of Buffer PB to remove trace nuclease activity. Samples were centrifuged at 16,000 x g for
60 seconds and the flow-through was again discarded. 750 µL of Buffer PE was added, samples
were centrifuged at 16,000 x g for 60 seconds and the flow-through was discarded. Samples were
then centrifuged at 16,000 x g for an additional 60 seconds to remove residual buffer that contains
ethanol and thus may inhibit subsequent enzymatic reactions. Finally, the QIAprep columns were
placed in clean 1.5 mL microcentrifuge tubes and the DNA was eluted by adding 30 µL of Buffer
EB to the centre of the membrane of each QIAprep spin column. This was allowed to stand for
60 seconds prior to centrifuging at 16,000 x g for 60 seconds. Plasmidic DNA concentration was
subsequently determined using a NanoDrop 1000 (Thermo Scientific) and samples were stored at
-20◦C.
2.16.6 Sequencing plasmid DNA
Plasmid DNA was diluted to a final concentration of 100 ng/µL using dH2O. Sequencing was
then carried out using Sanger sequencing as previously described (Section 2.3.3.2) using 3 µL of
plasmid DNA per sequencing reaction. Primers used to confirm the sequence of CCBL1 clones
are detailed in Table 2.16.1.
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Table 2.16.1: Details of "walking" primers used to verify the sequence of the CCBL1
clones. These primers are designed to “walk” across the clone sequence by
overlapping the PCR products to enable sequencing of the full clone sequence to
ensure that the sequence of the clone is as expected. F, forward; R, reverse.
Name Sequence 5’ → 3’
1 F GGATCGACTACAACCCCTGG
2 F TGACGAAGATCCTGGCAAGT
3 F GGGTCGTCCTGTGTTTGT
4 F GTGTTCTCCAGGGAAGAGCT
5 F CCAGAACTCCGTCTTCCACT
6 F GAAGATGCCTGACTTGCCTG
1 R CAAGTTCACGACGTCATGCT
2 R GGTCTATCTCCTGACCCAGC
3 R ATTCTGGATGGGACCCGG
4 R GCAATGCTGATGTGCTGGT
5 R CAAAGTAGCTGCTGGGTTGG
6 R TCTTGATCATCCACTTGACGAA
7 R AGTTCCACCTTCCACTTCCG
2.16.7 Engineering NdeI sites
Primers were designed to immediately flank the start and stop codon of the CCBL1 cDNA with
NdeI restriction enzyme sites and five additional random bases to allow correct restriction enzyme
cleavage. Primers are detailed in Table 2.16.2.
Engineering of NdeI sites was carried out using Phusion High-Fidelity DNA polymerase. In
this polymerase, a DNA binding domain is fused to a Pyrococcus-like proofreading polymerase.
This activity is necessary to avoid the introduction of unwanted mutations whilst amplifying large
targets. The reaction mix detailed in Table 2.16.3 was assembled on ice, taking care to add the
Phusion High Fidelity DNA polymerase last. Each reaction was then cycled using the parameters
outlined in Table 2.16.4 using a Veriti 96-well Thermal Cycler (Thermo Fisher, Loughborough,
UK).
Table 2.16.2: NdeI site engineered primers to allow insertion of cDNA into
pT7CFE1-CHis expression vector. NdeI sites are shown underlined and the
random five bases required for proper restriction enzyme cleavage are shown in
bold.
Name Sequence 5’ → 3’
Forward GCATGCATATGATGGCCAAACAGCTGCAGGCC
Reverse GCATGCATATGCTAGAGTTCCACCTTCCACTTCC
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Table 2.16.3: NdeI site engineering reaction mix.
Reagent Volume (µL)
Plasmid DNA (20 ng/ul) 1
5X Phusion GC Buffer 10
Forward primer (10 µM) 2.5
Reverse primer (10 µM) 2.5
dNTPs (10 mM) 1
DMSO 1.5
dH2O 31
Phusion DNA Polymerase 0.5
Table 2.16.4: NdeI site engineering reaction conditions.
Step Conditions
1 98◦C for 2 mins
2 98◦C for 10 secs
3 61◦C for 30 secs
4 72◦C for 60 secs
5 Repeat steps 2-4 24 times for a total of 25 cycles
6 72◦C for 10 mins
2.16.8 TOPO TA cloning
2.16.8.1 Addition of 3’ overhangs
Post PCR amplification, 0.2 µL of Taq polymerase was added to each 50 µL reaction. Samples
were mixed well, centrifuged and incubated at 72◦C for 10 minutes in a Veriti 96 Well Thermal
Cycler. Tubes were immediately transfered to ice before proceeding with the TOPO cloning
reaction.
2.16.8.2 TOPO cloning reaction
4 µL of PCR product, 1 µL of salt solution and 1 µL of TOPO vector were gently mixed
and incubated at room temperature for 30 minutes before placing the reaction on ice. TOP10
competent cells were subsequently transformed with the resulting ligation reaction as previously
described (Section 2.16.3.2). Orientation of plasmid inserts was carried out by restriction enzyme
digestion with EcoRI and NdeI. Details of reagents and digestion conditions are given in Table
2.16.5
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Table 2.16.5: Conditions for restriction enzyme digestion of plasmids.
EcoRI NdeI
(CCBL1 in
TOPO 2.1)
NdeI
(pT7CFE1
vector)
ApaI
Plasmid DNA (µL) 3 8 2 3
Buffer (µL) EcoRI buffer
(1.5)
Buffer 4
(1.5)
Buffer 4
(1.5)
Buffer 4
(1.5)
Restriction enzyme (µL) EcoRI (1.5) NdeI (1.5) NdeI (1.5) ApaI (1.5)
dH2O (µL) 9 4 10 7.5
BSA (µL) - - - 1.5
Incubation temperature (◦C) 37 37 37 25
Incubation time (hours) 3 2 2 2
2.16.9 Site-directed mutagenesis
Primers were designed to introduce the c.814C>T mutation present in our patient into the
wild-type CCBL1 clone. Mutagenic primers were designed using the following criteria:
1. Both mutagenic primers must contain the desired mutation and anneal to the same sequence
on opposite strands.
2. For optimal efficiency, primers should have a minimum of 40% G/C content and terminate
in one or more G/C bases.
3. The mutation must lie in the centre of the primers with 10-15 bases of correct flanking
sequence.
4. Primers should be between 25 and 45 bases in length with a melting temperature (Tm) of
≥78◦. Where:
Tm = 81.5+ 0.41(%GC)− (675/N)−%mismatch
The reaction mix detailed in Table 2.16.7 was assembled on ice, taking care to add the PfuUltra
High Fidelity DNA polymerase last. Each reaction was then cycled using the parameters outlined
in Table 2.16.8. The total size of the TOPO 2.1 vector with the addition of the CCBL1 insert is
Table 2.16.6: Site-directed mutagenesis primers to allow insertion of c.814C>T mu-
tation into CCBL1 clone. Mutated bases are shown underlined.
Name Sequence 5’ → 3’
Forward ATCATGAAGCACCTGCGGACCATGCACCAGAACTCCGTCTT
Reverse AAGACGGAGTTCTGGTGCATGGTCCGCAGGTGCTTCATGAT
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∼5.3 kb. PfuUltra High Fidelity DNA Polymerase has an extension rate of 1 kb/min, thus the
extension time is six minutes.
Table 2.16.7: Site-directed mutagenesis reaction mix using QuikChange II XL Site-
Directed Mutagenesis Kit. Volumes of plasmid DNA were adjusted accord-
ingly for a final concentration of 10 ng/reaction, thus volume is denoted as X
µL.
Reagent Volume (µL)
10X Reaction buffer 5
Forward primer (50 ng/µL) 2.5
Reverse primer (50 ng/µL) 2.5
dNTP mix 1
QuikSolution 3
PfuUltra High Fidelity DNA polymerase (2.5 U/µL) 1
Plasmid DNA (10 ng) X
dH2O To a final volume of 50 µL
Table 2.16.8: Mutant strand synthesis reaction conditions.
Step Conditions
1 95◦C for 1 min
2 95◦C for 50 secs
3 60◦C for 50 secs
4 68◦C for 6 mins
5 Repeat steps 2-4 17 times for a total of 18 cycles
6 68◦C for 7 mins
Following temperature cycling, reactions were placed on ice for 2 minutes to rapidly cool
to <37◦C. 1 µL of DpnI was then added to each product, mixed, briefly centrifuged to ensure
the contents were at the bottom of the tube and incubated at 37◦C for one hour. The DpnI
endonuclease (target sequence: 5’-Gm6ATC-3’) is specific for methylated and hemimethylated
DNA and is used to digest the parental DNA template and to select for mutation containing
synthesized DNA. Reactions were stored at -20◦C overnight.
2.16.10 Dephosphorylation to prevent plasmid re-ligation
2 µL of restriction enzyme buffer, 1 µL of calf intestinal phosphatase, 17 µL of dH2O and 15 µL
of digested DNA (Table 2.16.5) were mixed and incubated at 37◦C for 3 hours. Products were
stored at -20◦C overnight.
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2.16.11 Gel extraction
DNA was run on a 1% agarose gel (Section 2.3.2) at 95V for 1.5-2 hours to ensure good
separation of different sized DNA fragments. DNA fragments were visualised using an ultraviolet
transilluminator and excised from the agarose gel with a clean, sharp scalpel. Gel slices were
weighed in clean microcentrifuge tubes and DNA was extracted using the QIAquik Gel Extraction
Kit. Three volumes of Buffer QG was added to each volume of gel (e.g. 300 µL of Buffer QG to
each 100 mg of gel). Samples were incubated at 50◦C for 10 minutes in a water bath and were
vortexed every 2-3 minutes to make sure the gel slice had completely dissolved. One gel volume
of isopropanol was added to the samples, the mixture was applied to QIAquick columns and
centrifuged for 1 minute at 17,900 x g to bind DNA. The flow-through was discarded, 500 µL of
Buffer QG was added, centrifuged for 1 minute at 17,900 x g and the flow-through was discarded.
To wash the columns, 750 µL of Buffer PE was added and the columns were centrifuged for 1
minute at 17,900 x g. The flow-through was discarded and the columns were centrifuged for an
additional 1 minute at 17,900 x g to remove residual ethanol which may inhibit downstream
reactions. The columns were placed into clean microcentrifuge tubes and DNA was eluted by
addition of 30 µL of Buffer EB and centrifuging for 1 minute at 17,900 x g. A 5 µL aliquot of
the purified DNA was then analysed on an agarose gel (Section 2.3.2).
2.16.12 Ligation
For optimal ligation using T4 DNA ligase a molar ratio of 1:3 vector to insert and between
50-200 ng of vector DNA is required. In order to calculate the optimal amount of insert DNA
the following formula is used:
ng of insert = ng of insert× size of insert in kbsize of vector in kb ×
molar ratio of vector
insert
The appropriate volumes of pT7CFE1 vector and insert DNA were mixed, incubated at
45◦C for 5 minutes and then incubated on ice for 5 minutes. 1 µL of T4 DNA ligase, 2 µL
of ligase buffer and 1.6 µL of dH2O were added, the reactions were mixed and incubated at
room temperature for 2 hours. Enzymes were then heat inactivated at 65◦C for 10 minutes and
reactions were stored on ice until transformation of TOP10 chemically competent cells (Section
2.16.3.2).
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2.16.13 Protein expression using 1-Step Human Coupled IVT Kit
DNA was concentrated and RNase A (present from QIAprep Spin MiniPrep Kit) was removed
by adding 1.5 µL of 3 M sodium acetate (pH 5.2) and 30 µL of 100% ethanol to 15 µL of
plasmidic DNA (CCBL1 in pT7CFE1 vector). Samples were mixed and incubated at -20◦C for
15 minutes, prior to centrifugation at 14,000 x g for 15 minutes. The supernatant was removed
and 30 µL of 70% ethanol was added. Samples were centrifuged at 14,000 x g for 5 minutes, the
supernatant was removed and samples were air-dried for 5 minutes at room temperature. DNA
was resuspended in nuclease-free dH2O to a specific desired final concentration.
Protein expression was carried out using the 1-Step Human Coupled IVT Kit according to
the manufacturer’s instructions. All reagents were thawed on ice and reactions were assembled in
nuclease-free microcentrifuge tubes. 12.5 µL of HeLa cell lysate, 2.5 µL of accessory proteins, 5 µL
of reaction mix, 2 µL of plasmidic DNA (CCBL1 in pT7CFE1 vector) and 3 µL of nuclease-free
dH2O were mixed together gently at room temperature. Reactions were incubated at 30◦C for
between 90 minutes and 6 hours and maintained on ice for subsequent downstream applications.
2.17 q-tof analysis of in vitro protein expression
Proteins expressed using the 1-Step Human Coupled IVT Kit (Section 2.16.13) were lyophilised
overnight using a freeze-drier pror to resuspending in 20 µL of 100 mM Tris-HCl (pH 7.8)
containing 2% (w/v) amidosulphobetanine-14 (ASB-14), 6 M urea and 2 M thiourea. 1.5 µL of
200 mM dithioerythritol in 100 mM Tris-HCl (pH 7.8) was added to each sample, vortexed and
incubated with shaking at room temperature for 60 minutes. 3 µL of 200 mM iodoacetamide in
100 mM Tris-HCl (pH 7.8) was added to each sample, vortexed and incubated with shaking at
room temperature for 30 minutes whilst protected from light. 155 µL of dH2O and 1 µg of Mass
Spectrometry Grade Trypsin Gold was added and samples were incubated at 37◦C overnight to
digest the proteins.
Residual salts, detergents, urea, thiourea, iodoacetamide and dithioerythritol were removed
from samples prior to mass spectrometry analysis using C18 solid phase extraction columns. C18
columns were first primed with 1 mL of 50% acetonitrile (ACN) [0.1% TFA], followed by 1 mL
of 0.1% TFA. Samples which had been diluted 1:1 with 0.2% trifluoroacetic acid (TFA) to aid
binding of samples to the solid silica phase were subsequently applied to the primed columns.
The eluents were collected in siliconised microcentrifuge tubes before being re-applied to the
columns and collected again. Residual salts present in the samples were removed by washing
the columns with 1 mL 3% ACN [0.1% TFA]. Peptides were eluted in 500 µL 50% ACN [0.1%
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TFA] and collected in clean siliconised microcentrifuge tubes. Eluted peptides were lyophilised
overnight.
Peptide pellets were resuspended in 300 µL 3% ACN containing 0.1% TFA and 50 pmol/µL
enolase peptides standard (MassPREP) prior to centrifugation at 16,000 x g for 10 minutes. The
supernatant was then transferred to a TruView LCMS Certified, Total Recovery Vial. 1 µL of
sample was injected onto a nanoACQUITY ultra high performance liquid chromatography system
coupled to a SYNAPT G2-Si mass spectrometer (Waters). Peptides were separated using low
pH reverse phase chromatography on an ACQUITY UPLC Peptide BEH C18 nanoACQUITY
Column (130 Å, 1.7 µm, 75 µm x 150 mm). The column was maintained at 35◦C and the flow rate
was 400 nL/minute. The mobile phases used were as follows: A, 0.1% formic acid with 5% DMSO
and B, 0.1% formic acid in 100% acetonitrile with 5% DMSO. Peptides were diluted 1:10 during
trapping with mobile phase A and concentrated and desalted onto a nanoACQUITY UPLC
Symmetry C18 Trap Column (100 Å, 5 µm, 180 µm x 20 mm). Chromatographic separation
was achieved using the following gradient: 3% mobile phase B, increasing linearly to 40% over
40 minutes and increasing linearly to 85% over the following 2 minutes. The mobile phase
composition was held for a further 2 minutes, before returning to the initial conditions for 15
minutes of re-equilibration.
Mass spectrometry analysis was performed over 60 minutes on a SYNAPT G2-Si mass
spectrometer in UDMSE positive ion electrospray ionisation mode and operated in V-mode. One
second alternating high and low energy scans were performed at a capillary voltage of 3.0 kV,
sampling cone voltage of 40 V and a source temperature of 70◦C over a mass range of 50-2000 Da
in resolution analyser mode. Ion mobility separation was performed to separate similar precursor
ions using a wave velocity of 650 m/s and a wave height of 40 V. Low energy scans were performed
using a collision energy of 0 V and the high energy scans were performed using a gradient of
collision energies, optimised depending on the ion mobility bin. The collision energy was 13.6
V from 0-20 ion mobility bins increasing linearly to 49.1 V at 120 mobility bins, followed by
another linear gradient to 54.1 V at 200 mobility bins. Every 60 seconds [glu1]-fibrinopeptide
B was delivered via an auxiliary pump at a flow rate of 300 nL/min as a lock mass to permit
real-time recalibration by correcting m/z shifts arising from instrumental drift.
Raw data was imported into ProteinLynx GlobalServer version 3.0.1 (Waters, Manchester, UK)
in order to identify peptide masses corersponding to the fragmentation ion data. Mass corrections
were applied based on the [glu1]-fibrinopeptide B mass delivered via an auxillary pump. Spectra
were compared to the UniProt reviewed human proteome (www.uniprot.org/downloads) using
the following searching parameters: two fragment ions matched per peptide, four fragment ions
per protein, two peptides per protein and one missed enzymatic cleavage. Protein concentrations
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were determined by comparison to a known concentration (50 pmol/µL) of spiked enolase peptide
standard.
2.18 quantification of ccbl1 enzyme activity with respect to kynure-
nine using uplc-ms/ms
Experiments were undertaken to determine whether the overexpressed CCBL1 enzyme had
kynurenine aminotransferase activity. All reagents were made up in 200 mM sodium phosphate
buffer (pH 7.5). 2.5 µL of IVT mix was transferred into five labelled eppendorfs corresponding to
the five time-points used to measure the enzyme activity [0, 15, 30, 60, 120 minutes]. 47.5 µL of
master mix [containing 5 µL of 50 µM kynurenic acid, 2 µL of 50 µM oxaloacetate, 2 µL of 1 µM
PLP, 38.5 µL of 200 mM sodium phosphate (pH 7.5)] was then added. The 0 minute reaction was
stopped by adding 50 µL of 0.3 TCA and vortexing thoroughly for 30 seconds. The remaining
tubes were incubated with shaking at 37◦C for the appropriate times, and subsequently stopped
with 0.3N TCA. Tubes were then left on ice in the dark for 45 minutes to allow any protein to
precipitate, before centrifuging at 10,000 rpm for 10 minutes to pellet the proteins present in the
reaction mixture. The resulting supernatant was transferred to a HPLC vial and placed in an
autosampler, protected from light and kept at 4◦C until sample injection.
Stock solutions of kynurenine (KN), kynurenic acid (KA) and d5-kynurenic acid were made
up using dH2O and stored at -80◦C to prevent degradation. Quantification was achieved by
spiking 2 µL of 3 µM d5-KA to each reaction. Calibration curves were constructed using different
concentrations of KN and KA, whilst keeping the concentration of d5-KA identical to that spiked
into each reaction. Concentrations of KN and KA were then determined by ratioing the analyte
signal area to that of d5-KA. Analyte concentrations were expressed as nmol/L.
LC-MS/MS was performed using an Acquity Ultra Performance LC sytem linked to a triple
quandrupole Xevo TQ-S instrument (Waters, Manchester, UK). An Acquity UPLC HSS T3
column (1.8 µm x 2.1 mm x 50 mm) fitted with a HSS T3 VanGuard guard column (Waters)
was used with a mixture of mobile phase A (100% methanol) and B (4 mM ammonium acetate
pH 2.1 with formic acid) at a flow rate of 0.5 mL/minute. Details of the mobile phase gradients
are shown in Table 2.18.1.
Analytes were detected using the mass spectrometer in positive ion mode using multiple
reaction monitoring (MRM). Kynurenine and kynurenic acid could be identified based on their
retention time and the m/z ratios of their corresponding parent and daughter ions (Table 2.18.2).
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Table 2.18.1: Mobile phase gradient profile for separation of kynurenine and
kynurenic acid in fibroblasts.
Time (minutes) A (100% methanol) B (4 mM ammonium acetate pH
2.1 with formic acid)
Curve
0.00 0.2 99.8 0
1.00 0.2 99.8 6
2.00 85.0 15.0 6
5.00 85.0 15.0 2
6.00 0.2 99.8 6
8.00 0.2 99.8 11
Table 2.18.2: Mass transitions, cone voltages, collision energies and retention times
of analytes quantified using the CCBL1 enzyme assay. All analytes were
detected using a Xevo TQ-S mass spectrometer in positive ion mode using MRM.
Analyte Molecular
weight
(g/mol)
Parent
ion
(m/z)
Daughter
ion
(m/z)
Cone
voltage
(V)
Collision
energy
(V)
Retention
time
(mins)
Kynurenine 208.22 209.14 192.08 20 8 1.84
Kynurenic acid 189.17 190.20 144.00 30 12 2.11
d5-kynurenic acid 194.17 195.20 148.96 30 12 2.11
A 15 µL volume of each CCBL1 enzyme assay time-point mixture was injected on to the
mass spectrometer every 8 minutes and the data was acquired using MassLynx software (Waters).
Data processing was completed using QuanLynx software (Waters).
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2.19 quantification of endogenous kynurenine and kynurenic acid using
uplc-ms/ms
5 µL neat urine was added to 53 µL dH2O and 2 µL 3 µM d5-KA. 60 µL 0.3N TCA was then
added to each sample before being centrifuged to pellet any precipitated protein. The resulting
supernatant was transferred to a HPLC vial and placed in an autosampler, protected from
light and kept at 4◦C until sample injection. Quantitation of the endogenous KN and KA was
performed using the UPLC-MS/MS method detailed in Section 2.18. Results were corrected for
urinary creatinine concentration using the method described by (Mills et al., 2010).
2.20 colourmetric assays for detection of tertiary amines
2.20.1 Urinary ninhydrin assay
200 µL of urine was added to 300 µL of 3N perchloric acid and 200 µL of 2% (w/v) ninhydrin.
Samples were heated for 5 minutes at 100◦C and centrifuged at 16,000 x g for 10 minutes.
Absorbance was measured at 492 nm and 555 nm. Results were subsequently corrected by urinary
creatinine concentration using the method described by (Mills et al., 2010).
2.20.2 Urinary o-aminobenzaldehyde (o-AB) assay
250 µL of urine was added to 250 µL of 40 mM o-aminobenzaldehyde (o-AB) in 200 mM potassium
phosphate (pH 8). Samples were incubated at 37◦C overnight and the absorbance was measured
at 450 nm using a spectrophotometer. Results were subsequently corrected for urinary creatinine
concentration.
2.20.3 Detection of in vitro translation reaction products using o-aminobenzaldehyde (o-AB)
Experiments were designed to determine whether CCBL1 produced by an IVT reaction could con-
vert lysine to an equilibrium mixture of α-keto--aminocaproate and ∆1-piperideine-2-carboxylate.
The latter of which could be expected to produce a coloured reaction product with o-AB.
Mixes containing 5 mM L-lysine, 70 µM PLP, 100 mM α-keto acid, 100 mM potassium
phosphate buffer (pH 8.0) and 10 µL CCBL1 IVT reaction mix in a final volume of 250 µL
were prepared. Four different reactions were performed, each using a different α-keto acid:
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2-oxobutyrate, 2-oxoglutarate, pyruvate or oxaloacetate. An additional sample with no α-keto
acid substrate was also prepared. Each sample was incubated at 30◦C for 4 hours and terminated
by the addition of 11.4 µL 3N TCA and 113.6 µL 100% ethanol. 250 µL of the de-proteinised
supernatant was then mixed with 250 µL of o-AB mix [containing 40 mM o-AB in 200 mM
potassium phosphate buffer (pH 8.0)]. The samples were incubated at 37◦C overnight and the
absorbance was subsequently analysed at 450 nm.
2.21 synthesis of α-keto--aminocaproate and ∆1 -piperideine-2-carboxy-
late and detection of these compounds and lysine
Two methodologies were used to synthesise an equilibrium mixture of α-keto--aminocaproate and
∆1-piperideine-2-carboxylate from D-lysine using D-amino acid oxidase from porcine kidney. In
the first (based on Konno (1998)), 300 µL 0.133 M pyrophosphate buffer (pH 8.3), 700 IU catalase,
300 µL 0.1 M D-lysine, 200 µL 0.1 mM flavin adenine dinucleotide, 100 µL 70% methanol and
10 units of D-amino acid oxidase (in 100 µL of dH2O) was incubated at 37◦C for 2 hours. The
reaction was terminated by the addition of 1 mL 0.3 N TCA. In the second method (based on
Visser et al. (2012)), mixes containing 25 mM ammonium bicarbonate buffer (pH 8.3), 1 mM
D-lysine, 0.25 mg D-amino acid oxidase and 900 units of catalase in a total volume of 100 µL
were prepared. 0.1 mM flavin adenine dinucleotide was added to half of the reactions. Each
reaction was terminated by the addition of 100 µL 0.3 N TCA. Subsequently, each reaction
mix was desalted using C18 solid phase extraction columns prior to direct infusion into the
Xevo TQ-S mass spectrometer. Columns were primed with 1 mL 50% acetonitrile (ACN) [0.1%
TFA], followed by 1 mL 0.1% TFA. Samples were added to the primed columns, and the eluents
were reapplied to the columns. Salts were removed by washing the columns with 0.1% TFA.
Other molecules were eluted in 1 mL 50% ACN [0.1% TFA] followed by 100% methanol. The
transitions identified are shown in Table 2.21.1. LC-MS/MS was performed using the same mass
spectrometer and column as for the quantification of the B6 vitamers (Section 2.11) as many of
the methods published for the analysis of amino acids (such as lysine) use columns with similar
physicochemical properties. The gradient used is shown in Table 2.21.2 and the flow rate was
maintained at 0.6 mL/min. Analytes were detected in positive ion mode using multiple reaction
monitoring.
96
Table 2.21.1: Optimal transitions for the detection of lysine and ∆1-piperideine-2-
carboxylate (P2C). *, predicted compound.
Analyte Parent ion
(m/z)
Daughter ion
(m/z)
Cone
voltage
(V)
Collision
voltage
(V)
Retention
time (mins)
Lysine 147.10 56.08 28 24 0.58
Lysine 147.10 84.09 28 14 0.58
P2C* 128.10 55.04 40 20 0.54
P2C* 128.10 82.08 40 14 0.54
Table 2.21.2: Mobile phase gradient profile for the separation of lysine metabolites.
HFBA, heptafluorobutyric acid.
Time (minutes) A (3.7% acetic acid + 0.01% HFBA) B (100% acetonitrile) Curve
0.00 99.8 0.2 0
0.40 99.8 0.2 6
3.75 50.0 50.0 6
3.76 0.1 99.9 11
4.25 0.1 99.9 11
4.26 97.5 2.5 1
5.20 97.5 2.5 1
To assess the activity of CCBL1 towards lysine, 5 µL of IVT mix containing overexpressed
CCBL1 protein (Section 2.16.13) was transferred into five labelled eppendorfs corresponding
to five time-points [0, 30, 60, 120 and 180 minutes]. 45 µL of master mix containing 1 µM
L-lysine, 1 mM oxaloacetate, 40 µM PLP and 1000 units of catalase was then added. Each
sample was incubated at 37◦C for the appropriate time before terminating with 50 µL of 0.3 N
TCA. Samples were then precipitated and injected as previously (Section 2.18), before analysis
using the parameters described above (Tables 2.21.1 and 2.21.2).
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3
VALIDATION AND USE OF GENE PANEL SEQUENCING
TECHNOLOGY FOR THE DIAGNOSIS OF INBORN ERRORS OF
METABOLISM
3.1 introduction
As described in Chapter 1, there are many challenges to the accurate diagnosis of IEM, mainly
attributable to the clinical and genetic heterogeneity, the often-atypical presentation early
in the disease course, the lack of clinical awareness of rare entities and the unavailability of
certain diagnostic tests in non-specialist centres. Hence, patients with suspected IEM, especially
those with accompanying neurological signs, are often referred to specialist centres early in life.
However, despite this, there are very often diagnostic delays or difficulties establishing the correct
IEM diagnosis. Indeed, despite extensive genetic and biochemical investigations the underlying
aetiology remains undetermined in many cases, and in up to 50% of patients at some tertiary
referral centres. Next-generation sequencing technologies are ideal for the genetic diagnosis of
patients such as these, in which an unbiased approach is beneficial. Both WES and WGS have
been proven to be effective for the diagnosis of IEM in a research setting (Tarailo-Graovac et al.,
2016; Dinwiddie et al., 2013; Stranneheim et al., 2014). However, the identification of causal
variant(s) is a challenge requiring expert analysis and collaboration within a multidisciplinary
team. Indeed, much of the time taken for WES and WGS is primarily due to data analysis, which
is often prohibitive in clinical laboratories. Ideally, for those disorders which are amenable to
treatment, diagnosis should be more rapid than currently achievable using WES or WGS so as to
minimise the impact of any irreversible damage that may be caused. Examples include directing
early vitamin supplementation with pyridoxal 5’-phosphate in patients with pyridox(am)ine
5’-phosphate oxidase deficiency (Mills et al., 2014) or with biotin and thiamine in patients with
biotin-thiamine-responsive basal ganglia disease (Alfadhel et al., 2013). Misdiagnosis or diagnostic
delay of these disorders can lead to a variety of adverse outcomes including neuropsychological
dysfunction, mental retardation and death.
The objective of this chapter was to design and investigate the utility of a comprehensive gene
panel targeting all IEM-causing genes and use it to investigate patients presenting with complex
neurometabolic phenotypes. An Agilent HaloPlex Target Enrichment System was used which
makes use of restriction enzyme digestion and custom-designed probes to capture the genes of
interest prior to sequencing using an Illumina platform (Figure 3.1.1).
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Figure 3.1.1: Targeted gene capture using HaloPlex technology. (a) Each DNA sample is fragmented using restriction enzymes. (b) A library of
custom-designed probes which target the genes of interest are then added. (c) Each probe is an oligonucleotide designed to hybridise to both ends
of a targeted DNA restriction fragment. The ends of the probe are complementary to the desired fragment sequence, the middle part contains
a sequencing-specific motif and each is biotinylated to facilitate capture. (d) The probes hybridise to the target fragments, forming a circular
shape. (e) Magnetic streptavidin beads are added, (f) the circular DNA fragments are captured and the non-circular fragments are removed. (g)
DNA ligase closes the DNA circles and (h) the circular DNA fragments are then eluted from the beads. (i) PCR occurs using universal primers
containing a barcode which allows for sample multiplexing. (j) Multiple PCR cycles generates barcoded linear fragments ready for sequencing.
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The panel’s effectiveness in establishing diagnoses, clinical implications and contribution to
expansion of known phenotypes are discussed. The value of in silico tools commonly used by
research and clinical diagnostic laboratories to predict the pathogenicity of sequence variants are
also considered.
3.2 methods
3.2.1 Patient recruitment
A total of forty four patients were recruited from metabolic medicine clinics at Great Ormond
Street Hospital for Children. For panel validation purposes, fourteen patients with a known
genetic diagnosis were recruited to verify the panel’s ability to identify pathogenic variants (Table
3.3.4). Additionally, thirty patients presenting with neurometabolic disease and lacking a specific
genetic diagnosis were selected for targeted sequencing (Table 3.3.6 and Table 3.3.10). Written
informed consent was obtained in all cases.
3.2.2 Design of amplicons to enable maximal capture of IEM genes using HaloPlex enrichment
The design of the IEM gene panel was based on genes listed on the SSIEM Classification of
Inborn Errors of Metabolism (2011) (www.ssiem.org) with additions from recent publications,
existing smaller disease-specific panels [Mitome200-Nuclear (Baylor College of Medicine) and
Mitochondrial Disorders Panel (ARUP Laboratories)] and suggestions from the GOSH Metabolic
Team. The final design contained 614 genes known to cause IEM and covered 16 broad sub-classes
of this group of disorders (Table 3.2.1). A complete list of the genes included can be found in
(Appendix 9.1). The gene accession numbers and coordinates were downloaded from the UCSC
Genome Browser (www.genome.ucsc.edu) and the SureDesign system (Agilent Technologies Inc.
USA) was used to design the probe library for the genes of interest. The design was based on a
read length of 150bp on an Illumina platform and targeted all coding exons of the target genes
as well as 25bp of flanking intronic sequence. This created a 1.43Mbp design with a predicted
target coverage of 99.55%. 6471bp were predicted to not be covered. The failure to completely
cover a region of interest can be attributed to repeated regions in the flanking sequences, lack of
restriction fragments of appropriate size, or fragments too large relative to the read length leading
to partial sequencing of fragments. When using the SureDesign software, amplicons are selected
from only one DNA strand for each target and amplicons containing known polymorphisms are
excluded. Coverage was optimised, in collaboration with Agilent, by including amplicons from
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both strands of each target that was not initially fully covered and increasing the number of
probes to capture all known haplotypes in order to increase target coverage. By implementing
these changes, predicted coverage of 39% of the 6471bp that would not have been covered by the
original design was possible, without reducing the stringency of the design.
Table 3.2.1: The sixteen classes of IEM represented within the gene panel and the
distribution of the 614 genes amongst them. Note that due to the highly
interconnected and heterogeneous nature of metabolism, mutations in one gene
can give rise to multiple different disorders, leading to an apparently higher total
number of genes than stated in the text.
Disorder Class Number of genes
Amino acid and peptide metabolism 98
Carbohydrate metabolism 43
Fatty acid and ketone body metabolism 18
Energy metabolism 154
Metabolism of purines, pyrimidines and nucleotides 33
Metabolism of sterols 22
Porphyrin and haem metabolism 9
Lipid and lipoprotein metabolism 32
Congenital disorders of glycosylation and other disorders of protein
modification
76
Lysosomal disorders 54
Peroxisomal disorders 24
Neurotransmitter metabolism 8
Metabolism of vitamins and non-protein cofactors 40
Metabolism of trace elements and metals 24
Metabolism of xenobiotics 2
Other disorders 11
3.2.3 Target capture, library sequencing and variant calling
Genomic DNA was extracted from EDTA blood using the AutoGenFlex STAR automated system
according to the manufacturer’s instructions (Section 2.3). The materials and methods used for
HaloPlex target enrichment, next-generation sequencing using the Illumina platform and variant
calling are described in Section 2.4. Sequence variants with putatively deleterious effects were
confirmed by Sanger sequencing as described in Section 2.3.3.2. Primer sequences are detailed in
Appendix 9.1.1.
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3.3 results and discussion
3.3.1 Analysis pipeline for the indentification of potentially pathogenic variants
Raw FASTQ files were aligned to the hg19 reference genome and variants were called using the
method described in Section 2.4.11. Variants were initially filtered using the standard pipeline
used by the North East Thames Regional Genetics Service Laboratories (summarised in Figure
3.3.1). Firstly, the variant must be present in a homozygous or heterozygous state in the patient
of interest and not identified in any other patient analysed in the same sequencing run. An
exception to this can be made if siblings or other family members are analysed together. Due
to the rarity of individual IEM (even the most common, phenylketonuria and medium-chain-
acyl-CoA dehydrogenase deficiency, have an incidence of approximately 1 in 15,000), it is highly
unlikely that multiple unrelated patients with the same genetic defect and even less-so the same
mutation would be analysed in the same batch. Nevertheless, this analysis algorithm is not
fixed and multiple different iterations of analysis with varied parameters can be performed, thus
a good potentially pathogenic variant (e.g. strong phenotypic correlation with other patients
with mutations in that gene, low minor allele frequency etc.) may not be discarded based on a
single criterion. Similar flexibility can also be employed in the case of a candidate variant that is
identified in a heterozygous state in another unrelated patient.
Secondly, only variants with a minor allele frequency of less than 2% are selected as only
variants that are rare in the general population are likely to cause rare metabolic diseases. Finally,
the variants are ranked by their predicted consequence score (Table 3.3.1). This is an arbitrary
score that predicts the likelihood of a type of mutation causing disease; for example a synonymous
variant in the 3’UTR region of a protein is less likely to cause disease than an exonic stop gain
mutation. These filtering parameters are termed the "Lookup" filter and determine which of the
∼ 1500 variants identified in each patient are worthy of further scrutiny.
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Table 3.3.1: Consequence scores of gene panel variants. The set of consequence terms is
defined by the Sequence Ontology (http://www.sequenceontology.org/). Each
variant is mapped to the reference genome and a rule-based approach is used to
predict the effect that each variant may have on the gene transcript. Note that
each variation may have a different effect in different transcripts, hence more than
one term is often applied to each variant. These terms have been ranked from 1 -
5 based on their predicted effect on function, with 1 being the most likely to be
benign and 5 being the most likely to be damaging.
Consequence terms (i.e. the variant type) Consequence ranking
Stop lost 5
Stop gained 5
Frameshift variant 4
Splice donor variant 4
Splice acceptor variant 4
Splice region variant 3
In-frame insertion 3
In-frame deletion 3
Missense variant 3
Initiator codon variant 3
Stop retained variant 3
Transcription factor binding site variant 2
Synonymous variant 2
3’ untranslated region variant 1
5’ untranslated region variant 1
Upstream gene variant 1
Downstream gene variant 1
Regulatory region variant 1
Non-coding exon variant 1
Nonsense-mediated decay transcript variant 1
Non-coding transcript variant 1
Intron variant 1
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Figure 3.3.1: "Lookup" filtering pipeline applied to variants. Minor allele frequencies
were collated from 1000 Genomes Project (www.1000genomes.org/) and Ensembl
(www.ensembl.org/) using data from African, American, Asian and European
populations. Types of variants are ranked on their predicted consequence (i.e. a
3’ UTR variant has a ranking of 1, whereas a stop gain variant has a ranking of
5).
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After applying this filter, approximately 40 candidate variants remained for each patient. In
a routine diagnostic setting it is important to aim to minimise the time required for manual data
interrogation to reduce the costs and turn-around time for the assay. An analysis pipeline was
developed to help further filter these variants (shown in Figure 3.3.2). This algorithm was based
on a number of parameters assessed using the tools detailed in Section 2.6, including:
• Whether the variant had been reported as pathogenic previously;
• The frequency of the variant within populations;
• Predicted functional impact of the variant with nonsense and frameshift mutations, single
or multi-exon deletions, and variants affecting the canonical splice sites (± 1 or 2 bases
from econ boundaries) or initiation codons predicted to cause the greatest loss of function;
• Conservation of the mutated residue amongst species;
• Correlation of the patient’s phenotype with the clinical and biochemical features of other
cases reported in the literature with pathogenic mutations in the same gene;
• Segregation of the variant within the patient’s family (where samples were available);
Highly conserved DNA sequences are thought to have functional value as particular bases
or amino acids have been maintained by evolution despite speciation. The further back in the
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phylogenetic tree a residue occurs, the more highly conserved it is considered to be. Deleterious
sequence variants are also thought to be rare in the population as their presence reduces an
organism’s fitness. Variants such as this are removed from the population as the probability of
survival and subsequent reproduction are reduced. SIFT and PolyPhen-2 were the two online
tools used to predict the functional impact of variants. Both tools consider sequence homology
and physico-chemical amino acid properties to make predictions. PolyPhen-2 additionally uses
annotations of functionally important domains, 3D structures from the Protein Data Bank and a
number of other tools. SIFT provides qualitative predictions (either "tolerated" or "deleterious")
with normalised probabilities that amino acid changes are tolerated between 0-1. Substitutions
with a score < 0.05 are classified as "deleterious". PolyPhen-2 also provides qualitative predictions
(one of "probably damaging", "possibly damaging" or "benign") and a probability score between
0-1. Substitutions with a score nearer 1 are more confidently predicted to be deleterious.
Initially, the data was searched for any homozygous or compound heterozygous mutations
that are known to be pathogenic and would be consistent with the phenotype of the patient
(Figure 3.3.2). If none were identified, clinical phenotypic information was considered, either
by using a candidate gene list or filtering by disease class. Candidate gene lists were generated
using Phenomizer, a database based on Human Phenotype Ontology (HPO) terms, in which
the clinical and/or biochemical features of a particular patient were input to produce a list of
all the disorders and genes associated with them that could fit the phenotypic profile (Köhler
et al., 2009). The HPO provides a standardised vocabulary of phenotypic features seen in human
disease. It is collated using information from Online Mendelian Inheritance in Man (OMIM)
(www.omim.org) and the medical literature and contains approximately 10,000 terms (Kohler
et al., 2014). Alternatively, if applicable, variants were searched for within a certain disease class.
For example, if the patient had lactic acidosis or abnormal muscle respiratory chain activity,
variants within genes known to cause mitochondrial disorders were interrogated first.
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Figure 3.3.2: Analysis pipeline for IEM gene panel.
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Where phenotypic filtering was possible, the resulting reduced number of variants were
examined further in order to determine whether any homozygous or compound heterozygous non-
synonymous variants were present that may explain the patient’s phenotype. If plausible variants
were identified then SIFT and PolyPhen-2 scores were used to predict their functional impact,
multiple sequence alignments were generated using Clustal Omega to assess the cross-species
conservation of the mutated residue in the case of single nucleotide variants, and databases
of population statistics (Ensembl, Exome Aggregation Consortium and 1000 Genomes) were
interrogated to determine the minor allele frequency of the variant. If, after consultation with
the clinician looking after the patient, the variants were deemed likely to be pathogenic then
Sanger sequencing was used to confirm the mutation state in the patient and segregation in the
parents or other family members if DNA was available. When phenotypic filtering did not reveal
any candidate variants, all other variants meeting the minimal criteria for potentially causing
rare autosomal recessive disease (see "Lookup" filtering (Figure 3.3.1)) were also examined.
Once candidate variants had been identified, they were secondarily ranked according to
American College of Medical Genetics and Genomics (ACMG) guidelines (Richards et al., 2015).
These recommendations were compiled to enable the objective classification of sequence variants
into five classes using criteria informed by expert opinion and empirical data: pathogenic, likely
pathogenic, uncertain significance, likely benign or benign. These classes are determined based
on the strength of the evidence supporting pathogenicity from different sources including in silico
predictions, population databases and the scientific and medical literature.
3.3.2 Optimisation of target coverage and sequencing metrics
The gene panel was designed to target 7522 exons and 25 base pairs of flanking intronic sequence
of the 614 genes of interest. This created a 1.43Mbp design with a predicted coverage of 99.5%.
The sequencing parameters then needed to be optimised in order to maximise the utility of the
panel for clinical use. Read depth (i.e. the average number of times a base has been sequenced)
is critical for the ability to distinguish heterozygous and homozygous variations. In order to
confidently call a heterozygous variant, the DNA must be sequenced enough times so that there
is a reasonable probability of observing both alleles (Bentley et al., 2008). Traditionally, a read
depth of 30X was considered to be the threshold below which coverage is inadequate for accurate
variant calling. Practically however, covering all exons and intron-exon boundaries above a
30X threshold is often not achievable, especially with a panel this large. This is due to various
factors including variation in DNA capture, partial sequencing of fragments, repetitive regions
causing poor PCR amplification and variation in performance of the chosen sequencing platform
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(Berglund et al., 2013). As the use of NGS has become more widespread, guidelines have changed
and laboratories tend to use varying minimum thresholds, sometimes as low as 10X (Rehm et al.,
2013). Two of the most frequently used sequencing platforms in both research and diagnostic
laboratories, the Illumina MiSeq and HiSeq platforms, were used to sequence the capture regions
of our patients’ DNA. These platforms share the same functional chemistry; the major difference
is that the HiSeq can generate at least one order of magnitude more sequencing reads than
the MiSeq, thereby allowing greater multiplexing whilst maintaining target coverage. In some
cases, coverage of inadequate regions may be boosted simply by sequencing fewer samples per
batch thus allocating each sample more sequencing capacity leading to a higher average read
depth. However, a balance must be struck between the potential increase in data quality and the
consequent increase in cost per sample.
In order to ascertain the number of samples that could be run concurrently, initial studies
were performed using the Illumina MiSeq platform and involved varying the number of samples
pooled per sequencing lane in order to maximise target coverage. Graphical and numerical
representations of the sequencing metrics obtained are shown in Figure 3.3.3 and Table 3.3.2,
respectively. When seven patient samples were pooled, a mean depth of 174.0X sequencing
coverage was observed and 94.0% of the targeted regions were successfully sequenced with a
depth of at least 20X. On average 1099 (range: 1033 - 1157) variants were identified in each
patient with an average of 39 (range: 22 - 53) variants remaining after preliminary "Lookup"
filtering. When four patient samples were pooled, a mean depth of 462.4X sequencing coverage
was observed and 97.1% of the targeted regions were successfully sequenced with a depth of at
least 20X. On average 1060 (range: 973 - 1301) variants were identified in each patient with an
average of 32 (range: 18 - 61) variants remaining after filtering. In contrast, when 24 patient
samples were pooled and sequenced using Illumina HiSeq platform, a mean depth of 924.5X
sequencing coverage was observed and 97.8% of the targeted regions were successfully sequenced
with a depth of at least 20X. On average 1562 (range: 1456 - 1658) variants were identified
in each patient with an average of 28 (range: 14 - 38) variants remaining after filtering. This
revealed that when sequencing seven patients in one MiSeq run, fewer bases were covered at read
depths higher than 30X when compared to running 24 samples on the HiSeq or four samples on
the MiSeq (Figure 3.3.3).
108
Figure 3.3.3: Comparison of read depth parameters between differing batches of
samples analysed using either the MiSeq or HiSeq platform.
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Table 3.3.2: Percentage and range of alignment for all samples sequenced on the Illumina HiSeq/MiSeq platforms in the regions of interest
(ROI). The mean percentage and range of exons covered at greater than 10X, 20X, 30X, 50X and 100X are also shown. Finally, the mean and
range of base coverage across the samples is shown.
Sequencing
platform
(number of
samples)
% ROI coverage
>10X
% ROI coverage
>20X
% ROI coverage
>30X
% ROI coverage
>50X
% ROI coverage
>100X
Mean base coverage
per sample
Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range
MiSeq (7) 96.5 94.9 - 97.3 94.0 90.9 - 95.4 91.0 86.3 - 93.2 84.2 76.5 - 88.0 66.0 52.7 - 72.4 174.0 128 - 200.4
MiSeq (4) 98.0 97.9 - 98.1 97.1 96.7 - 97.4 96.2 95.4 - 96.7 94.2 92.9 - 95.1 88.2 86.0 - 89.8 462.4 406 - 488.1
HiSeq (24) 98.3 98.0 - 98.5 97.8 97.4 - 98.1 97.2 96.8 - 97.7 96.2 95.6 - 97.0 93.4 92.3 - 94.9 924.5 969.6 - 1006.0
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In summary, sequencing 24 patients in one HiSeq run resulted in double the average coverage
than sequencing four patients in one MiSeq run. However despite this, the proportion of target
regions meeting either a 20X or 30X threshold was not significantly different (Figure 3.3.3).
A cost analysis between these two options revealed that one large HiSeq run was more than
£100 cheaper per patient than analysing many small cohorts of patients on the MiSeq platform
(Table 3.3.3) and indeed within the diagnostic setting use of the HiSeq is preferential due to
less machine-time being required. Finally, the analysis of increased number of patients in the
same batch increases the power of the "Lookup" filter as the chance that sequencing artefacts
and common polymorphisms will be identified in more than one patient and thus discarded is
increased, leading to fewer candidate genes requiring further scrutiny (Section 3.3.2). Therefore,
sequencing 24 patients per HiSeq run was determined to be superior for gene panel analysis.
Table 3.3.3: Comparison of the costs required to prepare and sequence four patient
samples on the MiSeq platform and 24 patient samples on the HiSeq
platform.
Reagent Cost of MiSeq run
multiplexing four
patients (cost per
patient)
Cost of HiSeq run
multiplexing 24
patients (cost per
patient)
MiSeq Reagent Kit v2 (300 cycles) £165 -
HiSeq Rapid SBS Kit v2 (50 cycles x 3) - £41
HaloPlex 48-patient Custom Kit £270 £270
Other required reagents £10 £10
Total per patient £445 £321
3.3.3 Panel validation using patients with a known diagnosis and methods for the identification
of insertions and deletions
In order to validate the sensitivity and specificity of the gene panel methodology, fourteen
patients with a known genetic diagnosis were recruited to this study and analysed in a blinded
manner. Using the panel and pipeline outlined in Section 3.3.1, we were able to identify 71%
(15/21) of the pathogenic sequence variants previously identified in these patients including seven
heterozygous missense, four homozygous missense, one homozygous nonsense, two heterozygous
splice site mutations and one heterozygous combined insertion/deletion event. This still left 29%
of mutations which were not detected; these included four deletions ranging in size from 2 bp
to approximately 6 kb, one of which was in a homozygous state, one heterozygous combined
insertion/deletion event and one homozygous missense change (Table 3.3.4).
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Table 3.3.4: Patients analysed using the gene panel who had a prior known genetic diagnosis. -, not applicable due to SIFT and PolyPhen-2 only predicting the functional
consequence of missense mutations; *, reported at a low minor allele frequency in Ensembl; 1, Identified using gene panel analysis, in-house CNV analysis or not identified.
Patient Gender Phenotype Disorder Gene Nucleotide change Amino acid change Identified1 SIFT PolyPhen-2 Reference
1 Male Hyperammonaemia Arginosuccinic aciduria ASL c.925G>A p.Gly309Arg Panel Deleterious Benign Linnebank et al. (2002)
c.919-2A>G Splicing errors Panel - - Novel
2 Female Lysosomal storage
disorder
Hurler syndrome IDUA c.1469T>C; c.1469T>C p.Leu490Pro; p.Leu490Pro Panel Tolerated Benign Bach et al. (1993)
3 Female Epilepsy Pyridoxine-dependent
epilepsy
ALDH7A1 c.950C>T p.Ser317Leu Panel Deleterious Possibly
damaging
Mills et al. (2010)
∼6kb deletion
encompassing exons 14-17
∼6kb deletion
encompassing exons 14-17
CNV - - Mills et al. (2010)
4 Male Epilepsy Pyridox(am)ine
phosphate oxidase
deficiency
PNPO c.98A>T p.Asp33Val Panel Deleterious Possibly
damaging
Schmitt et al. (2010)
c.264-21_264-1delinsC Splicing errors CNV - - Mills et al. (2014)
5 Male Cholestasis Bile acid synthesis
defect
CYP7B1 c.1249C>T; c.1249C>T p.Arg417Cys; p.Arg417Cys Panel Deleterious Probably
damaging
Goizet et al. (2009)
6 Female Dystonia Hypermanganesemia
with dystonia,
polycythemia and
cirrhosis
SLC30A10 c.292_402del;
c.292_402del
p.Val98_Phe134del;
p.Val98_Phe134del
No - - Tuschl et al. (2012)
7 Un-
known
Mitochondrial
disease
Leigh syndrome due to
COX deficiency
SURF1 c.312_320del10insAT;
c.751+5G>A
-
Splicing errors
Panel
Panel
-
-
-
-
Wedatilake et al.
(2013)
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8 Un-
known
Mitochondrial
disease
Combined oxidative
phosphorylation
deficiency 8
AARS2 c.2033G>A
c.1195A>C
p.Arg678Gln
p.Asn399His
Panel
Panel
Tolerated
Deleterious
Benign
Benign
Novel*
Novel*
9 Male Mitochondrial
disease
Mitochondrial DNA
depletion syndrome
8A/B
RRM2B c.165G>A p.Met55Ile Panel Deleterious Possibly
damaging
Novel
deletion of exons 4-6 deletion of exons 4-6 CNV - - Novel
10 Female Mitochondrial
disease
Mitochondrial
complex I deficiency
NDUFS2 c.875T>C p.Met292Thr Panel Deleterious Possibly
damaging
Tuppen et al. (2010b)
c.840_842del p.Glu280-281del CNV - - Novel
11 Un-
known
Mitochondrial
disease
Leigh syndrome BCS1L c.385G>A; c.385G>A p.Gly129Arg; p.Gly129Arg Panel Deleterious Possibly
damaging
Tuppen et al. (2010a)
12 Female Mitochondrial
disease
Thiamine metabolism
dysfunction syndrome
2
SLC19A3 c.517A>G; c.517A>G p.Asn173Asp; p.Asn173Asp Panel Tolerated Probably
damaging
Fassone et al. (2013)
13 Male Folate metabolism
defect
Folate transporter
defect
SLC46A1 c.198C>A; c.198C>A p.Cys66*; p.Cys66* Panel - - Novel
14 Female Riboflavin
transporter defect
Brown-Vialetto-Van
Laere syndrome
SLC52A2 c.916G>A; c.916G>A p.Gly306Arg; p.Gly306Arg No Deleterious Probably
damaging
Johnson et al. (2012)
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A limitation of gene panel methodology and next-generation sequencing (NGS) is its inability
to easily detect insertions or deletions (indels) larger than approximately ten base pairs or if
the indel spans more than one short read. Multiplex ligation-dependent probe amplification
(MLPA) or array comparative genome hybridization (aCGH) are often requested alongside NGS
for these purposes. However, there are a number of ways in which these structural variations can
be detected from NGS data, including: de novo assembly, read splitting and inconsistencies of
insert sizes in pair-end mapping (Ye et al., 2009). Although de novo assembly is thought to be
the most accurate method, it is extremely problematic to apply to the human genome due to the
abundance and size of repetitive regions. Other algorithmic methods exist to identify the break
points of large deletions from short paired-end reads, such as Pindel (Ye et al., 2009). However,
these types of methods have not been implemented or validated in the clinical setting and would
only work if the breakpoints were covered by the gene panel design.
Deletions can also be detected by the analysis of read depth as this parameter is proportional
to the underlying genomic copy number. Read depth analysis is particularly effective for whole
exome or gene panel data because it does not rely on sequencing into or near the breakpoints.
These approaches compare the number of reads mapping to a certain genomic region with the
expected number under a certain statistical model which is specific to each algorithm. Similarly
to aCGH methodology, any deviations from these predictions indicate a possible copy number
variation (CNV). Due to the extensive variability in capture efficiency across exons, greater
CNV calling accuracy is achieved when the test sample is compared to a group of reference
samples sequenced using the same methodology and in the same batch. Multiple tools available
online, typically in the form of R packages, use different statistical models to calculate read
depth ratios. Both CNV-seq (Xie and Tammi, 2009) and ExomeCNV (Sathirapongsasuti et al.,
2011) assume a normal distribution of read count ratios. cn.MOPS assumes that read counts
are distributed according to a mixture of Poisson distributions (Klambauer et al., 2012) and
ExomeDepth uses a beta-binomial model (Plagnol et al., 2012). There are three main advantages
in estimating copy number variation using these packages compared to aCGH. Firstly, since
the depth of coverage shares a linear relationship with genomic copy number, the ability to
recognise CNVs is more accurate when the read depth at a particular position is high. Secondly,
certain methods allow the precise determination of the breakpoints because they do not rely
on predefined probes. Thirdly, because aCGH and MLPA use predefined probes, they cannot
detect alleles within patients that are incompatible with probe binding. Nevertheless, aCGH and
MLPA are still considered the "gold standard" methodologies for the detection of CNVs. This is
due to the sample preparation protocols being less complex and labour-intensive, a consensus
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analytical pipeline being established across clinical laboratories and a reduction in the number of
false-positives when compared to NGS.
The ability of both ExomeDepth and cn.MOPS to detect the five copy number variants
not identified by the standard pipeline were tested. All raw data was aligned to the hg19
reference genome and exon locations within our genes of interest were defined. ExomeDepth
analysis was carried out by Dr Chris Boustred, GOSH using the R package (www.cran.r-
project.org/web/packages/ExomeDepth/index.html) essentially as described by Plagnol et al.
(2012) and documentation available at the Comprehensive R Archive Network. None of the five
variants were identified. Analysis using cn.MOPS (www.bioconductor.org/packages/release/bioc/
html/cn.mops.html) was similarly performed according to Klambauer et al. (2012) and doc-
umentation available online. Patient 3, who has pyridoxine-dependent epilepsy, harbours a
heterozygous deletion encompassing exons 14 - 17 of ALDH7A1 that had been confirmed by
aCGH prior to this study commencing. cn.MOPS analysis called a heterozygous deletion on
chromosome 5 (chr5:125882015-125885985). This region encompasses the majority of exon 15
and 17, and the entirety of exon 16 of ALDH7A1. Although a deletion was called in the correct
region, the number and location of the deleted exons did not correspond to those identified by
aCGH. The remaining four variants were not identified.
One of the main limitations of tools such as those described above is the necessity for a
reference set of at least six samples to have been processed with the test sample using the same
capture methodology. Their power to detect CNVs is also largely affected by sample to sample
variability caused during target capture or sequencing (Plagnol et al., 2012). In addition, these
tools are best suited to the detection of CNVs whose size is greater than one exon as they are
only called if there is approximately a 50% reduction in expected reads i.e. a heterozygous exonic
deletion, or a 50% increase in expected reads i.e. an exonic duplication.
Read depth can also be assessed manually by using the Integrative Genomics Viewer (IGV)
(Robinson et al., 2011) to interrogate the BAM file in the genomic region of a strong candidate
gene. In the case of a homozygous deletion one would expect to see a gap in coverage or half the
number of amplicons in a region in the case of a heterozygous deletion. Although this method
has a lower specificity, the sensitivity is high as small increases or decreases in coverage can be
observed and quantified. However, this is generally not feasible when HaloPlex capture has been
used because amplicons are generated by restriction enzyme digestion as opposed to random
mechanical shearing and thus HaloPlex results in many reads covering identical or overlapping
genomic regions. As part of this study a method was therefore developed for identifying CNVs
based on comparison of the average coverage of each exon of a candidate gene across multiple
samples. Similarly to the algorithmic methods described above, the method also requires a cohort
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of reference samples with the use of higher numbers of samples affording greater CNV calling
accuracy. However, unlike the methods already described, these reference samples can be taken
from any batch sequenced using the same Illumina platform using the same capture methodology.
As the number of reads (and therefore the coverage) is inversely proportional to the number
of samples sequenced per lane, correcting for the sequencing capacity allocated to each sample
allows for direct comparisons between them. Firstly, candidate genes were identified using the
pipeline described in Section 3.3.1. The average read depth of each exon of the candidate gene
in the patient sample and multiple (>10) unrelated patients was then extracted. Read depth
parameters were corrected for the total sequencing capacity allocated to each sample (i.e. if
four samples were analysed in one MiSeq run and each sample used 25%, 20%, 27% and 28% of
the MiSeq capacity, then the average read depth would be divided by 0.25, 0.2, 0.27 and 0.28,
respectively). The data for all the "control" samples was then averaged and compared to the data
from the patient of interest. The data was also expressed as a percentage for ease of viewing and
analysis. A 100% reduction indicated a homozygous deletion; whilst a 50% reduction indicated a
heterozygous deletion of a whole of an exon. A deletion of a large region (i.e. < one exon) was
more difficult to interpret but corresponded to a reduction in coverage.
Using this method we were able to detect the presence of all heterozygous deletions and
insertion/deletion events in the patients with a prior genetic diagnosis which could then be
accurately determined by Sanger sequencing of the affected exon. The addition of this CNV
analysis method to the analysis pipeline increased the proportion of pathogenic sequence variants
identified to 90% (19/21). The main disadvantage of this method is its inability to detect
homozygous or compound heterozygous CNVs, as read depth analysis would only be carried
out in a targeted manner once a potentially pathogenic variant has been identified in a good
candidate gene. Indeed, one of the mutations that was not detected was the homozygous deletion
of 111 bp within the SLC30A10 gene in patient 6. However, when the coverage of this gene
was subsequently examined, the deletions was clearly evident (Figure 3.3.4). The other was a
homozygous missense variant in the SLC52A2 gene; this was not identified because the gene
was not included in the 614-gene design. Indeed, mutations in SLC52A2 were only identified
as causing a neurometabolic disorder in late-2012 (Haack et al., 2012). Encouragingly, no other
candidate genes were identified in this patient, illustrating the stringency of our methodology for
identifying potentially pathogenic variants. Many of the mutations identified in these patients
have not been reported in the literature previously (Table 3.3.4).
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Figure 3.3.4: Deletion analysis of SLC30A10 in patient 6 showing a reduction in
coverage of exon 1.
3.3.4 Identification of potentially pathogenic variants in patients without a prior genetic diag-
nosis
Following the validation of the gene panel sequencing and analysis methodology, 30 patients
with neurometabolic disease and lacking a specific genetic diagnosis were examined. The clinical,
biochemical and genotypic data of these patients is summarised in Tables 3.3.5 3.3.6, 3.3.7 and
3.3.10. Ages ranged from 1 to 20 years (mean 7.2 years, median 6 years). Of the 30 patients, only
9 had abnormal biochemical parameters pointing towards a specific underlying IEM. Despite this,
all patients had undergone extensive previous testing including multiple standard and specialised
biochemical blood tests, invasive investigations such as skin biopsies, muscle biopsies and lumbar
punctures, as well as targeted candidate gene testing. Gene panel sequencing identified a definitive
or likely genetic diagnosis that could at least partially explain the clinical phenotype in 53.3% of
patients (16/30).
3.3.5 Analysis of patients with strong biochemical indicators
Of the 9 patients (patients 15 - 22 and 31, Tables 3.3.5 and 3.3.6) with previous biochemical
testing indicating a specific diagnosis, identification of pathogenic variants was possible for
88.9% (8/9). Parental DNA to check segregation or whether mutations were in cis or trans
within the patient was not available for these cases. Pathogenic variants were not identified in
patient 31 in whom biochemical testing was suggestive of a diagnosis of hyperprolinaemia type II.
Candidate gene sequencing subsequently revealed that this patient was homozygous for a complex
insertion/deletion event in the ALDH4A1 gene (c.411_424delinsCGGCCC; p.Pro138Glyfs*13).
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In the remaining cases, one heterozygous insertion, six heterozygous and four homozygous
missense mutations were identified. The genetic diagnoses were consistent with the biochemical
findings in all cases. In the majority of cases, two pathogenic variants were identified in each
candidate gene. The three patients in which this was not the case are described below.
Three heterozygous variants in the HLCS gene were identified in patient 15; the first is a novel
insertion of one base causing a frameshift and premature stop codon (p.Val512Cysfs*65) and the
remaining two are novel missense variants. Both p.Pro709Leu and p.Val641Met are predicted
to be deleterious and probably damaging by SIFT and PolyPhen-2, respectively. However,
p.Val641Met is reported at a minor allele frequency of 0.48%, with four individuals homozygous
for this variant reported in the ExAC database. Indeed, when classifying the variants according
to American College of Medical Genetics and Genomics (AMCG) guidelines, this variant is
predicted to be of uncertain significance (Table 3.3.7).
A novel, likely pathogenic heterozygous variant (p.Val151Met) in the UMPS gene was identified
in patient 16. This patient was brought to the attention of the metabolic team as his older
sibling was born prematurely and died due to hyperammonaemia. There were no clinical concerns
regarding the patient, however urinary organic acid analysis showed moderately elevated orotic
acid levels between 9 - 48 µmol/mmol creatinine (ref: 0 - 5). Despite 95% of the UMPS gene
being covered at a read depth of > 30X, a second variant was not identified. Heterozygous
carriers of mutations in UMPS have been reported previously to have urinary orotic acid levels
between 2 and 7 times higher than that of controls (Suchi et al., 1997). In contrast, levels in
affected individuals are in the order of 200 times higher than the reference range (Grohmann
et al., 2015). Thus, the patient’s phenotypic features would be consistent with carrier status for
the UMPS mutation.
Similarly, only one variant was identified in patient 17. A biochemical diagnosis of carbamoyl
phosphate synthetase I deficiency had been made on the basis of a severely reduced carbamoyl
phosphate synthetase activity in a liver biopsy. In concordance with this, a known pathogenic
heterozygous missense change (p.His337Arg) was identified in exon 10 of CPS1 (Aoshima et al.,
2001). A second pathogenic mutation was not identified within CPS1 ; however, only 98.5% of
the gene was covered with a read depth > 30X and exon 21 had regions that were only covered at
a read depth of 3X. Therefore standard PCR of this exon was performed to examine the regions
that were insufficiently covered but no mutations were detected. Given that a second variant was
not identified, deletion screening was carried out which showed reduced coverage of exon 6 in the
patient, indicating a possible deletion (Figure 3.3.5a+b). Standard PCR and Sanger sequencing
of the region using intronic primers revealed a sequence identical to the reference, indicating that
if a deletion was present the breakpoints were not exonic. Long-range PCR was undertaken using
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Phusion DNA polymerase and primers located upstream of exon 5 and downstream of exon 7.
Whilst this revealed the same sized DNA fragments in both the patient and control, the results
were inconclusive as a small deletion could not be ruled out Figure 3.3.5c. Unfortunately, RNA
was not available for this patient so it was not possible to sequence the cDNA to evaluate the
entire gene for single nucleotide variants or gross structural variants.
Figure 3.3.5: Deletion analysis of CPS1 in patient 17 showing a reduction in cover-
age of exon 6. (a) average exon coverage corrected for sequencing capacity and
(b) expressed as a percentage. Pink, patient; purple, controls (n=10). (c) Long-
range PCR of both exons and introns adjacent to exon 6 as described in Section
3.3.14. (d) Schematic illustrating the position of the long-range PCR primers
used for amplification. The distance of each primer from the beginning/end of
each exon is shown in brackets.
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3.3.6 Identification of likely pathogenic variants in patients without an indicative biochemical
profile
Of the remaining 22 patients without a biochemical marker pointing towards a specific diagnosis,
a molecular genetic diagnosis that could at least partially explain the clinical-biochemical
phenotype was found for 36.4% of these (8/22) (patients 23 - 30, Table 3.3.6). In these 8
patients 11 variants were identified; three of which are known to be pathogenic. The variants
included three heterozygous and four homozygous missense mutations, one nonsense mutation,
one splice site mutation, one duplication leading to a frameshift and a premature stop codon and
one deletion/insertion event leading to a frameshift and a premature stop codon. All patients
presented in childhood and had neurological and biochemical abnormalities suggestive of a
neurometabolic disorder. Two variants were identified in each candidate gene. All mutations
were confirmed by Sanger sequencing in the proband and segregation within family members was
carried out where possible. Classification of the variants according to ACMG criteria is given in
Table 3.3.7. Detailed clinical case reports and contributions to the expansion of genotypes and
phenotypes associated with each disorder are described below.
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Table 3.3.5: Clinical details of patients without a prior genetic diagnosis who had pathogenic variants identified through gene panel sequencing. Details of
identified mutations can be found in Table 3.3.6. 5-HIAA, 5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate; BH4, tetrahydrobiopterin; BMI, body
mass index; CK, creatine kinase; DHA, docosahexaenoic acid; DHCA, 3α,7α-dihydroxycholestanoic acid; GSD, glycogen storage disease; HVA, homovanillic acid; IgA,
immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; THCA, trihydroxycholestanoic acid; VSD, ventricular septal defect.
Patient Age of
patient
Gender Primary clinical phenotype Other phenotypic features Relevant specialist investigations Diagnosis Gene
15 4 Male Organic acidaemia, no further
information available.
Short stature, asthma, development
unremarkable.
Elevated 3-methylcrotonylglycine (112
µmol/mmol creatinine), methylcitrate (66
µmol/mmol creatinine) and
3-hydroxyisovalerate in urine. Normal
biotinidase activity
Holocarboxylase
synthetase deficiency
HLCS
16 1 Male Sibling born prematurely and passed
away due to hyperammonaemia. No
clinical concerns.
N/A Moderately elevated urinary orotic acid
between 9-48 µmol/mmol creatinine (ref: 0-5)
Orotic aciduria UMPS
17 15 Male At 3.5 years: lethargy, vomiting,
alkalosis and hyperammonaemia.
Learning and behavioural difficulties
Day 2 of life: lethargy and irritability,
presumed sepsis but negative cultures.
Ammonia not measured.
Raised glutamine in plasma. Low
carbomyl-phosphate synthase activity in liver
biopsy (0.15 mmol/hr/mg protein)
Carbomoyl-
phosphate synthetase
I deficiency
CPS1
18 17 Female At 3 years: short stature, high BMI,
distended abdomen.
Hepatomegaly, no documented learning
difficulties.
Low GSD debranching enzyme activity of 0.07
µmol/min/g protein (ref: 0.3-3.0)
Glycogen storage
disease type III
AGL
19 9 Female Galactosaemia picked up through
newborn screening and treated early
Normal development apart from mild
difficulties in mathematics
Low gal-1-P-uridyltransferase activity of 1.8
µmol/hr/g Hb (ref: 18-40), elevated
galactose-1-phosphate of 2.4 µmol/g Hb (ref:
<0.1)
Galactosaemia GALT
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20 5 Male Global delay, one of monozygotic
twins.
Hypotonia, brachycephaly, long face. Brain
MRI: delayed myelination, lack of white
matter bulk.
Elevated plasma lysine ranging between
439-449 µmol/L (ref: 100-300), elevated CSF
lysine of 67 µmol/L (ref: 10-32)
Hyperlysinaemia AASS
21 5 Male Global delay, well-controlled epilepsy,
one of monozygotic twins.
Hypotonia, brachycephaly, long face. Elevated plasma lysine ranging between
440-780 µmol/L (ref: 100-300), elevated CSF
lysine of 92 µmol/L (ref: 10-32)
Hyperlysinaemia AASS
22 20 Female Sensorineural hearing loss, ataxia,
neurological regression, similarly
affected sister.
Scoliosis, constipation. Brain MRI:
leukodystrophy.
Bile acid analysis and skin fibroblast studies
suggestive of a peroxisomal biogenesis defect.
Elevated C26:C22 ratio of 0.038 (ref: 0 -
0.026), elevated phytanate of 20.21 (ref: 0 -
15), elevated pristanate of 30.11 (ref: 0 - 2),
low DHA of 58 (ref: 75 - 180). Presence of
THCA, DHCA and C29 dicarboxylic acid on
bile acid analysis. Absence of peroxisomes by
immunofluorescence microscopy.
Peroxisome
biogenesis disorder
PEX6
23 11 Female Developmental delay, ataxia,
horizontal nystagmus.
Microcephaly, retinal dystrophy. CSF: low 5-MTHF and high HVA and BH4.
Blood: Elevated prolactin, alanine,
intermittently high CK and plasma lactate.
Muscle: Normal respiratory chain enzymes
Muscular dystrophy-
dystroglycanopathy
POMGNT1
24 6 Male Neonatal jitteriness, developmental
delay, autism.
Joint hypermobility Persistent methylmalonic and malonic aciduria Combined malonic
and methylmalonic
aciduria
ACSF3
25 9 Male Congenital ataxia, diplegia, drop
attacks with no obvious EEG
correlate.
Brain MRI: Abnormal signal in caudate and
lentiform nuclei bilaterally.
Plasma: mildly raised alanine and normal
lactate. CSF: low 5-HIAA
Spinocerebellar
ataxia 28 /
Autosomal recessive
spastic ataxia 5
AFG3L2
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26 4 Male Developmental delay, subsequent
regression with progressive dyskinetic
movement disorder and dysphagia.
Sensorineural deafness. Brain MRI: High T2
signal in the basal ganglia and cerebellar
atrophy.
Raised 3-methylglutaconic acid with normal
3-methylglutaric acid levels
3-methylglutaconic
aciduria with
deafness,
encephalopathy and
Leigh-like syndrome
SERAC1
27 2 Male Global severe developmental delay,
tonic seizures.
Multi-organ malformations including VSD and
Hirschprung’s disease, dysmorphism. Brain
MRI: Dandy-Walker malformation and
reduced white matter bulk.
Recurrent hypoglycaemia,
hypogammaglobulinaemia, hyperphosphatasia
Hyperphosphatasia
with mental
retardation syndrome
3
PGAP2
28 6 Male Developmental delay, microcephaly,
lower limb hyper-reflexia.
Brain MRI: lack of white matter bulk. Abnormal transferrin isoelectric focusing (type
I pattern)
Late infantile
neuronal ceroid
lipofuscinosis
TPP1
Hereditary fructose
intolerance
ALDOB
29 6 Male Global developmental delay,
sensorineural hearing loss.
Neonatal acute liver failure which
subsequently resolved. Recurrent
hypoglycaemia and recurrent infections.
Abnormal isoelectric focusing (type I pattern),
normal phosphomannomutase and
phosphomannisomerase. Low IgA/IgM,
normal IgG and lymphocyte subsets
Galactose epimerase
deficiency
GALE
30 2 Male Microcephaly, developmental delay. Dysplastic kidneys. Neonatal lactic acidosis, high plasma
triglycerides, elevated urine thymidine and
uracil, low plasma urate and detectable
thymine
Dihydropyrimidinase
deficiency
DPYS
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Table 3.3.6: Pathogenic or likely pathogenic variants identified through gene panel sequencing in patients without a prior genetic diagnosis. -, not applicable due
to SIFT and PolyPhen-2 only predicting the functional consequence of missense mutations; *, siblings; 1, second mutation not identified; 2, parental DNA was unavailable
but Sanger sequencing identified the same homozygous mutation in a similarly affected sister; 3, parental DNA was unavailable but Sanger sequencing identified the same
homozygous pathogenic mutation in a brother who also had an abnormal type I transferrin isoelectric focussing pattern.
Patient Gene Nucleotide change Amino acid change Segregation
confirmed
SIFT PolyPhen-2 Minor allele
frequency
(ExAC)
Reference Phenotype
fully
explained
15 HLCS c.2126C>T p.Pro709Leu No Damaging Probably damaging 0% Novel Yes
c.1921G>A p.Val641Met Damaging Possibly damaging 0.48% Novel
c.1533dupT p.Val512Cysfs*65 - - 0.00082% Novel
161 UMPS c.451G>A p.Val151Met No Damaging Probably damaging 0.00082% Novel Yes
171 CPS1 c.1010A>G p.His337Arg No Damaging Probably damaging 0% Aoshima et al. (2001) No
18 AGL c.2590C>T p.Arg864* No - - 0.0083% Shen et al. (1996) Yes
c.2590C>T p.Arg864*
19 GALT c.563A>G p.Gln188Arg No Damaging Probably damaging 0.13% Reichardt et al. (1991) Yes
c.584T>C p.Leu195Pro Damaging Benign Reichardt et al. (1992)
20* AASS c.965G>A p.Arg322His No Tolerated Probably damaging 0% Novel No
c.965G>A p.Arg322His
21* AASS c.965G>A p.Arg322His No Tolerated Probably damaging 0% Novel No
c.965G>A p.Arg322His
22 PEX6 c.2734G>A p.Ala912Thr No2 Damaging Probably damaging 0.0025% Novel Yes
c.2743G>A p.Ala912Thr
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23 POMGNT1 c.373C>G p.Arg125Gly No Tolerated Benign 0.0017% Novel Yes
c.1539+1G>A Splicing errors - - 0.092% Yoshida et al. (2001)
24 ACSF3 c.1453A>C p.Ser485Arg Yes Damaging Probably damaging 0% Novel Yes
c.1453A>C p.Ser485Arg
25 AFG3L2 c.1067T>G p.Leu356Arg No Damaging Probably damaging 0% Novel Yes
c.1067T>G p.Leu356Arg
26 SERAC1 c.1850delinsCA p.Ile617Thrfs*6 Yes - - 0% Novel Yes
c.1850delinsCA p.Ile617Thrfs*6
27 PGAP2 c.560C>T p.Ala187Val Yes Damaging Probably damaging 0.0025% Novel Yes
c.560C>T p.Ala187Val
28 TPP1 c.887G>A p.Gly296Asp No Damaging Probably damaging 0.0032% Novel Yes
c.887G>A p.Gly296Asp
ALDOB c.178C>T p.Arg60* No3 - - 0.0091% Santer et al. (2005) Yes
c.178C>T p.Arg60*
29 GALE c.280G>A p.Val94Met No Damaging Probably damaging 0.00083% Wohlers et al. (1999) Yes
c.284G>A p.Gly95Asp Damaging Probably damaging 0% Novel
30 DPYS c.144_151dupGCTGCGGG p.Val51Glyfs*50 No - - 0% Novel No
c.144_151dupGCTGCGGG p.Val51Glyfs*50
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Table 3.3.7: Classification of the variants identified in the 30 patients without a prior genetic diagnosis according to the recommendations
of the American College of Medical Genetics and Genomics (AMCG) guidelines. Definitions of the criteria used to classify the strength
of the evidence to support pathogenicity are shown in Table 3.3.8.
Gene Variant Very strong evidence Strong evidence Moderate evidence Supporting evidence Final classification
HLCS c.2126C>T; p.Pro709Leu PM2 PP2, PP3, PP4 Uncertain significance
HLCS c.1921G>A; p.Val641Met PM1, PM2 PP2, PP3, PP4 Likely pathogenic
HLCS c.1533dupT; p.Val512Cysfs*65 PVS1 PM1, PM2 PP2, PP4 Pathogenic
UMPS c.451G>A; p.Val151Met PM1, PM2 PP2, PP3, PP4 Likely pathogenic
CPS1 c.1010A>G; p.His337Arg PS1, PS3 PM1, PM2 PP2, PP3, PP4 Pathogenic
AGL c.2590C>T; p.Arg864* PS1, PS3 PM2 PP2, PP4 Pathogenic
GALT c.563A>G; p.Gln188Arg PS1, PS3 PM1, PM2, PM3 PP2, PP3, PP4 Pathogenic
GALT c.584T>C; p.Leu195Pro PS1, PS3 PM1, PM2, PM3 PP2, PP3, PP4 Pathogenic
AASS c.965G>A; p.Arg322His PM2 PP1, PP2, PP3, PP4 Likely pathogenic
POMGNT1 c.373C>G; p.Arg125Gly PM2, PM3 PP2, PP3, PP4 Likely pathogenic
POMGNT1 c.1539+1G>A; Splicing errors PVS1 PS3 PM2 PP2, PP4 Pathogenic
DPYS c.144_151dupGCTGCGGG; p.Val51Glyfs*50 PVS1 PM2 PP2, PP4 Pathogenic
ACSF3 c.1453A>C; p.Ser485Arg PM1, PM2 PP1, PP2, PP3, PP4 Likely pathogenic
PEX6 c.2734G>A; p.Ala912Thr PM1, PM2 PP1, PP2, PP3, PP4 Likely pathogenic
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AFG3L2 c.1067T>G; p.Leu356Arg PM1, PM2 PP1, PP2, PP3, PP4 Likely pathogenic
SERAC1 c.1850_1851delinsCA; p.Ile617Thrfs*6 PVS1 PM2 PP1, PP2, PP4 Pathogenic
PGAP2 c.560C>T; p.Ala187Val PM2 PP1, PP2, PP3, PP4 Likely pathogenic
TPP1 c.887G>A; p.Gly296Asp PM1, PM2 PP2, PP3, PP4 Likely pathogenic
ALDOB c.178C>T; p.Arg60* PVS1 PS3 PM2 PP1, PP2, PP3, PP4 Pathogenic
GALE c.280G>A; p.Val94Met PS1, PS3 PM1, PM2 PP2, PP3, PP4 Pathogenic
GALE c.284G>A; p.Gly95Asp PM1, PM2, PM3 PP2, PP3, PP4 Likely pathogenic
EARS2 c.760A>G; p.Thr254Ala PM1, PM2 PP2, PP3, PP4 Likely pathogenic
IDH2 c.673G>A; p.Asp225Asn PM2 PP3, PP4 Uncertain significance
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Table 3.3.8: Criteria for classifying potentially pathogenic variants according to
ACMG Guidelines. These criteria were applied to the variants identified in our
patient cohort (Table 3.3.7).
Disorder Class Number of genes
PVS1 Null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation
codon, single or multiexon deletion) in a gene where loss of function is a
known mechanism of disease
PS1 Same amino acid change as a previously established pathogenic variant
regardless of nucleotide change
PS3 Well-established in vitro or in vivo functional studies supportive of a
damaging effect on the gene or gene product
PM1 Located in a mutational hot spot and/or critical and well-established
functional domain without benign variation
PM2 Absent from controls (or at extremely low frequency if recessive) in Exome
Sequencing Project, 1000 Genomes Project or Exome Aggregation
Consortium
PM3 For recessive disorders, detected in trans with a pathogenic variant
PP1 Co-segregation with disease in multiple affected family members in a gene
definitively known to cause disease
PP2 Missense variant in a gene that has a low rate of benign missense variation
and in which missense variants are a common mechanism of disease
PP3 Multiple lines of computational evidence support a deleterious effect on the
gene or gene product (conservation, evolutionary, splicing impact, etc.)
PP4 Patient’s phenotype or family history is highly specific for a disease with a
single genetic aetiology
3.3.6.1 Patient 23
Patient 23 is an 11 year old female. She was born by normal vaginal delivery at 36 weeks gestation
following spontaneous rupture of membranes with a birth weight of 1900g. She was nursed in
special care for two weeks and discharged home at three weeks of age on formula feeds. At
eight weeks of age she was admitted to hospital in Germany with pneumonia. She was noted
to be hypotonic, displayed abnormal movements and required tube feeding. Investigations at
this time showed elevated plasma and CSF lactate (7.0 and 2.7 nmol/L) and intermittently
raised creatine kinase (CK). A muscle biopsy was performed but only histology was carried
out at this time. She was given a working diagnosis of a "likely mitochondrial disorder" and
started on various vitamin supplements including coenzyme Q10, riboflavin and carnitine. These
were of no benefit and were gradually discontinued. The family moved to London and she
was referred to the Metabolic Medicine Department at GOSH at four years of age. Her main
presenting problems were poor appetite, developmental delay, frequent falls and limited exercise
tolerance. Although she could only speak two words, she appeared to understand language
and could indicate her needs by pointing. She had an ataxic gait and myopic astigmatism, left
128
esotropia with manifest horizontal nystagmus but normal ophthalmological electrodiagnostic
testing. Further investigation undertaken at this age confirmed raised plasma and CSF lactate,
whilst CK and white cell ubiquinone were normal. She was still considered to have a possible
mitochondrial disorder and had annual monitoring of cardiac and renal function which remained
normal. Her vision has improved slightly with time although nystagmus and squint remain
present. A brain MRI at seven years of age was normal. At this age, a muscle biopsy was
repeated and showed normal respiratory chain enzymology and normal histology. Chromosomal
analysis was also normal. Cultured fibroblasts demonstrated normal fatty acid oxidation and
pyruvate dehydrogenase, although just under the normal range, was considered normal. CSF
neurotransmitter analysis identified low 5-methyltetrahydrofolate so calcium folinate therapy was
commenced. Her condition has remained fairly static. Over time she continues to have good
general health, her appetite has improved and she no longer requires tube feeding. Her growth is
normal; she can walk and run although she is ataxic. Her appearance is somewhat coarse with
hirsutism.
DNA analysis revealed compound heterozygous variants in the POMGNT1 gene. Parental
DNA was not available to determine the segregation of each variant. The first was a splice site
variant (c.1539+1G>T) affecting the invariant GT donor site. This mutation has been reported
previously to generate two aberrant mRNA transcripts; a read-through of intron 17 with a
premature stop codon at position 484 and a skipping of exon 17 resulting in an in-frame deletion
of 42 amino acids (Yoshida et al., 2001). This mutation is found in 37/38 alleles from 14 families
of Finnish origin and represents a common founder mutation in this population (Diesen et al.,
2004). The second variant identified was a missense change (p.Arg125Gly) which is predicted to
be tolerated and benign by SIFT and PolyPhen-2, respectively. It is reported with a minor allele
frequency of 0.0017%. Two other variants affecting this amino acid residue have been reported
in the ExAC database, p.Arg125Gln and p.Arg125Trp. These have a minor allele frequency of
0.0025% and 0.0017%, respectively. Therefore in total, six individuals have been identified with
heterozygous variants that alter the Arg125 amino acid in POMGNT1 giving a combined minor
allele frequency of 0.0058%. Whilst the presence of POMGNT1 has not been reported in lower
organisms, a multiple sequence alignment of higher organisms showed that Arg125 is conserved
from humans to zebrafish.
The dystroglycan complex, comprised of α- and β-dystroglycan, links the extracellular matrix
to intracellular actin cables and provides structural integrity in muscle tissues. For correct α-
dystroglycan function the protein must be O-glycosylated; POMGNT1 participates in O-mannosyl
glycan synthesis by transferring N-acetylglucosamine to the O-linked mannose (Martin, 2007).
Patients with mutations in this gene typically present with neonatal hypotonia, mental retardation,
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moderate to severe muscle weakness, seizures, myopia, glaucoma and retinal hypoplasia (Yiş
et al., 2014). Brain MRI in these patients typically display abnormalities including cobblestone
lissencephaly, ventriculomegaly, white matter changes, cerebellar cysts and brainstem hypoplasia.
However, similarly to our patient, normal brain imaging has been reported on multiple occasions
(Yiş et al., 2014).
Given the glycosylation abnormalities present in these patients, immunofluorescence staining
of the glycosylated epitope of α-dystroglycan in muscle is typically absent or reduced, alongside
myopathic changes including the presence of small round muscle fibres of variable size. Therefore,
upon the identification of the two POMGNT1 variants in our patient, the muscle biopsy taken at
seven years of age was re-evaluated by Dr Tom Jacques, Histopathology Department, GOSH.
As identified at the time of intial evaluation, there was increased variation in fibre size ranging
from 7 - 37 µm (normal: 31 - 39 µm) due to scattered small angular and rounded fibres, as
well as prominent lipid accumulation for the age of the patient. All other histological and
immunohistochemical investigations undertaken at the time were normal. In view of the potential
diagnosis, immunohistochemistry and immunofluorescence staining of α-dystroglycan using
the VIA4 antibody was completed (Dubowitz Neuromuscular Centre, ICH). Allowing for the
artefactual vacuolation in the biopsy, no diagnostic loss of α-dystroglycan was reported (Figure
3.3.6). However, this does not exclude an abnormality of O-glycosylation, with patients having
been reported in the literature with only very mild changes detected using this method (Clement
et al., 2008; Jimenez-Mallebrera et al., 2009). Indeed, evidence suggests that the degree of
hypoglycosylation does not consistently correlate with clinical severity (Jimenez-Mallebrera et al.,
2009).
Our patient’s phenotype is very consistent with a mild α-dystroglycanopathy caused by
mutations in POMGNT1. Up to 30% of patients are able to walk independently and similarly to
our patient, speak some words (Yiş et al., 2014). Indeed there has been a case report with an
even milder presentation; she has normal intellect and attends university as well as having normal
glycosylated α-dystroglycan staining. Whilst no clear genotype-phenotype correlations have been
found in the α-dystroglcanopathies a phenotype with mental retardation with a normal MRI is
not normally associated with mutations in POMGNT1 but instead with mutations in POMT1,
POMT2 and ISPD which highlights the difficulty in detecting some of the α-dystroglycanopathies.
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Figure 3.3.6: Skeletal muscle biopsy analysis in patient 23 and a healthy control. (A
and C) Immunofluorescence staining of β-dystroglycan using the 43DAG1/8D5
antibody. (B and D) Immunofluorescence staining of α-dystroglycan using the
VIA4-1 antibody against the glycosylated epitope. Scale bars: 50 µm.
3.3.6.2 Patient 24
Patient 24 is a six year old male and the third child born to consanguineous parents. The
mother had previously suffered one still birth and there was a family history of two cousins
living abroad who had seizures and developmental delay. The patient presented with delayed
motor milestones in the first year of life, accompanied by autistic features and significant speech
and language delay. He was seen in the Metabolic Medicine Department at GOSH at two years
of age as routine investigations for developmental delay showed methylmalonic acid (MMA)
in urine. He was not dysmorphic, had normal growth, normal brain MRI and had never
had a metabolic decompensation. Further detailed metabolic investigations showed multiple
abnormalities including: elevated urinary MMA concentration on two occasions over the course
of four years ranging between 36 - 89 µmol/mmol creatinine (ref: 0 - 30), elevated plasma
MMA of 2.85 µmol/L (ref: 0 - 0.29), low plasma homocysteine of 4 µmol/L (ref: 5 - 15), mild
generalised aminoaciduria and elevated urinary N-acetyl-β-D-glucosaminidase of 76 unit/µmol.
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A number of biochemical parameters were also found to lie within the normal range, including:
methylcitrate/creatinine ratio, vitamin B12, blood spot carnitine profile and CSF amino acids.
Now at the age of six, he is autistic but is making slow developmental progress. Next-generation
sequencing using the gene panel revealed a novel homozygous missense mutation (p.Ser485Arg)
in ACSF3. Sanger sequencing confirmed that the variant segregated within the family with both
parents being heterozygous for p.Ser485Arg. This variant is predicted to be deleterious and
probably damaging by SIFT and PolyPhen-2, respectively. The variant lies with the second motif
region of ACSF3. This region is conserved amongst the acyl-coA synthetase family of enzymes
which function to activate fatty acids for intermediary metabolism and is predicted to be involved
in conformational change and catalytic function (Hiltunen et al., 2010). The mutated Ser485
residue is conserved in all other known ACSF3 family members from humans through to zebrafish
and Xenopus (Figure 3.3.7).
Figure 3.3.7: Multiple sequence alignment of the ACSF3 protein across species. (*)
positions with have a single fully conserved residue, (:) conservation between
amino acids with strongly similar properties, (.) conservation between amino
acids with weakly similar properties. The alignment was generated using Clustal
Omega.
ACSF3 encodes a mitochondrial methylmalonyl-coA and malonyl-coA synthetase and is
postulated to catalyse the first step of intramitochondrial fatty acid synthesis (Sloan et al., 2011).
Mutations in this gene causing combined malonic and methylmalonic aciduria were first described
in two back-to-back publications in 2011 (Sloan et al.; Alfares et al.). Since then two other
reports have been published bringing the total number of cases to 17 (de Sain-van der Velden
et al., 2016; Pupavac et al., 2016). Whilst a significant proportion of patients presented after
the fourth decade of life with memory problems, seizures and T2 hyperintensities on brain MRI
(Sloan et al., 2011), the majority of individuals present in childhood with symptoms suggestive
of a metabolic disorder. These include ketoacidosis, hypoglycaemia, metabolic acidosis, failure
to thrive, elevated transaminases, seizures, encephalopathy, microcephaly, developmental delay,
dystonia and hypotonia. Some patients are clinically asymptomatic, only being identified though
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urine screening programs (Alfares et al., 2011). The majority of patients have methylmalonic acid
(MMA) concentrations at least ten times the upper limit of the reference range in both plasma
and urine, with concentrations ranging between 5 - 50 µmol/L and 30 - 600 µmol/mmol creatinine,
respectively (Sloan et al., 2011). In the case of patient 24, plasma MMA concentrations were
comparable to the previously described patients with the mildest elevation, being ten-fold elevated
above the reference range. In contrast, his urinary MMA concentrations were much more mildly
elevated than any cases in the literature being only increased 2.5-fold relative to the reference
range. In some patients, MMA is the only accumulated metabolite; however, others also have
detectable malonic acid (MA) in their urine (Pupavac et al., 2016). In patient 24, MA was not
consistently seen in urine and when it was present it was not quantified (as this is not routinely
done in the laboratory where the sample was analysed). These apparently milder biochemical
abnormalities are mirrored by his milder clinical features, presenting only with developmental
delay and autism. Given its conservation, location in a functionally important part of the protein,
predicted damaging impact and the consistent biochemical findings it is likely that this variant is
pathogenic. Thus, this case expands the genotypic/phenotypic spectrum of a recently described
disease.
3.3.6.3 Patient 25
Patient 25 is the second child born to first cousin Pakistani parents. The perinatal history was
unremarkable, he was bottle-fed and gained weight satisfactorily. He had the usual immunisations
and his parents were not concerned about his progress until the second year of life. He did not
start walking until he was 18 months old and when he did, he was very unsteady and had frequent
falls. He was slow to start speaking and said his first words at 2 1/2 years of age. At 4 1/2 years
of age he had short phrases in the parent’s language of Punjabi/Urdu but very little English. He
started school at this time but had difficulty in keeping up with the other children and suffered
frequent drop attacks consisting of episodes of acute onset marked hypotonia associated with
noisy breathing and cyanosis. At 4 years of age, he was not able to use a spoon but could
scribble with a pencil despite not holding it with a pincer grasp. Examination at 9 years of age
demonstrated generalised dystonia with variable upper limb tone and clearly increased lower limb
tone, sustained ankle clonus and brisk reflexes throughout. His voluntary tongue movements
were uncoordinated and he could not blow up his cheeks. He had difficulties in following with his
eyes but there were no abnormal eye movements. Major clinical features were noted to be ataxia
with diplegia, developmental delay and drop attacks. Numerous investigations had been carried
out with the aim of establishing a diagnosis for this patient. Brain MRI demonstrated abnormal
signal in the caudate and lentiform nuclei as well as some abnormal signal in the midbrain. This
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was suggestive of a metabolic disorder and perhaps more specifically, a mitochondrial abnormality.
Multiple EEGs have been normal. Extensive metabolic investigations including CSF lactate,
neurotransmitter analysis, white cell enzymes and muscle mitochondrial respiratory chain enzymes
were normal. Pyruvate dehydrogenase was found to be slightly low in skin fibroblasts but much
higher than the affected range.
Sequencing identified a homozygous missense variant in AFG3L2 (p.Leu356Arg), which
encodes the catalytic subunit of the mitochondrial-AAA (m-AAA) protease. The variant is
predicted deleterious and probably damaging by SIFT and PolyPhen-2, respectively. The Leu356
residue is conserved from humans to yeast and is part of an 18-amino acid region that is
100% conserved across this evolutionary time. m-AAA proteases can be formed from homo-
oligomeric complexes of AFG3L2 or hetero-oligomeric complexes of AFG3L2 and paraplegin
(SPG7 ). Mutations in AFG3L2 can therefore result in much more severe phenotypes than those
in SPG7 as all m-AAA protease isoenzymes are affected (Elleuch et al., 2006). These complexes
are located within the inner mitochondrial membrane are responsible for degrading misfolded
proteins and regulating ribosome assembly by promoting the maturation of proteins such as
MrpL32, a critical component of the large subunit of mitochondrial ribosomes (Gerdes et al.,
2012). These functions are thought to be propagated by the recognition of the folded state of
substrate proteins (i.e. in the case of MrpL32, degradation begins at the unstructured N-terminus
but cannot proceed beyond the tightly-folded, cysteine-containing C-terminal region and the
protein dissociates resulting in correct N-terminal processing) (Bonn et al., 2011).
Mutations in AFG3L2 can cause two distinct disorders, autosomal dominant spinocerebellar
ataxia 28 (characterised by adult-onset dysarthria, ptosis and cerebellar ataxia) and autosomal
recessive spastic ataxia 5, of which there has only been one reported case (Pierson et al., 2011).
This case involved two affected siblings born to consanguineous parents presenting with spasticity
before the second year of life, tonic-clonic and myoclonic seizures, dystonia, dysarthria, dysphagia
and motor degeneration. One sibling died at 13 years of age due to complications as a result
of pneumonia. The other patient eventually lost the ability to ambulate and developed spastic
paraparesis, oculomotor apraxia and stimulus-induced myoclonus. He underwent extensive testing
with a view to achieving a diagnosis. He had normal cognition; brain MRI showed cerebellar
atrophy and nerve conduction studies revealed an axonal sensorimotor neuropathy. A muscle
biopsy examined by light microscopy was normal, however electron microscopy showed misplaced
mitochondria associated with large lipid droplets. Similar electron microscopy findings of large
lipid droplets, degraded mitochondria and some mitochondria with a disorganised cristae structure
were also identified in patient 25 (Figure 3.3.8). However, the significance of these findings is
uncertain.
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Figure 3.3.8: Electron microscopy of skeletal muscle (quadriceps) from patient 25.
(A) Control electron microscopy of skeletal muscle showing a normal muscle
architecture with normal mitochondrial localisation and sarcomere structure.
(B-I) Electron microscopy of skeletal muscle from patient 25. Mitochondria
were normally localised near the Z-discs and most had normal structure. Muscle
architecture and sarcomere sturcture was normal. Some lipid droplets were noted
but this was not deemed to be outside normal limits. (E-F) Evidence of degraded
mitochondria was noted, usually near the basal lamina, although this was likely
artefactual. (G-I) A small proportion of mitochondria had a disorganised cristae
structure, usually associated with close proximity to lipid droplets, of uncertain
significance. Scale bars: C, D, E, G, H, I: 500 nm; A, B, F: 2 µm.
The p.Leu365Arg identified in our patient is in close proximity to p.Lys354Ala which has
been found to severely impact upon AFG3L2 activity (Pierson et al., 2011). These functional
studies were performed in yeast lacking the ability to process MrpL32, abolishing the synthesis
of mitochondrial-encoded respiratory chain subunits and impairing aerobic respiration. The
p.Lys354Ala mutation abolished respiratory growth to a greater extent than the p.Tyr616Cys
mutation identified in the two affected siblings (Pierson et al., 2011). The p.Lys354Ala mutation
is situated within the Walker A motif which binds ATP in the ATPase domain of AFG3L2. The
mutated Leu365 in our patient immediately follows this Walker A motif but still resides within
the ATP-binding ATPase domain. Indeed, the substitution of a hydrophobic leucine residue to
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a larger electronically charged arginine residue may be predicted to cause a disruption of the
tertiary structure in this region and potentially impacting on ATP binding.
Collectively, this evidence suggests that this variant is likely to be pathogenic. Patient 25
had a milder clinical course than the patients described by Pierson et al. (2011). This is likely
explained by the fact that the p.Leu356Arg mutation is not predicted to affect the Walker A motif;
this sequence motif has a highly conserved 3D structure with the lysine residue being invariant
and critical for phosphate binding. This lysine compensates for the negative charges of the bound
nucleotide, thereby stabilising the hydrolysis transition state and facilitating ATPase activity
(Rosa and Nelson, 2011). On the other hand, the p.Leu356Arg mutation would likely disrupt ATP
binding but not directly impact the catalytic mechanism, resulting in a lesser degree of functional
impairment. In summary, we have identified a novel, likely pathogenic mutation in AFG3L2
which, if proven by functional studies, would be only the second reported case of this disorder. In
addition, the phenotypic spectrum would be widened to include significant intellectual disability
as well as independent ambulation. Finally, after having extensive investigations and multiple
EEGs in order to determine the cause of his drop attacks, these results also suggest that they
may be due to stimulus-induced myoclonus.
3.3.6.4 Patient 26
Patient 26 is the first child born to first cousin consanguineous Afghan parents. He was able to
sit by 10 months of age and crawl by 12 months. At 18 months of age, he was able to stand
for a few seconds and take a few steps. He was babbling with double syllable babble although
he never developed any words. Following a febrile illness at two years of age, he suffered acute
developmental regression and developed a progressive dyskinetic movement disorder with dystonia
and choreoathetoid movements. Brain MRI and CT demonstrated progressive abnormal signal in
the basal ganglia and cerebellum. Sensorineural deafness was diagnosed at the age of two years
and three months. The patient was also affected by dysphagia with failure to thrive requiring
gastrostomy feeding and renal tubular dysfunction. Urinary organic acid analysis revealed
an elevated 3-methylglutaconate with a normal level of 3-methylglutarate. The concentration
of these analytes were not determined as it is not standard practice in the laboratory where
these samples were analysed (Chemical Pathology Department, GOSH, UK). Orotate was also
mildly raised at 8 µmol/mmol creatinine (ref: 0 - 5). A repeat analysis showed a consistent
mildly raised 3-methylglutaconate with a normal 3-methylglutarate, although orotate was normal.
Plasma amino acid analysis demonstrated very strongly raised methionine and elevated proline.
Alanine was also elevated alongside mildly raised phenylalanine and tyrosine, possibly secondary
to liver dysfunction. Lactate was also occasionally mildly elevated. A muscle biopsy showed
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normal mitochondrial respiratory chain enzyme activities as well as normal mitochondrial DNA
sequencing. Unfortunately, he died at four years of age due to multi-organ failure associated
with infection. NGS analysis using the gene panel identified one novel homozygous mutation
in SERAC1 (c.1850delinsCA) which is predicted to cause a frameshift and the subsequent
introduction of a premature stop codon (p.Ile617Thrfs*6).
Only 20 mutations in 28 patients with SERAC1 mutations have been reported to date, all
with a fairly homogenous clinical phenotype including 3-methylglutaconic aciduria, sensorineural
deafness, encephalopathy and progressive Leigh-like (bilateral basal ganglia involvement on brain
MRI) syndrome. During the first year of life, affected children typically suffer feeding problems
and subsequent failure to thrive requiring gastrostomy feeding. Hypotonia and transient liver
involvement are also seen in some cases. By two years of age, children reach developmental stasis
or regress, ultimately being dependent on care-givers for all aspects of daily living. This can be
largely attributed to progressive deafness, lack of speech development, dystonia and spasticity
(Wortmann et al., 1993). Lactate and alanine can also be elevated in plasma, leading to suspicion
of a mitochondrial disorder. Our patient’s phenotype is therefore consistent with a diagnosis of
this disorder.
The exact function of SERAC1 still remains largely unknown and thus the pathogenic
mechanism of mutations affecting its function are elusive. SERAC1 encodes a phospholipase
consisting of 654 amino acids with a single transmembrane region at the N-terminus anchoring the
protein at the interface between the mitochondria and the endoplasmic reticulum and a conserved
lipase domain suggesting a role in lipid metabolism (Wortmann et al., 2012). Upon identification
of the underlying gene defect responsible for this disorder, functional studies were undertaken
using patient tissues (Wortmann et al., 2012). Phospholipid analysis showed elevated levels
of phosphatidylglycerol-34:1 and lower concentrations of phosphatidylglycerol-36:1 species in
patient fibroblasts. Filipin staining also demonstrated an accumulation of unesterified cholesterol
(Rodríguez-García et al., 2016). Finally, morphological examination of patient muscle biopsies
using electron microscopy revealed aggregates of degrading mitochondria. Collectively this data
indicates that SERAC1 plays a role in phosphatidylglycerol remodelling, cholesterol trafficking
and normal mitochondrial function.
The mutation identified in our patient results in truncation of SERAC1 by 32 amino acids.
Many truncating mutations have been described including two similarly affecting the carboxy-
terminal region resulting in the protein lacking the last 45 and 13 amino acids (Wortmann
et al., 2012). Given the pathogenic effect of smaller truncations than that seen in our patient
it is plausible to conclude that the p.Ile627Thrfs*6 mutation is pathogenic. This finding was
subsequently used to offer pre-natal testing for this family.
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3.3.6.5 Patient 27
This patient was the first child born to consanguineous parents from Kuwait, presenting with
a multisystemic and dysmorphic syndrome. Dysmorphic features such as microcephaly, retro-
and micrognathia, a cleft of soft and hard palate were noted early in life. Organ malformations
affected the brain (Dandy-Walker malformation), heart (doubly committed subarterial ventricular
septal defect), lung (bilateral pulmonary hypoplasia) and gut (Hirschsprung’s disease). He
suffered early-onset asymmetrical tonic seizures responding to levetiracetam, but non-responsive
to pyridoxine or pyridoxal 5’-phosphate. Continuous oxygen supplementation was required due
to central apnoeas. Severe peripheral and bulbar neuropathy, with motor more pronounced
than sensory, was also noted but assumed to have been secondarily acquired. He also had a
very disrupted sleep pattern. Initially some very slow developmental progress was seen but,
particularly following a prolonged stay in intensive care, he regressed. There was no speech
development. Hyperphosphatasia, hypoketotic hypoglycaemia and hypogammaglobulinaemia
were noted biochemically. Transferrin isoelectric focussing was normal. The child unfortunately
died following an acute enterocolitis. A novel homozygous missense mutation was identified
in the fourth transmembrane domain of PGAP2 (p.Ala187Val). This variant is reported to
have a minor allele frequency of 3/12052 alleles (0.0024%) and is predicted to be deleterious
and probably damaging by SIFT and PolyPhen-2, respectively. Sequence alignment of PGAP2
across species shows that Ala187 is conserved in mammals and birds but not zebrafish. Sanger
sequencing confirmed that both parents were heterozygous for this mutation.
PGAP2 has a role in the synthesis of the glycosylphosphatidylinositol (GPI) anchor, a
glycolipid which functions to tether approximately 150 proteins to lipid bilayers. These proteins
have diverse functional properties and include membrane-associated enzymes, adhesion molecules,
immunologically important proteins, antigens and receptors (Ferguson et al., 2009). One example
is alkaline phosphatase, a cell-surface hydrolase whose increased concentration in serum is
indicative of a GPI-anchor defect. GPI-anchor biosynthesis occurs in three steps. Firstly, the
GPI precursor is assembled in the endoplasmic reticulum (ER) membrane. Newly synthesised
proteins are then imported into the lumen of the ER, the GPI-addition signal peptide is cleaved
and the GPI moiety is added to the carboxy-terminus of the protein by a transamidation reaction.
Finally, lipid remodelling and modifications of carbohydrate side chains are carried out in the
ER and Golgi apparatus. PGAP2 functions in the third step of this pathway to reacylate the
GPI with a saturated fatty acid (Kinoshita, 2014). This is the last enzymatic modification prior
to correct expression of the GPI-anchored protein on the outer leaflet of the plasma membrane.
Without this correct modification, the lyso-GPI-anchored proteins are transported to the cell
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surface and secreted where they are susceptible to cleavage by phospholipase D (Tashima et al.,
2006).
To date, there have only been three reports detailing patients with mutations in PGAP2
in nine individuals from four families (Krawitz et al., 2013; Hansen et al., 2013; Jezela-Stanek
et al., 2016). Many features described in these cases are also present in our patient including:
microcephaly, cleft palate, Dandy-Walker malformation, heart septal defect, Hirschsprung’s
disease, epilepsy, hypotonia, profound developmental delay, disrupted sleep pattern, respiratory
insufficiency and hyperphosphatasia. Elevated serum alkaline phosphatase activity was evident
for all patients ranging between 1700 - 4455 U/L. The levels in our patient were consistent with
these reports (1192 U/L – 9120 U/L (ref: 145 - 320)).
Defects of GPI-anchor biosynthesis are difficult to diagnose, partly due to the relatively recent
description and a lack of clinical awareness of these disorders. Firstly, all patients have a normal
transferrin isoelectric focussing pattern which often directs focus away from a possible congenital
disorder of glycosylation. Secondly, elevated alkaline phosphatase is more commonly considered
an indicator of liver or bone disorders and thus overlooked, especially if the patient does not fit
these phenotypes and other liver function tests and calcium and phosphate levels are normal.
Indeed, in the case of our patient, his markedly elevated levels were thought to be a laboratory
mistake. In some inborn errors of GPI-anchor synthesis, lower expression of GPI-anchored
markers such as CD55 and CD59 are observed in patient cells such as lymphoblastoid cell lines
which can be discerned using flow cytometry (Sutherland et al., 2007). This is not the case in
patients with PGAP2 mutations. To assess pathogenicity, all previous reports have performed
in vitro analyses in Chinese hamster ovary (CHO) cell lines through transfection with mutant
constructs. Under these conditions, introduction of the wild-type PGAP2 protein was able to
restore surface expression of CD55 and CD59 to a greater extent than any of the PGAP2 proteins
containing the patient mutations (Krawitz et al., 2013; Hansen et al., 2013; Jezela-Stanek et al.,
2016). Although effective, these functional studies for examining the effects of mutations in
PGAP2 are extremely time- and labour-intensive and would not be possible in the clinical setting;
however, given the phenotypic correlation with the previously described cases, we are confident
that the p.Ala187Val mutation detected is pathogenic. Additional features in this patient which
have not been described previously include retro- and micrognathia, pulmonary hypoplasia,
central apnoeas, hypoketotic hypoglycaemia and hypogammaglobulinaemia. However, additional
cases are required to determine whether these features represent an expansion of the phenotypic
spectrum of PGAP2-deficicency.
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3.3.6.6 Patient 28
Patient 28 is a 7 year old male born to consanguineous first cousin parents, presenting mainly with
developmental delay. He sat at 9 months and achieved independent walking at 23 months of age.
He was affected by speech and language delay despite normal vision and hearing. Examination
revealed microcephaly (< 2nd centile), increased tone and hyper-reflexia in the lower limbs
with equivocal plantar responses but no ankle clonus. Brain MRI demonstrated a thin corpus
callosum but otherwise unremarkable intracranial appearances. Neurometabolic testing showed a
type-I transferrin isoelectric focussing pattern, suggesting an underlying congenital disorder of
glycosylation. Gene panel sequencing revealed a novel homozygous variant in the TPP1 gene
(p.Gly296Asp), alongside a homozygous known pathogenic mutation in ALDOB (p.Arg60*)
(Santer et al., 2005).
TPP1 encodes tripeptidyl peptidase I, a protein which degrades peptides within lysosomes.
Mutations were first described to cause late-infantile neuronal ceroid lipofuscinosis, typically im-
pairing motor and mental development early in childhood causing movement disorders, intellectual
decline, seizures and visual impairment. However, more recently a spectrum of disease severity
corresponding to different mutations and degrees of residual enzyme activity have been described
(Dy et al., 2015). Subsequent to the identification of the potentially pathogenic homozygous
TPP1 variant, the corresponding enzyme activity was measured as 28 nmol/hr/mg protein (ref:
42 - 339) in patient 28. Homozygote patients typically have values in the range of 0.4 - 26
(Chemical Pathology, GOSH). This patient’s clinical severity and progression is at the milder end
of the spectrum compared to other patients with mutations in TPP1 as he has never suffered
seizures or visual loss. p.Gly296Asp is predicted to be deleterious and probably damaging by
SIFT and PolyPhen-2, respectively. Whilst the presence of TPP1 has not been reported in lower
organisms, the mutated Gly296 residue is conserved from humans to Xenopus (Figure 3.3.9).
Figure 3.3.9: Multiple sequence alignment of the TPP1 protein from various species.
(*) positions with have a single fully conserved residue, (:) conservation between
amino acids with strongly similar properties, (.) conservation between amino
acids with weakly similar properties. The alignment was generated using Clustal
Omega.
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Mutations in ALDOB cause hereditary fructose intolerance, a disorder characterised by
recurrent vomiting, abdominal pain and hypoglycaemia when fructose or sucrose is added to
the diet at the time of weaning. Patients that survive infancy develop a natural avoidance of
sweets and fruit, however long-term fructose exposure can result in liver failure, renal tubulopathy
and growth retardation (Ali et al., 1998). Commonly, a hypoglycosylated pattern of transferrin
isoforms is identified and, as in our patient, misinterpreted as an indicator of a type-I CDG
(Adamowicz et al., 2007). Upon the identification of this mutation, further enquiries were made
to the responsible consultant who identified that the patient’s brother, although developmentally
normal, also had an abnormal transferrin pattern. Both children were described to be "very
much savoury boys". Sanger sequencing confirmed that both siblings were homozygous for the
p.Arg60Ter mutation. Both children have normal liver function tests and hepatic ultrasound
findings, suggesting that dietary self-selection has prevented serious liver dysfunction. Nevertheless,
this finding has important clinical implications as they should not receive any sugar-containing
medicines, especially not a fructose or sorbitol infusion which may be fatal.
3.3.6.7 Patient 29
Patient 29 is a 6 year old male who presented with neonatal jaundice, lethargy, deranged
liver function and hypoglycaemic episodes which subsequently subsided. Transferrin isoelectric
focussing revealed a Type-I pattern, suggestive of a congenital disorder of glycosylation. At 8
months of age he was found to have severe bilateral sensorineural hearing loss and eventually
required the insertion of cochlear implants. Post-infancy he remained clinically stable for
approximately three years, but in view of his previous medical history, routine immunisations
were delayed and remain incomplete. At four years of age he became unwell with pyrexia and
hyptonia within two hours of pneumococcal immunisation, followed by recurrent upper and lower
respiratory tract infections for several months. Immunological investigations revealed low levels
of plasma IgA and IgM in the context of normal IgG, pneumococcus-specific antibodies and
lymphocyte subsets, possibly reflective of transient hypogammaglobulinaemia of infancy.
Compound heterozygous mutations were found affecting adjacent amino acids in exon 3 of the
GALE gene. The first (p.Val94Met) is a known pathogenic mutation (Wohlers et al., 1999) and the
second is a novel missense mutation (p.Gly95Asp). Both variants are predicted to be deleterious
and probably damaging by SIFT and PolyPhen-2, respectively. GALE encodes UDP-galactose-
4’-epimerase, an enzyme which catalyses two analogous reactions: the interconversion between
UDP-galactose and UDP-glucose and between UDP-N-acetylgalactosamine (UDP-GlcNAc) and
UDP-N-acetylglucosamine (UDP-GalNAc). Each pair of molecules are epimers, differing only in
the position of one -OH group at one stereogenic centre within the sugar moiety. Mutations in this
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gene cause galactosaemia type III which can present with very variable symptoms. In its mildest
form, the enzyme deficiency is restricted to the circulating blood cells and considered clinically
benign. On the other hand, the severe generalised form presents similarly to classical galactosaemia
with jaundice, vomiting, hypotonia, sensorineural deafness, failure to thrive and hepatomegaly. To
date, 22 pathogenic mutations have been described (Timson, 2006). Unlike galactosaemia caused
by mutations in GALT and GALK, treatment with a galactose-free diet is not recommended
as patients cannot use the endogenous pathway to synthesise UDP-galactose (Figure 3.3.10).
Instead, a galatose-restricted diet and supplementation with N-acetylgalactosamine can be used
to slow disease progression (Kingsley et al., 1986).
Figure 3.3.10: Metabolic pathway showing the interconversions of galactose in the
human body. Mutations in GALT and GALK cause galactosaemia type I
and type II, respectively. Mutations in GALE (shown in red), as in our patient,
cause galactosaemia type III.
p.Val94Met was the first mutation identified in a patient with the severe, generalised form
of galactosaemia type III. At this time, activity of the mutant enzyme was quantified as 5%
with respect to UDP-galactose and 24% with respect to UDP-GalNAc (Wohlers et al., 1999).
Experiments have since demonstrated that this mutation does not significantly impact on substrate
binding but dramatically decreases the Vmax of the enzyme with respect to both substrates
(Wohlers and Fridovich-Keil, 2000). The 3D structure of GALE containing the p.Val94Met
mutation has been experimentally solved (Thoden et al., 2001) and has revealed that the Val94
residue prevents the substrates rotating out of the active site before undergoing modification
of the sugar moiety, hence preventing binding that does not result in the desired product. The
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mutation of this residue alters the shape of the substrate pocket and allows free rotation of the
sugar moieties, thereby affecting catalysis. The effect on enzyme activity is not as dramatic
when UDP-GalNAc is used as a substrate compared when UDP-galactose is used. This can
be explained by the fact that the bulkier sugar moieties of UDP-GalNAc can adopt fewer non-
productive binding conformations, thereby increasing the chances of effective catalysis. The
effects of p.Gly95Asp are likely to be similar to that of p.Val94Met as this amino acid also resides
within the binding pocket of the active site.
This case highlights how clinicians can be misguided by abnormal biochemical findings. A type-
I transferrin isoelectric focussing pattern is suggestive of a congenital disorder of glycosylation,
with over 40 defects known to cause this specific abnormality (Scott et al., 2014). However, an
abnormal transferrin pattern is seen in other disorders including untreated galactosaemia type
III (Walter et al., 1999). Given the patients’s clinical features, galatosaemia was considered
and functional studies were carried out at another specialist centre. Galactose-1-phosphate
uridylyltransferase activity (GALT) was measured as normal on two occassions. Galactose-
1-phosphate was not measured, but would have been expected to be elevated, suggesting a
defect in the metabolism of galactose (Walter et al., 1999). Following this, results stated
that galactosaemia had been "excluded", when in fact only one of the three possible enzyme
activities had been determined to be normal. Thus, in addition to considering all explanations
for a particular biochemical abnormality, it is crucial to critically interrogate the results of any
specialist investigations. A congenital disorder of glycosylation was also similarly assumed to be
the diagnosis in patient 28 due an abnormal type-I transferrin pattern (Section 3.3.6.6).
3.3.7 Patients with a diagnosis not fully explaining the phenotype
In three patients within our cohort, mutations were identified that were likely to explain only a
minority of their phenotypic features. Thus, it can be assumed that the remaining features are
attributable to other, as yet unidentified genetic defects.
Patients 20 and 21 are monozygotic twins and were found to be homozygous for a novel
missense variant in the AASS gene, encoding α-aminoadipic semialdehyde synthase. Mutations
in this gene cause hyperlysinaemia. Although some patients have been reported to present with
hypotonia, seizures or mild developmental delay, approximately 50% are asymptomatic (van
Gelderen and Teijema, 1973). Given this, some controversy exists as to whether hyperlysinaemia
should be considered a disease or a benign metabolic variant. There are two factors which make
the evidence for pathogenicity of AASS mutations relatively weak. Firstly, the vast majority of
the described cases, as well as our patients, are born to consanguineous parents which increases
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the probability of harbouring damaging mutations in more than one gene. Secondly, the range of
neurological phenotypes and severity of disease reported is very broad despite all cases having no
functional AASS protein. Both twins had global developmental delay, hypotonia, brachycephaly
and elevated lysine in plasma and CSF. One also had epilepsy that was well-controlled with
AEDs. These features would be consistent with some reported cases of hyperlysinaemia (Houten
et al., 2013) , although the lysine concentrations seen in our patients are much lower than those
described in this report. The missense variant in our patients (p.Arg322His) is conserved from
humans through to Xenopus, zebrafish and coelacanths indicating its functional importance and
predicted to be tolerated and probably damaging by SIFT and PolyPhen-2, respectively. It is
likely that this variant is responsible for the elevated lysine concentrations in these children.
However, it does not explain their global developmental delay, epilepsy, hypotonia or dysmorphism
and therefore whole exome or genome sequencing would be an appropriate second tier test for
these patients.
Patient 24 is a two year old male and the fourth child born of first cousin consanguineous
parents. They are originally from Bangladesh and have two fit and healthy girls aged 3 and 10
years old. There had been a previous neonatal death in the family of a baby born at 28 weeks
who sadly died at 8 months of age; he had renal dysplasia, bronchiolitis and raised triglycerides.
A diagnosis of neutral lipid storage disease was considered but never verified. Patient 24 was born
at 32 weeks after an emergency caesarean section. He was antenatally diagnosed with dysplastic
kidneys and anhydramnios on the 28-week scan. He was intubated and ventilated at birth. In the
very early neonatal period his renal function initially deteriorated but then gradually improved
in the following days. He had lactic acidosis with a maximum concentration of 8.4 nmol/L,
which subsequently resolved. He has been followed-up at the Metabolic Medicine Department at
GOSH but no diagnosis has been made. His most recent assessment showed small kidneys with a
normal renal function, hepatomegaly, elevated triglycerides and eczema. He is developmentally
delayed but is making progress. A brain MRI showed a reduction in the commissural calibre. He
has microcephaly (< 0.4th centile), his weight is on the 25th centile and height is on the 0.9th
centile. He also has elevated thymidine and uracil suggestive of dihydropyrimidine dehydrogenase
(DPD) deficiency. The pyrimidine degradation pathway functions to convert uracil and thymidine
to β-alanine and β-aminoisobutyric acid, respectively. This is catalysed by three enzymes:
dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase (DPYS) and β-ureidopropionase,
respectively. Mutations have been reported in genes encoding all three of these enzymes causing
varying degrees of neurological symptoms in affected patients. A novel homozygous duplication
resulting in a frameshift and premature stop codon (p.Val51Glyfs*50) in the DPYS gene was
identified in this patient. Similarly to hyperlysinaemia, approximately 50% of patients with DPYS
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deficiency are asymptomatic and are only diagnosed by biochemical testing. However, in others
neurological abnormalities including intellectual disability, seizures, hypotonia, microcephaly and
autistic features are seen. Some patients also present with gastrointestinal problems including
gastroesophageal reflux, cyclic vomiting, villous atrophy and failure to thrive (van Kuilenburg
et al., 2010). Pathogenesis is proposed to be propagated by the decrease of β-alanine and
β-aminoisobutyric acid which regulate dopamine and glycine neurotransmission, leptin levels and
fatty acid oxidation (Begriche et al., 2008; Ericson et al., 2010) (Figure 3.3.11).
Figure 3.3.11: Schematic illustrating the pathogenic mechanism underlying DPYS
deficiency.
Although certain features of patient 24 may at least in part be due to his DPYS deficiency
(developmental delay, microcephaly and pyrimidine abnormalities), his remaining phenotypic
features are likely to be attributable to other, as yet unidentified genetic defects. Other diagnoses
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that were considered include neutral lipid storage disease, however due to the lack of availability of
clinical Sanger sequencing of these genes this has yet to be done. Mutations in adipose triglyceride
lipase (PNPLA2 ) or its activator, 1-acylglycerol-3-phosphate O-acyltransferase (ABHD5 ) cause
neutral lipid storage disease with myopathy and Chanarin-Dorfman syndrome, respectively. Only
ABHD5 was included in our gene panel design. This had an overall coverage of 94.9% above 30X,
however, two exons contained small regions that were not covered by any reads. Nevertheless,
the coverage metrics of these regions were extremely similar across the other patient samples,
suggesting that this lack of coverage is likely sequence specific (e.g. GC-rich regions) rather than
due to the presence of a mutation in this patient. Indeed, no variants or putative CNVs were
identified in ABHD5 in patient 24. Although PNPLA2 was not included at the time of patient
analysis, this gene could be added in further iterations of the panel.
3.3.8 Patients with potential diagnoses called into question by experimental evidence
A final point of consideration emphasised by this study is the importance of stringent evaluation of
potential pathogenicity and confirmatory sequencing. Gene panel sequencing identified candidate
variants in three patients that were subsequently called into question or refuted based on additional
genetic or functional evidence.
3.3.8.1 Patient 38
Patient 38 is a 6 year old female who initially presented with neonatal seizures that were described
to have responded to treatment with vitamin B6. She is severely developmentally delayed and
suffered regression from three years of age. She has microcephaly, sensorineural deafness and
a movement disorder with chorea and non-epileptic myoclonic jerks. Biochemically, she has
been shown to excrete urinary methylmalonic acid (MMA). Sequencing identified a homozygous
variant in IDH2 (c.673G>A; p.Asp225Asn) which is predicted tolerated and possibly damaging
by SIFT and PolyPhen-2, respectively. Both parents were confirmed to be heterozygous for the
variant by Sanger sequencing. The variant is reported at a minor allele frequency of 0.02% and is
conserved from humans to yeast. ACMG guidelines suggest that this variant should be classified
as having uncertain significance (Table 3.3.7).
IDH2 encodes the mitochondrial NADP-dependent isocitrate dehydrogenase. Heterozygous
mutations affecting specific residues in this gene (Arg140) allow it to convert 2-oxoglutarate (the
product of the normal reaction) to D-2-hydroxyglutarate (Kranendijk et al., 2010). Hence these
mutations give rise to type II D-2-hydroxyglutaric aciduria. This would not be expected with
homozygous mutations causing a loss of function of isocitrate dehydrogenase activity and indeed,
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was not seen in patient 38. One of the main functions of the IDH2 gene product is to provide
NADPH in the mitochondrion which is important for the regeneration of reduced glutathione
from the oxidised form, thus providing protection from reactive oxygen and nitrogen species. The
IDH2 knockout mouse has increased hydrogen peroxide, increased malondialdehyde production
(a product of lipid peroxidation) and carbonylated proteins (derived from proteins attacked by
reactive oxygen species) (Kim et al., 2014). The urinary MMA excretion identified in this patient
may also have been explained by the fact that cobalamin can be inactivated by peroxynitrite as
well as other reactive oxygen or nitrogen species (Mukherjee and Brasch, 2011).
Figure 3.3.12: Hypothesised pathogenic mechanism of loss of function mutations
in IDH2. (a) The normal function of IDH2 is to catalyse the conversion
of isocitrate to 2-oxoglutarate, resulting in the formation of NADPH. In the
case of D-2-hydroxyglutaric aciduria, mutation of the Arg140 residue changes
the specificity of this enzyme, resulting in the conversion of 2-oxoglutarate to
form D-2-hydroxyglutarate. (b) In the case of mutations causing a loss of
IDH2 function, there would be predicted to be a deficiency of NADPH within
the mitochondria. Subsequently, reduced glutathione cannot be regenerated,
resulting in an increase of reactive oxygen species and ROS-related damage.
Following this finding, urinary conjugated metabolites of vitamin E were measured as a
marker of oxidative stress using the method developed by Sharma et al. (2013). No difference
was seen between patient 38 and a cohort of controls, providing no evidence for a disturbance in
redox state in this patient. The significance, if any, of this variant remains unknown and further
genetic and biochemical investigations will be required.
3.3.8.2 Patient 39
This patient is the third child of four children born to consanguineous parents. He was diagnosed
with generalised tonic-clonic seizures at 8 months of age, however when looking retrospectively
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seizures had occurred earlier in life. At this age he also had marked motor delay and hypotonia.
He subsequently developed feeding difficulties, gastroesophageal reflux, recurrent aspiration
pneumonia and had very limited developmental progress. At latest review aged 11 years, he is
wheelchair-bound, unable to sit, can chew on his fingers but has no speech or understanding. He
has increased tone throughout all limbs with brisk reflexes, as well as soft dysmorphic features
with deep-set eyes and a slightly beaked nose. He continues to have seizures although these are
relatively well-controlled with antiepileptic drugs. His older brother was similarly affected and
died without a diagnosis at the age of 11 years. A number of biochemical investigations have
yielded normal results including: plasma and CSF lactate, plasma amino acids, urinary organic
acids and acylcarnitines. Brain MRI has been carried out on three occasions. At one year of age
there was a generalised lack of white matter bulk. A repeat scan at three years of age showed an
increase in the prominence of the periventricular spaces, early signs of an evolving leukodystrophy
in the peritrigonal white matter with stable morphology of the corpus callosum and brain stem;
appearances similar to those of his affected older sibling at a similar age. Finally, an MRI with
contrast at eight years of age demonstrated subtle new changes at the level of the corticospinal
tract, an increase in the number of perivascular spaces but the periventricular deep white matter
abnormalities were unchanged. New diffuse brain leptomeningeal involvement was also noted.
The radiological appearances as a whole were largely those of a failure of formation of normal
white matter and not those of a progressive leukoencephalopathy.
No potentially pathogenic variants were identified in this patient using the standard analysis
pipeline. Thus, deletion screening was attempted and two putative deletions were identified
in NDUFS1 using cn.MOPS (Figure 3.3.13). Mutations in this gene are a common cause of
mitochondrial respiratory chain complex I deficiency and typically present with a severe and
rapidly progressive leukoencephalopathy, in which patients share similar MRI features to those
seen in our patient. Other features can include severe lactic acidosis, seizures, recurrent vomiting,
hypotonia, macrocytic anaemia and ocular abnormalities Unfortunately, a muscle biopsy to
determine the activity of the mitochondrial respiratory chain complexes had not been performed.
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Figure 3.3.13: CNV analysis of patient 39 using cn.MOPS. Two putative heterozygous
deletions in NDUFS1 were identified in (a-b) exon 2 and (c-d) exon 12. The
x-axis of each graph represents the genomic position. The y-axis represents
(a and c) the read depth and (b and d) the copy number at the position of
the call (i.e. 0 is wild-type, -1 is a heterozygous deletion, -2 is a homozygous
deletion).
Following this finding, intronic primers were designed to amplify exon 2 and 12 of NDUFS1.
Sanger sequencing revealed a sequence identical to the reference, indicating that if a deletion was
present the breakpoints were not exonic. Long-range PCR was attempted using primers located
upstream and downstream of the adjacent exons in order to sequence the adjacent intronic regions
and identify any breakpoints that were present (Figure 3.3.14). Amplification of these regions
was problematic as, despite the use of multiple DNA polymerases and PCR-enhancers, a single
DNA fragment of the expected size could not be obtained.
Therefore, in order to investigate the presence of these deletions further, RNA was extracted
from whole blood. cDNA was generated and the entire NDUFS1 gene was amplified using
Phusion DNA polymerase and the primers detailed in Appendix 2.8.1. The size of the wild-type
NDUFS1 cDNA is predicted to be 2537 bp, which agrees with the product seen in Figure 3.3.15.
Exon 2 is 65 bp and exon 12 is 130 bp in length. If, as predicted by the cn.MOPS analysis,
two heterozygous deletions were responsible for the disease in this family (i.e. one deletion was
inherited from each parent) two DNA fragments of 2472 bp and 2407 bp would be evident (Table
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Figure 3.3.14: Long range PCR methodology. (a) Schematic illustrating the locations of
the two sets of primers designed to amplify the complete intronic regions adjacent
to the deleted exon in order to identify any deletion breakpoints. Primer pairs
are shown in orange and green, respectively. F, forward primer; R, reverse
primer. Primer positions for the amplification of genomic regions surrounding
(b) exon 2 and (c) exon 12. The distance of each primer from the beginning/end
of each exon is shown in brackets.
3.3.9). In patient 39 there was only one DNA fragment of the same size as the control indicating
that no exonic deletions were present (Figure 3.3.15).
Table 3.3.9: Predicted sizes of wild-type and mutated NDUFS1 cDNA sequences.
Wild-type
NDUFS1 (bp)
Exon 2
(bp)
Exon 13
(bp)
Predicted size of
cDNA fragment (bp)
Wild-type 2537 - - 2537
Heterozygous deletion of
exon 2
2537 65 - 2472
Heterozygous deletion of
exon 12
2537 - 130 2407
Compound heterozygous
deletion of exon 2 and 12
2537
2537
65
-
-
130
2472
2407
Technological or genomic variations in the depth of coverage across chromosomal regions can
lead to high false-discovery rates when detecting CNVs (Klambauer et al., 2012). cn.MOPS claims
to reduce this false discovery rate by modelling the depth of coverage independently at each
genomic position and has been shown to be efficient for large-scale exome and genome sequencing
data. However, these algorithms may not be sufficient to normalise for the extreme variability in
read depth produced by the restriction enzyme-generated amplicons used by HaloPlex capture.
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Figure 3.3.15: Agarose gel electrophoresis illustrating the amplification of the full-
length NDUFS1 cDNA from control and patient blood. Additional gel
electrophoresis was performed in which the cDNA products were run further to
determine whether a small difference in fragment size could be determined. No
difference was observed, therefore the clearest image is shown.
3.3.8.3 Patient 43
Patient 43 presented to his local hospital at five weeks of age with failure to thrive, poor feeding,
hypoglycaemia and neurological dysfunction. He was noted to have marked hypotonia, brisk
tendon reflexes and an initially compensated metabolic acidosis. Investigations revealed a normal
echocardiogram and brain MRI showed agenesis of the corpus callosum and colpocephaly with
normal myelination. He was subsequently transferred to intensive care where a full septic screen
was negative. Serum ammonia was 89 µmol/L (ref: < 55 µmol/L) and he was commenced
on thiamine, carnitine, biotin and pyridoxine. One week later he developed a decompensated
metabolic acidosis with worsening hypotonia, poor cry, diminished spontaneous movement and
spontaneous eye movement with a conjugate gaze. Sodium bicarbonate treatment was initiated
with subsequent worsening of hypernatraemia. He was then noted to have prolonged clotting
time indicating significant liver dysfunction. Over the following days after transfer to GOSH
he continued to deteriorate with significant acidosis (pH of 6.9, lactate of 18 µmol/L) requir-
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ing tris-hydroxymethyl aminomethane and renal replacement therapy. He required significant
inotropic support and multiple blood product transfusions due to a coagulopathy. Following a
cardiorespiratory arrest and in view of a mitochondrial myopathy being the most likely diagnosis,
care was withdrawn and the patient died. A muscle biopsy taken at this time showed cytochrome
oxidase (COX)-negative fibres and severely reduced mitochondrial complex I and IV activities.
Sequencing identified a homozygous variant in EARS2 (c.760A>G; p.Thr254Ala). It was
predicted to be deleterious and probably damaging by SIFT and PolyPhen-2, respectively. The
residue is also conserved between humans and yeast, suggesting its functional importance, and is
not reported in any population database. EARS2 encodes glutamyl-tRNA synthetase 2 which
catalyses the ligation of glutamate to tRNA molecules.
There have only been six reports detailing 18 patients with mutations in this gene causing
early-onset leukoencephalopathy with thalamus and brainstem involvement and high lactate
levels in body fluids (LTBL). It has been shown that these patients can be can be affected
by a spectrum of disease severity ranging from a severe phenotype resulting in death in the
neonatal period (Danhauser et al., 2016) and a relatively mild phenotype characterised by elevated
lactate and psychomotor developmental delay, who show some spontaneous clinical improvement
including regression of MRI lesions and falling lactate concentrations (Steenweg et al., 2012).
There were various similarities when comparing our patient to those reported in the literature,
especially with regard to his biochemical parameters. All patients had grossly elevated lactate
concentrations, COX-negative fibres, ragged-red and ragged-blue fibres. Patients have been
described to have variable mitochondrial complex deficiencies including complex I, III and IV
deficiencies (Steenweg et al., 2012). Patient 43 had severely reduced complex I and IV enzyme
activity. MRI features are highly specific for the disorder including dysgenesis/agenesis of the
corpus callosum and symmetrical abnormalities of the cerebral and cerebellar white matter,
thalami, midbrain and brainstem. These features are highly consistent with those observed in
our case. Patients have also been described to have varying degrees of liver dysfunction including
elevated transaminases and α-fetoprotein, hepatomegaly, steatosis, fibrosis and cholestasis (Talim
et al., 2013). A post-mortem liver biopsy from our patient showed macro- and micro-vesicular
steatosis and marked cholestasis. His grossly prolonged clotting time also indicated a significant
liver abnormality. Clinical features in those patients with a poor outcome include hypotonia,
dystonia, spastic tetraparesis, bradykinesia, ptosis, opthalmoplegia, severe visual impairment,
reliance on tube-feeding and absence of speech.
Despite having a phenotype consistent with cases of EARS2 mutations and the variant
being classified as likely pathogenic using ACMG criteria (Table 3.3.7), this same variant was
subsequently independently identified in a second unrelated family by another research group
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in our department. The affected members of this family presented with a similar phenotype;
however, extensive screening within the family identified the variant in a homozygous state in an
unaffected sibling, calling the pathogenicity of this variant into question. Functional studies are
currently ongoing.
3.3.9 Patients who remained undiagnosed despite gene panel sequencing
Despite our panel’s demonstrated efficacy, there were also limitations when using this approach.
Of the 22 patients without a biochemical marker pointing towards a specific diagnosis, 63.6%
(14/22) remained undiagnosed after gene panel sequencing (patients 31 - 44). The clinical,
biochemical and MRI findings in these patients are described in Table 3.3.10. In 35.7% (5/14) of
patients a diagnosis was reached after our study had concluded. As detailed in Section 3.3.5, a
diagnosis of hyperprolinaemia type II was confirmed in patient 31 by Sanger sequencing. Patient
35 was suspected to have an inborn error of vitamin B12 metabolism as biochemical investigations
revealed persistently low plasma vitamin B12 concentrations. Gene panel sequencing identified one
heterozygous variant in CUBN (c.8741C>T; p.Ala2914Val), predicted deleterious and probably
damaging. Read depth analysis did not show any evidence of a CNV in this gene. Subsequent
Sanger sequencing of genes known to cause vitamin B12 confirmed the presence of the variant we
had identified but also revealed a heterozygous small deletion (c.328_332del) in CUBN and a
heterozygous known pathogenic variant (c.290T>C; p.Met97Thr) in the GIF gene. Re-analysis
of the data revealed that in the case of the deletion, the affected genomic region was covered
by nine HaloPlex reads and only one contained the 4 bp deletion; thus, the frequency of the
alternative allele did not meet the 20% cut-off to be reported as a possible variant. In addition,
the first iteration of the variant calling pipeline developed by the NE Thames Regional Genetics
Service at GOSH that was used to analyse our data, only called variants that were covered at a
read depth greater than 30X. Similarly, the missense mutation in the GIF gene was covered by
12 reads and whilst present in > 20% (25%) of amplicons, it was not called due to inadequate
coverage (i.e. < 30X). In the following iterations of the variant calling pipeline, this coverage
threshold was dramatically reduced in order to detect variants such as these. In the case of
patient 35, it remains unclear as to which of the identified variants are pathogenic.
In two patients, genetic findings associated with neurological abnormalities but not inborn
errors of metabolism have been identified. Microarray analysis revealed a de novo deletion at
7q36.2 in patient 40. This includes DPP6 which is known to be associated with microcephaly
and mental retardation (Liao et al., 2013). Although this may explain some of the patient’s
phenotypic features, it was thought that he may have a second genetic defect so he has been
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recruited into the Deciphering Developmental Disorders whole exome sequencing project. Patient
41 was found to have a mutation in the KANSL1 gene. Mutations in this gene have been shown
to result in Koolen-de Vries syndrome (Zollino et al., 2012). This protein is involved in histone
acetylation and the syndrome is characterised by developmental delay, intellectual disability
and distinctive facial features. Indeed, patient 41 shared a number of these features including
upslanting palpebral fissures, a large broad nose, abnormal hair pigmentation and coarsening
facial features. Interestingly, although they were both suspected to have a neurometabolic disease,
neither had strong biochemical indicators so these findings are somewhat unsurprising.
Finally, patient 44 was found to have mutations in the BCKDK gene, causing branched-chain
keto-acid dehydrogenase kinase deficiency. Affected patients were first described in 2012 by
Novarino et al., presenting with autism, epilepsy, intellectual disability and reduced concentrations
of branched-chain amino acids. This diagnosis was not made by our panel because the gene was
not included in our 614-gene panel as at the time of design a disorder had not been associated
with this gene. In any future versions or formats of the gene panel, genes such as these could be
added to the design.
Whilst in the remaining nine undiagnosed patients the sequencing metrics suggested that
the capture efficiency and depth of coverage was good, mutations may have been missed due
to inefficient capture of GC-rich regions or low coverage due to complexity. It is also plausible
that the disease-causing genes were not included in the design, the causative mutations were
intronic or homozygous/compound heterozygous CNVs were responsible for disease. Therefore
these patients are being considered for further genetic testing including whole exome and whole
genome sequencing.
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Table 3.3.10: Patients who remained undiagnosed after gene panel sequencing. Some of these patients have subsequently had diagnoses established via array CGH or candidate
gene testing.
Patient Age Gender Primary neurological phenotype Other phenotypic features Relevant specialist investigations Eventual diagnosis
31 6 Female Developmental delay, absence seizures. Bilateral sensorineural deafness. Grossly elevated plasma proline, elevated
n-pyrrole-2-carboxyglycine confirming
hyperprolinaemia type II.
Hyperprolinaemia type II (homozygous
complex insertion/deletion event in
ALDH4A1, c.411_424delinsCGGCCC;
p.Pro138GlyfsTer13)
32 7 Female Learning difficulties, delayed motor milestones,
reduced exercise tolerance, responsive to
intramuscular vitamin B12 injections.
Joint hypermobility. Methylmalonic aciduria, high plasma
homocysteine, normal muscle biopsy.
Not yet reached
33 8 Male Global developmental delay, neurological
regression, dysphagia, epilepsy.
Alopecia, gastro-oesophageal reflux disease,
neutropenia, treated with granulocyte-colony
stimulating factor, platelet dysfunction. Brain
MRI: Leigh-like changes in the basal ganglia
and brainstem.
Intermittently elevated plasma lactate but
normal CSF lactate, low plasma manganese.
Not yet reached
34 5 Female Episodes of severe ketotic hypoglycaemia with
seizures.
N/A Normal acylcarnitines and plasma amino acids.
Slightly low fructose-1,6-bisphosphatase
activity.
Not yet reached
35 3 Female Developmental delay and regression,
dysphagia.
Brain MRI: delayed myelination Low vitamin B12. Multiple mutations, only one of which
was picked up by gene panel (CUBN,
p.Ala2194Val)
36 5 Female One of similarly affected siblings, parental
consanguinity. Developmental delay, reduced
exercise tolerance, joint hypermobility.
Dysmorphic features, pancreatic insufficiency
and fat malabsorption.
Several raised plasma amino acids. Muscle
histology suggestive of a mitochondrial
disorder but normal respiratory chain
enzymes.
Not yet reached
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37 8 Female One of similarly affected siblings, parental
consanguinity. Developmental delay, reduced
exercise tolerance, joint hypermobility.
Pancreatic insufficiency and fat malabsorption. Several raised plasma amino acids Not yet reached
38 6 Female Global delay, microcephaly, movement disorder
with chorea and non-epileptic myoclonic jerks.
Previous faltering growth. Renal tubular
acidosis on NaHCO3 supplements. Brain MRI:
delayed myelination.
N/A Not yet reached
39 12 Male Global delay, seizures, dysphagia. Sibling with
similar features.
Dysmorphism. Brain MRI: leukodystrophy. Persistent low arginine but normal lactate,
carnitine profile and urinary organic acids.
Not yet reached. Unconfirmed
NDUFS1 deletions
40 5 Male Global delay, retinal dystrophy, dystonic
extensor spasms, epilepsy.
Gastro-oesophageal reflux disease, hip
dislocation, scoliosis. Brain MRI: progressive
cerebral and cerebellar atrophy.
EEG features consistent with electrical status
epilepticus during sleep (ESES).
Microarray: deletion at 7q36.2. De
novo change which includes the DPP6
gene which is known to be associated
with neurological disorders
41 15 Female Developmental delay, paroxysmal episodes of
gasping, opisthotonus and discomfort related
to food ingestion.
Distinct facial features, abnormal maculae on
optical coherence tomography and slightly
swollen optic discs, mild scoliosis and
hypermobility. Brain MRI: non-progressive
ventricular dilation.
Abnormal VEP/ERG. Diagnosis of Koolen-de Vries syndrome
made by geneticists. KANSL1 :
c.1635-3T>C
42 6 Male Global delay, four-limb motor disorder with
variable increased tone.
Xp21 in-frame deletion within dystrophin
gene. Sister with similar phenotype but
without the dystrophin deletion. Brain MRI:
arachnoid cyst.
High creatine kinase. Very long chain fatty
acids (VLCFA): moderately raised C26 and
C26:C22 ratio.
Not yet reached
43 1 Male Marked hypotonia and hyper-reflexia at birth.
Faltering growth, poor feeding, hypoglycaemia
and lethargy at five months.
Rapid evolution to multi-organ failure and
passed away shortly afterwards. Brain MRI:
agenesis of the corpus callosum and
colpocephaly.
Persistent lactic acidosis. Ammonia: 88.
Normal mitochondrial genome analysis, no
POLG common mutations identified.
EARS2 variants picked up the panel.
Functional work underway to establish
its significance
44 7 Male Global delay, acquired microcephaly. Brain MRI: lack of white matter bulk and
delayed myelination.
Persistently low levels of branched-chain
amino acids in plasma in CSF.
Mutations in BCKDK gene diagnosed
by candidate gene testing. Gene not
on panel.
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3.4 advantages and pitfalls of an extended gene panel for investigat-
ing complex neurometabolic phenotypes
The data presented in this chapter shows that many suspected cases of inborn errors of metabolism
will have mutations in known genes that are amenable to targeted screening and that when
used in combination with clinical and biochemical evidence it can be an invaluable front-line
approach within the clinical setting. Candidate gene sequencing is useful in cases that present
with disease-specific features such as microcephaly, intellectual disability, syndactyly of the
second and third toes and elevated 7-dehydrocholesterol in cases of Smith-Lemli-Opitz syndrome
(Bianconi et al., 2015) or elevated blood concentrations of phenylalanine in phenylketonuria
(Vockley et al., 2014). However, for the majority of IEM, a gene-by-gene Sanger sequencing
approach is not economical or efficient due to the genetic heterogeneity involved. For example, an
abnormal transferrin isoelectric focussing pattern suggests the presence of a congenital disorder
of glycosylation (CDG); however, there are more than 100 genetic disorders known to cause CDG
with more than 40 defects of N-glycosylation causing an abnormal transferrrin pattern, rendering
sequential candidate gene sequencing extremely time-consuming and often futile (Scott et al.,
2014). Given this extreme genetic and phenotypic heterogeneity seen in IEM, a wider screening
approach is necessary to facilitate timely genetic diagnosis. The advent of next-generation
sequencing surmounts these issues and is enabling us to achieve the identification of causative
genes in patients at an accelerating rate.
The gene panel methodology described in this chapter was shown to be a powerful tool
that enhances the diagnostic ability in the clinical setting. The panel includes 614 genes which
was comprehensive of all the genetic defects known to cause neurometabolic disorders in June
2013. Therefore, this methodology shares similarities with whole exome sequencing approaches
for diagnosing these conditions in a clinical setting but with the added advantage of higher
coverage of target regions (Sun et al., 2015). This approach was used to investigate a cohort
of 44 patients with a wide array of, often non-specific, neurometabolic symptomatology. We
successfully identified 44 causal or likely pathogenic variants in 31 of the patients investigated, of
which 24 were novel. Many of the 30 patients without a prior genetic diagnosis had biochemical
indicators that may suggest a certain class of disorders (e.g. intermittently raised plasma lactate
which would be suggestive of a mitochondrial disorder). However, only 30% had laboratory
results that indicated a more specific diagnosis, further indicating that candidate gene sequencing
would be unlikely to result in diagnoses in this patient cohort. In this sub-group of patients
with strong biochemical abnormalities, pathogenic or likely pathogenic variants were identified
in 88.9% of cases. This suggests that an extended panel approach with subsequent focus on
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the candidate gene(s) could be an initial cost-effective approach for patients with suggestive
biochemical findings. This is particularly pertinent where biochemical results point towards
a disorder for which routine genetic testing is not available or when abnormalities suggest a
group of disorders which can have multiple genetic aetiologies (e.g. mutations in twelve different
PEX genes can cause a peroxisome biogenesis disorder as seen in patient 22 (Steinberg et al.,
1993)). In the remaining 21 patients with variable clinical presentations and no obvious indicators
suggesting specific genes, likely pathogenic variants that could, at least partially, explain the
observed phenotypes were identified in eight cases (38.1%). Despite the fact that some mutations
failed to account for the entirety of the clinical picture, the diagnosis rate of our panel was
higher than most panels targeting smaller sub-sets of human disease with cohorts of patients
exhibiting less phenotypic heterogeneity, which typically range between 10 - 30% (Trump et al.,
2016; Kammermeier et al., 2014; Jones et al., 2013; Sommen et al., 2016).
The data presented not only expands the genotypic and phenotypic spectrum of many
well-described and recently documented neurometabolic disorders, but also re-empahsises the
complexity of diagnosing patients with IEM and the advantages of an untargeted approach. Recent
studies have shown that mutations at distinct disease loci in a patient can lead to complicated
phenotypes, with 4.6% of participants having blended phenotypes resulting from two single-gene
defects (Yang et al., 2014). The existence of pathogenic variants in two genes in one patient
is not surprising given that it has been shown that individuals harbour approximately 13,500
single nucleotide variants which alter the amino acid sequence within their exome (Marian, 2014).
Blended phenotypes were also seen in our patient cohort with 9.1% (4/44) having two or more
disorders, with this higher proportion likely occurring due to the high degree of consanguinity in
our cohort. These issues further contribute to the complexity of accurately diagnosing IEM and
highlight the power of NGS as a clinical tool for establishing molecular diagnoses. Conversely,
they emphasise the need for diagnosticians to perform elaborate and accurate clinical phenotyping
and not over-rely on sequencing results, especially when the identified gene defects do not fully
account for the observed clinical picture. Futhermore, we have highlighted how common it is for
clinicians investigating neurometabolic disorders to be misguided by investigation results with
consequential diagnostic delays. Finally, although applied on a paediatric cohort, our approach
would arguably be even more useful in adult populations, where neurometabolic phenotypes can
be even more atypical, presentations more variable and biochemical phenotypes even more subtle
(Sedel et al., 2007).
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3.4.1 Difficulties in the interpretation of the pathogenicity of novel variants
This study also highlighted the difficulties encountered in the interpretation of novel variants. Of
the pathogenic or likely pathogenic variants identified, 24 were novel and included one splice site
mutation, six insertions and/or deletions and 17 missense variants. Whilst splice site, nonsense
and frameshift variants are typically expected to have large effects on protein function, the
interpretation of novel missense variants can often be challenging. In silico prediction tools can
give indications of variant pathogenicity but other factors should also be considered (Richards
et al., 2015). In this chapter SIFT and PolyPhen-2 were used, both of which are based on
multiple sequencing alignments but with the latter also incorporating structure-based prediction
algorithms. As each tool uses a slightly different methodology, the interpretation of variants can
differ; hence, combinations of in silico tools should be used. However, the best combination is
often gene-dependent (Leong et al., 2015). Mutation Taster, Combined Annotation Dependent
Depletion and Likely Ratio Test are additional tools that are becoming more popular for these
type of functional consequence predictions (Schwarz et al., 2010; Kircher et al., 2014; Chun and
Fay, 2009). In this study, such discordance between prediction tools is evident not only for
novel variants such as p.Asn322His in AASS and p.Ser485Arg in ACSF3, but also for variants of
experimentally established pathogenicity such as p.Gly309Arg in ASL (Linnebank et al., 2002)
and p.Leu195Pro in GALT (Reichardt et al., 1992). Furthermore, both SIFT and PolyPhen-
2 classified a known pathogenic mutation in IDUA (p.Leu490Pro) as tolerated and benign,
respectively (Bach et al., 1993). Previous studies have also indicated the inability of these online
prediction tools to correctly predict the pathogenicity of all variants analysed, hence increased
awareness and caution in interpretation of these results is warranted (Walters-Sen et al., 2015).
Nevertheless, in silico tools, alongside population and evolutionary conservation data, remain
valuable in filtering large numbers of variants identified using NGS platforms but further evidence
to support or refute pathogenicity should be sought where appropriate. Indeed, in this emerging
era of genomic medicine, protein structural analysis to examine pathogenicity is increasing utility
and feasibility on a large-scale (Yue et al., 2014). This involves mapping the mutated proteins onto
the known structures of human wild-type structures or those of homologues from other species.
The potential effects of each variant on bonding interaction, packing and secondary structures
due to the amino acid substitution can then be inspected using in silico prediction software.
Should the 3-dimensional structures of more proteins with the human exome be experimentally
solved and become publicly available, this approach would be a valuable aid towards novel variant
analysis. Finally, it is crucial that the experimental evidence accompanying reports of rare
pathogenic variants are revisited and treated with scrutiny. One study has reported that 27%
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of mutations cited in the medical literature as pathogenic are common polymorphisms or have
been misannotated (Bell et al., 2011). Indeed, false assignments of pathogenicity may result
in incorrect prognostic, therapeutic and reproductive advice being given and having severely
detrimental consequences on patient care (MacArthur et al., 2014).
3.4.2 Summary: The future of IEM diagnosis
With decreasing NGS costs and the advent of the 100,000 Genomes Project, it is plausible that
WES and WGS will supersede the use of gene panels in the clinical diagnostic setting in the near
future. However, many challenges need to be addressed prior to this implementation, including
difficulties in interpreting the overwhelming amounts of data generated (WGS will identify
approximately 4 million variants per patient) and uncertainties regarding clinically reportable
and actionable findings (Dewey et al., 2014). Moreover, WES and WGS have proven invaluable in
the identification of novel genes in many disorders including inborn errors of metabolism (Howard
et al., 2014; Novarino et al., 2012; van Karnebeek et al., 2014), but such findings are often not
currently actionable within the diagnostic setting. Elucidating the significance of these variants is
not possible without functional characterisation in appropriate settings and models, which is often
expensive and beyond the capacity of most clinical diagnostic laboratories. Until such challenges
can be surpassed, the use of a targeted gene panel approach provides a rapid and cost-effective
method of evaluating patients with neurometabolic disorders and enables more timely diagnosis
and prompt treatment initiation in these conditions. Indeed, our panel has been incorporated into
the GOSHome Gene Panel (www.labs.gosh.nhs.uk/media/759058/goshome_v7.pdf) which targets
approximately 5000 known disease-causing genes. This panel is based on an Agilent SureSelect
design, meaning newly-identified genes can be easily added to future iterations and large-scale
deletion screening using tools such as ExomeDepth can be more effectively implemented as
sequencing fragments are generated using random mechanical shearing.
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4
SE IZURES DUE TO A KCNQ2 MUTATION - TREATMENT WITH
VITAMIN B 6
4.1 whole exome sequencing for the diagnosis of iem/nmd
As demonstrated in Chapter 3, many patients with a suspected IEM remain undiagnosed even
following extensive genetic testing. In cases such as these, and in patients presenting with atypical
phenotypes suspected to represent a novel disorder, whole exome sequencing (WES) can be used
to perform genetic screening of the protein-coding regions of the genome. Advantages of this
approach when compared to standard Sanger or gene panel sequencing is the ability to detect
variants in novel disease-causing genes and therefore not relying on the prior identification of
candidate genes or groups of disorders.
As part of this thesis, ten families comprising fifteen affected children underwent WES. All
had been comprehensively phenotyped and extensively genetically and biochemically investigated
previously by the Metabolic Medicine Team at GOSH. A definitive or potential diagnosis that
could be further investigated using functional studies was identified in four families. These
findings are described and their implications in relation to the medical literature are discussed
in Chapters 4, 5 and 6. The clinical details of the six families in whom a genetic diagnosis
was not made are given in Table 4.1.1. These patients will not be discussed further due to the
constraints of this thesis format. However, it is possible that potentially pathogenic variants
were not identified in these cases because they lie within intronic or regulatory regions, disease is
due to large CNVs or the mutated regions were not adequately captured by the SureSelect kit or
covered by sequencing reads.
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Table 4.1.1: Patients who underwent whole exome sequencing and remained undiagnosed.
Family Number of
affected
patients
Clinical and biochemical phenotype Hypothesised diagnoses
1 2 Failure to thrive, diarrhoea, vomiting, ketotic hypoglycaemia, hypermobile joints, ear
infections and croup, eosinophilic colitis/duodenitis, predominance of unconjugated bile acids
in urine.
Abnormality of bile acid metabolism, abnormal
liver X receptor (LXR) or farnesoid X receptor
(FXR) signalling.
2 2 Early-onset movement disorder, generalised dystonia, frequent epileptiform activity with
multifocal features on EEG, undetectable CSF PLP whilst off-treatment, muscle biopsy
in-keeping with myopathic features.
Inborn error of vitamin B6 metabolism or
homeostasis.
3 1 Episodes of encephalopathy, ataxia, dysarthria, regression from 22 months of age, dry and
scaly skin rash, skin and neurological problems improved by nicotinamide treatment, mild
aminoaciduria.
Inborn error of nicotinamide metabolism,
abnormality of NAD transport to
NAD-dependent enzymes, defect of kynurenine
metabolism, mitochondrial disorder.
4 1 Failure to thrive, hypotonia, interstitial lung disease, chronic cough and rhinitis, abnormal
shape of lower ribs, short stature with growth hormone resistance, developmental delay,
protein-losing enteropathy, calcification in basal ganglia and subcortically,
gastro-oesophageal reflux with funcoplication, abnormal fat distribution, bruises easily,
lethargy, mild dysmorphism, low albumin, elevated alanine transaminase.
Congenital disorder of glycosylation,
Aicardi-Goutieres syndrome, abnormality of
growth hormone/IGF1 axis, surfactant deficiency,
cutis laxa
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5 2 Seizures, developmental delay, abnormal MRI, neuropsychiatric abnormalities, spasticity,
motor impairment, neurodegeneration with brain and eye abnormalities.
Neurometabolic disorder.
6 1 Dilated cardiomyopathy with biventricular dysfunction and pulmonary hypertension,
perimembranous ventricular septal defect, pulmonary valve dysplasia, mild dysmorphic
features, generalised hypotonia, extreme joint laxity, umbilical hernia, cutis laxa, rocker
bottom feet with prominent heels, segmentation anomaly of cervical spine, acute metabolic
decompensation following chest infection complicated by low cardiac output, severe hepatic
and moderate renal dysfunction, mildly decreased mitochondrial complex IV activity,
vitamin D deficiency.
Noonan’s syndrome, connective tissue disorder,
neuromuscular disorder, mitochondriopathy,
congenital disorder of glycosylation.
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4.2 introduction
In this chapter, the case of a girl (patient X) whose neonatal-onset seizure disorder appeared
to respond to a multivitamin supplement containing pyridoxine is presented. At this time she
also had a high plasma (670 nmol/L; ref: 15 – 73 nmol/L) but low CSF (12 nmol/L; ref: 14 –
92 nmol/L) concentration of PLP, resulting in a high plasma:CSF ratio. Abnormalities such as
these are often indicative of a primary inborn error of vitamin B6 metabolism or a secondary
defect affecting PLP availability.
4.2.1 Vitamin B6-dependent and -responsive disorders
Since the mid-1900s it has been known that dietary vitamin B6 deficiency causes seizures in
infants. This was particularly noted during an epidemic of seizures in American infants between
1951 and 1953 who were fed a milk formula deficient in vitamin B6 (Coursin, 1954). These
seizures remit upon administration of physiological doses of vitamin B6 (0.2 - 0.5 mg for infants
and 0.5 - 1.5 mg for children) and is now extremely uncommon, especially in developed countries
(Ohtahara et al., 2011).
In contrast, genetic disorders disrupting the normal metabolism of dietary vitamin B6 cause
severe seizures remitting only upon administration of pharmacological doses of vitamin B6 (at
least 10 times higher that physiological requirements). These disorders and their pathogenesis
are described in detail in Chapter 7. Pyridoxine dependent epilepsy (PDE) was first described by
Hunt et al. (1954). Patients typically present with antiepileptic drug-resistant seizures in the
neonatal period that respond dramatically to pyridoxine (PN) and remain seizure free on this
treatment. This metabolic defect has been shown to be due to a deficiency of α-aminoadipic
semialdehyde (α-AASA) dehydrogenase (antiquitin), an enzyme on the lysine catabolic pathway
(Mills et al., 2010). The accumulating upstream metabolite, L-∆1-piperideine-6-carboxylate (P6C)
forms an adduct with pyridoxal 5’-phosphate (PLP), the active form of vitamin B6, rendering
it inactive as a cofactor. P6C is in equilibrium with α-AASA and it is measurement of these
compounds, primarily in urine but also in plasma and CSF, that now forms the biochemical basis
for diagnosis, alongside molecular genetic analysis of ALDH7A1. In the majority of patients with
PDE, treatment with intravenous PN (50 or 100 mg single dose) followed by a maintenance oral
dosing regimen of 5 – 30 mg/kg/day (maximum 200 mg/day) results in seizure resolution. Patients
with pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency, are also now being recognised as
responding to PN; despite early patient cohorts only showing a clinical response to PLP (Mills
et al., 2014).
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Only children with hypophosphatasia due to mutations in tissue non-specific alkaline phos-
phatase (ALPL) have been documented to have a high plasma:CSF ratio as seen in patient X
(Baumgartner-Sigl et al., 2007; de Roo et al., 2014). These ratios have been documented to be as
high as 36.1 prior to commencing PN treatment and 24.0 in a patient on 135 mg/day PN. In
contrast, our patient had a higher ratio of 55.8. Alkaline phosphatase is required for calcium up-
take, bone mineralisation and cellular uptake of PLP (hence why patients with hypophosphatasia
have abnormal PLP levels); patients typically present with severe bone disease which can be
fatal during infancy (Baumgartner-Sigl et al., 2007). Patients with severe disease may also have
AED-resistant seizures that can be ameliorated with PN. However, there are milder forms of the
disease which can present in childhood or adulthood with rickets, premature loss of deciduous
teeth and repeated bone fractures.
A low CSF PLP concentration alone is a more non-specific finding that can be seen in a
number of disorders. Low CSF and plasma PLP concentrations are indicative of both PNPO and
antiquitin deficiencies (Mills et al., 2005; Ormazabal et al., 2008; Footitt et al., 2013; Stockler et al.,
2011). Two other classes of disorder have been described to cause vitamin B6-responsive seizures,
namely hyperprolinaemia type II and disorders of glycosylphosphatidylinositol (GPI) anchor
biosynthesis. Given the pathophysiology of these conditions, we might expect patients to have low
CSF PLP, however there are no reports of patients having this measured. Hyperprolinaemia type
II, like PDE, results in an accumulation of a metabolite (L-∆1-pyrroline-5-carboxylate (P5C))
which forms an adduct with PLP, rendering it inactive and causing seizures. Patients have
grossly elevated proline concentrations in plasma and elevated P5C in plasma, urine and CSF
(Flynn et al., 1989). Disorders of GPI anchor biosynthesis have only recently been identified
over the past five years to cause a subclass of congenital disorders of glycosylation. To date,
mutations have been identified in eleven genes: PIGV, PIGO, PIGL, PIGW, PIGT, PIGA,
PIGM, PIGN, PIGY PGAP2 and PGAP3. Alkaline phosphatase is normally GPI anchored to
the cell surface and must be correctly located to facilitate PLP to enter the brain. Thus, these
disorders lead to hyperphosphatasia (elevated serum alkaline phosphatase) and epileptic seizures
in almost all cases. Indeed, treatment with high-dose PN monotherapy resulted in complete
cessation of seizures in two cases (Thompson et al., 2006; Kuki et al., 2013). Despite affecting a
common metabolic pathway, GPI anchor defects are characterised by vast additional phenotypic
diversity including characteristic dysmorphic facial features, cleft palate, short terminal phalanges,
occular abnormalities, sensorineural deafness, heart defects, renal abnormalities, Hirschsprung
disease and cerebellar atrophy (Almeida et al., 2006; Krawitz et al., 2010, 2012, 2013; Ohba
et al., 2014; Howard et al., 2014; Chiyonobu et al., 2014; Fujiwara et al., 2015; Lam et al., 2015;
Tarailo-Graovac et al., 2015; Ilkovski et al., 2015).
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The patient described in this chapter was referred to the metabolic clinic at GOSH because of
her biochemical abnormalities indicative of an inborn error of vitamin B6 metabolism. Urinary α-
AASA analysis and sequencing of the PNPO gene excluded both antiquitin and PNPO deficiency
and her clinical phenotype was not typical of any of the disorders described above.
4.2.2 Vitamin B6 to treat idiopathic epilepsy
Since the recognition that vitamin B6 plays a critical role in normal brain function, many trials
of supplementation with PN or PLP in children with epilepsy of various aetiologies have been
carried out, with variable outcomes. Many studies have demonstrated that an average of 13%
of patients with West syndrome (a severe epilepsy syndrome with patients typically affected by
infantile spasms, hypsarrythmia and mental retardation) are responsive to either PN or PLP
(Table 4.2.1) (French et al., 1965; Hansson and Hagberg, 1968). Indeed, in Japan high-dose
vitamin B6 treatment is the initial therapy given to children with this diagnosis (Tsuji et al.,
2007), despite the disorder having a multitude of possible aetiologies. The addition of high-dose
PN treatment to current AED regimens also improved response rates and decreased time taken
for seizure cessation in children with recurrent convulsions due to infection (Jiao et al., 1997).
Vitamin B6 treatment has also been shown to be effective in between 5 - 9.5% of children with
idiopathic epilepsy, with PLP being more effective than PN (Wang et al., 2005; Mishra et al.,
2010).
Table 4.2.1: Efficacy of vitamin B6 treatment in West syndrome (modified from
Ohtahara et al. (2011)). None of these reports stated that a maximum threshold
of vitamin B6 that could be administered to each patient per day was used. PN,
pyridoxine; PLP, pyridoxal 5’-phosphate.
Reference PN/PLP Dose per day Efficacy
Fukuyama et al. (1980) PLP 10-30 mg/kg 3/64 (4.7%)
Izuora and Iloeje (1989) PN 150-1200 mg 0/9 (0.0%)
Ito et al. (1991) PN 10-50 mg/kg 1/20 (5.0%)
Pietz et al. (1993) PN 100-300 mg/kg 5/17 (29.4%)
Yoshida (1993) PLP 10-70 mg/kg 9/59 (15.3%)
Suzuki et al. (1996) PLP 20-50 mg/kg 2/25 (8.0%)
Takuma and Seki (1996) PLP 20-50 mg/kg 3/28 (10.7)
Ohtsuka et al. (2000) PLP 30-400 mg 30/216 (13.9%)
Toribe (2001) PLP 20-50 mg/kg 6/50 (12.0%)
Wang et al. (2005) PN 10-20 mg/kg 2/13 (15.4%)
PLP 30-50 mg/kg 4/13 (30.1%)
Total 65/501 (13.0%)
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A recent review of 216 West syndrome patients treated with PLP between 1969 and 1998 at
Okayama University Hospital revealed many interesting findings including higher response rates
amongst patients receiving higher-dose supplementation and with an unknown seizure aetiology
(Ohtahara et al., 2011). Whilst the genetic and biochemical basis for the response of many
of these patients has not been investigated, the proportion responding is so high it is highly
unlikely that a significant proportion have antiquitin or PNPO deficiency. One explanation may
be genetic heterogeneity in genes involved in vitamin B6 metabolism. This is supported by the
variability in B6 requirements amongst patients and efficacy in children with various seizure
semiologies and aetiologies. Another may be that a B6-response is age-dependent and related
to changing requirements for neurotransmitter synthesis by B6-dependent enzymes. Supporting
this, successful withdrawal of PN or PLP has only been reported to occur after two years of age
(Ohtahara et al., 2011). Whole exome sequencing is one method that can be used to investigate
the genetic aetiologies of idiopathic cases such as these. This approach was used to investigate
the underlying aetiology of disease in patient X.
4.3 case report
Patient X, a daughter of unrelated parents, was born by spontaneous labour at 38+6 weeks
after an uneventful pregnancy. Good foetal movements were reported. The baby had hiccoughs
during the last trimester, although similar movements were also reported during the mother’s
first pregnancy with an unaffected child.
She was born in good condition and discharged on day three of life. Prior to this she suffered
two episodes of facial reddening, stiffening and then becoming pale; these were associated with
feeding and thus assumed to be reflux. One day post discharge, she had episodes of choking and
cyanosis, associated with stiffening after which she became floppy. Further seizures on day 4
were documented at her local hospital; these were accompanied by "cycling" movements of her
arms with oxygen saturations dropping to 68%, lasting less than one minute. A full septic screen
including a lumbar puncture was negative and she was given a loading dose of phenobarbitone.
Seizures continued following this requiring control with phenobarbitone, phenytoin and lorazepam.
At nine days of age she had a normal cranial ultrasound and CT scan but an electroencephalogram
(EEG) demonstrated some asymmetry with larger amplitude responses on the right and abnormal
paroxysmal components. A brain MRI on day 28 demonstrated normal brain structures with
appropriate maturation, but some increased signal intensity in the subthalamic nuclei around the
lateral geniculate nuclei bilaterally.
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A series of biochemical investigations between seven days and one month of age demonstrated
mild, but likely insignificant, abnormalities of plasma amino acids (Table 4.3.1). Urine analysis
showed widespread mild elevation of multiple amino acids (Table 4.3.2) and organic acid analysis
revealed mildly elevated 2-oxoglutarate and pyruvate (not quantified) interpreted as a possible
renal tubule leak or immaturity. Other analytes found to be high were gamma-glutamyl transferase
256 U/L (ref: 12 – 43 U/L) and alkaline phosphatase 342 U/L (ref: 129 – 291 U/L), a common
finding in children on anticonvulsants.
Table 4.3.1: Plasma amino acid abnormalities identified in patient X with a sus-
pected inborn error of metabolism. The samples were analysed by high-
performance liquid chromatography (HPLC) as part of the patient’s clinical care.
Only amino acids which were reported to be abnormal on at least one occasion
are shown. -, reported as normal. All results are expressed in µmol/L.
Amino acid Age at time of sampling Reference range
7 days 30 days 4 months 5 days
Glutamine 876 882 - 400 - 800
Lysine 87 - - 100 - 300
Phenylalanine 33 - - 35 - 100
Arginine - 172 - 40 - 120
Ornithine - 146 238 25 - 120
Taurine - 168 216 40 - 140
Glutamate - 173 264 25 - 130
Glycine - - 341 100 - 300
Serine - - 431 90 - 290
Alanine - - 499 150 - 450
By six weeks of age seizures continued to occur sporadically, beginning with both eyes
staring towards the corner of the room, mouth pouting, clonic movements of both limbs and
respiratory grunting sounds. A repeat EEG at this time demonstrated abnormal delta activities
and intermittently occurring angular or sharp waves, mainly anteriorly whilst at rest. Conversely,
when she cried or had been alerted, the recording was of lower voltage without sharp waves but
the content was abnormal. At two months of age she was commenced on 0.3 mL of DaliVit
multivitamin oral drops per day; a dose which contained 0.25 mg of PN. Seizures were reported
to have ceased six days after this, at a time when she was also receiving 6.7 mg/kg/day of
phenytoin and 11 mg/kg/day of carbamazepine. Further biochemical testing at three months of
age, revealed a plasma PLP level of 670 nmol/L (ref: 15 – 73 nmol/L) but a CSF PLP level of
12 nmol/L (ref: 14 – 92 nmol/L). This high plasma:CSF PLP gradient suggested an abnormality
of vitamin B6 metabolism, thus she was commenced on 5 mg/kg/day of PN at four months of
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Table 4.3.2: Urine amino acid abnormalities identified in patient X with a suspected
inborn error of metabolism. Samples were analysed by ion exchange chro-
matography with post column ninhydrin derivatisation using the Biochrom 30+
amino acid analyser as part of the patient’s clinical care. Only amino acids which
were reported to be abnormal on at least one occasion are shown. -, reported as
normal. All results are expressed in µmol/mmol creatinine.
Amino acid 30 days Reference ranges
Glycine 1254 300 - 950
Serine 192 25 - 95
Threonine 61 10 - 45
Alanine 167 30 - 130
Glutamine 247 40 - 120
Lysine 115 5 - 20
Cystine 41 5 - 35
Taurine 316 30 - 55
Histidine 263 50 - 155
Aspartate 61 10 - 45
age. Phenytoin was then weaned with no increase in seizure frequency. Urinary α-AASA was not
elevated and no mutations were detected in ALDH7A1 or PNPO.
Throughout the following two years she continued to have seizures, mainly during intercurrent
illness, requiring 15 mg/kg/day of carbamazepine for control, in addition to PN supplementation.
An MRI and EEG were unremarkable, therefore weaning of carbamazepine was carried out
over a period of two months. Three days after weaning she had two generalised seizures lasting
between 3 – 4 minutes, consisting of tongue biting, stiffening, going pale, grunting, frothing at
the mouth and becoming floppy afterwards. The carbamazepine was recommenced at her original
dose but she became very ataxic (a side effect of this medication) therefore the dose was halved
(7.3 mg/kg/day). Neurotransmitter analysis at four years of age revealed a slightly low level of
methyltetrahydrofolate of 41 nmol/L (ref: 52 – 178 nmol/L), thus she was started on calcium
folinate (7.5 mg/day).
Since commencing PN treatment at four months of age her dose had been increased to 15.6
mg/kg/day in addition to 7.3 mg/kg/day of carbamazepine, in line with weight gain. At seven
years old, she was developmentally delayed with minimal expressive language and attends a
school for children with special needs but remains healthy except for seizures in the context of
intercurrent illness. A recent EEG has shown a change to a left temporal lobe focus.
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4.4 methods
Whole exome sequencing was performed as described in Section 2.5 and filtered to look for variants
inherited in both an autosomal dominant and recessive manner (Section 4.5). Confirmation of
the pathogenic KCNQ2 mutation was carried out using the PCR conditions outlined in Tables
4.4.1 and 4.4.2. Visualisation of amplification products, PCR clean-up and Sanger sequencing
were performed as described in Section 2.3.2.
Table 4.4.1: Composition of the reaction mix used to amplify the mutation-
containing region of KCNQ2. Amplification was carried out using a GoTaq
DNA Polymerase Kit (Promega, Maddison, WI).
Reagent Volume (µL)
Nuclease-free water 16.35
5X PCR reaction buffer 6
MgCl2 (25 mM) 2.4
dNTP mixture (10 mM) 0.6
Forward primer (5 µM) 1
Reverse primer (5 µM) 1
GoTaq DNA polymerase (5 U/µL) 0.15
Genomic DNA (75 ng) 1
Table 4.4.2: Touchdown PCR cycling conditions used to amplify the mutation-
containing region of KCNQ2.
Step Conditions
1 95◦C for 3 mins
2 95◦C for 30 secs
3 64◦C for 30 secs (-1◦C per cycle)
4 72◦C for 1 min
5 Repeat steps 2-4 9 times for a total of 10 cycles
6 95◦C for 30 secs
7 54◦C for 30 secs
8 72◦C for 1 min
9 Repeat steps 6-8 24 times for a total of 25 cycles
10 71◦C for 7 mins
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4.5 results and discussion
4.5.1 Autosomal recessive filtering
Whole exome sequencing data was initially filtered and analysed assuming that the patient’s
disorder had been inherited in an autosomal recessive manner. Variants classified as "pathogenic"
or "likely pathogenic" according to computed American College of Medical Genetics and Genomics
(ACMG) Guidelines (detailed in Tables 3.3.7 and 3.3.8) were included. Only variants associated
with a loss of gene function, including missense, splice site, insertions, deletions or variants
affecting start or stop codons were considered. Five missense variants were identified in five
genes (Table 4.5.1). Of these, only CHD2, encoding chromodomain helicase DNA binding 2,
is known to cause a seizure phenotype when mutated. De novo mutations in this gene cause
childhood-onset epileptic encephalopathy with a typical onset of seizures in the second year of life.
Patients typically develop normally in the first year of life before presenting with developmental
delay, followed by the onset of myoclonic, absence and tonic-clonic seizures (Thomas et al.,
2015). The majority of patients (up to 70%) have seizures which are refractory to treatment
with anti-epileptic drugs (Thomas et al., 2015). CHD2 encephalopathy is also characterised by
extreme clinical photosensitivity and self-induced photic seizures.
The clinical phenotype of our patient would be an atypical presentation for a child affected
by CHD2 encephalopathy. Tonic-clonic seizures commenced on day four of life and she has
never demonstrated any photosensitivity or photoparoxysmal response. Her seizures additionally
showed a good response to anti-epileptic drugs, particularly carbamazepine. Furthermore, CHD2
encephalopathy is typically caused by de novo mutations in CHD2, whereas the variant detected
(p.Ser1407Thr) was in a homozgous state in our patient and heterozygous in both parents. The
same variant was also detected in one of four unrelated samples run in the same sequencing
batch. This missense variant has not been previously associated with disease and has been
reported in publicly available databases at a minor allele frequency of approximately 1% (1000
Genomes Project, 0.88%; NHLBI Exome Sequencing Project, 1.22%, ExAC, 1.53%). However,
this frequency rises to 3.24% in South Asian populations. Our family is of Asian origin and hence
this variant was considered unlikely to be pathogenic in this case.
The other variants identified were present in genes that have been associated with disorders,
but were not consistent with the clinical phenotype of patient X (Table 4.5.1). The LCT
gene encodes lactase which catalyses the metabolism of lactose to form glucose and galactose.
Mutations in this gene cause lactose intolerance resulting in abdominal pain, diarrhoea and
nausea upon the consumption of lactose-containing dairy products. Although its physiological role
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remains unclear, PNMA2 has been tentatively linked to paraneoplastic neurological syndrome
(i.e. indirect remote effects of cancer on the nervous system) due to the detection of this protein
using antibodies in the serum of affected patients (Hoffmann et al., 2008). Finally, TRIP11
encodes Golgi microtubule-associated protein 210 in which mutations cause achondrogenesis type
1A. This disorder is characterised by extremely short limbs, narrow chest, short ribs, and bones
that are poorly ossified and fracture-prone. Indeed, affected infants usually die before or soon
after birth (Smits et al., 2010).
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Table 4.5.1: Whole exome sequencing data was filtered to show autosomal recessive variants. Chr, chromosome; n/a, not applicable due to both SIFT and
PolyPhen-2 only predicting functional impact for simple variants that change the protein sequence; -, not stated in Ingenuity Variant Analysis software.
Chr Position Reference
Allele
Patient
Allele
Gene Protein
Variant
Het/Hom SIFT PolyPhen dbSNP ID 1000 Genomes
Frequency
NHLBI ESP
Frequency
ExAC
Frequency
2 136552328 T G LCT p.Glu1665Ala Het Tolerated Benign - - - -
2 136562522 C T LCT
p.Asp1427Asn
Het Tolerated Possibly damaging 776196678 - - -
8 26365425 G A PNMA2 p.Arg283Cys Hom Tolerated Possibly damaging 78548714 0.92 0.02 0.49
14 92473994 T G TRIP11 p.Glu506Ala Hom Damaging Probably damaging 2273186 1.54 0.93 0.66
15 93545488 T A CHD2 p.Ser1407Thr Hom Tolerated Benign 61756301 0.88 1.22 1.53
4.5.2 Variants in genes known to cause inborn errors of vitamin B6 metabolism
One of the most striking features seen in our patient, which directed further metabolic investi-
gations, was her abnormally high plasma:CSF PLP ratio as well as her apparent improvement
in seizure control on PN treatment. Antiquitin and PNPO deficiency were both ruled out
biochemically and/or genetically. The high plasma PLP level in patient X whilst on only 0.07
mg/kg/day PN was noteworthy; being much higher than levels reported in healthy individuals
and similar to levels in adults taking 0.63 mg/kg/day PN (Midttun et al., 2005), and in fact
more comparable to children 8.0 mg/kg/day for treatment of PDE or 30 mg/kg/day for PNPO
deficiency (Footitt et al., 2013) (Table 4.5.2). Moreover, the plasma:CSF PLP ratio of 55.8
was very striking; being much higher than the upper limit of 4.4 in paediatric patients with
neurological disease (Footitt et al., 2011). The only other genetically defined disorder in which
a high plasma:CSF PLP ratio has been documented is hypophosphatasia due to mutations in
alkaline phosphatase (ALPL).
Table 4.5.2: Comparison of plasma PLP concentrations in patient X and in patients
described in theliterature on differing doses of PN supplementation for
various conditions. 1, Midttun et al. (2005); 2, patients 5 and 6 from Footitt
et al. (2013); 3, patients 1 and 2 from Footitt et al. (2013); PDE, pyridoxine
dependent epilepsy; PNPO, pyridox(am)ine 5’-phosphate oxidase.
Patient PN supplementation Plasma PLP
(nmol/L)
Reference
range
(nmol/L)
Patient X 0.25 mg/day (0.07 mg/kg/day) 670.0 15.0 - 73
Cardiovascular patients1 40 mg/day (0.63 mg/kg/day) 234.0 - 585.0 17.0 - 102.3
PDE patients2 200 mg/day (8 mg/kg/day) 587.9 - 603.3 46.0 - 321.0
PNPO-deficient patients3 30 mg/kg/day 580.0 - 632.6 46.0 - 321.0
Given these metabolic abnormalities, whole exome sequencing data was also scrutinised for
potentially pathogenic variants in genes known to cause inborn errors of vitamin B6 metabolism,
a high plasma:CSF PLP ratio or hyperphosphatasia; namely, PNPO, ALDH7A1, ALPL and
genes involved in glycosylphosphatidylinositol (GPI) anchor synthesis. Twenty variants were
identified in the candidate genes (Table 4.5.3), including eleven synonymous variants and nine
single amino acid substitutions.
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Table 4.5.3: Autosomal recessive variants present in vitamin B6-related genes in patient X. Splice site prediction was performed using tools available at
(www.fruitfly.org/seq_tools/splice.html) (Reese et al., 1997). Chr, chromosome; n/a, not applicable.
Chr Position Reference
Allele
Sample
Allele
Gene Protein
Variant
Splicing
effect
Het/Hom SIFT PolyPhen dbSNP ID 1000 Genomes
Frequency
NHLBI ESP
Frequency
ExAC
Frequency
1 21889635 T C ALPL p.Ser110Ser None Hom n/a n/a 1780316 92.95 92.17 94.50
1 21904131 T C ALPL p.Val522Ala n/a Het Tolerated Benign 34605986 7.19 7.61 11.07
1 77634948 G A PIGK p.Tyr124Tyr None Hom n/a n/a 1779199 98.66 98.32 99.55
1 77685042 T C PIGK p.Thr16Ala n/a Het Damaging Benign 12723684 19.17 17.97 12.28
2 46839477 T C PIGF p.Ala109Ala None Het n/a n/a 1824050 18.03 21.76 32.75
3 196674307 C T PIGZ p.Met487Ile n/a Het Damaging Benign 17855662 3.04 5.29 6.66
3 196674749 C T PIGZ p.Arg340Gln n/a Hom Tolerated Benign 4916589 63.22 60.77 59.11
3 196674879 A G PIGZ p.Leu297Leu None Hom n/a n/a 12636891 59.25 49.22 53.81
3 196674916 A C PIGZ p.Ala284Ala None Het n/a n/a 1147240 57.73 45.76 45.96
3 196674972 C T PIGZ p.Ala266Thr n/a Hom Tolerated Benign 574365 80.51 57.58 76.99
3 196674973 T C PIGZ p.Ala265Ala None Hom n/a n/a 573708 81.75 61.94 77.16
4 509850 T C PIGG p.Ser197Ser None Het n/a n/a 11726338 2.06 2.72 2.21
4 515489 G A PIGG p.Ala296Ala None Het n/a n/a 13115344 20.33 18.87 13.76
4 517376 T C PIGG p.Leu448Leu None Het n/a n/a 76662266 22.42 19.64 15.18
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4 517461 T C PIGG p.Cys477Arg n/a Het Tolerated Benign 7666425 22.42 19.65 15.18
4 517622 C T PIGG p.Ala530Ala None Het n/a n/a 13150531 22.42 19.09 21.86
4 520853 G A PIGG p.Val566Ile n/a Het Tolerated Benign 13114026 17.83 15.67 13.81
4 527677 T C PIGG p.Ile748Thr n/a Het Tolerated Benign 34623004 20.79 19.26 15.02
4 533001 T C PIGG p.Phe799Ser n/a Het Tolerated Benign 1127410 20.87 19.31 15.04
17 37830900 A G PGAP3 p.Val104Val None Hom n/a n/a 2941504 57.79 65.76 69.83
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All of the variants were listed in dbSNP, reported to have minor allele frequencies of at least
2%. In silico splice site prediction revealed that none of the synonymous variants would be
predicted to affecting correct mRNA splicing. All of the missense variants were predicted to be
benign by PolyPhen-2 and 7/9 were also predicted to be tolerated by SIFT. The remaining two
variants were p.Thr16Ala in PIGK and p.Met487Ile in PIGZ. The first variant is reported in
publicly available databases at a minor allele frequency of approximately 15% (1000 Genomes
Project, 19.17%; NHLBI Exome Sequencing Project, 17.97%, ExAC, 12.28%). The second variant
occurs with a minor allele frequency of approximately 5% (1000 Genomes Project, 3.04%; NHLBI
Exome Sequencing Project, 5.29%, ExAC, 6.66%). In addition, two other missense variants
affecting amino acid 487 have been described (p.Met487Thr and p.Met487Leu) indicating that
this residue is not likely to have high importance for protein function.
The only variant of the 20 detected for which there is evidence of a physiological effect is
p.Val522Ala in ALPL. This variant is annotated as a gain of function as a genome-wide association
study investigating factors associated with recurrent kidney stones identified this variant both as
being correlated with the formation of kidney stones and with increased serum levels of alkaline
phosphatase protein and increased enzyme activity (Oddsson et al., 2015; Orimo et al., 2001).
This variant is very common with minor allele frequencies of over 10% (1000 Genomes Project,
7.19%; NHLBI Exome Sequencing Project, 7.61%, ExAC, 11.07%). However, this frequency rises
to 17.89% in South Asian populations. Thus, reference ranges for serum alkaline phosphatase
concentrations are likely to already incorporate this variation. In addition, this variant was
detected in a homozygous state in one of the patient’s parents and in a heterozygous state in
one of four unrelated individuals run in the same sequencing batch. Nevertheless, a gain of
function of ALPL would not be consistent with the biochemistry seen in our patient. ALP
is a glycophosphatidylinositol (GPI) anchored protein which functions as a PLP phosphatase,
allowing unphosphorylated species to enter the brain (Whyte et al., 1985; Giocondi et al., 2008).
Thus, an increase in circulating alkaline phosphatase may be expected to result in a decrease in
plasma PLP and less available to enter the brain. Furthermore, this residue is extremely poorly
conserved with other hydrophobic as well as polar amino acids found at this position (Figure
4.5.1). The observed substitution of a valine for an alanine residue is a very minimal change with
the removal of a -CHCH3 group, resulting in an amino acid with very similar physicochemical
properties. Collectively the evidence, i.e. the high frequency in the general population, effect
on circulating ALP levels (Oddsson et al., 2015; Orimo et al., 2001), poor conservation across
species and minimal change in amino acid properties, suggests that this variant would be unlikely
to result in the elevated plasma and reduced CSF concentrations of PLP reported in patient X.
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Figure 4.5.1: Multiple sequence alignment of the ALPL gene across species. The
lack of sequence conservation of the site of the p.Val522Ala variant is highlighted
in yellow. The alignment was generated using Clustal Omega.
4.5.3 Autosomal dominant filtering
Given that no plausible variants were identified that fitted an autosomal recessive pattern of
inheritance (i.e. homozygous or compound heterozygous variants) and that there was no family
history of seizures, the data was re-analysed to look for de novo variants. Data was scrutinised
using the same classification and inclusion criteria as for the autosomal recessive analysis. Ten
variants were identified in nine genes, including seven missense variants, one insertion and two
deletions (Table 4.5.4). Many of the variants were identified in genes that encode proteins of
unknown function or that have not yet been associated with disease. The first is BAIAP2L2,
whose protein product is involved in receptor-mediated endocytosis (Veltman et al., 2011). KIF12
is a member of the kinesin superfamily of microtubule-associated molecular motors that play
an important role in intracellular transport and cell division (Chen et al., 2007). FOXRED2
is thought to encode a flavoprotein which may function in endoplasmic reticulum-associated
degradation of non-native proteins. RNF145 encodes ring finger protein 145, a protein of unknown
function (Shim et al., 2011). Finally, WDR26 enncodes a member of the WD repeat protein
family. It is thought that this protein plays a role in cell signal transduction and leukocyte
migration (Zhu et al., 2004; Sun et al., 2011).
178
Table 4.5.4: Whole exome sequencing data was filtered to show autosomal dominant and de novo variants. Chr, chromosome; n/a, not applicable due to
both SIFT and PolyPhen-2 only predicting functional impact for simple variants that change the protein sequence; -, not stated in Ingenuity Variant Analysis
software.
Chr Position Reference Allele Sample
Allele
Gene Protein Variant SIFT PolyPhen dbSNP ID 1000 Genomes
Frequency
NHLBI ESP
Frequency
ExAC
Frequency
1 224621770 CCA - WDR26 p.Gly25del n/a n/a - - - -
4 3076604 CAGCAGCAG - HTT p.Gln38_Gln40del n/a n/a 757035717 - - -
5 158630629 - T RNF145 p.Asn13fs*44 n/a n/a 762761147 - - -
9 116854149 G C KIF12 p.Pro512Ala Deleterious Probably damaging 530640960 0.26 - 0.32
10 6262778 C G PFKFB3 p.Leu241Val Tolerated Benign 758281350 - - -
19 55879672 C T IL11 p.Arg112His Tolerated Probably damaging 4252548 1.2 1.67 4.99
20 62076073 C T KCNQ2 p.Arg210His Damaging Probably damaging - - - -
22 36894150 C T FOXRED2 p.Ala424Thr Tolerated Benign 149345662 - 0.02 0.01
22 38383171 G A BAIAP2L2 p.Pro407Ser Tolerated Benign 142001534 2.16 2.44 3.75
22 38483174 A T BAIAP2L2 p.Ser406Thr Tolerated Benign 78489217 1.68 - 1.81
The remaining four genes in which variants have been identified have been associated with
human disease, three of which (PFKFB3, IL11 and HTT ) were not consistent with the clinical
phenotype of patient X. PFKFB3 encodes a bifunctional enzyme with both 6-phosphofructo-2-
kinase and fructose-2,6-biphosphatase activity. This protein is required for cell cycle progression
and prevention of apoptosis. It functions as a regulator of cyclin-dependent kinase 1, linking
glucose metabolism to cell proliferation and survival in tumor cells. Hence increased PFKFB3
activity has been associated with multiple types of cancer (Chen et al., 2016). Although mutations
in IL11 have not been associated with disease in humans, this interleukin has been reported to
have diverse roles including effects in osteoclastogenesis, neurogenesis, adipogenesis, promotion of
stem cell development, haematopoiesis, immunological activity and anti-inflammatory pathways.
As such, altered levels of this protein and/or its potential as a treatment candidate in multiple
diseases such as haemophilia A, Crohn’s disease, rheumatoid arthritis and multiple types of cancer
have been reported (Negahdaripour et al., 2016). Finally, the HTT gene encodes huntingtin,
a protein in which mutations cause Huntington’s disease. This disorder is characterised by
progressive neurodegeneration with chorea, dystonia, incooridination, cognitive decline and
behavioural difficulties with onset typically in mid- to late-adulthood. Disease is caused by an
expansion of a trinucleotide repeat (CAG)n encoding a string of glutamine residues within the
protein. In normal individuals the number of glutamine residues ranges between 9 - 36, whereas
affected patients have more than 37. Although juvenile forms of Huntington’s disease exist, they
are associated with greater degrees of expansion (typically > 60 repeats) (Quarrell et al., 2013).
Therefore, this is highly unlikely to be the cause of disease in patient X given that the identified
mutation results in the deletion of three glutamine residues.
The only gene in which mutations are known to cause a seizure phenotype was KCNQ2,
encoding a voltage-gated potassium channel that is expressed in the brain. De novo mutations in
KCNQ2 are known to cause a range of epileptic disorders including neonatal epileptic encephalopa-
thy and benign familial neonatal seizures. The variant identified in our patient (p.Arg210His)
is a known pathogenic mutation that has been reported previously in four patients to cause a
severe epileptic encephalopathy (Weckhuysen et al., 2013; Numis et al., 2014). Sanger sequencing
of the affected region of KCNQ2 confirmed the presence of the mutation in the patient and its
absence in both parents, thus confirming the expected de novo inheritance pattern (Figure 4.5.2).
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Figure 4.5.2: KCNQ2 sequence analysis of affected family using Sanger sequencing.
Patient X shows a heterozygous missense change from G to A at position 629
of the cDNA (c.629G>A) causing a change of amino acid 210 from arginine to
histidine (p.Arg210His).
4.5.4 Function of KCNQ2
KCNQ2 encodes a voltage-gated potassium channel expressed in the brain (Biervert et al.,
1998) and plays a critical role in determining response to synaptic inputs and sub-threshold
electroexcitability of neurons. Typical features of voltage-gated potassium channels include
six transmembrane domains (S1-S6) and a pore loop between S5 and S6 (Hartmann et al.,
1991) (Figure 4.5.3). This pore loop domain contains a conserved sequence of eight amino acids
(T/SxxTxGxG) which confers selectivity for potassium ions (Miller, 2000). There is also a long
intracellular C terminus which contains highly conserved domains important for correct channel
tetramerisation, stability, trafficking and insertion into the neuronal membrane (Haitin and Attali,
2008). The Arg210 residue which is mutated in patient X lies within the transmembrane domain
(S4) and the implications of this substitution are described in Section 4.5.7. Voltage-gated ion
channels contain positively charged residues that can move within the cell membrane, thus
sensing the electric field within it. In turn, these movements then produce a current forcing a
conformational change of the channel and opening or closing a gate that controls the flow of ions
through the pore (Cha et al., 1999). This voltage-sensing region lies within the S4 transmembrane
domain and consists of several well-conserved, evenly spaced arginine and lysine residues with
mostly non-polar amino acids between them. Site-directed mutagenesis studies have shown that
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a reduction of the net positive charge within the voltage-sensing region causes a reduction in
gating charge and in the steepness of the potential dependence of activation (Stühmer et al.,
1989).
All known potassium channels are tetramers of identical or homologous α-subunits. KCNQ2
and its homologue KCNQ3, form a single functional heteromeric potassium channel that facilitate
currents 11-fold higher than either homomeric channel (i.e. channels formed of either four KCNQ2
or KCNQ3 monomers) (Singh et al., 2003) and assemble in a 1:1 stoichiometric ratio (Hadley et al.,
2003). It is these heteromeric and homomeric channels that control a slow potassium current,
termed the M-current. The M-current was first discovered in bullfrog sympathetic ganglion cells
and regulates the ability of a neuron to fire an action potential (Brown and Adams, 1980). When
a neuron is initially polarised the likelihood that KCNQ2/KCNQ3 channels will open increases,
leading to the generation of an outward potassium current. This potassium eﬄux counteracts
the sodium influx generated by an action potential and thus, a full action potential is prevented.
Inhibition of the M-current by neurotransmitters or drugs leads to neuronal hyperexcitability
and subsequently, seizures (Marrion, 1997).
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Figure 4.5.3: Schematic representation of KCNQ2. The six transmembrane domains (S1-S6), pore loop domain containing the potassium selectivity
sequence and the long intracellular C-terminus are illustrated. Pore loop domain containing the potassium selectivity sequence (green). Mutations
were curated using the Human Genome Mutation Database and manual literature searching. Positions at which single nucleotide (i.e. missense or
nonsense) mutations are known to cause either benign familial neonatal seizures (orange) or neonatal epileptic encephalopathy (blue), insertions
(yellow) and deletions (pink) are highlighted. The mutated arginine at position 210 identified in our patient is also depicted (red). Figure created
using Protter (www.wlab.ethz.ch/protter/) (Omasits et al., 2014).
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4.5.5 Phenotypic spectrum of KCNQ2 mutations
Dominant mutations in KCNQ2 result in a range of (mostly epileptic) disorders including
peripheral nerve hyperexcitability (PNH), neonatal epileptic encephalopathy (NEE) and 60-70%
of benign familial neonatal seizures (BFNS) (Weckhuysen et al., 2012).
BFNS are characterised by recurrent seizures commencing within the first few days following
birth, which are typically tonic-clonic in nature although other seizure types may be observed.
Interictal EEG activity is usually normal or demonstrates only mild abnormalities and cognitive
development is typically normal. The seizures then resolve spontaneously between one and twelve
months of age. However, approximately 15% of patients will be affected by epilepsy later in life
(Massingale and Buttross, 1993). A second phenotypically overlapping syndrome, benign familial
infantile seizures (BFIS), is differentiated from BFNS by the age of seizure onset occurring after
three months of age, although seizure course and developmental outcome is comparable (Franzoni
et al., 2005). NEE is a more severe seizure disorder characterised by intractable seizures and a
burst-suppression pattern on EEG, evolving to multifocal epileptiform activity with transient T1
and T2 hyperintensities of the basal ganglia. Although seizures may remit by five years of age,
the majority of patients suffer neurological impairment and severe psychomotor developmental
delay presenting with axial hypotonia and/or spastic quadriplegia. Additionally, a proportion
of patients with NEE do not survive their first years of life (Dalen Meurs-van der Schoor et al.,
2014; Weckhuysen et al., 2013; Kato et al., 2013). In BFNS, KCNQ2 mutations are inherited in a
classical autosomal dominant pattern from an affected parent or occur de novo. Whilst mutations
causing NEE are primarily de novo, as is the case in patient X (Bellini et al., 1993). However,
recently it has been shown that a KCNQ2 mutation can be inherited from an apparently healthy
parent and cause the more severe NEE phenotype in the affected child. In cases such as these,
investigations have demonstrated that one parent had mosaicism, with between 5 - 30% of cells
carrying the KCNQ2 mutation (Milh et al., 2015).
PNH is characterised by spontaneous and continuous muscle overactivity in the form of
myokymia (continuous undulating movements of distal skeletal muscle), fasciculations, cramps or
other symptoms. The underlying aetiology can be heterogeneous, although the most commmon
is autoimmune-mediated PNH, where the production of antibodies directed against voltage-gated
potassium channels occurs (Hart et al., 2002). Two mutations affecting the same residue in
KCNQ2 (p.Arg207Gln and p.Arg207Trp) have been described to cause myokymia by altering the
excitability of peripheral motorneurons with p.Arg207Trp also associated with neonatal seizures
(Dedek et al., 2001; Blumkin et al., 2012).
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4.5.6 Location and pathogenic mechanisms of KCNQ2 mutations
As illustrated in Figure 4.5.3, mutations causing infantile seizures have been identified in all
regions of KCNQ2 and there is no clear relationship between the mutation location and whether
a child will be affected by BFNS or NEE. In addition to those shown, more than 15 splice site
mutations and four large deletions encompassing either entire KCNQ2 exons or whole genes
including KCNQ2 have also been described (Bellini et al., 1993). Many studies have sought to
examine the electrophysiological effects of particular KCNQ2 mutations, the functional role of
each channel region and whether any genotype-phenotype correlations exist. It has been suggested
that the clinical severity of disease may be related to the extent of potassium channel impairment.
The majority of mutations in KCNQ2, particularly those associated with BFNS, cause varying
degrees of loss of function of the mutant allele resulting in haploinsufficiency. Indeed, a 20 - 30%
reduction in KCNQ2/3 current is sufficient to increase neuronal excitability under physiological
conditions (Schroeder et al., 1998; Maljevic et al., 2008) and result in epileptic seizures during
the neonatal period. However, a minority of mutations cause a dominant-negative effect on
protein function thereby reducing the current through the channel by more than the expected
50%. These effects are caused when the assembly of mutant and wild-type subunits results in the
formation of non-functional tetramers.
Figure 4.5.4: Conformation of tetrameric KCNQ2/KCNQ3 channels in patients
with a de novo mutation in KCNQ2.
One study introduced mutations causing either NEE or BFNS into Xenpus oocytes and
compared their effects using voltage clamping (Orhan et al., 2014). All mutant alleles showed a
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loss of function when expressed in a 1:1:2 ratio with wild-type KCNQ2 and KCNQ3 channels,
as would be expected in an affected individual (Figure 4.5.4). A dominant-negative effect was
found in 5/7 (71%) of the mutations causing NEE that were analysed, compared with only
4 of more than 50 (8%) known BFNS mutations (Orhan et al., 2014), suggesting that this
mechanism may underlie the pathogenesis of the severe epileptic phenotype. More specifically,
mutations within the voltage-sensing S4 domain such as that in patient X typically cause large
shifts in voltage-dependent activation and a slowing of both activation and deactivation kinetics,
suggesting that affected channels fail to open in response to depolarisation.
4.5.7 Clinical comparison of patient X with patients previously reported with a p.Arg210His
mutation in KCNQ2
The evidence that the mutation found in patient X causes epileptic encephalopathy is strong.
Four patients have been reported previously to have the same de novo p.Arg210His mutation
(Weckhuysen et al., 2013; Numis et al., 2014). All had NEE presenting with tonic asymmetrical
seizures within the first two days of life accompanied by apnoea and cyanosis. Seizures occurred
multiple times per day becoming almost continuous at times; this was so severe in one patient
that intubation and transfer to intensive care was required on day five of life. Other seizure
types were also observed including: hemi-clonic, asymmetric tonic, tonic-vibratory, seizures
with bradycardia and status epilepticus. EEGs at seizure onset revealed multifocal epileptic
activity which evolved into a burst-supression pattern in all but one patient, whereas most
recent follow-up EEGs (where available) showed slow background activity in all cases. MRI was
only available for one case and showed diffuse hypomyelination with marked thinning of the
corpus callosum at two months of age. Similarly, patient X presented with seizures characterised
by cyanosis and apnoea. Brain MRI revealed hyperintensities of the subthalamic nucleus and
geniculate nuclei, similar to other cases, albeit with different mutations, with hyperintensities
of the basal ganglia (Weckhuysen et al., 2012). The tonic stiffening and choking seen in the
first months of life, associated with asynchronous discontinuity of EEG activities have parallels
with the severe electro-clinical phenotype described in NEE. However, in patient X the EEG
abnormalities remained mild, with resolution of any discontinuity within two weeks and normal
findings during initial treatment with vitamin B6. All EEG changes were non-specific and
no distinctive electroclinical pattern was discernible. As expected for patients with NEE, all
children described in the literature were developmentally delayed with severe axial or generalised
hypotonia, poor motor skills and some were unable to stand (Weckhuysen et al., 2013; Numis
et al., 2014). One patient also had intermittent dystonic posturing and swallowing difficulties
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requiring nasogastric tube feeding (Weckhuysen et al., 2013). None of these four patients were
trialled on vitamin B6. In contrast, delay was moderate but largely intellectual in nature with
minimal expressive language in patient X. However, she was able to walk independently and
attend a school for children with special needs. It is impossible to know whether this somewhat
milder developmental delay is the result of the prolonged vitamin B6 supplementation in patient
X.
All children were trialled on multiple AEDs with only minimal or temporary response
(Weckhuysen et al., 2013; Numis et al., 2014). Similarly to patient X, two became seizure-free
on administration of carbamazepine at two months and four months of age. In another, a
combination of valproate, topiramate, clobazam, dexamethasone and the ketogenic diet resulted
in seizure freedom at four months of age (Weckhuysen et al., 2013). The fourth patient showed
no improvement after ten days of carbamazepine treatment and died shortly afterwards due
to respiratory failure in the context of infection (Numis et al., 2014). Carbamazepine acts to
stabilise the inactive state of voltage-gated sodium channels and blocks the movement of sodium
ions through the channel during an action potential. The resulting decrease in neuron excitability
prevents the development of seizure activity until the AED dissociates. Although seemingly
unrelated, voltage-gated sodium channels co-localise with KCNQ potassium channels at critical
locations in neuronal membranes including the axonal initial segment and node of Ranvier in the
hippocampus, cerebral and cerebellar cortex, the ventral horn and the sciatic nerve (Pan et al.,
2006). Thus it has been proposed, and recently confirmed (Nguyen et al., 2012), that modulation
of sodium channels can alter the activation kinetics and voltage dependence of KCNQ channels.
Further evidence of the pathogenicity of this mutation is the recent identification of a second
mutation affecting the same residue (p.Arg210Cys) in a seven year old female described to have
KCNQ2-related epileptic encephalopathy (Mercimek-Mahmutoglu et al., 2015). From the limited
phenotypic information available, her presentation appears atypical with seizure onset at three
years of age. Seizures were of generalised tonic-clonic and absence type and she was affected by
global developmental delay, hyperactivity and aggressive behaviour. EEG showed generalised
spike-and-waves, MRI showed thin white matter and magnetic resonance spectroscopy was normal.
Although this patient, along with the others described with a mutation affecting this residue, are
affected by the more severe epileptic encephalopathy phenotype, the age of seizure onset in this
case was much later. A possible explanation for this is the different physical properties of each
amino acid involved.
Indeed, two different mutations affecting another arginine residue in close proximity to
Arg210, also within the voltage-sensing S4 domain, can result in either a mild or severe phenotype.
Substitution with a polar uncharged residue (p.Arg213Gln) showed a much more severe functional
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defect when compared to that with a bulky aromatic residue (p.Arg213Trp) which is associated
with BFNS (Miceli et al., 2013). In the case of variants affecting the Arg210 residue, it appears that
substitution with a positively charged aromatic residue (histidine) may be more damaging than
the smaller thiol group (cysteine), despite both amino acids being unfavoured in transmembrane
α-helical structures (Pace and Scholtz, 1998). We can thus hypothesise that maintaining the
structural integrity and charge interactions of the S4 domain is critical for correct channel function
and that the Arg210 residue plays a crucial role in voltage-sensing.
4.5.8 Other patients with KCNQ2 mutations showing a response to vitamin B6 treatment
To our knowledge no metabolic abnormalities have been documented in patients with KCNQ2
mutations. One reason for this may be that the majority of these children present to neurology
clinics, where mild abnormalities, for example the amino acid variations seen in our patient, would
be reported as normal because results are not dramatically different from the reference ranges.
Indeed these results may be irrelevant and were, in addition to mildly elevated 2-oxoglutarate and
pyruvate levels, proposed to be due to an age-associated renal tubule immaturity. Serum hepatic
enzymes were also elevated, although this is a common finding in children taking AEDs with one
study finding 50% of patients taking carbamazepine having elevated alkaline phosphatase levels
(Hussein et al., 2013). However, the abnormal vitamin B6 metabolite levels and apparent response
to pyridoxine treatment in patient X are novel findings and more difficult to explain. Furthermore,
evidence suggests that this apparent clinical improvement in response to vitamin B6 treatment in
the neonatal period and early infancy has not led to a dependency on supplementation for seizure
control later in life. Indeed, since genetic diagnosis, weaning of pyridoxine has commenced and
her dose has been halved with no increase in seizures.
In order to determine whether vitamin B6 had been reported as being beneficial for other
patients with mutations in KCNQ2, a comprehensive literature review of reports indexed in
PubMed describing patients with KCNQ2 mutations was performed using the terms "KCNQ2"
and "epilepsy". Ten reports were identified detailing 23 patients with KCNQ2 mutations that have
been trialled on vitamin B6, either transiently or on a long-term basis (Appendix 9.3). Three of the
23 patients were reported to have had a clinical response to varying degrees. The first, a patient
with a 1.5 Mb terminal deletion of the long arm of chromosome 20 which encompasses KCNQ2,
carried a clinical diagnosis of pyridoxine-dependent epilepsy for seven years (Mefford et al., 2012).
This patient suffered from tonic seizures from two weeks of age accompanied by hypsarrhythmia
on EEG whilst on treatment with phenobarbital. Upon intravenous administration of 100 mg of
pyridoxine, a 95% reduction of epileptiform activity was observed within one minute, leading to
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a diagnosis of PDE. At seven years of age he remained on 200 mg pyridoxine monotherapy and
free of clinical seizures but affected by severe developmental delay. The second was a child with
benign familial neonatal seizures who presented at four days of age with clonic and tonic seizures.
At one year of age, the patient was developmentally normal and although suffered sporadic minor
breakthrough seizures, was well-maintained on levetiracetam. However, the patient was also
reported to have been treated acutely with pyridoxal 5’-phosphate in the initial period (Allen
et al., 2014). Finally, a patient with neonatal epileptic encephalopathy commencing at two days of
age with generalised tonic-clonic seizures and multifocal epileptic activity on EEG was reported,
in which a combination of topiramate, vigabatrin and pyridoxine controlled seizures (Weckhuysen
et al., 2012).
There is very little phenotypic information regarding the three patients that showed a clinical re-
sponse. There was no similarity in mutations with one chromosomal deletion encompassing the en-
tirety of KCNQ2, one insertion in the transmembrane S2 domain (p.Val143_Arg144insGlnTyrPhe
Val) and one missense mutation in the transmembrane S4 domain (p.Ile205Val). Developmental
outcome was also variable. One patient had BFNS which ceased at one year of age and neu-
rodevelopmental examination remained normal (Allen et al., 2014). One had NEE and was with
moderate mental retardation, with only the ability to follow two commands at eight years of age
(Weckhuysen et al., 2012). The final patient whose seizures were controlled on PN monother-
apy was severely developmentally delayed with minimal expressive language, incontinence and
blindness (Mefford et al., 2012). Additionally, 6/23 of the patients were treated with vitamin
B6 during the first month of life; however, responses to each AED were not stated. Whilst in
the majority of patients identified no clinical improvement was noted, this may be related to
the length of trial they received and other AEDs that were being taken concurrently. Current
guidelines recommend that on an acute basis in individuals experiencing clinical seizures, 100 mg
of PN should be administered intravenously whilst monitoring the EEG, oxygen saturation and
vital signs for several hours. If no clinical response is demonstrated, this dose should then be
repeated up to a maximum of 500 mg. Alternatively, a trial can be performed by administering
30 mg/kg/day of PN orally for at least one week (Gospe, 1993). There is also increasing evidence
that vitamin B6, given either as PN or PLP, can result in improved seizure control in idiopathic
epilepsy (Ohtahara et al., 2011). However, the mechanisms underlying this response in clinically
and genetic diverse patients are currently unknown and will be explored in Sections 4.5.9, 4.5.10
and 4.5.11.
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4.5.9 PLP is required for the synthesis of inhibitory neurotransmitters
PLP, either administered directly or formed within the liver through the metabolism of PN by
pyridoxal kinase and pyridox(am)ine 5’-phosphate oxidase, may act as a general anticonvulsant
by promoting the synthesis of inhibitory neurotransmitters. It is well known that uncontrolled or
abnormal alterations in the ratios of neurotransmitters in the brain can affect the propensity for
seizure activity. Excitatory and inhibitory neurotransmission are largely controlled by glutamate
and γ-aminobutyric acid (GABA), respectively. Indeed, GABA release at inhibitory synapses
plays an integral role in suppressing both the origin and spread of seizure activity. As such,
drugs which enhance the activity of GABA receptors, inhibit GABA degradation or the uptake
of GABA from the extracellular space have antiepileptic properties (Treiman, 2001).
There are three types of GABA receptors, GABAA, GABAB and GABAC (Briggs et al.,
2011). Both GABAA and GABAC are ionotropic receptors activated by the binding of GABA
and allow the flow of chloride and bicarbonate to cross the cell membrane. In contrast, GABAB
receptors are metabotropic and linked to potassium channels by G-proteins; the binding of GABA
results in an eﬄux of potassium ions across the cell membrane. Although acting through different
mechanisms, all function to hyperpolarise neurons, preventing opening of voltage-gated sodium
channels and generation of action potentials. Thus, voltage-dependent calcium channels do not
open and neurotransmitters are not released.
There is considerable evidence that seizures can alter GABAergic signalling and result in the
depletion of GABA. CSF GABA concentrations are significantly lower in patients with intractable
seizures and to a greater extent in those with generalised tonic-clonic and complex partial seizures
compared to those with simple partial seizures (Wood et al., 1979), indicating a correlation
with disease severity. Reduced levels of GABA within the brain have also been associated with
worse seizure control (Petroff et al., 1996). Loss of GABAergic neurons is often seen in focal
epilepsies and has been recapitulated in many inducible mouse models (Fritschy et al., 1999; Ni
et al., 2005). Experiments in rats have also shown that seizures reduce the amplitude of GABA
inhibitory postsynaptic currents (Isaeva et al., 2009), abolish normal receptor subunit expression
(Laurén et al., 2005) and alter the expression of cation-chloride cotransporters altering the effect
of GABAA receptor activation from hyperpolarising to depolarising (Li et al., 2008).
The presence of a pathogenic KCNQ2 mutation results in the impairment of the M-current,
leading to a state of neuronal hyperexcitability and the propagation of seizures. This would
therefore be predicted, as in other epileptic disorders, to result in a depletion of GABA and/or
other electrophysiological changes that result in ineffective inhibitory GABAergic signalling.
GABA is synthesised from glutamate by the enzyme glutamate decarboxylase (GAD) for which
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PLP is a cofactor (Figure 4.5.5). Inhibition of this enzyme by PLP-γ-glutamyl hydrazone has
been shown to result in fatal convulsions that could be rescued by administration of PLP (Tapia
and Pasantes, 1971). Homozygous knock-outs of GAD in mice have increased susceptibility to
chemically induced seizures (Asada et al., 1996) or develop spontaneous seizures which are easily
precipitated by mild stress (Kash et al., 1997), depending on the genetic background of the mice.
In vivo studies of GAD from human brain tissue demonstrate that both isoforms (GAD65kDA
and GAD67kDa) show increased enzymatic activity with increasing concentrations of PLP. Taken
together, it is plausible that supplementation of patients with either PN or PLP may favour the
conversion of glutamate to GABA in the brain, leading to anticonvulsant effects.
Figure 4.5.5: Glutamate decarboxylase converts glutmate to form GABA using PLP
as a cofactor.
4.5.10 PLP as an ion channel antagonist
In addition to PLP being an essential cofactor for enzymes involved in neurotransmitter
metabolism, recent work has also shown that PLP may act directly on ion channels. Indeed,
synthetic vitamin B6 derivatives and PLP itself have been found to be effective antagonists
of P2X receptors. These receptors belong to the P2 receptor family which were identified in
1978 and found to be activated by the binding of adenosine 5’-triphosphate (ATP) (Burnstock,
2007). Within this family there are two sub-classes; the ionotropic P2X and metabotropic P2Y
receptors, containing seven and eight subtypes, respectively. P2Y receptors are G protein-coupled,
activated by the binding of ATP or uridine 5’-triphosphate (UTP) and mediate cell proliferation,
differentiation and death during development and regeneration (Burnstock, 2007). P2X receptors
are cation-permeable ion channels which allow the rapid and non-selective passage of sodium,
potassium and calcium ions resulting in neuron depolarisation in response to the binding of ATP.
Amongst the P2X class of receptors, there is one receptor (P2X7R) which has been implicated in
the pathogenesis of epilepsy (Engel et al., 2012; Henshall et al., 2013). The activation of P2X7R
occurs only when ATP concentrations are in the mM range as, unlike other members of the
191
P2X family, it has a relatively low affinity for the ligand (Engel et al., 2012). However, these
extremely elevated extracellular concentrations can occur when ATP is released from damaged or
overstimulated cells during seizure activity (Wieraszko and Seyfried, 1989). Prolonged P2X7R
activation causes increased neuronal excitability, inflammation, oxidative stress and apoptosis
through the action of diverse pathways. In addition, the activation of this particular receptor has
been shown to promote the assembly of a pore within plasma membranes permeable to hydrophilic
molecules up to 800 Da in size. Although reversible, this pore formation has been hypothesised
to be involved in mediating the cytotoxic effects of P2X7R activation (Sperlágh et al., 2006).
Studies have demonstrated that P2X7R knockout mice have reduced seizure severity compared
to wild-type animals subjected to chemical-induced seizures (Solle et al., 2001). Furthermore,
in mice affected by refractory seizures, a combination of treatment with both lorazepam and a
P2X7R antagonist controlled seizures, when neither could solely achieve the same result (Engel
et al., 2012).
The two B6 derivatives based on the synthetic modification of PLP found to be effective
antagonists of these receptors are pyridoxal phosphate-6-azophenyl-2-4-disulfonic acid (PPADS)
and pyridoxal-5’-phosphate-6-(2’-naphthylazo-6’-nitro-4’,8’-disulfonate) (PPNDS). The former is
a non-selective antagonist which blocks P2X and P2Y receptors with a similar potency (North
and Surprenant, 2000). The latter is selective for P2X1 receptors and estimated to be seven-fold
more potent than PPADS (Lambrecht et al., 2000). PLP has been shown to be as effective at
inhibiting P2X7R activity as PPADS, requiring a concentration of 10 µmol/L to induce 50%
inhibition. Two other studies showed that PLP could block P2X receptor activation in the
rat vagus nerve, vas deferens (Trezise et al., 1994) and cardiomyocytes (Wang et al., 1999).
Although PLP levels are tightly controlled in all cells (including those of the brain), individuals
on pyridoxine supplementation have gross elevations of multiple B6 vitamers in their CSF. CSF
PLP levels are also typically at the upper end of reference ranges in these patients, regardless of
whether the indication for supplementation is PDE, PNPO deficiency or a disease of unknown
aetiology (Jaeger et al., 2016; van der Ham et al., 2012). Indeed, a neonate with an unknown
B6-responsive disorder was reported to have CSF concentrations of 3776 nmol/L pyridoxal (ref:
14.8 - 42.5), 29.6 nmol/L pyridoxamine (ref: 0.1 - 0.5) and 18,881 nmol/L PN (ref: <0.03) whilst
on treatment with 30 mg/kg/day PN (van der Ham et al., 2012). These vitamers can then be
converted to PLP by the action of pyridoxal kinase and pyridox(am)ine 5’-phosphate oxidase.
Thus, supplementation with PN results in a sustained increase in PLP levels within the brain,
may result in the curtailing of P2X7R activation caused by seizure-induced ATP production and
subsequently the clinical improvement seen in patient X. Finally, it is possible that the action of
PLP is not only limited to P2X receptors and to date, no study has investigated whether PLP
192
may modulate the KCNQ family of potassium channels. Further work is warranted to investigate
the potentially widespread action of vitamin B6 on ion channels.
4.5.11 Oxidative stress in the propagation of epilepsy and PLP as an antioxidant
A final potential mechanism which may underlie the generalised anticonvulsant effect of vitamin
B6 is the role of these compounds as antioxidants. Although the contribution of oxidative stress
to disease pathogenesis is established in many neurological conditions such as Parkinson’s disease,
Alzheimer’s disease and amyotrophic lateral sclerosis (Hwang, 2013; Markesbery, 1997; Barber
et al., 2006), the role of oxidative stress resulting from excessive free-radical production in epilepsy
initiation and propagation has only recently been recognised.
Oxidative stress is caused by an imbalance between the production of damaging reactive
oxygen species (ROS) and the antioxidant systems which act to defend against them. ROS
are chemically reactive oxygen-containing molecules which are generated during normal cellular
metabolism (e.g. superoxide radicals (·O2−), hydrogen peroxide (H2O2), hydroxyl radicals (·OH)
and singlet oxygen (1O2)) and cause cellular damage through the chemical modification of
various biomolecules such as proteins, lipid and nucleic acids which ultimately result in cell death.
Protein oxidation leads to functional changes of a number of enzymes, often rendering them
less catalytically active, more sensitive to heat inactivation and with an altered susceptibility
to proteolytic degradation (Stadtman, 2001). Lipids, particularly unsaturated lipids which
contain multiple double bonds and reactive hydrogen atoms, are easily susceptible to peroxidation.
Peroxidation of phospholipids within lipid bilayers has been shown to induce conformational
and electrostatic changes which both increases the area per lipid and reduces the thickness of
the bilayer. Together this increases membrane permeability and reduces membrane integrity
(Wong-Ekkabut et al., 2007). Finally, DNA can be oxidised by ROS; this occurs most readily at
guanine residues forming 8-hydroxy-2-deoxyguanosine. Consequences of this oxidation include a
propensity for mutagenesis if the oxidised residues are not correctly repaired by base excision
repair, and the possibility of epigenetic alterations resulting in the inappropriate repression or
activation of genes (Mikhed et al., 2015).
The antioxidant defence systems including enzymes (e.g. superoxide dismutase, catalase,
glutathione peroxidase, glutathione reductase and peroxiredoxins) and non-enzymatic molecules
(e.g. vitamin C, vitamin E and reduced glutathione) (Matés, 2000) have been well documented.
However, more recently the antioxidant properties of vitamin B6 are becoming increasingly
recognised (Figure 4.5.6). Multiple vitamers including pyridoxine, pyridoxamine and PLP are
able to scavenge superoxide radicals induced by hydrogen peroxide treatment, reduce lipid
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peroxidation and prevent ROS-induced changes in mitochondrial transmembrane potential in
U937 monocytes (Kann and Kovács, 2007). Analogous experiments were also performed in
endothelial cells, yielding similar results (Mahfouz et al., 2009). B6 vitamers have also been
shown to prevent the death of yeast cells from oxidative damage, with PLP, pyridoxamine 5’-
phosphate and pyridoxamine showing a higher antioxidant activity than vitamin C (Chumnantana
et al., 2005), detoxifying superoxide and/or singlet oxygen via reactivity of the pyridine ring and
phenolic hydroxyl group (Ohta and Foote, 2002) (Figure 4.5.6). However, the quenching of ROS
comes at a price, with collisions between B6 vitamers and singlet oxygen resulting in vitamer
degradation (Natera et al., 2012). A similar finding has been shown for folates, which can also
act as antioxidants with depletion upon collision with ROS being found to occur (Rezk et al.,
2003). Indeed, ROS-induced degradation of PLP and folate may explain the low concentrations
of PLP and 5-methyltetrahydrofolate seen in the CSF of patient X. If excessive ROS production
due to unregulated neuronal firing results in the CSF PLP deficiency seen in our patient, it is
intuitive that PN supplementation should correct this abnormality.
In addition to direct quenching of ROS, PLP functions as a cofactor for more than 140
enzyme-catalysed reactions in the human body. One example is the synthesis of cysteine from
homocysteine which requires the action of two PLP-dependent enzymes, cystathione-β-synthase
and cystathione-γ-lysase (Meier et al., 2001) (Figure 4.5.6). Cysteine is a unique proteinogenic
amino acid which is susceptible to oxidation within proteins to form disulphide bonds which
are important for maintaining protein secondary and tertiary structure. In addition, cysteine
is essential for the synthesis of reduced glutathione (GSH) which is able to neutralise reactive
oxygen species through the donation of a reducing equivalent, resulting in the formation of
oxidised glutathione disulphide (GSSG) (Meister, 1994). GSH is then regenerated from GSSG by
glutathione reductase. Additionally, GSH is essential for the detoxification of peroxidised lipids
and xenobiotics and the reduction of hydrogen peroxide to water by glutathione S-transferase
and glutathione peroxidase, respectively (Meister, 1994). Thus, PLP is critical for the optimal
function of the glutathione antioxidant defence system. Indeed, the mechanisms described above
have been corroborated in animal studies where vitamin B6 status altered oxidative stress markers.
One study in mice fed a diet supplemented with homocysteine thiolactone to induce oxidative
stress, found that this effect was exacerbated in mice given a B6-deficient diet (Hsu et al., 2015).
Although the antioxidant effects of vitamin B6 in epilepsy have yet to be evaluated, the efficacy
of other antioxidants as antiepileptic agents have been repeatedly demonstrated. Research has
shown that melatonin, in addition to its role in regulating circadian biology, can also act as a free-
radical scavenger and it has been shown that levels are reduced in children with epilepsy (Ardura
et al., 2010). Treatment with this indoleamine prevents seizure activity, promotes glutathione
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Figure 4.5.6: Function of vitamin B6 as an antioxidant. (a) Oxidative stress can result
in mitochondrial dysfunction, DNA damage and lipid peroxidation, which can be
ameliorated by the quenching of ROS by vitamin B6. (b) Pyridoxal 5’-phosphate
(and the other B6 vitamers) can react with singlet oxygen (red) which leads to
addition at C5 and proton transfer. The equilibrium partner is then formed by
solvolysis or direct solvent addition leading to hydrogen migration and elimination
of water. (c) Pyridoxal 5’-phosphate can also act as a cofactor for cystathione-β-
synthase which catalyses the conversion of homocysteine (HC) to form cystathione
(CYT), as well as cystathione-γ-lysae which catalyses the conversion of CYT to
form cysteine (CYS). The production of cysteine is essential for the synthesis of
reduced glutathione (GSH).
function and suppresses ROS production, lipid peroxidation and nucleotide oxidation (Mohanan
and Yamamoto, 2002). Dietary intake of other endogenous antioxidants such as lipoic acid also
produced similar results with the additional benefit of an increase in antioxidant enzyme activities
(Rochette et al., 2013). Ascorbate and α-tocopherol are the active forms of vitamin C and E,
respectively. Both are dietary antioxidants whose mechanism of action is not fully understood
and antiepileptic potential are somewhat controversial. Although ascorbate supplementation
ameliorates convulsions and has neuroprotective effects, studies have indicated that when iron
concentrations are high (e.g. an abundance of haemoglobin following a haemorrhage) ascorbate
promotes oxidation (Sadrzadeh and Eaton, 1988). Effects of α-tocopherol include preventing
damage to the blood-brain-barrier through the inhibition of lipid peroxidation (Levy et al., 1992).
Fundamental to the utilisation of antioxidants as adjunctive treatments is the understanding
of the paradigm of how ROS contributes to seizure pathogenesis. The brain is highly susceptible
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to oxidative stress because it contains high levels of polyunsaturated fatty acids, high iron
concentrations which catalyse the formation of hydroxyl radicals and a low catalase activity
which normally functions to eliminate hydrogen peroxide (Mariani et al., 2005). Additionally,
mitochondrial oxidative phosphorylation is the principle source of cellular superoxide; thus high
ATP requirements to maintain ionic gradients across neuronal membranes and for neurotrans-
mission are counterbalanced by concurrent high ROS levels (Kann and Kovács, 2007). It has
been hypothesised that a cascade of events following seizures produces a self-perpetuating vicious
cycle of oxidative stress (Figure 4.5.7).
Figure 4.5.7: Proposed mechanism of reactive oxygen and nitrogen species genera-
tion and cellular damage following epileptic seizures.
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Excessive neuronal firing as occurs during seizure activity, results in the release of glutamate
(the major excitatory neurotransmitter in the brain) into the intracellular space. This glutamate
then results in the activation of NMDA (N-methyl-D-aspartate) and AMPA (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid) receptors and an influx of calcium ions into neurons (DeLorenzo
et al., 1998). One of the many roles of mitochondria is to serve as a calcium ion buffer to maintain
cellular homeostasis. The increase in calcium concentration within the mitochondria following
seizures results in the activation of enzymes within the tricarboxylic acid cycle (McCormack and
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Denton, 1993), increased reduced substrates for oxidative phosphorylation (NADH and FADH2),
increased respiratory chain activity and increased ROS generation. High levels of cellular calcium
can also activate other enzymes such as nitric oxide synthase which result in the production of
reactive nitrogen species (closely related to ROS and causing similar oxidative stress) (Alderton
et al., 2001). These species can inhibit complex IV activity resulting in the inappropriate transfer
of electrons to oxygen, as well as promote further synaptic glutamate release (Brookes et al.,
2004). Calcium overload also triggers the activation of mitochondrial permeability transition
pores causing the membrane to become permeable to molecules smaller than 1.5 kDa and the loss
of molecules such as cytochrome c. This can then result in cell death by apoptosis or necrosis
(Zoratti and Szabò, 1995).
Many studies in rat and mouse models of epilepsy have shown neuronal loss, mitochondrial
dysfunction, decreased reduced glutathione, increased lipid peroxidation, protein oxidation (Shin
et al., 2008) and DNA damage (Tang et al., 1998) following seizures. Increases in the binding of
oxidative stress-activated transcription factors such as NF-κB have also been observed in seizure
models (Rong and Baudry, 1996), as have increases in the activities of multiple antioxidant
enzymes such as catalase, superoxide dismutase and glutathione peroxidase after chemically-
induced seizures (Tejada et al., 2007), suggesting an attempt to counteract ROS overproduction.
Evidence of mitochondrial dysfunction and oxidative stress have also been identified in patients
with various types of seizures including temporal lobe epilepsy, idiopathic generalised epilepsy,
complex partial seizures (Rowley and Patel, 2013; Menon et al., 2012; Rumià et al., 2013).
Finally, as well as seizures themselves causing oxidative stress, there is evidence that treatment
with AEDs including valproate, phenytoin, phenobarbital and carbamazepine can exacerbate this
phenomenon (Schulpis et al., 2006; Varoglu et al., 2010). Patient X has been on carbamazepine
treatment from two months of age; dosage was increased in line with weight gain to a maximum
of 15 mg/kg/day with good seizure control. Multiple studies have investigated the effects of
carbamazepine and concluded that treatment increases plasma peroxide, lipid peroxidation
in plasma and DNA damage markers in leukocytes, whilst it reduces superoxide dismutase,
glutathione peroxidase and catalase activity in erythrocytes (Hamed et al., 2004; Aycicek and
Iscan, 2007; Varoglu et al., 2010; Niketić et al., 1995). Therefore, it is possible that the treatment
of patient X and the general epileptic population with conventional AEDs may promote oxidative
stress which may be ameliorated by treatment with vitamin B6 or other antioxidants. In addition,
treatment with PN or PLP improve the clinical outcome of patients by curtailing the cycle of
mitochondrial and neuronal dysfunction caused by seizure-induced oxidative stress.
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4.6 summary
In this chapter, the case of a girl whose severe neonatal seizures showed an apparent response
to pyridoxine treatment and had an abnormally high plasma:CSF PLP ratio was presented.
This case confirms the utility of whole exome sequencing for the diagnosis of childhood epilepsy,
revealing that this patient’s neonatal seizures and developmental disorder were caused by a de
novo mutation in KCNQ2. However, with the benefit of hindsight, this potassium channelopathy
may have been diagnosed using a targeted epilepsy gene panel such as that described by Lemke
et al. (2012). Targeted gene panel sequencing has advantages over whole exome sequencing,
including increased depth of coverage, more robust coverage of regions of interest and reduced
incidental findings (de Koning et al., 2015). In this case, whole exome sequencing was employed
due to the patient’s atypical clinical presentation and biochemical findings; it was hypothesised
that she had a novel inborn error of vitamin B6 metabolism. Indeed, if this approach had not
been undertaken, the possibility that patient X harboured mutations or polymorphisms in genes
affecting vitamin B6 metabolism could not have been refuted. However, diagnostic panels remain
a timely and cost-effective alternative for the diagnostic work-up of children with neonatal or
infantile epilepsies.
Despite the potential benefits of vitamin B6 as an anticonvulsant, there are well-documented
adverse effects that can occur in patients taking high doses. Treatment with PLP can com-
monly cause nausea, vomiting, diarrhoea, loss of appetite and mild elevations in serum alanine
aminotransferase (Ohtahara et al., 2011; Toribe, 2001). Two reports have also documented rare
complications including rhabdomyolysis and an increase in seizure frequency (Wang et al., 2005).
High-dose PLP can also cause more severe liver dysfunction. A child with PNPO deficiency
treated with 100 mg/kg/day PLP due to repeated encephalopathy developed hepatic cirrhosis,
fibrosis and portal hypertension; liver function tests improved substantially when his dose was
halved but did not entirely normalise (Sudarsanam et al., 2014). Liver toxicity was also noted in a
child with homocysteinuria who developed hepatitis following an increase of his PLP dose to 1000
mg/day (Yoshida et al., 1985). In contrast, long-term high-dose PN supplementation can cause
sensory and motor neuropathy (Schaumburg et al., 1983). Treatment can also be pro-convulsant
in some circumstances; a newborn at risk of PDE due to having an affected sibling was treated
prophylactically with PN but developed status epilepticus. Antiquitin deficiency was subsequently
excluded and seizures stopped with pyridoxine cessation, therefore seizures were due to pyridoxine
toxicity (Hartmann et al., 2011). Ideally patients with intractable epilepsy, including those with
channelopathies, should be trialled on vitamin B6. In those showing a response, liver function
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and nerve conduction should be tested periodically. A trial of discontinuation should also be
carried out to confirm that there is a real necessity for PN/PLP supplementation.
Finally, we hypothesise that the anticonvulsant effect of B6 vitamers may be more universal
than previously thought and represents a promising adjunctive treatment for patients, not only
with channelopathies, but also the wider epileptic population. Whole exome sequencing of patient
X, combined with a review of the literature, identified a small group of patients with mutations in
KCNQ2 that were described to have varying degrees of clinical response to vitamin B6 treatment.
It is possible that this response may be due to the mechanisms described in this chapter, including
replenishing the pool of PLP needed for the synthesis of inhibitory neurotransmitter, direct
antagonist action on ion channels and antioxidant action of excess reactive oxygen species
generated by increased and abnormal neuronal firing. Unfortunately, information that may
facilitate understanding of the differences between "responders" and "non-responders" such as
PN/PLP dosage, length of B6 trial, age of patient during B6 trial and other AEDs being taken
concurrently are not available. Indeed, with the exception of cases of West syndrome, reports
often assume any observed anticonvulsant effect of vitamin B6 to be coincidental or simply not
discussed further. This may be due to the lack of a dramatic response or the low response rate
amongst patients. Additional well-controlled trials are needed to determine optimal treatment
regimens and identify which patients may benefit from vitamin B6 treatment.
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5
MUTATIONS IN SLC25A22 : EXPANDING THE SPECTRUM OF
MUTATIONS AND THE CLIN ICAL AND BIOCHEMICAL PHENOTYPE
5.1 introduction
In this chapter, whole exome sequencing was used to investigate the underlying aetiology of
disease in two unrelated families comprising a total of three affected patients. The proband
in both families presented with features of early infantile epileptic encephalopathy with severe
refractory seizures and hypotonia. The first proband was referred to the metabolic clinic because
of persistent hyperprolinaemia. In contrast, the two patients from the second family were referred
due to fibroblast vacuolation upon ultrastructural examination, of unknown cause and significance.
It was also noteworthy that the younger sibling in this family presented with a much milder
phenotype, having no history of seizures at the time of presentation.
5.1.1 Causes of hyperprolinaemia
Hyperprolinaemia is defined as an excess accumulation of proline in the body. Mutations
in PRODH and ALDH4A1 cause hyperprolinaemia type I (HPI) and II (HPII), respectively.
PRODH encodes proline dehydrogenase, which catalyses the first step in the catabolism of proline
within the mitochondria forming ∆1-pyrroline-5-carboxylate (P5C) (Figure 5.1.1). This can then
undergo non-enzymatic hydrolysis of the pyrroline ring to form glutamate-γ-semialdehyde (GSA).
ALDH4A1 encodes P5C dehydrogenase which catalyses the oxidation of GSA to form glutamate
(Figure 5.1.1). This reaction is required to connect the urea cycle with the tricarboxylic acid
cycle within the mitochondria (Geraghty et al., 1998). A deficiency of either enzyme results in an
accumulation of cellular proline which can be detected in blood, urine and CSF. The two disorders
can be differentiated biochemically; HPI presents solely with elevated proline levels, whilst HPII
is also accompanied by urinary P5C excretion which is undetectable in control samples. The
degree of proline accumulation also differs with HPI patients having concentrations between 3-
and 10-fold higher than controls, whereas those in HPII patients are between 10- and 15-fold
elevated.
The proband in the first family described in this chapter had persistently elevated proline
concentrations in plasma, urine and CSF. In contrast, the proband in the second family was
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Figure 5.1.1: Primary genetic defects causing hyperprolinaemia. Schematic illustrat-
ing the synthesis, degradation and interconversions of proline within the mito-
chondrion. Mutations in proline dehydrogenase (1; PRODH ) cause hyperpro-
linaemia type I and those in P5C dehydrogenase (5; ALDH4A1 ) cause hyper-
prolinaemia type II. 1, proline dehydrogenase; 2, P5C reductase; 3, ornithine-
δ-aminotransferase; 4, P5C synthase; 5, P5C dehydrogenase; 6, non-enzymatic
reaction.
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not initially reported to have hyperprolinaemia as an indication for whole exome sequencing.
However, scrutiny of first-line biochemical screening results following genetic diagnosis also
revealed elevated proline levels. Despite this, proline concentrations were not as high as those
typical of classical hyperprolinaemia and the early onset and severity of seizures accompanied
by ocular abnormalities were atypical for either HPI and HPII; therefore these diagnoses were
deemed unlikely.
Hyperprolinaemia can also be secondary to other genetic and environmentally-acquired
conditions. An example of the former can be seen in patients with mitochondrial disorders. Despite
encompassing more than 250 distinct gene defects, lactic acidosis is present as a biochemical
abnormality in between 30 - 50% of mitochondrial disorders (Koenig, 2008). This occurs when
the mitochondria’s capacity to metabolise pyruvate through the Krebs cycle and oxidative
phosphorylation to produce ATP is impaired. To compensate for this reduced ATP synthesis,
glycolysis and therefore pyruvate production is increased. The addition of hydrogen ions (resulting
from impaired oxidative phosphorylation) to pyruvate then generates lactic acid. Lactic acid can
non-competitively inhibit proline dehydrogenase activity resulting in hyperprolinaemia (Kowaloff
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et al., 1977). This inhibition, which occurs readily at the concentrations observed in patients
with mitochondrial disorders (5 - 10 mmol/L), also causes a secondary decrease in the formation
of ornithine, citrulline and arginine due to reduced flux through the proline catabolic pathway
with the mitochondria (Dillon et al., 1999). An alternative hypothesis for the elevated proline
concentrations seen in patients with mitochondrial disorders is that an abnormal mitochondrial
redox state results in an altered reaction equilibrium of the proline dehydrogenase enzyme, thereby
affecting intracellular proline concentrations (Wood, 1987).
Proline concentrations can also be high in patients with other conditions in which elevated
venous lactic acid can be present including hypoxia, renal failure, drug toxicity, sepsis and
neurodegenerative diseases (Kang et al., 2001; Koenig, 2008). A mitochondrial disorder was
thought to be the most plausible differential diagnosis in both families, however, mitochondrial
respiratory chain analysis was uninformative in the probands from both families. Thus, whole
exome sequencing was performed.
5.2 methods
Whole exome sequencing was performed as described in Section 2.5 and filtered to look for
variants inherited in an autosomal recessive manner. Confirmation of the pathogenic SLC25A22
mutations were carried out using PCR conditions outlined in Section 2.3.2 with the addition of 5%
DMSO. Standard PCR cycling conditions were used with an annealing temperature of 66◦C for
the region surrounding the p.Thr56Pro mutation and 68◦C for that surrounding the p.Ala296Thr
mutation. Fibroblasts were cultured from patient skin punch biopsies in the Chemical Pathology
Department, GOSH. These were then transferred to our laboratory and cultured as described in
Section 2.7 before carrying out electron microscopy, tinctorial and immunohistochemical staining
(Section 2.14). Analysis of intracellular glutamate-γ-semialdehyde using UPLC-MS/MS was
carried out using the method described in Section 2.15.
5.3 case reports
5.3.1 Patient 1
A 2 year old boy (patient 1) presented to our clinic for evaluation of epilepsy, severe developmental
delay, and hyperprolinaemia. His parents are first cousins of Afghan origin. He was born at
term following an uneventful pregnancy with a birth weight of 3.3 kg. At birth he was noted to
be non-specifically neurologically abnormal with central and peripheral hypotonia and delayed
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feeding. However, at six weeks of age he developed myoclonic and tonic-clonic seizures, dystonic
movements and a failure to fix and follow. At two months of age, his main symptoms were severe
global developmental delay, visually unresponsive behaviour with impaired cortical responses
to light and a myoclonic and generalised tonic-clonic seizure disorder. Brain MRI performed
at 2 years of age showed frontotemporal hypoplasia, globally delayed myelination, delayed
temporal pole myelination, prominent cerebellar folia and a small splenium. Extensive genetic
and biochemical investigations had been carried out (Table 5.3.1). Amino acid profiles were
consistently abnormal in plasma, urine and CSF (detailed in Results). Plasma proline was
between 322 – 1195 µmol/L (ref: 85 – 290 µmol/L). At the age of 2 years and 8 months, a
series of plasma amino acid determinations were done – after a 6 hour fast and at 1h, 2h and
4h postprandially. A muscle biopsy showed increased lipid and glycogen but neither ragged red
nor cytochrome oxidase-negative fibres, and normal activities of respiratory chain complexes.
Ammonia had also been slightly raised on one occasion (50; ref: <40 µmol/L) and white cell
ubiquinone was low (24; ref: 37 – 133 pmol/mg). At the age of 7 years, patient 1’s seizures
are well controlled on a combination of levetiracetam (40 mg/kg/day), sodium valproate (20
mg/kg/day) and pyridoxine (15 mg bd). At his most recent clinic assessment at the age of 7
years and 11 months, he was in a wheelchair and globally severely developmentally delayed,
although he continues to make slow progress. He appeared to have a full range of eye movements
but could not fix or follow. He had no dystonic movements, whilst reflexes were elicitable in the
upper limbs they were absent in the lower limbs.
5.3.2 Patients 4 and 5
Patient 4, a 7-year old girl, presented to our clinic for evaluation of epilepsy and severe develop-
mental delay. Her parents are first cousins of Syrian origin. The patient is the second child of
her parents, with a healthy older brother and an affected younger sister. Within the first month
of life she developed a febrile illness followed by seizures after the fever had settled. The seizures
continued so sodium valproate was commenced, with some clinical improvement. Clonazepam
was subsequently added. Her current treatment is sodium valproate 260 mg b.d. and clonazepam
500 µg once at night. She continues to have brief seizures lasting less than a minute at least
once a week. These are usually tonic seizures and sometimes occur in clusters several times
per day. The patient started crawling and sitting independently at the age of 2 years and 6
months. At 7 years she could babble but had no identifiable words. Developmental progress is
very slow although she has never suffered developmental regression. On physical examination she
appeared globally hypotonic although the lower limb reflexes were brisk and plantar responses
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were equivocal. An EEG at 6 years of age showed symmetrical diffuse irregular slow wave activity.
Brain MRI also performed at 6 years demonstrated some symmetrical signal abnormalities of the
insular cortex bilaterally and adjacent capsular white matter. Delayed temporal pole myelination,
prominent cerebellar folia and a small splenium were also noted. Appearances suggested a possible
underlying neurometabolic or neurogenetic disorder, with no specific features. Plasma proline
was consistently raised above 350 µmol/L (ref: 85 – 290 µmol/L).
Patient 5, the younger sister of patient 4, presented to our clinic alongside her sister for
further investigation. Although some features of her condition resemble those of her sister, she is
much more mildly affected. At the time of examination at 3 years of age, her main presenting
symptom was developmental delay. She has never had any seizures. She started walking at 3
years and six months later was able to take ten steps. At this age she had almost ten words,
including "mum" and "dada". Although having progressed much further than her sister, she is
delayed compared to her peers at school and is making very slow developmental progress. She
has also never suffered periods of developmental regression. Physical examination demonstrated
hypotonia with normal reflexes. Her ankle and other joints appeared lax. She walked with a
broad-based gait and very flat feet. She had hypermetropia, astigmatism and a right convergent
squint. She is microcephalic and a brain MRI at 2 years of age demonstrated delayed temporal
pole myelination, prominent cerebellar folia and a small splenium. Plasma proline was normal
and no other amino acid abnormalities were identified. Absence seizures were detected at seven
years of age.
Both sisters have had extensive biochemical investigations (Table 5.3.1). Ammonia has been
mildly raised in the plasma of patient 4 (56; ref: < 40 µmol/L). Abnormalities of amino acid
concentrations were also noted (detailed in Results). Patient 4 had a muscle biopsy, which showed
increased lipid, increased variation in fibre size due to scattered small fibres and mild myopathic
features. Activities of the respiratory chain complexes were normal.
Table 5.3.1: Results of metabolic and genetic investigations carried out in patients
1, 4 and 5 at the time that whole exome sequencing was performed.
nd; not measured or not stated in clinical notes; 5-HIAA, 5-hydroxyindoleacetic
acid; 5-MTHF, 5-methyltetrahydrofolate; BH2, dihydrobiopterin; BH4, tetrahy-
drobiopterin; HVA, homovanillic acid; TSH, thyroid-stimulating hormone. Specific
amino acid abnormalities are detailed in Figures 5.4.4 - 5.4.7.
Test Patient 1 Patient 4 Patient 5
White cell lysosomal
enzymes
Normal Normal Normal
Urine glycosaminoglycans
(GAGs)
nd Normal Normal
Vacuolated lymphocytes Normal Normal Normal
Full blood count Normal Normal nd
DNA repair studies nd Normal nd
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Plasma PLP nd Normal nd
Very long chain fatty acids
(VLCFA)
Normal Normal Normal
Plasma glucose Normal Normal nd
Plasma lactate Normal Normal Normal
Parathyroid hormone nd Normal nd
Biotinidase Normal Normal Normal
Vitamin A nd Normal nd
Vitamin E nd Normal nd
Carnitines Normal Normal nd
Creatine kinase (CK) Normal Normal nd
White cell ubiquinone Low: 24 (ref: 37-133
pmol/mg)
nd nd
Purines nd Normal nd
Transferrin isoelectric
focussing
Normal Normal nd
Mitochondrial DNA
mutations
nd Normal nd
Urine organic acids Normal nd Normal
CSF neurotransmitters Low BH4: 21 (ref:
27-105 nmol/L).
Normal HVA,
5-HIAA, Neopterin,
BH2 and 5-MTHF.
nd All normal
CSF PLP Low: 37 (ref: 44-89
nmol/L)
nd Normal
CSF glucose/lactate Normal nd Normal
CSF amino acids Abnormal nd Abnormal
Plasma amino acids Abnormal Mild abnormalities Normal
Urine amino acids Mild abnormalities nd Mild abnormalities
Liver function tests Normal Normal nd
Array CGH nd Normal Normal
Fragile X analysis nd Normal nd
Thyroid function test Normal Raised TSH: 8.9 (ref:
0-6 mU/L)
Normal
Calcium Normal nd Normal
Phosphate Slightly raised: 2.0
(ref: 1.2-1.8)
nd Normal
Electrolytes nd nd Normal
Fibroblast electron
microscopy
nd Cytoplasmic vacuoles
(mostly empty but
some with electron
dense lamellar
bodies)
Cytoplasmic vacuoles
(mostly empty)
Muscle biopsy Increased lipid and
glycogen. Normal
respiratory chain
analysis and
histology enzymes.
Increased variation
in fibre size due to
scattered small fibres.
Increased lipid. Mild
myopathic features.
Normal respiratory
chain enzymes.
nd
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5.4 results and discussion
5.4.1 Whole exome sequencing
Whole exome sequencing was employed to identify the aetiology of disease in two unrelated
families that had been extensively biochemically investigated and for whom it had not been
possible to identify a diagnosis. Data was filtered and analysed assuming that each patients’
disorder had been inherited in an autosomal recessive manner. Each family was sequenced and
analysed separately. Common variants with a minor allele frequency of > 3% in the 1000 Genomes
Project or NHLBI ESP databases were excluded, as were variants with a read depth of less than 5.
Variants classified as "pathogenic" or "likely pathogenic" according to computed American College
of Medical Genetics and Genomics (ACMG) Guidelines (detailed in Tables 3.3.7 and 3.3.8) were
included. Only variants associated with a loss of gene function including missense, splice site,
insertions, deletions or variants affecting start or stop codons were considered. In patient 1 this
generated a list of 186 variants in 108 genes. This included, 126 missense variants, 34 deletions,
20 insertions and 6 variants affecting splice sites. In patients 4 and 5, 17 homozygous variants
were identified, including 16 missense changes and one affecting a splice donor site. Variants
were then further filtered to those associated with the biological term "epilepsy". In the case
of patients 4 and 5, any potentially pathogenic variants had to be present in the same state in
both siblings to be considered (Table 5.4.1). In patient 1, only one variant in SLC25A22 was
identified. A variant in SLC25A22 was also identified in patients 4 and 5. However, three other
variants were also identified in the following genes: (i) LOX which encodes lysyl oxidase with
secondarily reduced levels of this enzyme being implicated in occipital horn syndrome and Menkes
disease, (ii) DRD4 which encodes for dopamine receptor D4 and has been identified as a risk
factor for developing attention deficit-hyperactivity disorder, (iii) SMPD1 which encodes acid
sphingomyelinase and mutations in this gene cause Niemann-Pick disease type A/B. Although
this latter disorder shares some clinical similarities with those seen in patients 4 and 5 (e.g.
developmental delay and hyptonia), overall the phenotypic correlation was poor and after further
detailed consideration (discussed in Section 5.4.6.1) this variant was not deemed to be relevant
to disease pathogenesis.
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Table 5.4.1: Whole exome sequencing data after having been filtered to show autosomal recessive variants associated with the biological term "epilepsy".
-, not stated in Ingenuity Variant Analysis software.
Chr Position Reference
Allele
Sample
Allele
Gene Protein
Variant
Het/Hom SIFT PolyPhen dbSNP ID 1000 Genomes
Frequency
NHLBI ESP
Frequency
ExAC
Frequency
Patient 1
11 794494 T G SLC25A22 p.Thr56Pro Hom Damaging Probably damaging - - - -
Patients 4 and 5
1 152573420 C A LCE3C p.Asn71Lys Hom - Benign 138652729 0.44 0.61 0.21
5 121413581 C G LOX p.Glu34Gln Hom Tolerated Benign 777431502 - - -
5 137688497 G A KDM3B p.Ala5Thr Hom - Possibly damaging 200772506 0.88 - 7.30
11 640157 C A DRD4 p.Pro303Gln Hom Tolerated - 752533625 - - 0.58
11 792001 C T SLC25A22 p.Ala296Thr Hom Damaging Probably damaging 773825846 - - 0.001
11 6412635 G A SMPD1 p.Val113Met Hom Damaging - 142215226 0.06 0.06 0.08
Homozygous sequence changes in SLC25A22, encoding solute carrier family 25 member 22,
were identified in all three patients and deemed to be the best candidate for pathogenesis in both
families due to the phenotypic similarities between our patients and those described previously
in the literature (reviewed in detail in Table 5.4.3) and the predicted functional impact of each
variant. Mutations in this gene are known to cause neonatal epileptic encephalopathy and
migrating partial seizures of infancy. Only three pathogenic mutations in SLC25A22 have been
described previously in nine patients (Molinari et al., 2005, 2009; Poduri et al., 2013; Cohen
et al., 2014), all of which are single amino acid substitutions that alter key residues involved
in the transport mechanism of the protein. Two novel mutations in SLC25A22 were identified
in patient 1 (c.166A>C; p.Thr56Pro) and patients 4 and 5 (c.886G>A; p.Ala296Thr) (Figure
5.4.1).
Figure 5.4.1: Schematic representation of SLC25A22. (a) Six transmembrane domains
of SLC25A22. Mutations reported in the literature causing a seizure disorder
are shown in blue and the mutated residues in our families are shown in orange.
(b) Regions corresponding to each of the nine exons of SLC25A22 (aligned to
transmembrane domains above).
Both variants were predicted damaging by SIFT and probably damaging by PolyPhen-2.
Neither mutation has been reported in the 1000 Genomes Project or NHLBI Exome Sequencing
Project databases. p.Thr56Pro has also not been reported in the ExAC database but p.Ala296Thr
has been identified in a heterozygous state in one European individual, resulting in a minor allele
frequency of 0.0012%. Segregation of the p.Thr56Pro mutation was confirmed in the parents
of patient 1 by restriction enzyme digestion with HpyCH4III (Figure 5.4.2b). This restriction
enzyme recognises ACNGT sequences, cutting between the N and G nucleotides. Digestion of
PCR products containing the wild-type sequence would be expected to result in three DNA
fragments of 30, 90 and 160 bp. In contrast, the presence of the p.Thr56Pro mutation would be
expected to abolish the second HypCH4III restriction site, therefore resulting in two fragments
of 30 and 250 bp. Segregation of p.Ala296Thr in the parents of patients 4 and 5 was confirmed
by Sanger sequencing (Figure 5.4.2c).
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Figure 5.4.2: SLC25A22 mutation analysis in affected families. (a) Sanger sequencing
illustrating the p.Thr56Pro mutation in patient 1. (b) HpyCH4III restriction
enzyme digestion of patient 1 and parental DNA. Both parents have a heterozygous
pattern and patient 1 is homozygous for the mutation. (c) Sanger sequencing
illustrating the homozygous p.Ala296Thr mutation in patients 4 and 5. Both
parents are heterozygous for the mutation.
Both mutations also affect highly conserved regions of the protein with each residue being
conserved from humans to Drosophila and C. elegans. There is no known ortholog of SLC25A22
in bacterial species. No potentially pathogenic changes in genes known to cause hyperprolinaemia,
namely PRODH and ALDH4A1, were identified in the the whole exome sequencing data for any
of the patients.
209
Figure 5.4.3: Conservation of mutation sites in SLC25A22. Multiple sequence alignment
of the SLC25A22 gene across species generated using Clustal Omega illustrating
the conservation of the sites of the p.Thr56Pro and p.Ala296Thr mutations,
respectively.
5.4.2 Function of SLC25A22
In humans, the SLC25 gene family encodes 53 mitochondrial carriers that function to import
and/or export a variety of metabolites from the mitochondria (Palmieri, 2014). In 2002, Fier-
monte et al. identified two proteins that could catalyse the transport of glutamate across the
mitochondrial membrane, SLC25A22 and SLC25A18. These transporters share 63% sequence
identity to each other and 33% to the C-terminal domain of the aspartate/glutamate carrier.
SLC25A22 is more highly expressed than SLC25A18 in all human tissues with the exception of
the brain, where their expression is equal. The substrate specificities and transport abilities of
each protein were assayed by reconstituting each in proteoliposomes. Both were able to catalyse
glutamate uniport (i.e. transport in one direction) and exchange (i.e. concurrent influx and
eﬄux). When comparing the kinetic characteristics of the two transporters, SLC25A22 had a
higher Km and Vmax and thus a lower affinity for glutamate. It has therefore been hypothesised
that SLC25A22 only becomes active to cope with higher cytosolic concentrations of glutamate
and regulate the transport rate of this amino acid into the mitochondria to satisfy tissue-specific
needs, for example after a protein-rich meal.
Further studies using liposomes confirmed that SLC25A22 was not only able to facilitate the
uptake of [U-14]-glutamate but, albeit at a reduced rate, also other molecules with a structural
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similarity to glutmate (Figure 5.4.4). These molecules are structurally similar to glutamate with
the following modifications: the removal of the amine group (-NH2), addition of a methylene
group (-CH2-) to the carbon backbone, the addition of a methylene group and removal of the
amine group, or the addition of a methyl group at the α-position (-CH3).
Figure 5.4.4: Substrates transported by SLC25A22 and the exchange rates with
respect to each substrate. Exchange rates were quantified as µmol/min/g
protein (purple text).
Very few members of the SLC25 family have had their 3-dimensional structure solved due to
difficulties in crystallisation. However, sequence alignment analysis and site-directed mutagenesis
studies have provided further information regarding structural-functional links and transport
mechanisms. All members of the SLC25 protein family share a common membrane topology which
consists of three homologous domains. Each domain contains two hydrophobic transmembrane
α-helices separated by a highly conserved hydrophillic region protruding into the mitochondrial
matrix, each containing a short helix (Figure 5.4.5a). The six transmembrane α-helices form
a funnel-shaped cavity in the inner mitochondrial membrane through which the transported
substrates can pass. Each of the three hydrophillic regions contains the following sequence motif:
PX[D/E]XX[K/R]X[K/R] (20-30 residues) [D/E]GXXXX[W/Y/F][K/R]G (Palmieri, 2014). The
first segment of this motif is located at the C-terminus of the odd-numbered helices and the third
segment is located at the N-terminus of the even-numbered helices. The proline residue beginning
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each motif acts to sharply kink each odd-numbered helix, bringing the sequence motifs into close
proximity (Figure 5.4.5). The charged residues are then able to form a network of salt bridges
that closes the transporter cavity on the side of the mitochondrial matrix. It has also been
proposed that all SLC25 transporters share a similarly located substrate binding site formed by
residues within the three even-numbered helices. These residues are centrally located in each helix
(one and a half helix turns above the salt bridge network) and protrude into transporter cavity
(Palmieri and Pierri, 2010). These residues also determine substrate specificity, for example the
presence of R[D/E] amino acids within the fourth helix is specific for amino acid carriers. A
second proposed salt bridge network formed by the motif [F/Y][D/E]XX[R/K] is hypothesised to
close the transporter cavity on the cytosolic side, facilitating bidirectional transport (Robinson
et al., 2008).
In order to predict the possible effect of the mutations identified in our patients, their position
within the protein was examined. Residue Thr56 is located within the first matrix α-helix. In
patient 1, this residue is mutated to proline, which is likely to affect this secondary structure
as proline is a known helix-breaker. In turn, the Thr56Pro mutation may cause structural
instability of the first domain which consists of the first and second transmembrane helices and
the first matrix α-helix. Ala296 is located within the sixth transmembrane helix and faces the
hydrophobic core of the inner mitochondrial membrane. In the siblings patients 4 and 5, this
residue is mutated to a threonine residue. The introduction of a polar residue into a hydrophobic
area might lead to a destabilisation of the helical structure. Sequence alignment of all 53 human
mitochondrial carriers revealed that six other SLC25 proteins (SLC25A27, SLC25A31, SLC25A32,
SLC25A38, SLC35A44 and SLC25A46) also have a threonine at the equivalent position (Figure
5.4.6a). However, an alignment of these six proteins revealed that this amino acid is not part of
a conserved region within these transporters. In contrast, when comparing the two glutamate
transporters (SLC25A22 and SLC25A18), Ala296 and the surrounding the residues are highly
conserved indicating that this region is likely to play an important role in glutamate transport.
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Figure 5.4.5: Schematic representation of SLC25 transporter family. (a) Schematic
representation illustrating the membrane topology shared by members of the
SLC25 transporter family. Each contains six transmembrane helices (H1 - H6)
and the structure can be divided into three repeated domains (Repeat 1 - 3).
Each domain contains two transmembrane helices connected by a matrix loop
which contains a short helix (h12, h34 and h56, respectively). The three domains
are joined by short loops that protrude into the intermembrane space. Adapted
from Palmieri (2014). (b) Membrane topology of SLC25A22. Mutations reported
in the literature causing a seizure disorder are shown in blue and the mutated
residues in our families are shown in orange.
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Figure 5.4.6: Conservation of p.Ala296 position across SLC25 family. (a) Multiple
sequence alignment of the 53 human mitochondrial carriers (SLC25 family)
showing the amino acid residues corresponding to the p.Ala296 position in
SLC25A22 (yellow). Proteins with a threonine at this position are highlighted
in blue and SLC25A22 is in green. (b) Multiple sequence alignment of the six
SLC25 proteins with a threonine at this position (yellow) compared to SLC25A22
(green).
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5.4.3 Phenotypic correlation with other patients with SLC25A22 deficiency
Only three pathogenic mutations in SLC25A22 have been described previously in nine patients (Molinari et al., 2005, 2009; Poduri et al., 2013; Cohen et al.,
2014) (summary in Table 5.4.2). Prior to the description of the patients in this chapter, all previously described cases had early-onset intractable seizures with
a burst-suppression pattern on EEG, hypotonia, occular abnormalities (especially abnormal VEP), generalised brain atrophy and abnormalities of the corpus
callosum evolving into a severe encephalopathy with spasticity and a poor developmental outcome. All patients underwent extensive biochemical testing to
investigate the possibility of a metabolic disorder causing disease pathogenesis. However, no abnormalities were reported in any of the nine patients.
Table 5.4.2: Phenotypic comparison of our five patients compared to those described in the literature with mutations in SLC25A22. ERG,
electroretinography; VEP, visual evoked potential; nd, not done; *, patient may have been too young to detect abnormalities.
Patient Consan-
guineous
(country of
origin)
Age at
presenta-
tion
Age at
seizure
onset
Main presenting
features
Electroen-
cephalogram
(EEG)
Eye abnormalities Brain imaging Mutation
Patient 1 Yes
(Afghanistan)
Birth 6 weeks Refractory
seizures +
hypotonia
Abnormal No response to light,
abnormal VEP
Small splenium, prominent
cerebellar folia, frontotemporal
hypoplasia, delayed
myelination.
c.166A>C;
p.Thr56Pro
Patient 2 Yes
(Afghanistan)
Birth 10 weeks Refractory
seizures +
hypotonia
Multifocal Occasional visual
fixation but not
following
nd c.166A>C;
p.Thr56Pro
Patient 3 Yes
(Afghanistan)
Birth 10 weeks Refractory
seizures +
hyptonia
Multifocal Occasional visual
fixation but no
following
nd c.166A>C;
p.Thr56Pro
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Patient 4 Yes (Syria) First
month
First
month
Refractory
seizures +
hypotonia
6 years:
Symmetrical
diffuse
irregular slow
wave activity
Normal Small splenium, prominent
cerebellar folia, delayed
temporal pole myelination.
Symmetrical signal
abnormalities of the insular
cortex bilaterally and adjacent
capsular white matter.
c.886G>A;
p.Ala296Thr
Patient 5 Yes (Syria) 3 years 7 years Developmental
delay +
hypotonia
nd Hypermetropia, an
astigmatism and
right convergent
squint
Small splenium, prominent
cerebellar folia, delayed
temporal pole myelination.
c.886G>A;
p.Ala296Thr
Molinari
et al.
(2005)
Yes (Israel) First 48
hours
(n=4)
First 48
hours
(n=4)
Refractory
seizures +
hypotonia
Burst-
suppression
(n=2)
Abnormal ERG
(n=2), VEP (n=2)
Brain atrophy (n=2),
subarachnoid enlargement
(n=1), cerebellar hypoplasia
(n=1), hypoplastic corpus
callosum with abnormal
splenium (n=1).
c.617C>T;
p.Pro206Leu
Molinari
et al.
(2009)
Yes (Algeria) Birth 5 days Refractory
seizures +
hypotonia
8 days: Burst
suppression. 6
months: Hyp-
sarrhythmia
Abnormal ERG,
VEP
Cerebellar hypoplasia,
abnormal corpus callosum
abnormal gyration of both
temporo-parieital poles with
lack of differentiation of white
and grey matter.
c.706G>T;
p.Gly236Trp
Poduri
et al.
(2013)
Yes (Saudi
Arabia)
1 week
(n=1), 2
weeks
(n=1)
1 week
(n=1), 2
weeks
(n=1)
Refractory
seizures +
hypotonia (n=2)
1 month:
Delta brush
pattern (n=1),
positive spikes
and
high-voltage
focal spikes
(n=2)
Normal (n=1),
abnormal VEP
(n=1)
Normal (n=1), delayed
myelination and thin corpus
callosum (n=1).
c.328G>C;
p.Gly110Arg
Cohen
et al.
(2014)
Yes (Israel) First
months
(n=1), 2
weeks
(n=1)
First
months
(n=1), 2
weeks
(n=1)
Refractory
seizures +
hypotonia (n=2)
Burst-
suppression
(n=2)
No response to light
or movement (n=2),
retinal pigmentation
(n=1)
Thin corpus callosum and brain
atrophy (n=2), increased
Virchow-Robin spaces and
increased subarachnoid spaces
(n=1).
c.617C>T;
p.Pro206Leu
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The severe seizures affecting these patients have been proposed by Molinari et al. (2009) to
be due to an accumulation of glutamate, a powerful excitatory neurotransmitter, in brain cells.
This accumulation is predicted to occur to a greater extent within astrocytes than neurons as
the expression of the mitochondrial aspartate/glutamate carriers (SLC25A12 and SLC25A13 ) is
restricted to neurons (Berkich et al., 2007). Thus, the lack of glutamate uptake in astrocytes
would not be compensated for by the aspartate/glutamate carriers, leading to cytosolic glutamate
accumulation followed by inappropriate release into the synaptic cleft. As described previously
in the context of oxidative stress (Section 4.5.11 and Figure 4.5.7), glutamate release causes
activation of NMDA and AMPA receptors and excessive neuronal calcium influx. The result
is a vicious cycle of damage including the generation of reactive oxygen and nitrogen species,
mitochondrial dysfunction, cell death and neuronal hyperexcitability resulting in the propagation
of seizures.
Despite harbouring novel mutations, patients 1 and 4 share similar clinical features to
those described previously (Table 5.4.2). These include refractory seizures and psychomotor
developmental delay. Patient 1 also displays an impaired cortical response to light and abnormal
VEP seen in 63% (5/8) patients. Patient 5 however, presented atypically with features not
present in her sister including hypermetropia, an astigmatism and a right convergent squint.
Although visual pathway dysfunction is common in patients with SLC25A22 mutations, these
mild eye abnormalities have not been reported previously; indeed, they may be unrelated to
her genetic diagnosis. Most notably though, she is much more mildly affected than her sister
and did not present with seizures until much later on in life. This also contrasts to the other
patients described thus far, the vast majority of which presented with seizures within the first
two weeks of life. Indeed, all of the new patients described in this chapter begin seizing later than
those reported in the literature (one month - seven years). Our second family was also atypical
with regard to their developmental outcome. All patients reported in the literature developed a
severe encephalopathy with spasticity rendering them wheelchair-bound and unable to achieve
developmental milestones. In contrast, patient 4 could sit and crawl independently at 2 years and
6 months of age and babble at 7 years of age. Consistent with her other clinical features, patient
5 was not affected as severely. Although making very slow progress, at 3 years of age she was
able to take ten steps independently and had a limited vocabulary of approximately ten words.
As described above (Section 5.4.2) this milder neurological impairment may be due to greater
residual activity of the p.Ala296Thr mutation relative to the other variants. This hypothesis will
however require corroboration with functional studies.
Previously reported MRI changes in patients with SLC25A22 mutations include cerebellar
hypoplasia, dysmorphism of the corpus callosum with hypoplasia and abnormal splenium, sub-
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arachnoid enlargement and generalised brain atrophy (Table 5.4.2). The findings in our patients
were very similar. Scans performed after two years of age all showed a small splenium, delayed
temporal pole myelination and prominent cerebellar folia indicating cerebellar hypoplasia. In
addition, we noted that in all of our patients who had imaging investigations, the optic chiasma
was small, consistent with post-retinal dysfunction (Figure 5.4.7).
Figure 5.4.7: Brain magnetic resonance imaging of SLC25A22-deficient patients. (A,
D and G) T2-weighted images. (B, C, F and H) T1-weighted images. (E
and H) T1-weighted images with inversion recovery sequence. Patient 1 (2 y
1m), Patient 4 (6y 8m) and Patient 5 (2y 10m). All patients show frontotemporal
hypoplasia/atrophy (A, D and G) and prominence of cerebellar folia, consistent
with cerebellar hypoplasia/atrophy (B, E and H). All patients also have a
small splenium, with the splenium of the corpus callosum smaller than the genu
and a small optic chiasma (smaller than the mammillary body) (C, F and I).
Abnormal appearance of the insular cortex is also noted in Patient 4 (D).
5.4.3.1 Patients 2 and 3
After patient 1 was diagnosed, his mother had a subsequent pregnancy. All of the evidence,
including the whole exome sequencing data and strong phenotypic correlation between patient
1 and the nine patients with mutations in SLC25A22 previously described, was critically con-
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sidered before prenatal diagnosis was offered. This Sanger sequencing (performed by the North
East Thames Regional Genetics Service, GOSH, UK) indicated that the foetus had the same
homozygous p.Thr56Pro mutation in SLC25A22 as patient 1 and the parents elected to terminate
the pregnancy. His mother then had a second pregnancy with twins and prenatal diagnosis
indicated that both foetuses (patients 2 and 3) had homozygous SLC25A22 mutations. However,
on this occasion the parents decided not to terminate the pregnancy. Pedigrees illustrating the
relationship between the affected patients in each family are shown in Figure 5.4.8.
Figure 5.4.8: Pedigrees of both families found to have mutations in SLC25A22. The
mutation status of the unaffected brother in family 1 is not known.
Since it could be hypothesised that abnormal mitochondrial glutamate levels related to
the SLC25A22 mutations could lead to impaired mitochondrial redox balance with increased
ROS production and on the basis that their affected brother had low levels of ubiquinone in
his white cells, the twins were commenced on supplemental ubiquinone (10 mg/kg/day) as a
mitochondrially targeted antioxidant from birth. Initially they appeared less severely affected
than their brother. Whereas at 6 weeks patient 1 was profoundly hypotonic, visually inattentive
and had both seizures and dystonic movements, at 6 weeks the twins had milder, and mainly
axial, hypotonia. They were both smiling and fixing and had no abnormal movements. Both
appeared slightly dysmorphic, with a smooth philtrum and low set ears. Sadly, at the age of
16 weeks, both twins developed seizures with a flexor spasm-like semiology and multifocal EEG.
In addition to ubiquinone, they are currently both on levetiracetam (40 mg/kg/day). At last
review aged almost 12 months old, both twins continue to have generalized tonic-clonic seizures
once or twice a week and have developmental stasis. Patient 2 occasionally fixes and smiles
and patient 3 occasionally fixes but does not smile. They are hypotonic with no head control
and have normal tendon reflexes. Most recent amino acid quantitation at 11 months of age
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identified an elevated proline concentration in patient 2 of 418 µmol/L (ref: 85 – 290 µmol/L),
whereas in patient 3 levels remained within the control range (274 µmol/L). Other mild amino
acid abnormalities were also detected in both twins. Given that patients 2 and 3 were prenatally
diagnosed, extensive biochemical investigations similar to those carried out for patients 1, 4 and
5 were not performed. The amalgamated prevalence of each symptomatology in all patients
described to date are summarised in 5.4.3.
Table 5.4.3: Clinical phenotype and demographics of patients with SLC25A22
mutations.
Clinical features and
demographics
Incidence
Gender 8/14 male; 6/14 female
Country of origin Afghanistan 3/14; Syria 2/14; Israel 6/14; Algeria 1/14, Saudi
Arabia 2/14
Parental consanguinity 14/14 (100%)
Age at seizure onset First week; 6/14 (43%)
1 week - 1 month; 3/14 (21%)
1 - 3 months; 4/14 (29%)
7 years; 1/14 (7%)
Seizure type Neonatal/early infantile epileptic encephalopathy; 11/14 (79%)
Migrating partial seizures of infancy; 2/14 (14%)
Absence seizures in childhood 1/14 (7%)
Response to AEDs None; 5/11 (45%)
Partial; 5/11 (45%)
Yes; 1/11 (9%)
Distinct EEG features Burst-suppression; 5/11 (45%)
Multifocal; 4/11 (36%)
Delta brush pattern; 1/11 (9%)
Irregular slow wave activity; 1/11 (9%)
Visual evoked potential
(VEP)
Abnormal; 5/8 (63%)
Normal; 3/8 (37%)
Electroretinogram (ERG) Abnormal; 2/4 (50%)
Normal 2/4 (50%)
Other ocular findings
described
No fixing/following; 2/11 (18%)
No response to light; 5/11 (45%)
Retinal pigmentation; 1/11 (9%)
Hypermetropia, astigmatism and convergent squint; 1/11 (9%)
Normal; 2/11 (18%)
Microcephaly 7/7 (100%)
MRI Hypoplastic corpus callosum/splenium; 8/11 (72%)
Cerebellar hypoplasia/prominent folia; 5/11 (45%)
Delayed myelination; 4/11 (36%)
Brain atrophy; 4/11 (36%)
Subarachnoid enlargement; 2/11 (18%)
White matter abnormalities; 2/11 (18%)
Frontotemporal hypoplasia; 1/11 (9%)
Normal; 1/11 (9%)
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Biochemical findings Persistently elevated plasma proline; 2/5 (40%)
Intermittently elevated plasma proline; 1/5 (20%)
Intermittently elevated plasma ornithine or arginine; 4/5 (80%)
Vacuolated fibroblasts (mostly empty); 3/3 (100%)
5.4.4 Catabolism, cycling and synthesis of proline
Prior to the identification of patients 1 - 5, biochemical abnormalities have not been associated
previously with this disorder. This is not the case in the patients we have described. One patient
was referred because of hyperprolinaemia (patient 1) and in another two it was detected on first
line investigations (patients 2 and 4). However, it was uncertain whether these elevated proline
levels were an incidental unrelated finding or could be explained by mutations in SLC25A22.
The metabolic pathways involved in catabolism, cycling and synthesis of proline are shown in
Figure 5.4.9.
Figure 5.4.9: Proline biosynthetic and catabolic pathways. Schematic illustrating the
synthesis, degradation and interconversions of proline, pyrroline-5-carboxylate
(P5C), glutamate-γ-semialdehyde (GSA) and glutamate within the mitochondrion.
1, proline dehydrogenase; 2, P5C reductase; 3, ornithine-δ-aminotransferase; 4,
P5C synthase; 5, P5C dehydrogenase; 6, non-enzymatic reaction.
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Proline enters the mitochondrion from the cytosol and intramitochondrial FAD-dependent
proline dehydrogenase converts proline to L-∆1-pyrroline-5-carboxylate (P5C). P5C can then
either be transported out of the mitochondrion or be further metabolised. The transporter
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responsible for the eﬄux of P5C has not been identified (Miller et al., 2009). However, P5C in the
mitochondrion can undergo non-enzymatic hydrolysis which opens the ring structure to generate
glutamate-γ-semialdehyde (GSA), its equilibrium partner. Given the structural similarity of GSA
and glutamate (Figure 5.4.10), it is possible that GSA, as well as glutamate, may be transported
out of the mitochondrion by SLC25A22. Glutamate-γ-semialdehyde is structurally identical to
glutamate with the exception of the γ-carboxylic acid (-COOH) which is exchanged with an
aldehyde group (-COH). This substrate was not included in those tested by Fiermonte et al.
(2002). Subsequently in the cytosol GSA could then spontaneously re-cyclise to form P5C.
Figure 5.4.10: Structural similarity of L-glutamate and glutamate-γ-semialdehyde.
Once in the cytosol P5C can be converted back to proline by P5C reductase, thus completing
the proline/P5C shuttle and the transfer of reducing equivalents from cytosolic NADPH to the
mitochondrial respiratory chain. Alternatively GSA, which is in equilibrium with P5C, can be
further metabolised to either glutamate or ornithine and arginine. In the pathway to glutamate,
P5C dehydrogenase uses nicotinamide adenine dinucleotide (NAD+) to remove two electrons from
GSA during the conversion (Arentson et al., 2012). The pathway from P5C/GSA to ornithine
proceeds via ornithine δ-aminotransferase (OAT), with the subsequent production of arginine
occurring within the urea cycle.
Proline can also be synthesised from glutamate. This involves three enzymatic steps; the first
two of which are catalysed by P5C synthase, a bifunctional enzyme that exhibits glutamate kinase
and γ-glutamyl phosphate reductase activities (Pérez-Arellano et al., 2010). Glutamate kinase uses
ATP to generate γ-glutamyl phosphate, which is subsequently reduced by γ-glutamyl phosphate
reductase using NADPH to produce GSA. GSA then non-enzymatically cyclizes to form P5C and
subsequently is reduced to proline in the cytosol by P5C reductase. All the intramitochondrial
metabolic interconversions can have an effect on plasma amino acid concentrations with defects
in these enzymes causing characteristic abnormalities. Indeed, plasma proline is elevated in
proline dehydrogenase and P5C dehydrogenase deficiencies, whilst proline, ornithine, arginine
(and citrulline) are all low in P5C synthase deficiency (Baumgartner et al., 2005). In contrast,
OAT deficiency causes variable age-dependent abnormalities with plasma ornithine, arginine
and citrulline being deficient in infancy (often accompanied by hyperammonaemia due to urea
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cycle impairment) but elevated after a year of age. This can be explained by the fact that OAT
not only catalyses the transamination of P5C to form ornithine, but also the reverse reaction
from ornithine to P5C which predominates after the first year of life. Therefore, mutations in
SLC25A22 may cause elevated proline concentrations in biofluids by reducing flux through the
proline/P5C shuttle if GSA cannot exit the mitochondria.
5.4.5 Amino acid abnormalities in patients with SLC25A22 deficiency
In addition to the plasma proline levels which were consistently elevated in two patients and
elevated in the most recent sample from one of the pre-natally diagnosed twins (Figure 5.4.11),
other plasma amino acid abnormalities were also detected in multiple samples from the other
patients. Amongst the most consistently elevated were glutamate, ornithine and arginine (Table
5.4.4 and Table 5.4.5). A defect in the export of GSA/P5C or glutamate from the mitochondrion
could be expected to result in reduced catabolism of proline and increased production of glutamate
and/or ornithine and arginine. The fact that 60% (3/5) of patients had elevated plasma
proline concentrations and 80% (4/5) had elevated glutamate and/or ornithine and arginine
on multiple occasions supports the hypothesis that the export of GSA/P5C and/or glutamate
from the mitochondrion may be disturbed in SLC25A22 deficiency. This hypothesis requires
that SLC25A22 catalyses the eﬄux as well as influx of GSA/P5C and/or glutamate into the
mitochondria. As described in Section 5.4.2, this bidirectional transport of glutamate is supported
by studies in reconstituted liposomes (Fiermonte et al., 2002). An obvious concern regarding
these experiments is the possibility that transporters may insert into liposomal membranes in
both orientations leading to false reporting of bidirectional transport activity. However, kinetic
data has shown that using this methodology, the transporters unidirectionally inserted into the
liposomal membrane, suggesting that the observed bidirectional transport activity of SLC25A22
in vivo in not artefactual (Palmieri et al., 1995).
The reasons for the lack of hyperprolinaemia in patients 3 and 5 are unclear, although the
age of sampling for amino acid analysis may be important for detecting this mild abnormality.
As described in the context of OAT deficiency, during the neonatal and young infant periods
the flux of amino acid conversion within the mitochondria is proline → ornithine, but in older
children the direction of flux is reversed (Figure 5.4.9). In order to investigate this further the
plasma concentrations of proline, ornithine, glutamate and glutamine from patient 1 were plotted
to examine the changes in these analytes over time, as this was the only patient for which amino
acid concentrations had been quantified on more than two occassions over an extended period
of time. As expected, there was a trend for proline concentrations to increase with age, whilst
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Figure 5.4.11: Plasma proline concentrations in patients 1 - 5 with mutations in
SLC25A22. Multiple data points at 32.8 months in patient 1 represent a pre-
and post-prandial series of samples. Dotted lines represent reference ranges. All
analysis was performed in the Chemical Pathology Department, GOSH, UK.
glutamate concentrations decreased (Figure 5.4.12). This may explain the normal plasma proline
in patient 5 (4 years 6 months) as she was younger than her sister (7 years 6 months) at the
time of sampling. However, patient 1 was much younger than this when proline was found to
be elevated, suggesting that this effect may be mutation-specific. Indeed, there are likely to
be additional environmental factors influencing plasma proline concentrations in these patients
as, despite sharing the same genotype and treatment regimen, only one of the affected twins
(patients 2) had an elevated proline concentration. These factors may include seizure control,
antiepileptic drug treatment, diet and polymorphisms in mitochondrial genes or those that are
involved in the synthesis, catabolism or transport of amino acids.
Moreover, if SLC25A22 can indeed catalyse the eﬄux of GSA/P5C, the accumulation of
P5C inside the mitochondria of patients with SLC25A22-deficiency may contribute to seizure
propagation. Neurotransmitter analysis undertaken at the time of CSF amino acid quantitation
revealed a low concentration of pyridoxal 5’-phosphate (PLP) in patient 1. As described in Section
4.2.1, hyperprolinaemia type II is caused by a deficiency of P5C dehydrogenase (Figure 5.4.9)
resulting in an accumulation of P5C. In the brain, excess P5C inactivates PLP by Knoevenagel
condensation. If, as we have proposed, levels of P5C are high in the mitochondria then PLP
could be inactivated in this site. Thus, as in hyperprolinaemia type II, this secondary PLP
deficiency may be contributing to the propagation of seizures (Farrant et al., 2001). Interestingly,
patient 5 had not presented with seizures at the time of sampling and had a normal CSF PLP
concentration, which again may be explained by the milder predicted impact of the p.Ala296Thr
mutation. CSF analysis was not performed in patients 2 - 4.
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Figure 5.4.12: Plasma amino acid analysis in patient 1. (a) proline, (b) ornithine, (c)
glutamine and (d) glutamate. Multiple data points at 32.8 months represent
pre- and post-prandial samples. Dotted lines represent reference ranges. All
analysis was performed in the Chemical Pathology Department, GOSH, UK.
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Table 5.4.4: Profile of plasma amino acids for patients 1 - 5. Samples were analysed by high-performance liquid chromatography (HPLC) as part of
patients clinical care. Amino acid concentrations elevated above the reference range are shown in orange and those below the reference range are
shown in blue. * Amino acids were not quantified at this time.
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Table 5.4.5: (Continued) Profile of plasma amino acids for patients 1 - 5. Samples were analysed by high-performance liquid chromatography (HPLC)
as part of patients clinical care. Amino acid concentrations elevated above the reference range are shown in orange and those below the reference
range are shown in blue. * Amino acids were not quantified at this time.
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In order to investigate whether SLC25A22 can transport GSA or P5C, the concentration of
GSA in fibroblasts from SLC25A22-deficient patients were analysed by mass spectrometry. This
method was based on the method of Mills et al. (2006) to measure α-AASA in patients with
pyridoxine-dependent epilepsy (Section 2.15). α-AASA is structurally and physicochemically
similar to GSA, differing only in the addition of a -CH2 group (Figure 5.4.13a). Although not
statistically significant, the levels of GSA in the fibroblasts of the three SLC25A22-deficient
patients were found to be lower than in control cells (Figure 5.4.13b). This would be consistent
with the hypothesis that GSA/P5C cannot exit the mitochondrion and therefore is converted
into other metabolites including glutamate and ornithine.
Figure 5.4.13: Measurement of glutamate-γ-semialdehyde (GSA) in control and
SLC25A22-deficient fibroblasts. Calibration curves could not be con-
structed so values were normalised against an internal standard, d3-aminoadipic
acid (d3-AAA).
5.4.5.1 Secondary amino acid abnormalities due to glutamate deficiency
With a view to identifying factors which may have been contributing to the consistent hyper-
prolinaemia that was presumed to be related to disease pathogenesis in patient 1, a series of
post-prandial plasma amino acids were quantified at 2 years 8 months of age. Levels were
measured following a 6 hour fast and then 1, 2 and 4 hours post-prandial. Only proline was
elevated in the fasting sample, but in the post-prandial samples the concentrations of several
amino acids were mildly elevated including leucine, isoleucine, alanine, valine, lysine, tyrosine
arginine and threonine (Figure 5.4.14). Random plasma samples from patients 2 - 4 also showed
variable elevations of the same amino acids in addition to glutamate, arginine and ornithine. A
random plasma sample from patient 5 showed no abnormality. These samples may also have
been taken post-prandially.
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Figure 5.4.14: Plasma amino acid concentrations in patient 1 at 2 years and 8 months of age in response to feeding. Samples were taken after a
six hour fast and 1, 2 and 4 hours after eating. Dotted lines represent the reference ranges used in the clinical laboratory where these analyses
were performed (Chemical Pathology Laboratory at GOSH). There were no reference ranges for asparagine and aspartate.
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The increase in plasma amino acid concentrations following a protein- or carbohydrate-rich
meal is a well-documented effect (Schmid et al., 1992; Frame, 1958; Yokogoshi and Wurtman,
1986). These increases are not uniform, with the absolute increases ranging between 20 - 400
µmol/L. Maximal levels are typically observed between 90 and 120 minutes after the ingestion of
a meal. The majority of the post-prandial increases observed in patient 1 were within the ranges
reported by others, with the exception of proline, alanine and tyrosine which were outside both
the reference ranges reported at GOSH and others published in the literature.
The potential mechanism underlying this widespread post-prandial elevation of amino acids
in patient 1 and how it may occur as a consequence of the SLC25A22 transporter defect were
then considered. In the fed state, amino acids are the preferred fuel of the liver. The influx from
the portal vein leads to high concentrations in the cytosol of the hepatocytes. Leucine, isoleucine,
valine, alanine and tyrosine can all undergo reversible transamination with 2-oxoglutarate to
produce glutamate (Figure 5.4.15a). These high levels of glutamate need to be transported into
the mitochondria for deamination by glutamate dehydrogenase to re-form 2-oxoglutarate, a role
that is likely fulfilled by SLC25A22. The transport of glutamate to the mitochondria is therefore
critical for replenishing the 2-oxoglutarate levels required for the adequate metabolism of the
high concentrations of amino acids entering the liver after a meal. Therefore, when SLC25A22 is
dysfunctional, cytosolic deamination will be impaired and hence the plasma concentrations of
amino acids such as leucine, isoleucine, valine, alanine and tyrosine will be higher than normal in
this post-prandial period, as observed in patient 1. In the case of lysine, the first step in the major
catabolic pathway occurs in the mitochondrion but requires 2-oxoglutarate (Blemings et al., 1998)
(the catabolic pathways of lysine metabolism are described in detail in Section 6.1). Reduced
glutamate influx may lead to reduced 2-oxoglutarate and hence reduced hepatic catabolism of
lysine (Figure 5.4.15b).
5.4.5.2 Urinary and cerebrospinal fluid (CSF) amino acid abnormalities
Urinary amino acid analysis was only carried out in patients 1 (on two occasions) and patient 5.
The first sample from patient 1 at two months of age demonstrated generalised aminoaciduria of
uncertain significance. However, it is noteworthy that proline was elevated 6.5-fold higher than the
upper limit of the reference range compared to the 3.4-fold average of the other amino acids that
were increased in concentration. Nevertheless, the remaining two samples showed consistently
elevated proline and glutamate (Table 5.4.6), similar to those observations made in plasma
samples. Taurine, tyrosine and aspartate concentrations were also observed to be mildly elevated
in urine samples which was not seen in plasma analysis. Urinary amino acid concentrations can
be non-specifically affected by renal tubular dysfunction (which can be inherited or secondarily
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Figure 5.4.15: Potential mechanisms underlying the secondary amino acid abnor-
malities identified in patients with SLC25A22 deficiency. (a) Impaired
cytosolic transamination of amino acids by 2-oxoglutarate. (b) Lysine catabolism
may be impaired by a lack of 2-oxoglutarate.
acquired), diurnal variation, sample storage, infection and mild vitamin/trace metal deficiencies.
Indeed, the significance of these mild amino acid abnormalities in patients 1 and 5 is uncertain.
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Table 5.4.6: Profile of urinary amino acids for patients 1 and 5. Samples were analysed by ion exchange chromatography with post column ninhydrin
derivatisation using the Biochrom 30+ amino acid analyser as part of patients clinical care. Amino acid concentrations elevated above the reference
range are shown in orange and those below the reference range are shown in blue. * Amino acids were not quantified at this time.
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Both patients also underwent CSF amino acid analysis which revealed low levels of glutamate
in both patients and elevated proline in patient 1 (Table 5.4.7). This CSF glutamate deficiency
was somewhat paradoxical given the elevated concentrations of this amino acid in urine and in
approximately half of plasma samples. Two excitatory amino acid transporters, EEAT1 and
EEAT3, localised to ependymal and choroid plexus epithelial cells have recently been shown to
transport L-glutamate from the CSF to the brain in rats (Akanuma et al., 2015). It has been
suggested that the seizures seen in patients with SLC25A22 deficiency are propagated by the
accumulation of glutamate in the cytosol of astrocytes and its subsequent inappropriate release
into the synaptic cleft (Molinari et al., 2009). It has also been reported that the processes of
astrocytes assembled next to the CSF take up glutamate via EAAT1 and EAAT2. This uptake
is increased in a dose-dependent manner by the presence of glutamate, mediated by increased
cell-surface expression of EAAT1 (Duan et al., 1999). It is therefore plausible that inappropriate
glutamate release from astrocytes triggers an increase in EAAT1 cell-surface expression, not
only on astrocytes, but also ependymal and choroid plexus epithelial cells resulting in increased
glutamate uptake from the CSF and the low levels we observe in our patients.
A second possibility is based on the hypothesis that the direction of glutamate flux through
SLC25A22 may be dependent on the intra- and extra-mitochondrial conditions. As also de-
scribed in relation to mutations in KCNQ2 (Section 4.5.11), glutamate is the major excitatory
neurotransmitter in the mammalian brain. Unlike astrocytes, neurons are unable to carry out de
novo synthesis of glutamate from glucose. Instead, astrocytes release glutamine into intercellular
compartments within the brain which can then be taken up by neurons and recycled back to
glutamate by glutaminase (Bak et al., 2006). This enzyme is solely localised to the mitochondria
meaning that the synthesised glutamate must be exported to the cytosol to be packaged into
synaptic vesicles (Daikhin and Yudkoff, 2000). Thus, dysfunction of SLC25A22 may lead to
glutamate being trapped inside the neuronal mitochondria and to the low levels seen in patients
1 and 5.
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Table 5.4.7: Profile of CSF amino acids for patients 1 and 5. Samples were analysed by
high-performance liquid chromatography (HPLC) as part of patients clinical care.
Amino acid concentrations elevated above the reference range are shown in orange
and those below the reference range are shown in blue.
5.4.6 Investigation of fibroblast vacuolation identified in patients with SLC25A22 mutations
In addition to amino acid analyses which, although revealing subtle abnormalities remained
non-diagnostic, three patients had additional extensive biochemical investigations as part of
the diagnostic work-up for a potential metabolic disorder (Table 5.3.1). This included the
examination of fibroblasts obtained from a skin biopsy by electron microscopy to investigate
any potential storage or mitochondrial disorder. Observation of the cellular ultrastructural
morphology revealed extensive vacuolation with the presence of empty, single membrane-bound
vacuoles being evident in all patients (Figure 5.4.16). This is a characteristic feature of defects of
lysosomal enzymes and can indicate the presence of a storage material, with each type having a
distinctive ultrastructural appearance (Alroy and Ucci, 2006). The vacuoles were of a regular size
and present in the vast majority of cells examined. At higher magnification, some of the vacuoles
in the SLC25A22-deficient patients clearly contained electron-lucent or fine fibrillar material or
had remnants of this material adjacent to the membrane (Figure 5.4.16). These appearances
were consistent with the lysosomal accumulation of lipids.
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Figure 5.4.16: Ultrastructural features of the vacuoles identified in patients with
SLC25A22 mutations. (A and B) Vacuoles contain (or contain remnants
of) fine fibrillar and electron-lucent material. (C) Vacuoles are bound by a
single membrane. (D) Vacuoles are regularly sized. Ultrastructure of control
fibroblasts can be seen in Figure 5.4.17. Scale bars: A-C: 500 nm; D: 2 µm.
5.4.6.1 Histological staining and interrogation of whole exome data to investigate the contents
of the vacuoles in patient fibroblasts
In order to investigate whether any soluble storage material had been washed away during sample
processing, fibroblasts were re-examined using both tinctorial stains and immunohistochemical
methods (Figure 5.4.17). The histological identification of lipids is challenging because droplets
can dissolve upon fixation or staining with alcohol-based chemicals. Hence, when carrying out
each stain, care was taken not to fix cells with alcohol and to minimise the time slides were
washed in alcoholic solutions. Fibroblasts from all patients showed a punctate staining pattern
using Oil Red O (Section 2.14.1.3) and Sudan Black (Section 2.14.1.4) indicating the presence of
both neutral lipids and phospholipids, respectively. Luxol Fast Blue staining was negative for
the presence of sphingomyelin (Section 2.14.1.5). LAMP2 immunostaining was comparable to
controls providing no evidence to support any lysosomal dysfunction (Section 2.14.1.6). These
results were consistent with the vacuoles seen by electron microscopy containing soluble lipid
that had been washed away during sample processing. Two possibilities were then considered:
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both families have a second metabolic disorder leading to the production of lipid vacuoles or that
the accumulation was secondary to SLC25A22 deficiency.
Figure 5.4.17: Structural and ultrastructural examinations of SLC25A22-deficient
fibroblasts. Fibroblast cell culture from control (A, E, I, M, Q, U), patient
1 (B, F, J, N, R, V), patient 4 (C, G, K, O, S, W) and patient 5 (D,
H, L, P, T, X). Ultrastructural examination by electron microscopy revealed
widespread, almost exclusively empty vacuoles in all patients (A-H). Patients
showed excess accumulation of lipid (I-L, Oil Red O; M-P, Sudan Black).
Luxol Fast Blue staining was negative for the presence of sphingomyelin (Q-T).
LAMP2 immunostaining was comparable to controls (U-X). Scale bars: A-E:
2 µm; F-H: 500 nm; I-X: 100 µm.
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In light of the possibility that a second metabolic disorder was present in the patients described
in this chapter, whole exome sequencing data was scrutinised for variants in genes known to cause
lysosomal storage disorders and a homozygous variant was identified in SMPD1 (c.340G>A;
p.Val114Met) in patients 4 and 5.
Figure 5.4.18: Electropherograms showing SMPD1 mutation analysis in patient 4
and 5. Sanger sequencing confirmed the presence of a homozygous p.Val114Met
mutation in SMPD1 in patients 4 and 5.
The variant is reported in publicly available databases at a minor allele frequency of less than
1% (1000 Genomes Project, 0.06%; NHLBI Exome Sequencing Project, 0.06%, ExAC, 0.076%)
and is predicted tolerated and benign by SIFT and PolyPhen-2, respectively. Segregation of the
variant and confirmation of its presence in a homozygous state in both patients was confirmed
by Sanger sequencing (Figure 5.4.18). Mutations in this gene cause Niemann-Pick disease type
A/B which presents either in early infancy or mid-childhood with a combination of the following
features: hepatosplenomegaly, psychomotor regression, interstitial lung disease, delayed bone
mineralisation, thrombocytopenia and a cherry-red spot in the macula of the eye (Irun et al.,
2013). Our patients do not share any of these features. Leukocyte acid sphingomyelinase (encoded
by SMPD1 ) activity was subsequently measured as 0.43 nmol/hr/mg protein (ref: 0.86 – 2.8) by
the Chemical Pathology Department, GOSH. Although this activity is lower than that reported
in heterozygotes (ref: 0.7 – 1.3), it is higher than that reported in affected homozygotes (ref:
0.08 – 0.18). Luxol fast blue (LFB) staining has been used previously to detect sphingomyelin,
the storage material that accumulates in Niemann-Pick type A/B (Aronson and Volk, 2013).
Given that the vacuolation was present to a comparable degree in all patients and there was no
evidence of punctate LFB staining indicating an accumulation of sphingomyelin (Figure 5.4.17),
it was concluded that this SMPD1 variant was not pathogenic.
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Accumulation of neutral lipids can occur in defects of adipose triglyceride lipase (PNPLA2 )
or its activator, 1-acylglycerol-3-phosphate O-acyltransferase (ABHD5 ) causing neutral lipid
storage disease with myopathy and Chanarin-Dorfman syndrome, respectively. Lipids can also
accumulate intracellularly in patients with Wolman disease, deficiencies of carnitine, carnitine
palmitolytransferase and mitochondrial fatty acid oxidation enzymes. Whole exome sequencing
data was scrutinised for potentially pathogenic variants in any of the genes responsible for
these diseases. None were identified, therefore we concluded that our patients do not harbour a
second genetic defect resulting in excess lipid production. Following the exclusion of a secondary
metabolic defect in our patients, two possibilities regarding how lipid vacuole accumulation could
be secondary to SLC25A22 deficiency were considered.
5.4.6.2 Vacuolation due to impaired transport of reducing equivalents
One hypothesis would be that an excess of nicotinamide-adenine dinucleotide phosphate (NADPH)
and citrate within the cytosol may drive increased lipid synthesis and the second was that
SLC25A22-deficiency may drive an increase in autophagy (Figure 5.4.19).
Figure 5.4.19: Proposed mechanism of lipid synthesis based on the impaired trans-
port of reducing equivalents and accumulation of citrate in patients
with SLC25A22 deficiency. 1, proline dehydrogenase; 2, P5C reductase.
In both proliferating and quiescent fibroblasts the pentose phosphate pathway is the major
source of cytosolic NADPH through the oxidation of glucose (Lemons et al., 2010). These
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reducing equivalents are then transferred to the mitochondria via the proline/P5C shuttle.
Firstly, hydride ions (H−) from NADPH are transferred to proline and subsequently to the
respiratory chain upon the conversion back to P5C by proline dehydrogenase (Hagedorn and
Phang, 1983). The P5C then exits the mitochondria and is converted back to proline by the
cytosolic P5C reductase. The proline/P5C shuttle can also regulate cytosolic and mitochondrial
redox states because the production of NADP+ by P5C reductase increases the activity of glucose-
6-phosphate dehydrogenase which catalyses the rate-limiting step of the pentose phosphate
pathway. Both this enzyme and 6-phosphoglutaconate dehydrogenase, which catalyses the
following enzymatic conversion, produce one molecule of NADPH through the utilisation of
NADP+ (Figure 5.4.20). Therefore, this upregulation of glucose-6-phosphate dehydrogenase by
NADP+ from the proline/P5C shuttle, results in increased production of cytosolic NADPH.
Figure 5.4.20: Schematic of the pentose phosphate pathway. 1, glucose-6-phosphate
dehydrogenase; 2, 6-phosphoglutaconate dehydrogenase.
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Given that one molecule of succinate entering the tricarboxylic acid (TCA) cycle generates
100 times more ATP than the proline/P5C shuttle, it is unlikely that this mechanism represents
a major energy source. However, this may be untrue in certain conditions, including situations
where the TCA cycle is not operating maximally. This may be the case in SLC25A22 deficiency
due to the abnormal transport of glutamate. Within the mitochondria, glutamate dehydrogenase
catalyses the conversion of glutamate to 2-oxoglutarate which then enters the TCA cycle. Thus,
as in glutamate dehydrogenase deficiency (Nissen et al., 2015), a lack of 2-oxoglutarate could
cause TCA cycle dysfunction, possibly increasing the functional importance of the proline/P5C
shuttle. If, as we have proposed, SLC25A22 facilitates the export of P5C (or its equilibrium
partner GSA) from the mitochondria, mutations would result in shuttle impairment and an
increase of cytosolic NADPH/NADP+.
A second hypothesis is that citrate may accumulate in patients with SLC25A22 deficiency.
When quiescent cells are supplemented with stable isotope-labelled glutamine, approximately
15% of the cellular citrate became labelled (Lemons et al., 2010). The only known mechanism
to generate the specific configuration of labelled citrate identified is through the conversion of
glutamine → glutamate → 2-oxoglutarate → citrate; this corresponds to a reversed direction of
TCA cycle flux. If glutamate is trapped inside the mitochondrion a similar increase in citrate
synthesis could occur. Under normal conditions, glucose is converted to pyruvate by glycolysis in
the cytosol. Pyruvate is then converted to acetyl-coA followed by citrate within the mitochondria.
This citrate is then exported to the cytosol where it is cleaved by ATP citrate lyase back to
acetyl-coA. Carboxylation then occurs by acetyl-coA carboxylase to form malonyl-coA. This is
the first step in the synthesis of a range of lipids including sphingolipids, plasmalogens, fatty
acids and glycerophospholipids (Figure 5.4.21).
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Figure 5.4.21: Schematic illustrating the requirements of citrate and
NADP+/NADPH for the synthesis of fatty acids and complex
lipids. Figure adapted from Lamari et al. (2013)).
Similarly, NADPH is a critical cofactor for many enzymes involved in lipid synthesis (Figure
5.4.21). Thus, it would be intuitive that any increase in the cytosolic concentrations of NADPH
or citrate could result in an increase in lipid synthesis. Indeed, one of the postulated mechanisms
for the lipid accumulation often seen in muscle biopsies of patients with mitochondrial respiratory
chain disorders is the build-up of reducing equivalents and export of TCA cycle intermediates
such as citrate. It is therefore possible that, providing that SLC25A22 can catalyse glutamate
exchange in vivo, impairment of the transporter could lead to conditions favouring increased lipid
synthesis in fibroblasts.
5.4.6.3 Vacuolation due to increased autophagy
A second hypothesis for the formation of the vacuoles evident in patient fibroblasts is that abnormal
mitochondrial metabolism triggers an autophagy response. Autophagy is an intracellular pathway
which is required for the elimination of damaged organelles and intracellular pathogens, as well as
the recycling of cytoplasmic macromolecules (Levine and Kroemer, 2008). Three distinct types
of autophagy have been identified to-date: chaperone-mediated autophagy, microautophagy and
macroautophagy. These share common degradative mechanisms within the lysosome but differ in
241
the way that substrates are delivered to the organelle. The predominant type, macroautophagy,
is a synonym for autophagy and involves the formation of a double membrane structure around
the material targeted for destruction. This autophagosome then travels through the cytoplasm
and fuses with a lysosome, which uses acidic hydrolytic enzymes to degrade the contents of each
autophagosome (Klionsky, 2007). Amino acids are known to influence autophagy through the
regulation of the mammalian target of rapamycin complex 1 (mTORC1), a protein complex
which functions as a sensor of nutrient, energy and redox state within cells and controls protein
translation accordingly (Hay and Sonenberg, 2004). Amino acids suppress autophagy, whereas
their deficiency stimulates the pathway (Mortimore and Schworer, 1977). This increase in
autophagy under conditions of stress promotes the recycling of nutrients to enable the production
of glucose, signalling molecules and neurotransmitters, as well as the maintenance of immune and
endocrine function (Wu, 2013). In many cell types, the majority of the stimulatory/inhibitory
effects can be attributed to concentrations of leucine and, to a lesser extent, the other branched
chain amino acids (Lynch, 2001). However, in vitro studies have shown that pheochromocytoma
cells supplemented with low concentrations of glutamate undergo an autophagic pro-survival
response which can be accompanied by cytoplasmic vacuolation, reminiscent of that observed in
the fibroblasts of our patients (Stamoula et al., 2015). Thus, it is possible that the dysregulation
of glutamate levels both within the cytosol and mitochondria of SLC25A22-deficient cells may
result in increased autophagy.
Accumulation of nucleoporin 62 (p62) can be used as a marker for the induction of the
autophagy pathway. Therefore to investigate whether mitochondrial dysfunction caused by
SLC25A22 mutations may drive an increase in autophagy/mitophagy and account for the
fibroblast vacuolation, the amount and subcellular localisaation of p62 was investigated in patient
fibroblasts by immunofluorescence (Section 2.14.3). Proteins can be targeted for autophagic
degradation through ubiquitination, a process which is dependent on the binding of p62 to
targeted substrates (Kim et al., 2008). This complex then associates with proteins within the
autophagosome membrane via an LC3-interacting region prior to transporting the cargo to the
lysosome (Lamark et al., 2009). Four representative immunofluorescence images per case were
analysed using CellProfiler 2.1.1. Image analysis showed that the mean feret diameter and radius
of p62 punctae remained constant between controls and patients with SLC25A22 mutations.
However, the mean number and area of autophagosomes appeared to be increased in patient
cells indicating a possible increase in autophagy or mitophagy due to mitochondrial dysfunction
(Figure 5.4.22). This increase in number of p62-positive autophagosomes was significant (p =
0.002) in patient 4. Similarly, when the results were taken together, the mean total area of p62
staining per cell was increased in all patients compared to controls and significantly in patient 4
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(p = 0.002). In order to investigate this further, electron microscopy images were scrutinised. In
all patients, the majority of membrane-bound vacuolar structures were empty. However, some
vacuoles in patient 4 contained cellular debris or electron-dense lamellar bodies (Figure 5.4.22L).
This would be consistent with the p62 staining and indicates a greater degree of autophagy
occurring in these cells (Ylä-Anttila et al., 2009). Further work is needed to determine whether
this trend is a consistent observation and how it is affected by stressing mitochondria or blocking
autophagic degradation using bafilomycin or chloroquine.
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Figure 5.4.22: Immunofluorescence of the autophagy marker nucleoporin 62 (p62). (A) Control 1, (B) Control 2, (C) Control 3, (D) Patient 1, (E
and L) Patient 4, (F) Patient 5. Blue, nuclear staining with DAPI; red, p62 punctae. Analysis of mean (G) number, (H) area, (I) maximum
ferret diameter, (J) radius and (K) and total area of p62 staining per cell (** p = 0.002). (L) Electron microscopy of patient 4. Scale bars:
A-F: 50 nm; L: 2 µm.
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5.4.7 Investigation of the efficacy of ubiquinone treatment for patients with SLC25A22 deficiency
An additional noteworthy biochemical finding for patient 1 was that he had a low white cell
ubiquinone level of 24 pmol/mg (ref: 37 - 133). This test was not performed in patients 4 or 5.
Our hypothesis for the elevated proline levels observed in patients with SLC25A22-deficiency is
that disruption of the proline/P5C shuttle results in reduced flux through proline dehydrogenase.
Reducing equivalents from proline are transferred via a flavin adenine dinucleotide (FAD) cofactor
to an acceptor. Although detailed kinetic studies of human proline dehydrogenase have not been
carried out to-date, characterisation of proline utilization A (PutA) in Gram-negative bacteria
and proline dehydrogenase from Thermus thermophilus have provided mechanistic insights. Both
enzymes share high sequence identity with human proline dehydrogenase, particularly within
the active site region. The conversion of proline to P5C by proline dehydrogenase occurs via a
ping-pong mechanism, meaning that the first product is formed in a reductive half-reaction and
released prior to the second substrate binding and the completion of the oxidative half-reaction.
In the former, proline binds to the active site and is oxidised to P5C with the concurrent reduction
of the FAD cofactor to FADH2. In the oxidative half-reaction these electrons are then transferred
from FADH2 to ubiquinone situated within the membrane, which binds to to the enzyme at an
alternative site (Moxley et al., 2011). Although remaining unproven, it is likely that proline
dehydrogenase in humans also uses a similar mechanism to transfer electrons from FADH2 to
ubiquinone in the respiratory chain. The pair of electrons can also result in the reduction of
oxygen to form superoxide (Tanner, 2008). Indeed, ubiquinone could be being consumed due to
impaired redox balance, reduced proline flux somehow leading to increased losses of ubiquinone,
or a combination of the two.
Ubiquinone plays a central role in the respiratory chain within mitochondria by carrying
electrons from complex I and II to complex III (Crane et al., 1957). Inborn errors affecting
ubiquinone biosynthesis typically present with brain involvement including seizures, cognitive
impairment and cerebellar signs (Quinzii et al., 2007). Unfortunately, ubiquinone supplementation
in patients 2 and 3 did not ameliorate the onset of a seizure disorder despite being commenced
at birth. This indicates that respiratory chain dysfunction secondary to ubiquinone deficiency
within the mitochondria is not a major pathogenic mechanism in SLC25A22 deficiency; this is
also supported by normal activity of the respiratory chain enzymes in muscle in patients 1 and 4.
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5.5 summary
In this chapter, the cases of five children from two unrelated families found to have a severe
developmental disorder accompanied by early-onset seizures in the majority of cases are described.
Whole exome sequencing was utilised to identify mutations in SLC25A22 in three patients
including the proband in each family. Three siblings were subsequently prenatally diagnosed by
Sanger sequencing.
This cohort again demonstrates the power of using whole exome sequencing for the identi-
fication of patients presenting with non-classical phenotypes and for providing potential new
insights into protein function. We have shown that mutations in SLC25A22 can not only cause a
neonatal-onset seizure disorder, but also a developmental disorder presenting without seizures
until seven years of age. In this particular patient, the absence of seizures but presence of
developmental delay and fibroblast vacuolation would likely have resulted in screening using
a metabolic next-generation sequencing gene panel as opposed to an epilepsy panel. Thus, it
is likely that this disorder remains underdiagnosed as only patients with a seizure disorder
will currently be screened for mutations in SLC25A22. In addition, we have demonstrated the
presence of biochemical abnormalities including hyperprolinaemia, low CSF glutamate and lipid
accumulation in our cohort that may provide useful diagnostic indicators in future patients.
These abnormalities may have not been reported previously due to the specific investigations not
being carried out or amino acid concentrations not being dramatically elevated above reference
ranges. Increased cytosolic lipid synthesis could indicate an accumulation of cytosolic NADPH
and this, alongside hyperprolinaemia suggests impairment of the proline/P5C shuttle. Thus
we hypothesise that SLC25A22 functions in vivo as a mitochondrial P5C/GSA transporter in
addition to its previously described function as a glutamate transporter. Future studies on
additional cohorts of patients presenting with these features will be required to determine the
full phenotypic range associated with this gene. Finally, further functional studies to determine
whether or not SLC25A22 can catalyse the transport or exchange of P5C or GSA will need to be
undertaken. This could be carried out through the reconstitution of SLC25A22 into liposomes as
descibed by Molinari et al. (2005) and/or by measuring of flux through the proline/P5C shuttle in
patient cells using stable isotopes. The latter could be achieved by culturing fibroblasts in media
containing d7-proline; this isotope would then enter the mitochondria and undergo enzymatic
oxidation by proline dehydrogenase. The creation of the double bond in P5C would result in the
removal of one of the deuterium atoms and the formation of d6-P5C. If SLC25A22 can transport
GSA, the d6-P5C would be expected to non-enzymatically hydrolyse to form d6-GSA before
undergoing eﬄux to the cytosol and re-cyclisation to d6-P5C. P5C reductase would then complete
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the proline/P5C shuttle. However, in this case the replacing hydrogen atoms would be derived
from NADPH rather than a stable isotope (deuterium). Thus, the recycled proline would be in
the d6 form (Figure 5.5.1). The ratio between d7- and d6-proline could then be used to assess
any differences in function of the proline/P5C shuttle in patient cells.
Figure 5.5.1: Schematic showing the conversion of d7-proline to d6 proline that
would occur if SLC25A22 transports P5C/GSA.
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6
CYSTEINE CONJUGATE β - LYASE : A PROTEIN OF MANY
FUNCTIONS?
6.1 introduction
In this chapter, whole exome sequencing was used to investigate the underlying aetiology of
disease in a patient Y presenting with a movement disorder and developmental delay, alongside
persistently elevated lysine concentrations in blood, urine and CSF.
Lysine is one of the nine essential proteinogenic amino acids in humans; its side chain consists
of a charged aliphatic group ((CH2)4NH2). It is an essential precursor for many molecules which
are important for the optimal function of the mammalian central nervous system including the
excitatory neurotransmitter glutamate (Papes et al., 2001), carnitine which is required for the
β-oxidation of fatty acids (Tanphaichitr et al., 1971) and intermediates such as crotonyl-CoA
which can provide carbon-units to the tricarboxylic acid (TCA) cycle for ATP production (Sauer
et al., 2011).
The degradation of lysine occurs via two distinct pathways (Figure 6.1.1). The first, termed
the saccharopine pathway, predominates in extracerebral tissues and the foetal brain. The
second, termed the pipecolate pathway, is the major catabolic pathway in the adult brain. Indeed,
enzymatic assays have demonstrated a reduction in the capacity of the saccharopine pathway and
an increase in that of the pipecolate pathway throughout gestation and neonatal life within the
brain (Rao et al., 1992). This suggests that pipecolic acid or the other intermediate metabolites of
this pathway may play a role in neuronal development. Although the two pathways are typically
spatially isolated, they share common intermediates and converge to form a common degradative
mechanism (Figure 6.1.1). The catabolism of lysine is also unique because transamination (i.e.
the transfer of the α-amino group to an α-keto acid acceptor which occurs early-on in the
catabolism of most amino acids) is irreversible. This is due to the production of a compound that
spontaneously and rapidly cyclises, thereby not favouring the reverse transamination reaction.
This occurs regardless of whether the initial catabolic steps involve the conversion of the α-amino
group to a keto group (pipecolate pathway) or the conversion of the -amino group to an aldehyde
(saccharopine pathway).
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Figure 6.1.1: Catabolic pathways of of lysine metabolism. The saccaropine pathway
(right) is the major pathway in tissues outside of the brain. The pipeco-
late pathway (left) is the major pathway within the mammalian brain. 1,
L-lysine-α-ketoglutarate reductase/saccaropine dehydrogenase (LKR/SDH); 2, α-
aminoadipate semialdehyde dehydrogenase (AASDH); 3, α-aminoadipate amino-
transferase/kynurenine aminotransferase II (AADT/KATII), 4; currently un-
known (converts α-amino group of L-lysine to a keto group); 5, ketimine reductase
µ crystallin (CRYM/KR); 6, L-pipecolate oxidase (POX); 7, D-amino acid oxi-
dase.
Given the persistent elevation of lysine in the biofluids of the patient described in this chapter
(patient Y), extensive genetic testing of genes known to be involved in the metabolism of lysine
had been performed prior to the beginning of this PhD project. Sanger sequencing had failed
to identify mutations in (1) α-aminoadipic semialdehyde synthase (AASS), (activator of 2)
L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT),
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(2) L-aminoadipate-semialdehyde dehydrogenase (AASDH ), (6) pipecolic acid oxidase (PPOX)
and (7) D-amino acid oxidase (DAO).
Despite well-established causes of hyperlysinaemia (mutations in AASS) being excluded,
mild elevations of lysine are often seen in disorders which result in decreased availability of α-
ketoglutarate (required for the formation of saccharopine) such as urea cycle disorders, propionic
acidaemia and methylmalonic aciduria (Kamoun et al., 2002). Furthermore, the movement
disorder exhibited by patient Y shared similarities with that seen in patients with amyotrophic
lateral sclerosis (ALS). Levels of lysine have been shown to be significantly elevated in the plasma
of patients with ALS, a neurodegenerative disease which affects approximately 5000 patients
in the UK and results in the progressive loss of motor functions due to muscle paralysis and
ultimately, death. This accumulation was particularly pronounced in patients with early-onset
symptoms, although the reason for this biochemical abnormality is unclear (Cecchi et al., 2014).
Due to the failure of targeted single-gene sequencing to find a diagnosis for patient Y, whole
exome sequencing was performed.
6.2 methods
Sanger sequencing of the CCBL1 gene was performed using the primer conditions detailed in
Appendix 9.5.1 using the standard PCR conditions outlined in Section 2.3.2. The details of
the individual protocols used to sub-clone the CCBL1 cDNA sequence into the pT7CFE1-CHis
vector, introduce the c.814G>A mutation and carry out in vitro translation of the proteins are
detailed in Section 2.16. Analysis of the proteins contained within each in vitro translation assay
was carried out using label-free mass spectrometry (Section 2.17).
Quantitation of the enzyme activity of CCBL1 with respect to kynurenine was determined
using the method described in Section 2.18. Endogenous KN and KA were also quantified in
urine using this UPLC-MS/MS method (Section 2.19). The methods for the detection of tertiary
amines in urine using both o-aminobenzaldehyde and ninhydrin are described in Section 2.20.
Finally, the methods used to synthesise α-keto--aminocaproate/∆1-piperideine-2-carboxylate
from D-lysine using D-amino acid oxidase and to assess the ability of the overexpressed CCBL1
enzymes to catalyse the conversion of L-lysine to KAC/P2C are described in Section 2.21.
6.3 case report
An 18 year old female (patient Y) presented to the metabolic clinic at GOSH. Her parents are
first cousins of Pakistani origin and they have five other children. One of these children (the
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older brother of the proband) also had difficulties with walking and speech. At 20 years of age he
could only use 2 - 3 word sentences. However, examination did not reveal spastic paraparesis
nor did he have any amino acid abnormalities. In addition, his disorder did not appear to
be progressive in nature. There was also a family history of movement disorders with three
cousins of the proband being affected by an inability to walk and speech problems, although
they resided in India and more detailed clinical information was not available. Patient Y had
movement problems beginning in infancy with walking compromised by marked scissoring of
her legs at 2 years of age. This abnormal gait persisted until she fell and broke her ankle at 5
years of age, following which she could only walk with support. Her upper limb movements were
abnormal with consequential functional impairment; she could feed herself with a spoon and
hold a glass with two hands but could not wash her face or do up buttons. She had difficulty
with speech and particularly word pronunciation throughout her life and tended to point to
indicate her needs. She also had problems with poor sleep. Clinical examination at 18 years of
age revealed profound muscle weakness, hypertonia, hyperreflexia, spastic paraparesis and speech
difficulties. Electrophysiology indicated impaired upper and lower motor neuron dysfunction. She
had dry, wrinkled skin without the typical flaking of ichthyosis. Brain MRI showed widespread
cerebral and cerebellar atrophy with some high signal in the perotrigonal white matter; this was
non-specific and compatible with a neurometabolic or neurodegenerative disorder. Biochemical
investigations revealed significantly elevated levels of lysine in plasma, urine and CSF and she was
subsequently diagnosed with hyperlysinaemia (Tables 6.3.1, 6.3.2 and 6.3.3). This finding was
both striking and persistent, with all samples taken showing the same abnormality. Pyridoxine
supplementation (20 mg bd) was started as elevated plasma and CSF threonine concentrations
raised the possibility of a PLP deficiency; the conversion of lysine to α-keto--aminocaproate/
∆1-piperideine-2-carboxylate is also believed to be PLP-dependent. This increased her sleep
quality and reduced vomiting frequency but no improvement in motor function was observed.
Haemoglobin was also noted to be low, associated with microcytic hyperchromic cells and low
ferritin which was treated with iron supplementation. Unfortunately at 23 years of age she
presented with severe cachexia as a result of progressive motor neuron disease-related weakness
compounded by a refusal to eat which resulted in her death shortly afterwards.
Metabolic investigations which yielded normal results included fatty aldehyde NAD+ oxi-
doreductase (excluding Sjörgren-Larsson syndrome), plasmalogen biosynthesis, peroxisomal fatty
acid β-oxidation, localisation of peroxisomal enzymes, plasma very long chain fatty acids, urine
glycosaminoglycans, urine organic acids, leukocyte ubiquinone, free and acylcarnitines, leukocyte
lysosomal enzymes and urine α-AASA (excluding pyridoxine-dependent epilepsy due to antiquitin
deficiency).
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Table 6.3.1: Profile of plasma amino acids for patient Y. Samples were analysed by
high-performance liquid chromatography (HPLC) as part of the patient’s clinical
care. Amino acid concentrations elevated above the reference range are shown in
orange and those below the reference range are shown in blue. * Amino acids were
not quantified at this time.
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Table 6.3.2: Profile of urinary amino acids in patient Y. Samples were analysed by ion
exchange chromatography with post column ninhydrin derivatisation using the
Biochrom 30+ amino acid analyser as part of patients clinical care. Amino acid
concentrations elevated above the reference range are shown in orange.
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Table 6.3.3: Profile of amino acids in the cerebrospinal fluid of patient Y. The sample
was analysed by high-performance liquid chromatography (HPLC) as part of
patients clinical care. Amino acid concentrations elevated above the reference
range are shown in orange and those below the reference range are shown in blue.
6.4 results and discussion
6.4.1 Whole exome and confirmatory Sanger sequencing
Whole exome sequencing was performed by Dr Olaf Bodamer, University of Miami, USA. The
data was analysed to look for variants that fitted an autosomal recessive pattern of inheritance in
the affected family. Twenty eight missense variants were identified, many of which were in genes
that encode proteins of unknown function or that have not yet been associated with disease.
MROH9, EGFLAM, AKNA, ADAMTS12, MYO1H, BLZF1 and AMOTL2 are protein-coding
genes whose physiological role is unknown. OR6A2 and OR1L6 encode olfactory receptors, in
which mutations have not been associated with disease. The protein encoded by PSMD9 forms
part of the 26S proteasome complex which functions to cleave peptides in an ATP/ubiquitin-
dependent pathway (Watanabe et al., 1998). NDUFA8 encodes a component of mitochondrial
respiratory chain complex I (Szklarczyk et al., 2011). KDM2B encodes a histone demethylase
and ITGA1 encodes the alpha 1 subunit of integrin receptors, forming a cell-surface receptor for
collagen and lamin (Andricovich et al., 2016; Lee et al., 2007). The protein encoded by ASTN2 is
expressed in the brain and is thought to function in neuronal migration based on mouse studies
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(Wilson et al., 2010). DAB2 encodes a clathrin adaptor protein and is key component in the
trafficking of the cystic fibrosis transmembrane conductance regulator (Fu et al., 2012). BARX1
encodes a transcription factor with many diverse functions including stomach smooth muscle
development and intestinal rotation (Jayewickreme and Shivdasani, 2015). TRPV2 encodes an
ion channel which acts as a mechanosensor, thermosensor and lipid sensor. These diverse function
enable roles in axon growth, thermosensation and gastrointestinal transit (Shibasaki, 2016).
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Table 6.4.1: Whole exome sequencing data was filtered to show autosomal recessive variants in patient Y. All variants were homozygous
in patient Y. Chr, chromosome; -, not present in database.
Chr Position Reference
Allele
Sample
Allele
Gene Protein Variant SIFT PolyPhen dbSNP ID NHLBI ESP
Frequency
ExAC
Frequency
1 169347686 G A BLZF1 p.Arg196Gln Tolerated Benign 1064274 2.10 0.85
1 170967395 G A MROH9 p.Val526Ile Deleterious Benign 151291051 - 0.02
3 134078284 G A AMOTL2 p.Arg649Cys Deleterious Probably damaging 140029062 0.10 0.12
5 33881252 G A ADAMTS12 p.Thr154Met Benign Probably damaging 117518215 3.30 2.19
5 38370532 G A EGFLAM p.Arg227His Tolerated Benign 199795131 1.10 0.62
5 39382748 T C DAB2 p.Lys417Arg Tolerated Benign - - -
5 52097489 A C ITGA1 p.Thr325Pro Deleterious Benign - - -
6 7583703 G A DSP p.Asp1471Asn Tolerated Possibly damaging 41302885 - -
7 158380295 C A PTPRN2 p.Ala23Ser Tolerated Benign - - 0.60
8 102631911 G A GRHL2 p.Val415Ile Benign Probably damaging 3779617 2.00 1.29
8 29053708 G T KIF13B p.Pro53Gln Deleterious Probably damaging 200573525 0.20 0.43
9 96715374 C A BARX1 p.Gly107Trp Tolerated Benign - - 0.29
9 117124785 G A AKNA p.Ala606Val Tolerated Benign 41278657 0.70 2.18
9 117849138 C T TNC p.Arg291His Tolerated Possibly damaging 141281085 0.12 0.0008
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9 119448979 C T ASTN2 p.Glu36Lys Tolerated Benign 10983304 1.20 -
9 124910416 C G NDUFA8 p.Arg119Pro Tolerated Possibly damaging - - 0.0008
9 125512943 C T OR1L6 p.Arg273Trp Deleterious Benign 117703463 0.90 1.43
9 126132826 G T CRB2 p.Trp498Cys Tolerated Possibly damaging 144803819 0.04 0.08
9 131598099 C T CCBL1 p.Val272Met Deleterious Probably damaging - - 0.003
11 6816792 T C OR6A2 p.Ile50Val Tolerated Benign 61741824 1.70 3.02
12 109839021 C T MYO1H p.Arg216Cys Deleterious Probably damaging 146988917 - 0.02
12 121416864 C T HNF1A p.Ala98Val Tolerated Benign 1800574 2.00 3.67
12 121880564 C T KDM2B p.Glu825Lys Tolerated Benign 201943632 0.01 -
12 122353798 A G PSMD9 p.Lys93Glu Deleterious Probably damaging - - -
16 53682949 C T RPGRIP1L p.Arg744Gln Deleterious Benign 2302677 6.20 4.63
17 16335357 A G TRPV2 p.Met578Val Deleterious Possibly damaging - - 0.29
17 16843729 G A TNFRSF13B p.Ala181Val Tolerated Benign 72553883 0.20 0.004
19 1469469 C - APC2 p.Ala2057Thr Tolerated Benign 189440287 4.80 2.47
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The remaining variants were identified in genes that have been associated with human disease,
but the respective disorders were not consistent with the phenotypic features seen in patient Y.
Mutations in GRHL2 cause sensorineural deafness autosomal dominant type 28 and ectodermal
dysplasia/short stature syndrome (Vona et al., 2013; Petrof et al., 2014). Mutations in TNC also
cause sensorineural deafness autosomal dominant type 56 (Zhao et al., 2013). A genome-wide
associated study identified an association at a locus corresponding to the KIF13B gene with
corticobasal degeneration. This disorder shares similarities with Parkinson’s disease with typical
onset between 50 - 70 years of age, movement and cognitive decline (Kouri et al., 2015). Mutations
in the DSP gene cause a spectrum of disorders presenting with cardiac and/or cutaneous disease
ranging from lethal epidermolysis bullosa to cardiomyopathy (Boyden et al., 2016). Mutations
in HNF1A cause maturity-onset diabetes of the young type 3 (Bellanné-Chantelot et al., 2008).
Similarly, antibodies generated against PTPRN2 have been identified in patients with type
I diabetes (Hoppu et al., 2006). Mutations in CRB2 cause two different diseases presenting
solely with renal abnormalities: focal segmental glomerulosclerosis 9 and ventriculomegaly with
cystic kidney disease (Lamont et al., 2016). Mutations in RPGRIP1L can also cause multiple
different disorders including COACH syndrome (cerebellar hypo/aplasia, mental retardation,
ataxia, ocular coloboma and hepatic fibrosis), Joubert syndrome 7 (molar tooth sign on brain
MRI, oculomotor apraxia, ptosis, nystagmus, cerebellar ataxia and nephronophthisis) and Meckel
syndrome 5 (anencephaly, occipital encephalocele, postaxial polydactyly, cleft lip and palate,
microphthalmia, severe cystic kidney disease and bowing of the long bones) (Delous et al., 2007).
Mutations in APC2 causes Sotos syndrome, a disorder characterised by a language disorder,
learning difficulties, hyperactivity and macrocephaly (Almuriekhi et al., 2015). Finally, mutations
in TNFRSF13B cause common variable immunodeficiency 2 and immunoglobulin A deficiency 2.
These disorders are characterised by recurrent infections, splenomegaly and an increased risk of
malignancies.
Of the variants identified, only one offered a potential explanation for the hyperlysinaemia
phenotype. This was a missense variant (c.814G>A; p.Val272Met) in the CCBL1 gene encoding
cysteine conjugate β-lyase. p.Val272Met is predicted to be deleterious and probably damaging
by SIFT and PolyPhen-2, respectively. Futhermore, the mutated Val272 residue is conserved
from humans to fruit flies (Figure 6.4.1). Segregation of this variant was confirmed by Sanger
sequencing (Figure 6.4.2).
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Figure 6.4.1: Multiple sequence alignment of the CCBL1 protein across species. (*)
positions with have a single fully conserved residue, (:) conservation between
amino acids with strongly similar properties, (.) conservation between amino
acids with weakly similar properties. The alignment was generated using Clustal
Omega.
Figure 6.4.2: Segregation of the p.Val272Met mutation in the CCBL1 gene in the
family of patient Y.
Following the identification of this variant, sequencing of the CCBL1 gene was carried out
for an unrelated patient presenting with similar phenotypic features including hyperlysinaemia,
seizures and spastic parparesis. His detailed case history is described in (Yiannikas and Cordato,
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1996). No potentially pathogenic variants were identified in any of the 14 exons of the CCBL1
gene.
6.4.2 Rationale underlying CCBL1 as a potential candidate
CCBL1, alongside the three other enzymes known to exhibit kynurenine aminotransferase activity
and which may also have lysine aminotransferase activity, are candidates for the enzyme which
catalyses the first step in the pipecolate pathway of lysine metabolism in the brain. It has
been known for nearly 40 years that the injection of L-lysine into the brain of rats results
in the production of labelled L-pipecolate (Chang, 1978). L-lysine is first oxidised to form
α-keto--aminocaproate which cyclises to form ∆1-piperideine-2-carboxylate (P2C); the enzyme
responsible for this catalysis is unknown (Figure 6.1.1). In vivo, P2C is rapidly reduced to form
L-pipecolate by ketimine reductases.
The removal of the α-amino group of L-lysine to form α-keto--aminocaproate is likely to be
catalysed by either an L-amino acid oxidase or an aminotransferase. Many L-amino acid oxidases
have been examined for their ability to deaminate L-lysine. However, in vitro experiments
have shown L-lysine to be either a poor or completely ineffective substrate of these enzymes
(Murthy and Janardanasarma, 1999; Mason et al., 2004; Wiemann et al., 2005; Urban et al.,
1988). Despite aminotransferases tranditionally not being thought to act upon L-lysine, when
isotope-labelled glutamate is incubated with brain slices from mice the isotope was detected within
the α-amino group of L-lysine, suggesting this is not the case (Papes et al., 2001). The likely
explanation for this finding is that L-lysine and α-keto--aminocaproate can undergo reversible
transamination using glutamate as a carrier of the amine group and being made possible by the
high concentrations of glutamate within the brain. One family of enzymes which are known to
exhibit broad substrate and α-keto acid specificities are the kynurenine aminotransferases. Given
their catalysis of many reactions, they are known by multiple synonyms (Table 6.4.2).
The kynurenine aminotransferases are already of interest to neurologists given their ability to
catalyse the transamination of kynurenine to form kynurenic acid. Kynurenic acid is not only the
sole known endogenous antagonist of the N-methyl-D-aspartate subclass of glutamate receptors,
but also is an antagonist of the α7-nicotinic acetylcholine receptor (Han et al., 2009a). Indeed,
abnormal concentrations of kynurenic acid have been documented in many neurodegenerative
disorders including Alzheimer’s disease, Huntington’s disease, schizophrenia and dementia (Beal
et al., 1990; Widner et al., 2000; Erhardt et al., 2007; Guillemin et al., 2005). In addition, the
β-lyase activity of CCBL1 can mediate the toxicity of sulphur-containing fragments released from
halogenated alkene-derived cysteine S-conjugates. Indeed, the cysteine S-conjugate of dopamine
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Table 6.4.2: Synonyms of members of the kynurenine aminotransferase enzyme
family. The name by which they are referred to in this chapter is highlighted in
bold.
Gene Enzyme names
CCBL1 Cysteine conjugate β-lyase isozyme 1 (CCBL1)
Glutamine transaminase K (GTK)
Kynurenine aminotransferase I (KAT I)
CCBL2 Cysteine conjugate β-lyase isozyme 2 (CCBL2)
Glutamine transaminase L (GTL)
Kynurenine aminotransferase III (KAT III)
AADAT α-aminoadipate aminotransferase (AADT)
Kynurenine aminotransferase II (KAT II)
GOT2 Mitochondrial aspartate aminotransferase (AspAT)
Glutamic-oxaloacetic transaminase 2
Kynurenine aminotransferase IV (KAT IV)
has been demonstrated to be a substrate of CCBL1, which may play an important role in the
pathogenesis of Parkinson’s disease (Cooper et al., 2008).
In vitro experiments have been carried out to investigate the ability of recombinant human
kynurenine aminotransferases to catalyse the transamination of L-lysine (Han et al., 2009a;
Hallen et al., 2013). In alkaline conditions (pH 9.2) L-lysine was found to be 5% as effective
as L-glutamine (one of the substrates exhibiting the highest activity) as a substrate of CCBL2.
The activity of CCBL1 under the same conditions was not measured. However, under more
physiological conditions (pH 7.4) the activity of CCBL1 and CCBL2 with respect to L-lysine
is less than 1%. The higher activity at more alkaline pH’s may be explained by a mechanism
similar to that observed in the pathogenesis of pyridoxine-dependent epilepsy (Section 4.2.1) and
hyperprolinaemia type II. In these disorders, P6C or P5C complex with pyridoxal 5’-phosphate
(PLP) through a Knoevenagel condensation thereby inactivating PLP-dependent enzymes. An
analogous inactivation would be expected to occur upon the production of P2C, resulting in
product inhibition of the PLP-dependent aminotransferase. Imines such as P2C, P5C and P6C
exist in equilibrium with their enamine tautomers (Lu and Lewin, 1998). At higher pH’s the
equilibrium shifts to favour the enamine structure which is less reactive with PLP as it is less
nucleophilic. In summary, it is possible that α-keto--aminocaproate in the brain is produced by
the action of a kynurenine aminotransferase. Although both CCBL1 and CCBL2 are present in the
mammalian brain (Han et al., 2009a), it remains unclear whether these enzymes can catalyse the
transamination of L-lysine at physiologically relevant pH values. However, the identification of a
homozygous variant in CCBL1 in patient Y, whose phenotype included persistent hyperlysinaemia
as a prominent feature, indicates that CCBL1 may function to catalyse this enzymatic reaction.
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6.4.3 Molecular cloning of CCBL1
In order to determine whether or not the identified variants in CCBL1 were pathogenic in patient
Y, functional studies to examine the effect on enzymatic activity were required. Patient fibroblasts
were available; however, these cells metabolise L-lysine via the saccharopine pathway (Struys and
Jakobs, 2010), therefore examining the ability of endogenous CCBL1 to catalyse the conversion
of L-lysine to α-keto--aminocaproate/P2C in patient cells was not possible. An additional factor
complicating the characterisation of CCBL1 in vivo is the fact that there are at least four distinct
enzymes which can catalyse transamination of kynurenine (Table 6.4.2). Although CCBL1 is
ubiquitously expressed (Figure 6.4.3), the other kynurenine aminotransferases are also highly
expressed in the skin making the contributions of each enzyme activity difficult to discriminate.
Therefore in order to determine whether the p.Val272Met variant has any functional impact on
the CCBL1 protein, the cDNA sequence of CCBL1 was cloned in order to overexpress the protein.
Firstly, the cDNA clone corresponding to the NM_004059 transcript in the pME18SFL3 vector
(Section 2.16.1) was transformed into XL-1 Blue cells (Section 2.16.3.1) and sequenced to confirm
the sequence was that of the wild-type gene (Section 2.16.6). NdeI restriction enzyme sites were
then engineered at the 5’ and 3’ ends of the transcript using PCR without disrupting the open
reading frame (Section 2.16.7). The resultant amplification products were sub-cloned into the
TOPO 2.1 vector (Section 2.16.8), transformed into One Shot TOP10 Chemically Competent E.
coli (Section 2.16.3.2) and correct insertion was validated by restriction enzyme digestion with
EcoRI. Digestion with EcoRI would be expected to result in the excision of the CCBL1 cDNA
fragment (1281 bp) from the TOPO 2.1 vector (3956 bp). Indeed all, with the exception of clone
17, revealed that the correct cDNA fragment had been inserted (Figure 6.4.4a).
Subsequently, site-directed mutagenesis was used to introduce the c.814G>A variant into
the wild-type CCBL1 cDNA sequence cloned into the TOPO 2.1 vector and the resultant
site-direct mutagenesis product was transformed into TOP10 cells (Section 2.16.9). Sanger
sequencing confirmed the presence of the desired mutation (Figure 6.4.4b). Prior to cloning into
the multiple cloning site of the pT7CFE1-CHis vector, which is suggested for use for optimal
protein expression with the HeLa cell lysate-based 1-step human in vitro protein translation
(IVT) kit, wild-type and mutant CCBL1 cDNA in the TOPO 2.1 vector were digested with NdeI
to facilitate cloning (Section 2.16.8). The empty pT7CFE1-CHis vector was also digested using
NdeI and dephosphorylated to prevent re-ligation (Section 2.16.10). The products were run on
an agarose gel, the linear pT7CFE1-CHis vector and the gel fragments containing the CCBL1
cDNA inserts were excised and the DNA was extracted from the gel (Section 2.16.11 and Figure
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Figure 6.4.3: Profile of protein and RNA expression of CCBL1 in human tissues.
Data was extracted from the Human Protein Atlas (www.proteinatlas.org). The
size of each coloured bar indicates the degree of expression in the respective tissue.
FPKM; Fragments Per Kilobase of transcript per Million mapped reads.
6.4.4c). The purified DNA was analysed on an agarose gel and the concentration was quantified
prior to ligation into pT7CFE1-CHis and transformation into XL-1 Blue cells (Section 2.16.12).
The direction in which the CCBL1 cDNA had been inserted into the vector was then analysed
by restriction enzyme digestion with ApaI (Section 2.16.8). The CCBL1 cDNA insert sequencing
contains one ApaI restriction enzyme site 309 bp from the cDNA start codon. The pT7CFE1
vector also contains one ApaI restriction enzyme site 76 bp from the T7 promoter region.
Therefore, if the cDNA sequence was cloned in the forward direction, a 779 bp fragment (309
bp [ApaI site in CCBL1 insert from cDNA start codon] + 546 bp [NdeI site where cDNA
sequence has been inserted from the T7 promoter] - 76 bp [Apa I site in pT7CFE1 vector from
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Figure 6.4.4: Molecular cloning of the CCBL1 cDNA. (a) Digestion of TOPO 2.1 clones
with EcoRI to check for the presence of the CCBL1 cDNA insert. (b) Sanger
sequencing confirming the introduction of the c.814G>A mutation by site-directed
mutagenesis in all three mutated clones. WT, wild-type. (c) Analysis of the
pT7CFE1-CHis vector and the TOPO 2.1 plasmids containing the CCBL1 inserts
digested using NdeI (left). The linear pT7CFE1-CHis and both the wild-type
and mutated CCBL1 cDNA fragments were excised from the agarose gel (right).
T7 promoter]) would be identified upon digestion with ApaI. This analysis revealed one plasmid
containing the wild-type and five plasmids containing the mutant cDNA sequence cloned in
the forward orientation (Figure 6.4.5). Each insert of clones 5 (wild-type) and 7, 8, 9, 11 and
14 (mutant) were determined to be in-frame with the initiator methionine residue by Sanger
sequencing and these were used for subsequent studies.
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Figure 6.4.5: Validating the orientation of the CCBL1 cDNA insert within the
pT7CFE1-CHis vector. Schematics illustrating the restriction enzyme sites
and the predicted sizes of the DNA fragments that would result for the (a) correct
and (b) incorrect orientation. (c) Agarose gel electrophoresis showing the results
of restriction enzyme digestion of each clone with ApaI. Clone 5 (wild-type) and
7, 8, 9, 11 and 14 (mutant) revealed a fragment of 779 bp indicating the correct
orientation of the insert.
6.4.4 In vitro protein translation and analysis of the products
Prior to the expression of protein for enzyme activity quantitation, the relationship between the
amount of CCBL1 protein produced and incubation time of the IVT reaction was investigated
using label-free mass spectrometry (Section 2.17). This technique is an untargeted approach which
can be used to identify and quantify proteins within a biological sample. This analysis showed
that a five hour incubation resulted in maximal translation of the CCBL1 protein, producing a
total of 21.2 ng/µl of CCBL1 protein (Figure 6.4.6). Thereafter, all experiments were performed
using this parameter. Reactions incubated with only the empty pT7CFE1-CHis vector did not
identify any CCBL1 protein, indicating it is not a component of the accessory proteins or HeLa
cell lysate that is used during the IVT reaction. Moreover comparison of the reaction containing
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the vector with the mutant sequence with that of the vector containing wild-type protein, did
not show any reduction in the concentration of CCBL1 produced, suggesting that p.Val272Met
does not result in mRNA decay.
Figure 6.4.6: Effect of incubation time on the amount of CCBL1 produced by the
in vitro translation system. WT, pT7CFE1-CHis vector containing the wild-
type CCBL1 sequence; MUT, pT7CFE1-CHis vector containing the mutant
(p.Val272Met) CCBL1 sequence; pT7CFE1, empty pT7CFE1-CHis vector not
containing any inserted sequence.
Concurrently to the quantitation of CCBL1, 898 proteins were identified within the IVT
reaction mix (Appendix 9.5). Analysis of this list of proteins using the WEB-based Gene Set
Analysis Toolkit (WebGestalt), revealed Gene Ontology terms that were over-represented when
compared to the reference genome (i.e. if <1% of the proteins encoded by the human genome
play a role in RNA binding, but 10% of the proteins identified in our sample were associated with
this process, then the corresponding Gene Ontology term would be considered over-represented)
(Zhang et al., 2005) (Table 6.4.3). Unsurprisingly, these included genes involved in the initiation,
elongation and termination of protein translation, mRNA generation and the binding of proteins,
RNA, small molecules, nucleosides, nucleoside phosphates and nucleotides. Importantly, none
of the other kynurenine aminotransferases nor enzymes catalysing steps of the saccharopine or
pipecolate pathways of L-lysine metabolism were present within the IVT reaction mix.
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Table 6.4.3: Pathway analysis of in vitro reaction mix. Solutions were analysed by label-
free mass spectrometry and showthe number of identified proteins corresponding
to each Gene Ontology term.
Gene Ontology terms Number of proteins
identified
Biological process and molecular function
Establishment of protein localisation to endoplasmic reticulum 46
Cellular macromolecule (catabolic process) 109
mRNA (metabolic process) 116
mRNA (catabolic process) 59
Nuclear-transcribed mRNA (catabolic process) 57
Nonsense-mediated decay 52
Translational initiation 66
Translational elongation 52
Translational termination 45
Small molecule binding 205
Protein binding 389
Organic cyclic compound binding 315
Heterocyclic compound binding 314
Nucleoside binding 156
Nucleoside phosphate binding 196
RNA binding 114
Nucleotide binding 195
Purine nucleoside triphosphate binding 153
Structural constituent of ribosome 45
Cellular component
Macromolecular complex 284
Intracellular 542
Cytoplasmic 495
Non-membrane-bounded organelle 272
6.4.5 Quantitation of kynurenine aminotransferase activity
Prior to examining whether or not CCBL1 can catalyse the first enzymatic step in the pipecolate
pathway of lysine metabolism, the kynurenine aminotransferase activity of both the wild-type
and mutant CCBL1 was determined in order to determine whether synthesis using the IVT kit
produced active enzymes (Section 2.18). The UPLC-MS/MS method used was adapted from that
of Han et al. (2004) which uses high-performance liquid chromatography coupled to an ultraviolet
detector (HPLC-UV). A summary of the differences between the two methods can be found in
Table 6.4.4.
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Table 6.4.4: Comparison of the method published by Han et al. (2004) and our
UPLC-MS/MS method used for the investigation of the kynurenine
aminotransferase activity of CCBL1.
Han et al. (2004) UPLC-MS/MS Reason for change
Reaction volume 50 µL 50 µL -
Kynurenine
concentration
5 mM 5 µM Greater sensitivity of
UPLC-MS/MS
α-keto acid
substrate
α-ketobutyrate Oxaloacetate
α-keto acid
concentration
2 mM 2 µM Greater sensitivity of
UPLC-MS/MS
PLP concentration 40 µM 40 nM Greater sensitivity of
UPLC-MS/MS
Potassium
phosphate buffer
(pH 7.5)
concentration
200 mM 200 mM -
Enzyme 2 µg recombinant
human CCBL1
2.5 µL IVT reaction
mix containing
approximately 50 ng
CCBL1 protein
Purpose of assay.
Reaction
incubation
10 mins at 45◦C 2 hours at 37◦C Ability to measure activity
over extended time-course
to detect subtle differences
between enzymes. More
physiological conditions.
Reaction
termination
0.8 M formic acid 0.3 N TCA Established for many
assays within the
laboratory including the B6
vitamer analysis.
Analysis method HPLC-UV UPLC-MS/MS Greater sensitivity of
UPLC-MS/MS
CCBL1 proteins containing both the wild-type and mutant sequences were expressed and the
ability of each enzyme to catalyse the conversion of kynurenine (KN) to kynurenic acid (KA)
was assayed. Both wild-type and mutant CCBL1 enzymes were active and had similar activities,
with the rate of KA production being 190.2 and 212.5 pmol/hr/µg protein for the wild-type and
mutant protein, respectively (Figure 6.4.7). No conversion of KN to KA was evident when the
reaction mix was incubated with only the pT7CFE1 vector containing no CCBL1 cDNA insert,
indicating that the translated CCBL1 protein was responsible for catalysis.
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Figure 6.4.7: Assay of kynurenine aminotransferase activity of CCBL1 expressed
using the in vitro translation system.
6.4.6 Quantitation of kynurenine and kynurenic acid in patient urine
Endogenous KN and KA was also quantified in urine using this UPLC-MS/MS method (Section
2.19). The concentrations of KN and KA in the urine of patient Y were within the range of the
six paediatric control samples analysed (Figure 6.4.8). Indeed, the urinary ranges and degree of
variability of both KN and KA concentrations were comparable to those that have been reported
using alternative methodologies (Zhao et al., 2011; Marcos et al., 2016).
Figure 6.4.8: Quantitation of endogenous kynurenine and kynurenic acid in urine.
(a) Kynurenine and (b) kynurenic acid concentrations in the urine of patient Y
and controls (n = 6). Two aliquots of patient urine was prepared and each sample
was analysed in triplicate (three injections into the UPLC-MS/MS). Error bars
represent ± standard deviation.
However, an additional peak in the KA chromatogram that had a different retention time
to KA was identified in urine which was found to be present in larger amounts in the patients’
sample (Figure 6.4.9).
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Figure 6.4.9: Quantitation of additional peak in kynurenic acid channel in urine. (a)
Chromatogram illustrating the additional peak observed in the kynurenic acid
channel (190.20 > 144.00) in patient urine. (b) Quantitation of the additional
peak in control (n = 6) and patient urine. Two aliquots of patient urine was
prepared and each sample was analysed in triplicate (three injections into the
UPLC-MS/MS). Error bars represent ± standard deviation.
Molecules can exist as structural isomers (which share the same molecular formula but differ
in their arrangement) and sterioisomers (which have the same molecular formula and sequence of
bonded atoms but differ in the three-dimensional orientation of the atoms in space). However,
given that the second peak eluted 0.84 minutes prior to that of kynurenic acid, it is more likely
that this peak represents an isobaric species (an unrelated compound with the same m/z ratio)
rather than an isomer of KA (Figure 6.4.10a).
The Human Metabolome Database (HMDB) is a freely available resource containing experi-
mental MS/MS data for over 800 compounds (Wishart et al., 2007). Searching this extensive
database for molecules that share the 190.20 > 144.00 transition, corresponding to the loss of
a carboxylic acid group, identified homocitrulline, N-acetylglutamic acid and 3-indolepropionic
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acid as potential candidates. The structure and chemical properties of each molecule can give an
indication of their retention time. In the case of reverse phase HPLC, generally the retention time
of a compound increases with decreasing water solubility and increasing numbers of carbon atoms
(Hanai and of Chemistry , Great Britain). In addition, neutral and charged species typically show
the least retention, followed by acidic and basic molecules (Law, 1990). These parameters for each
candidate are shown in Table 6.4.5 (Wishart et al., 2007). Given that KA and 3-indolepropionic
acid share a similar bicyclic structure, water solubility, carbon content and pKa value, it is likely
that their retention times would be similar. Conversely, homocitrulline and N-acetylglutamic
acid have approximately 10- and 20-fold higher solubility in water than KA, respectively. This
factor alone is likely to result in these compounds being less retained on the column and being
plausible candidates for the identity of the isobaric species.
Table 6.4.5: Chemical characteristics of the possible compounds sharing the 190.20
> 144.00 transition. All parameters were extracted from the Human
Metabolome Database.
Compound Water solubility
(mg/mL)
Number of
carbon atoms
Physiological
charge
pKa (strongest
acid)
Kynurenic acid 0.95 10 -1 3.17
3-indolepropionic acid 0.73 11 -1 4.8
N-acetylglutamic acid 18.6 7 -2 3.43
Homocitrulline 12.1 7 0 2.35
N-acetylgluatamic acid is synthesised from glutamate and acetyl-CoA by N-acetylglutamate
synthase. In humans it is an essential allosteric cofactor for carbamoyl phosphate synthetase I,
the first enzyme of the urea cycle (Caldovic and Tuchman, 2003). Indeed, N-acetylglutamic is
typically undetectable in plasma and urine of healthy subjects regardless of age (Tavazzi et al.,
2005). In contrast, homocitrulline is readily quantified in urine with control ranges being between
0 - 10 µmol/mmol creatinine (Al-Dirbashi et al., 2006; Korman et al., 2004) and is elevated in
patients with urea cycle disorders. Homocitrulline is an amino acid which is formed through the
carbamoylation of lysine. This can occur spontaneously through a reaction with cyanate, which
exists in equilibrium with urea in the human body (Figure 6.4.10b). Alternatively, it can be
synthesised enzymatically by lysine carbamoyltransferase catalysing the reaction of lysine with
carbamoyl phosphate (Figure 6.4.10c). Therefore, the synthesis of homocitrulline is enhanced
when either lysine or carbamoyl phosphate is accumulated. Examples of this phenomenon are
observed in hyperlysinaemia type I (Heiden et al., 1978) and type II (Carson et al., 1968),
lysinuric protein intolerance (Habib et al., 2013) and hyperornithinaemia, hyperammonaemia and
homocitrullinuria (HHH) syndrome (Martinelli et al., 2015). Patient Y did not have any symptoms
of a urea cycle disorder including hyperammonaemia, episodes of metabolic decompensation or
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protein intolerance. Therefore, it is possible that the hyperlysinaemia present in our patient may
result in increased production and urinary excretion of homocitrulline which is observed as an
isobaric species in the KA MS/MS channel.
Homocitrulline has recently been made available as a standard from Santa Cruz Biotechnology.
In the future, this compound should be purchased and injected into the UPLC-MS/MS using the
same chromatography conditions as described in Section 2.18 to determine its retention time.
It is also worth noting that the urine sample from patient Y had been stored at -20◦C for five
years following the patient’s death. Therefore, it is possible that the unknown compound may
be present as a consequence of sample degradation and this should be considered in any further
experiments.
Figure 6.4.10: Synthesis of homocitrulline. L-homocitrulline is generated through the
carbamylation of L-lysine. This can occur (b) through the reaction with
cyanate (which is equilibrium with urea under physiological conditions) or (c)
reaction with carbamoyl phosphate.
6.4.7 Attempts to measure activity of CCBL1 towards lysine
In order to assess the activity of the CCBL1 enzyme towards lysine, spectrophotometric method-
ologies were evaluated. Both o-aminobenzaldehyde (o-AB) (Namwat et al., 2002) and ninhydrin
(Kim et al., 1994) are known to react with tertiary amines such as ∆1-piperideine-2-carboxylate
(P2C) to produce a coloured product. A positive control, i.e. a urine sample from a patient
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with pyridoxine-dependent epilepsy where α-AASA and its equilibrium partner ∆1-piperideine-6-
carboxylate (P6C) accumulates, was used as P6C shares a similar structure to P2C. Both are
tertiary amines and simply differ in the position of the double bond within the piperideine ring.
Although methods were not available to determine the concentration of P6C in this urine sample,
the concentration of α-AASA was quantified as part of the routine diagnostic service as 286.8
µmol/mmol creatinine (ref: < 4) (Yi Yang, ICH, UK). Five age-matched paediatric controls were
also analysed. Both methods demonstrated an increased absorbance in the AASA-positive urine
upon correction for urinary creatinine concentration, although derivatisation with o-AB gave
greater discrimination between samples (Figure 6.4.11).
Figure 6.4.11: Colourmetric reactions of AASA-positive urine to detect tertiary
amines. Absorbance of urine when reacted with o-aminobenzaldehyde (a) and
corrected for creatinine concentration (b). Absorbance of urine when reacted
with ninhydrin (c) and corrected for creatinine concentration (d). Aliquots
of the same urine samples were used for both derivitisation reactions. PDE,
pyridoxine-dependent epilepsy.
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Accordingly, the same derivatisation method using o-AB was then used to assess the conversion
of lysine to P2C by wild-type and mutant CCBL1. Four different α-keto acids, 2-oxobutyrate,
2-oxoglutarate, pyruvate and oxaloacetate were tested as the amine group acceptor. However, no
significant production of a molecule causing a colourmetric reaction was observed using any of
the assay conditions.
It was possible that no enzymatic activity was identified because the colourmetric assay did
not have adequate sensitivity to detect the low concentrations of P2C being produced. Therefore,
mass spectrometry-based assays were investigated. Neither α-keto--aminocaproate (KAC),
the product of the proposed reaction, nor its equilibrium partner ∆1-piperideine-2-carboxylate
(P2C) are commercially available for infusion and therefore determination of mass spectrometry
parameters required for analysis, thus attempts were made to synthesise them enzymatically.
Two publications report methods for the reaction of D-alanine and D-proline with D-amino acid
oxidase (Konno, 1998; Visser et al., 2012). These were adapted accordingly (Table 6.4.6). Each
solution was desalted prior to direct infusion into the mass spectrometer (Section 2.21).
Table 6.4.6: Differences between published and novel methods for the reaction of
D-amino acids with DAAO. Methods published by Konno (1998) and Visser
et al. (2012) for the reaction of D-amino acids with D-amino acid oxidase and
the adaptations made to these assays for the oxidation of D-lysine prior to direct
infusion into the mass spectrometer. -, identical to original method; *, FAD was
added to half of the reactions during the optimisation process; DAAO, D-amino
acid oxidase.
Konno (1998) Method for
MS/MS
infusion
Visser et al. (2012) Method for
MS/MS
infusion
Buffer 40 mM
pyrophosphate (pH
8.3)
- 25 mM ammonium
bicarbonate (pH 8.3)
-
Catalase 700 IU - 900 IU -
D-amino acid D-alanine D-lysine D-proline D-lysine
D-amino acid
concentration
30 mM - 1 mM -
Flavin adenine
dinucleotide
20 mM - None 20 mM*
70% methanol 100 µL (final 7%
(v/v))
- None -
DAAO 0.1 mL homogenised
tissue supernatant
containing DAAO
10 units in 100
µL dH2O
0.25 mg -
Reaction
incubation
1 hour at 37◦C 2 hours at
37◦C
1 hour at 37◦C 2 hours at
37◦C
Total reaction
volume
1 mL 1 mL 100 µL 100 µL
Reaction
termination
1 mL 10% TCA 1 mL 0.3 N
TCA
700 µL ice cold
acetonitrile
100 µL 0.3 N
TCA
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The mixtures were analysed in both positive and negative mode using a scan window between
50 - 800 m/z. L-lysine was commercially available and this compound was directly infused
to generate transitions (Figure 6.4.12a). Using the method adapted from Konno (1998), no
peak with an m/z corresponding to either KAC or P2C was seen. Derivatisation of the assay
mixture with fluorenylmethyloxycarbonyl chloride (FMOC-Cl) was then performed to increase
the sensitivity of analytes containing a primary or secondary amine group. Nevertheless, only an
ion corresponding to the derivatised lysine was observed (m/z 369.18) (Figure 6.4.12b). Using
the method adapted from Visser et al. (2012), an ion with a m/z of 128.10 which was a possible
match for P2C was identified (Figure 6.4.12c).
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Figure 6.4.12: D-amino acid oxidase reaction products. MS scan spectra illustrating the peaks resulting from the reaction of D-amino acid oxidase with
D-lysine. Highlighted in orange are the m/z ratios corresponding to (a) D/L-lysine, (b) FMOC-lysine and (c) P2C (potentially).
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This was subsequently tuned and the four transitions obtained are as detailed in Table 6.4.7.
The chromatography and peak shape generated by each transition were evaluated using a range
of mobile phases (with varying concentrations) including: dH2O, formic acid, ammonium acetate,
acetic acid, acetonitrile (with and without formic acid), methanol (with and without formic
acid). A combination of 3.7% acetic acid and 100% acetonitrile was found to give a good and
reproducible peak shape (Figure 6.4.13). The two transitions for each compound generating the
highest sensitivity under these UPLC-MS/MS conditions were selected (Figure 6.4.13). The final
assay parameters can be found in (Section 2.21).
Table 6.4.7: Transitions identified to detect lysine and ∆1-piperideine-2-carboxylate
(P2C).*, predicted compound.
Analyte Parent ion
(m/z)
Daughter ion
(m/z)
Cone
voltage (V)
Collision
voltage (V)
Retention
time (mins)
Lysine 147.10 41.91 28 22 0.58
Lysine 147.10 56.08 28 24 0.58
Lysine 147.10 67.06 28 20 0.58
Lysine 147.10 74.02 28 20 0.58
Lysine 147.10 84.09 28 14 0.58
P2C* 128.10 55.04 40 20 0.54
P2C* 128.10 82.08 40 14 0.54
P2C* 128.10 86.96 40 6 0.54
P2C* 128.10 100.08 40 14 0.54
Investigation of the possible conversion of L-lysine to KAC/P2C was carried out under varying
conditions. Firstly, an enzyme assay identical to that performed for the assessment of CCBL1
activity towards kynurenine was carried out using lysine as a substrate (Section 2.18). Secondly,
an enzyme assay based on the method described in Hallen et al. (2013) which suggested the use
of an alternative buffer was performed (Section 2.21). No reduction in lysine concentration nor
increase in that of the possible P2C transition was observed within a three hour time-course
when using either method.
There are two possibilities as to why we found no evidence to suggest that CCBL1 catalyses
the first step of the pipecolate pathway of L-lysine metabolism: either CCBL1 does not catalyse
this reaction or the conditions used in our experiments didn’t facilitate this activity. Future
experiments to further investigate the potential role of CCBL1 in lysine metabolism should
consider the following issues:
• The concentration of CCBL1 protein synthesised using the in vitro translation (IVT) system
(approximately 20 ng/µL) may not have been sufficient to produce enough P2C for detection
using the spectrophotometric or mass spectrometry-based assays. A high-yield IVT kit
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Figure 6.4.13: Chromatograms illustrating the transitions identified through the
enzymatic conversion of D-lysine by D-amino acid oxidase. The two
transitions for each analyte with superior peak shape and signal intensity are
shown. textbf(a) Lysine and (b) theoretical ∆1-piperideine-2-carboxylate (P2C).
which can produce up to 100 times more overexpressed protein than the system used in
this chapter is commercially available. Therefore, this kit may be used to produce higher
concentrations of CCBL1 for further experiments.
• Although D-amino acid oxidase (DAAO) has been shown to catalyse the oxidative deami-
nation of D-lysine to form KAC/P2C, this reaction proceeds extremely slowly as a result of
product inhibition (Yagi et al., 1969). Oxidised DAAO forms a charge-transfer complex
with the enamine form of P2C; this involves an association of the two molecules in which
a fraction of electronic charge is transferred between them (Nishina et al., 1991). The
reactions described in this chapter were performed at pH 8.3 as these conditions have
been repeatedly published for the reaction of other D-amino acids with DAAO. However,
lowering the pH at which the reaction is carried out may reduce the product inhibition of
DAAO as the imine form of P2C would be expected to predominate (Nishina et al., 1991).
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Therefore, solutions with wider ranges of buffering capacity should be assessed in order to
maximise the chances of detecting KAC or P2C.
• Previous studies examining the ability of members of the kynurenine aminotransferase
enzyme family to catalyse the transamination of L-lysine have demonstrated an increased
catalytic ability in strongly alkaline conditions (Han et al., 2009a; Hallen et al., 2013). Thus,
enzyme activity may be more readily observed at higher pH’s. However, these conditions
would not be representative of those present physiologically in vivo.
• Namwat et al. (2002) performed functional characterisation of the VisA gene in Streptomyces
virginiae, encoding an enzyme which catalyses the conversion of L-lysine to KAC/P2C.
Enzyme activity was optimal at 35◦C and between pH 7.5 - 8.5. Multiple different α-keto
acid amino acceptors were investigated and revealed that at a concentration of 100 nM
2-oxobutyrate resulted in the highest activity, whereas at 10 nM 2-oxohexanoate and
2-oxovalerate were optimal. Although for the majority of α-keto acids tested, using higher
concentrations resulted in enhanced enzyme activity, this was not always the case. This
may be explained by the fact that some α-keto acids can have inhibitory effects at high
concentrations (Bruntner and Bormann, 1998). If CCBL1 similarly catalyses this reaction
in humans, activity would likely be highly dependent on the α-keto acid substrate. During
initial experiments, 100 nM of 2-oxobutyrate, 2-oxoglutarate, pyruvate and oxaloacetate
were tested as α-keto substrates for CCBL1. Thus, production of KAC/P2C may not
have been observed because either the substrates were not efficient amine acceptors or the
concentrations used were inhibiting CCBL1 activity. Further experiments using lower (10
nM) concentrations of a wide range of substrates including 2-oxohexanoate and 2-oxovalerate
should be performed.
• There is experimental evidence for the existence of three CCBL1 mRNA transcripts encoding
proteins of differing lengths (Figure 6.4.14). The first to be identified was CCBL1_001, which
encodes a polypeptide of 422 amino acids (Perry et al., 1995). The second, CCBL1_002,
lacks the third coding exon resulting in a smaller 372 amino acid isoform (Gerhard et al.,
2004). Finally, CCBL1_201 uses an alternate upstream translation start codon, resulting
in an additional 94 N-terminal amino acids compared to CCBL1_001. Although the latter
has been deposited in both the National Center for Biotechnology Information (NCBI)
and Ensembl genome databases the sequence was identified as part of a large-scale cDNA
sequencing project for which neither the full study methodology nor results are publicly
available. Therefore further confirmation of its existence in vivo is required (Han et al.,
2010). In silico prediction suggests that the additional N-terminal region may contain a
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putative mitochondrial targeting sequence (Claros and Vincens, 1996). The CCBL1_001
transcript was used in the studies described in this chapter due to its established expression
and activity in human tissues. Although the Val272 residue which is mutated in patient Y
does not lie within this N-terminal region of CCBL1_201, it is possible that this residue
may interact with others in this region to confer a different biological role to CCBL1_001
in vivo. Indeed, the additional N-terminal amino acids may result an altered tertiary
protein structure which in turn may confer different catalytic capabilities, including activity
towards L-lysine. Further studies should be performed to investigate the potentially different
physiological roles of this protein transcript.
Figure 6.4.14: Sequence alignment of the three human CCBL1 transcripts. Green,
additional N-terminal 94-amino acid sequence in CCBL1_201; orange, sequence
of 50 amino acids which is absent in the CCBL1_002 transcript.
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6.5 summary
In this chapter we have described a patient affected by severe spastic paraparesis, speech difficulties
and persistent hyperlysinaemia. Disease was progressive with severe cachexia resulting in her
death at 23 years of age. After extensive genetic and biochemical investigations, combined
homozygosity mapping and whole exome sequencing identified a homozygous missense variant
in the CCBL1 gene. This was deemed to be a plausible candidate for pathogenesis in this
family given the known role of this enzyme in the homeostasis of kynurenic acid in the brain and
postulated function in lysine metabolism.
We have established a LC-MS/MS method for the quantitation of kynurenine and kynurenic
acid, which may also be used for the assessment of kynurenine aminotransferase activity in
patients with other neurological disorders. Although it has been determined that the p.Val272Met
variant identified in our patient does not adversely affect kynurenine aminotransferase activity,
the possibility of CCBL1 having a role in L-lysine metabolism has not been ruled out. Indeed,
further experimentation as described above may provide more insights into the validity of this
hypothesis. Furthermore, the structure of recombinant CCBL1 has already been solved by X-ray
crystallography (Han et al., 2009b). Expert analysis of these models using in silico tools to
predict the localisation and conformation of any solvent pockets or cavities that could bind
L-lysine may also provide supplementary supportive or contradictory evidence.
Finally, the possibility remains that the variants in CCBL1 are not pathogenic in this family.
Disease may be caused by copy number variants or mutations in intronic or regulatory regions
that were not detectable by whole exome sequencing. If more detailed and rigorous scrutiny of
the genetic data obtained to-date did not reveal any alternative candidate mutations, a whole
genome sequencing approach may be beneficial in this case. Another possibility is that this
family is affected by two recessive disorders. Recent studies have suggested that 4.6% of patients
have a blended phenotype (Yang et al., 2014); however in cohorts comprising a high degree of
consanguinity such as that analysed using our gene panel, this proportion was much higher at
9.1%. The patient described in this chapter had a brother who, although also had difficulties with
walking and speech, did not have spastic paraparesis or any amino acid abnormalities. Three
cousins were also described to have an inability to walk and speech problems, although they
resided in India and more detailed clinical information was not available. Therefore, it is possible
that two recessive disorders are present in this family and the hyperlysinaemia identified in the
proband may be caused by a secondary genetic defect. Indeed, this metabolic abnormality may
not be contributing to pathogenicity nor be a result of the defect underlying the motor and
speech difficulties in this family. In order to examine this possibility further, the segregation
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of the CCBL1 variant and any other candidate mutations should be carried out in as many
extended family members as possible including the affected cousins.
In summary, this case again demonstrates the difficulties encountered when interpreting
next-generation sequencing data without functional characterisation of candidate variants. These
issues are even more pronounced when confirmatory assays are not already established or a novel
gene or protein function is being postulated. In the future we will need to find better, more
high-throughput methodologies that will enable us to confirm the effects of variants of uncertain
significance identified by whole exome or whole genome sequencing.
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7
FUNCTIONAL CHARACTERISATION OF INBORN ERRORS OF
VITAMIN B 6 METABOLISM USING NOVEL ASSAYS
7.1 introduction
With the increasing prevalence of next-generation sequencing for the diagnosis of patients where
traditional genetic and biochemical testing has been uninformative, there is an ever-growing need
for functional assays to determine if the identified variants are pathogenic. This chapter describes
the adaptation of an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-
MS/MS) method to measure B6 vitamer profiles in human fibroblasts and quantify PNPO enzyme
activity. Its application to exploring the mechanisms and abnormalities underlying disease in
both patients with and without a diagnosis are described. The pathogenic aetiology of a novel
disorder, PROSC deficiency, was also examined using conventional molecular techniques and the
newly established mass spectrometry-based methods.
7.1.1 Vitamin B6 metabolism and the importance of pyridoxal 5’-phosphate
Epilepsy is the most common neurological disorder of childhood, with around one child in every
two hundred suffering with the condition (Shinnar and Pellock, 2002). For most children that
have epilepsy there is not a clear aetiology and approximately a third of all affected children have
seizures that cannot be controlled with anti-epileptic drugs (AEDs) (Sisodiya et al., 2002). These
children have an increased risk of death and may need to undergo high-risk invasive surgery.
Inborn errors of metabolism are rarely found to be the cause of epilepsy. However, seizures
are a common finding in children with neurometabolic disorders (NMD) and can be due to
one of many pathogenic mechanisms including: energy deficiency, toxicity, impaired neuronal
function, disturbance of neurotransmitter systems, vitamin/cofactor disturbances or associated
brain malformations (Wolf et al., 2005). A well known group of NMD are the seizure disorders in
which patients respond to treatment with vitamin B6.
7.1.1.1 Pathway of vitamin B6 metabolism
Vitamin B6 is present in the body as 6 vitamers: pyridoxine (PN), pyridoxamine (PM) and
pyridoxal (PL) and their 5’ phosphate esters. However, only pyridoxal 5’-phosphate (PLP) is the
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active vitamer and has cofactor activity. Vitamin B6 is present in a variety of foods including
meats, pulses, cereals, vegetables and fruit (Reynolds, 1988; Roth-Maier et al., 2002). Some is
also derived from the intestinal flora, where it is then taken up by colonocytes via a specific
carrier-mediated mechanism (Said et al., 2008). The majority of animal-derived B6 consists of
PLP and pyridoxamine 5’-phosphate (PMP), whilst that from human milk primarily exists as PLP
or PL. In contrast plants contain mostly PN, pyridoxine 5’-phosphate (PNP) and the glycosylated
form of pyridoxine, pyridoxine-5’-β-D-glucoside (PNG). Enterocytes, and cell membranes in
general, are not permeable to the phosphorylated B6 vitamers, therefore these are hydrolysed to
their free bases by intestinal phosphatases prior to absorption in the upper small intestine. PNG
is hydrolysed to PN by pyridoxine-5’-β-D-glucoside hydrolase, and the brush border membrane
lactase phlorizin hydrolase (Mackey et al., 2004). This uptake occurs via a carrier-mediated
system, although the molecular identity of this transporter (T1) remains unknown (Said, 2004).
PL, PM and PN are then trapped within the enterocytes through phosphorylation by pyridoxal
kinase (PK), prior to being dephosphorylated by plasma membrane phosphatases and released
into the portal vein to be transported to the liver. Once localised in the hepatocytes, the
vitamers are again phosphorylated by PK; PMP and PNP are then converted to PLP by cytosolic
pyridox(am)ine 5’-phosphate oxidase (PNPO). This PLP is then released into the blood where
it is transported to the relevant tissues; the PLP is bound to erythrocyte haemoglobin or the
lysine-190 amino acid residue of plasma albumin in order to protect the vitamer from hydrolysis
(Bohney et al., 1992). However, only the free bases can cross the blood-brain barrier and therefore
PLP is first cleaved to PL by the ectoenzyme tissue non-specific membrane-associated alkaline
phosphatase and transported into the CSF by an active transport mechanism. Uptake of the free
vitamins from CSF into brain cells then occurs via a similar mechanism. Once in the brain cell,
PL is phosphorylated by pyridoxal kinase, thereby trapping the active cofactor (Spector, 1978).
Approximately 50% of the dietary intake of vitamin B6 is excreted in the urine as 4-pyridoxic
acid, a compound which is synthesised when unbound pyridoxal is oxidised by aldehyde oxidase
or β-NAD dehydrogenase (Schwartz and Kjeldgaard, 1951; Stanulović et al., 1976).
In addition to the de novo synthesis of PLP from dietary sources, PLP can also be recycled from
the degraded apoenzymes within which it was functioning as a cofactor (González et al., 2007).
This "salvage pathway" functions to maintain PLP homeostasis by catalysing the interconversions
of the six vitamers using the enzymes described above; pyridoxal kinase converts the free vitamers
to their phosphorylated forms and PNP and PMP can be oxidised by PNPO to form PLP.
The later reaction is particularly important as PMP is the major vitamer released from the
degradation of apoenzymes which catalyse transamination reactions (Figure 7.1.1).
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Figure 7.1.1: Enzymes and transporters involved in the metabolism of dietary vitamin B6 and
the synthesis and homeostasis of pyridoxal 5’-phosphate. (1) PNPO is subject to
feedback inhibition from PLP. (2) PLP forms Schiff base interactions with the -amino group
of lysine residues within proteins which is essential for cofactor activity. (3) The "salvage
pathway" recycles the PLP cofactor from degraded enzymes by transamination reactions. (4)
PLP can react with small molecules rendering it unavailable as a cofactor. These molecules
include L-∆1-pyrroline-5-carboxylic acid (P5C) and ∆1-piperideine-6-carboxylic acid (P6C),
causing hyperprolinaemia type II and antiquitin deficency, respectively and drugs such as
isoniazid and penicillamine.
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7.1.1.2 Inborn errors of metabolism resulting in a deficiency of PLP
As described above, all dietary forms of B6 can be converted to PLP which is a cofactor for more
than 140 enzymes in humans, many of which are involved in the synthesis and degradation of
neurotransmitters. PLP has excellent electron sink properties that make it a versatile organic
catalyst; meaning that the molecule contains a group that can pull electrons from a reactive centre,
stabilising an electron-deficient intermediate or transition state. In the case of PLP, the aldehyde
group forms the electron sink which reacts with endogenous and exogenous nucleophiles (Christen
and Mehta, 2001). All PLP-dependent enzymes, with the exception of glycogen phosphorylase,
act upon amino acids or amines. In the brain, PLP-dependent enzymes are involved in the
metabolism of many amino acid and amine neurotransmitters, including dopamine, serotonin,
GABA, glutamate, d-serine, glycine and taurine. These enzymes are also important in the
synthesis of neuroprotective compounds such as kynurenic acid (Table 7.1.1).
Table 7.1.1: PLP-dependent enzymes important for normal neurological function.
Adapted from Surtees et al. (2006)).
Enzyme Function
Aromatic amino acid decarboxylase Dopamine and serotonin synthesis
Branched chain amino acid, 2-oxoglutarate
aminotransferase
Glutamate synthesis
GABA transaminase GABA catabolism
Glutamate decarboxylase GABA synthesis
Glycine cleavage system Glycine catabolism
Kynureninase Quinolinic acid synthesis
Kynurenine aminotransferase Kynurenic acid synthesis
L-serine racemase D-serine synthesis
Given the central importance of PLP in amino acid and neurotransmitter metabolism it
is not surprising that inborn errors of metabolism which affect availability of PLP present
with a neurological phenotype frequently involving seizures; these include pyridoxine dependent
epilepsy (PDE) due to mutations in ALDH7A1, hyperprolinaemia type II, hypophosphatasia and
pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency. Both PDE and hyperprolinaemia type II
are secondary PLP disorders, resulting in the accumulation of L-∆1-piperideine-6-carboxylic acid
(P6C) and L-∆1-pyrroline-5-carboxylic acid (P5C) respectively, which react with PLP thereby
sequestering it and rendering it inactive. Hypophosphatasia however, directly affects the vitamin
B6 pathway, resulting in a deficiency of the tissue non-specific alkaline phosphatase which is
required for the dephosphorylation of circulating PLP to PL therefore allowing it to cross the
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blood-brain barrier. The main B6 responsive seizure disorders, PDE and PNPO deficiency, are
described in more detail in Section 7.1.2 and Section 7.1.3.
7.1.2 Antiquitin (ALDH7A1) deficiency
Pyridoxine-dependent epilepsy (PDE) due to mutations in ALDH7A1 and dysfunction of the an-
tiquitin protein has already been briefly described in Section 4.2.1. A deficiency of α-aminoadipic
semialdehyde (α-AASA) dehydrogenase, otherwise known as antiquitin, results in the accumula-
tion of L-∆1-piperideine-6-carboxylate (P6C). This metabolite then forms an adduct with PLP
rendering it inactive as a cofactor (Mills et al., 2006). More than 200 patients with genetically
confirmed PDE have been reported in the literature, although many more patients are being diag-
nosed in clinical practice. More than 80 pathogenic mutations have been reported in ALDH7A1,
with one missense mutation (p.Glu399Gln) accounting for approximately 30% published alleles
(Mills et al., 2010). Classically, patients present with seizures beginning within the first month of
life which are unresponsive to conventional AEDs but respond, at least partially, to treatment
with PN. Global developmental delay or intellectual disability is present in up to 75% of patients
(van Karnebeek et al., 2016) and the severity of this impairment does not correlate with age
at seizure onset or diagnosis, seizure type or biochemical abnormalities at presentation (Bok
et al., 2012). Biochemically, elevations of α-AASA, P6C and pipecolic acid can be identified.
Patients may also be misdiagnosed with hypoxic ischaemic encephalopathy in the newborn period
as infants are commonly born in poor condition with evidence of foetal distress. Diagnosis
can be complicated by the multiple metabolic abnormalities that can be present during the
acute phase including hypoglycaemia, lactic acidosis, electrolyte disturbances, coaguolpathy and
abnormal plasma and CSF amino acid concentrations. Similarly, the presence of structural brain
abnormalities such as ventriculomegaly, corpus callosum and cerebellar hypoplasia, white matter
abnormalities and delayed myelination may also increase the list of differential diagnoses (van
Karnebeek et al., 2016).
In the vast majority of patients, treatment with a single intra-venous dose of 100 mg PN,
followed by an oral regimen of 5 - 10 mg/kg/day results in seizure resolution without the need
for additional AED treatment. However, breakthrough seizures during periods of intercurrent
illness are common (Mills et al., 2010; Stockler et al., 2011). Given the high prevalence of adverse
developmental outcomes, PN has been administered to pregnant mothers and newborn infants
before the onset of seizures. Although neonatal seizures were prevented, neurodevelopmental
delay persisted, albeit to a lesser degree than siblings who were antenatally untreated (Rankin
et al., 2007; Bok et al., 2010). This suggests that there may be a secondary mechanism besides
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the deficiency of PLP within the brain, causing neurological sequelae. Indeed, reducing the
potentially neurotoxic accumulation of P6C/α-AASA by decreasing flux through the lysine
catabolic pathway by dietary lysine restriction and arginine supplementation has been shown to
improve behavioural and language skills in some patients (van Karnebeek et al., 2012; Coughlin
et al., 2015).
7.1.3 Pyridox(am)ine 5’-phosphate oxidase (PNPO) deficiency
PNPO deficiency is a primary disorder which directly affects PLP synthesis. It is caused by
autosomal recessive loss-of-function mutations in PNPO, whose function is described in Section
7.1.1.1. The molecular basis of PNPO deficiency and initial cohort of patients were first defined in
2005 by Mills et al.. Classically these children were born prematurely and presented with seizures
shortly after birth, including myoclonic jerks and severe tonic-clonic seizures, associated with an
EEG showing a burst suppression pattern. Within the early cohorts of patients it was thought
that the disorder was associated with typical biochemical findings that could be attributed to
the impaired activity of PLP-dependent enzymes including aromatic L-amino acid decarboxylase,
threonine dehydratase, glycine cleavage enzyme and ornithine δ-aminotransferase (Mills et al.,
2005). However, this has since been shown not to hold true and the biochemical phenotype is in fact
much more broad, with many patients having unremarkable metabolic investigations (Hoffmann
et al., 2007). In the few patients who have had CSF PLP measured prior to supplementation,
levels were reduced (Ormazabal et al., 2008) although normal concentrations have also been
reported (Levtova et al., 2015).
One of the most noticeable initial differences between children with PNPO and those with
antiquitin deficiency was that PNPO deficient neonates responded to treatment with PLP with
a complete cessation of seizures within hours, but did not respond to trials of PN. This is
intuitive because PLP can be transported from the gut through all the necessary conversions
without any participation of PNPO whereas PN given either intra-venously or orally, requires the
activity of PNPO to produce PLP in the brain (Figure 7.1.1). However, three recent studies have
shown that some patients with PNPO deficiency do in fact respond to PN treatment, with a
few experiencing a clinical deterioration upon switching to PLP (Mills et al., 2014; Plecko et al.,
2014; Jaeger et al., 2016). Collectively, they identified twenty patients harbouring nine mutations
in differing homozygous or compound heterozygous combinations. The residual PNPO activity
of each of these mutations was examined using either a cell-free in vitro translation asssay or
transfection into Chinese hamster ovary cells but no clear relationship between higher activity
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and PN-responsiveness, as would be expected if this response to PN was simply due to residual
PNPO activity allowing conversion through the pathway, was found.
7.1.4 PROSC deficiency
Prior to the beginning of this PhD project, combined homozygosity mapping and whole ex-
ome sequencing identified a homozygous nonsense mutation in PROSC (proline synthetase
co-transcribed [bacterial homolog]) in a consanguineous pedigree of Syrian origin containing three
children with vitamin B6-responsive seizures (unpublished data; Dr Niklas Darin, The Queen
Silvia Children’s Hospital, Sweden). Following this, sequencing of the PROSC gene was carried
out in a cohort of children whose epilepsy had shown some response to treatment with PN or
PLP and antiquitin and PNPO deficiency had been excluded genetically and/or biochemically.
Four additional patients were identified harbouring an additional nonsense, three missense and
two splice site mutations (unpublished data; Dr Philippa Mills, ICH, UK). All patients presented
with seizures on the first day of life, with the exception of one patient who presented at one
month of age. All also had acquired microcephaly and differing degrees of developmental delay.
Plasma PLP concentrations were elevated in all patients that were tested; although all were on
PN supplementation at the time, these levels were at least four-fold higher than PDE patients
taking a similar PN dose.
PROSC encodes a ubiquitously expressed cytosolic protein of unknown function first identified
in 1999 by Ikegawa et al.. Orthologs of PROSC are highly conserved and present in bacteria, plants
and yeast, indicating an important role in cellular function. All orthologs share a PLP-binding site
which is postulated to bind PLP through a Schiff base linkage to a conserved lysine residue (Ito
et al., 2013). Indeed, the structure of PROSC orthologs are extremely similar to the N-terminal
domain of bacterial alanine racemase and eukaryotic ornithine decarboxylase. However, unlike
alanine racemase, in PROSC orthologs the PLP is solvent exposed rather than interacting with
a tyrosine residue within the polypeptide which is critical for catalytic racemisation activity
(Watanabe et al., 2002; Ito et al., 2013). Supporting this, studies of the bacterial homologue, YggS,
showed that the protein has no racemisation, transamination, deamination or decarboxylation
activity against proteinogenic amino acids (Ito et al., 2013). A more recent study has suggested
that Yggs may be involved in PLP homeostasis (Prunetti et al., 2016). The YggS-deficient E.
coli examined by Prunetti et al. (2016) accumulated pyridoxine 5’-phosphate (PNP) and showed
concentration-dependent toxicity towards pyridoxine (PN), therefore it has been hypothsised
that PROSC plays a role in vitamin B6 homeostasis. The exact function of PROSC and possible
pathogenic mechanisms underlying its deficiency were examined in this study.
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7.1.5 Maintenance of PLP concentrations and prevention of damaging reactions
The chemical properties of PLP make it highly reactive. In addition to facilitating its cofactor
activity, the reactive aldehyde group at the 4’-position of PLP can react with many endogenous
and exogenous nucleophiles within cells. This includes condensation reactions with hydrazines
and sulphydryl compounds such as isoniazid and penicillamine, respectively. Other small
molecules such as P6C and P5C which accumulate in patients with antiquitin deficiency and
hyperprolinaemia type II, respectively, can inactivate PLP through a Knoevenagel condensation
with the C3 carbon. Given that PLP can form aldimines with primary and secondary amines,
reactions with proteins can also occur; if unregulated it is thought that this may cause impairment
of enzymatic activity (Vermeersch et al., 2004). Similarly, PLP can form thiazolidine adducts
with molecules such as cysteine resulting in the accumulation of damaged metabolites (Liu et al.,
2013). Given this high degree of chemical reactivity, free pools of PLP must be tightly controlled
to both ensure that supplies are adequate for apoenzyme function and damaging interactions are
minimised.
As detailed in Section 7.1.1.1, the major synthesis and catabolic pathways of vitamin B6
metabolism are well characterised, however the mechanisms by which PLP concentrations within
tissues are tightly controlled are still not fully understood. Many studies have shown that although
4-pyridoxic acid excretion and plasma vitamer concentrations increase when subjects are fed a
diet containing a high B6 content, PLP concentrations within the tissues including muscle liver
and brain remain unchanged (Coburn et al., 1991; Schaeffer et al., 1995). This tight regulation is
likely to be due to multiple concurrent processes. When exogenous supplies of vitamin B6 are
sufficient, PLP concentrations are balanced by the degree of PLP binding to cellular proteins,
the transport of the precursor vitamers and phosphatase activity. Both PNPO and PK are also
subject to negative feedback inhibition by PLP (i.e. high PLP concentrations result in lower
activity) (di Salvo et al., 2015). Pyridoxal kinase also plays a role by compartmentalising the
phosphorylated vitamers as they cannot cross the plasma membrane. It has been suggested
that channelling, thereby avoiding the release of PLP into the cytoplasm and the occurrence of
damaging side-reactions, is the mechanism responsible for effective transfer of PLP to apoenzymes
(di Salvo et al., 2011). In addition to the active site, PNPO contains a secondary allosteric site
which binds PLP tightly and whose exact function is unknown (Musayev et al., 2003). Crystal
structures of PNPO show the presence of a putative tunnel between the active site and the
secondary PLP site, suggesting that the vitamer may be transferred across the protein without
contacting the solvent (Safo et al., 2005). The mechanism by which PLP is delivered to their
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target enzymes is still unknown. However, some mechanistic insight into how this occurs has
been gained from the study of patients with PROSC deficiency (Section 7.1.4).
7.1.6 Aims of this chapter and advantages of using mass spectrometry-based assays for the
evaluation of patients with inborn errors of vitamin B6 metabolism
The aim of this chapter was to adapt existing mass spectrometry-based methods to enable the ex-
amination of B6 vitamer profiles in cells and develop a novel method for the quantitation of PNPO
enzyme activity to examine mutation pathogenicity in patient cells. High-performance liquid
chromatography (HPLC) (Bisp et al., 2002; Rybak and Pfeiffer, 2004) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) (Footitt et al., 2013) techniques have already been
developed to quantify all of the B6 vitamers and 4-pyridoxic acid. The main advantages of these
methods compared to traditional methods for evaluating vitamin B6 status include the ability to
measure all of the vitameric forms of vitamin B6 and greater analytical sensitivity, which may
reveal subtle abnormalities indicative of specific known or novel disorders. Using these assays,
the differences between PNPO-deficient patients responsive to PN and PLP were examined and
the B6 vitameric profiles in patients with PROSC deficiency were determined. The pathogenic
aetiology underlying PROSC deficiency was also explored further using molecular biology, cell
culture and additional mass-spectrometry-based techniques.
7.2 methods
The methods described in this chapter were used to characterise fibroblast cell lines derived
from eight control patients, three children with confirmed or suspected PNPO deficiency, one
child with ALDH7A1 deficiency, three children with PROSC deficiency and one parent who was
heterozygous for a mutation in PROSC. Control fibroblasts were derived from patients having a
skin biopsy for the diagnostic work-up of a metabolic disease but with no evidence of a disorder
affecting vitamin B6 metabolism. Of the three patients with confirmed or suspected PNPO
deficiency, two were genetically confirmed to have PNPO deficiency; one was responsive to PLP
(PNPO 1) and the other to PN (PNPO 3). In the final patient (PNPO 2) who was responsive to
PLP, despite carrying a clinical diagnosis of PNPO deficiency, a definitive diagnosis had yet to
be made because despite extensive cDNA sequencing only one heterozygous frameshift mutation
had been identified. Details of mutations in each patient are shown in Table 7.2.1. The mutation
analysis of these patients was carried out by Dr Philippa Mills prior to this study commencing.
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Table 7.2.1: Mutations identified in the vitamin B6-responsive for which fibroblasts
were available for analysis in this study. (?), second mutation not identified.
Patient Gene Vitamer
response
Nucleotide change Amino acid change
PNPO 1 PNPO PLP c.364-1G>A; c.148G>A +
c.364-1G>A; c.148G>A
Splice error; p.Glu50Lys +
Splice error; p.Glu50Lys
PNPO 2 PNPO PLP c.641dupA; (?) p.Val215Glyfs*14; (?)
PNPO 3 PNPO PN c.674G>A; c.674G>A p.Arg225His; p.Arg225His
PDE 1 ALDH7A1 PN c.1195G>C; c.1195G>C p.Glu399Gln; p.Glu399Gln
PROSC 1 PROSC PLP c.524T>C; c.524T>C p.Leu175Pro; p.Leu175Pro
PROSC 2 PROSC PLP c.207+1G>A; c.320-2A>G Splice error; Splice error
PROSC 3 PROSC PN c.233C>G; c.233C>G p.Ser78*; p.Ser78*
PROSC het PROSC n/a c.233C>G p.Ser78*
The ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
method described in Section 2.11 was used to examine the B6 vitamer profiles in patient fibroblasts
and CSF. The enzyme activity of pyridoxal kinase (PK) and pyridox(am)ine 5’-phosphate oxidase
(PNPO) was assessed as described in Section 2.13.
In order to examine the subcellular location of the accumulated PLP in PROSC-deficient cells,
fibroblasts were harvested and lysed (Section 2.11) and the protein concentration was determined
(Section 2.7.4). 20 µL of supernatant was added to an Amicon Ultra-0.5 mL 3 kDa Centrifugal
Filter (Millipore) and centrifuged at 14,000 x g for 30 minutes. The B6 vitamers in the resulting
fractions (>3 kDa and <3 kDa) and in the unfiltered supernatant were analysed as described
previously (Section 2.11). Results were corrected for the unfiltered protein concentration.
The PLP-cysteine thiazolidine compound was synthesised by mixing 300 µL of 4.4 mM PLP,
300 µL of 61 mM L-cysteine and 2.4 mL of dH2O. The solution was then incubated in the dark at
37◦C for 3 hours. The method described in Section 2.12 was utilised to analyse the PLP-cysteine
content of the fibroblast samples.
In order to examine the effect of the PROSC mutations on protein translation, cDNA
analysis was undertaken. Total RNA was isolated from control and patient (PROSC 1 PROSC
2 and PROSC 3) fibroblasts using the method described in Section 2.8.1 and diluted to a final
concentration of approximately 200 ng/µL. Messenger RNA (mRNA) was then reverse-transcribed
to produce approximately 1 µg/µL of complementary DNA (cDNA) (Section 2.8.3). cDNA
corresponding to the PROSC and HPRT1 genes was amplified using the primers listed in
Appendix 2.8.1. Each fragment was excised and cloned into the TOPO 2.1 vector (Sections
2.16.11 and 2.16.8) prior to Sanger sequencing (Section 2.3.3.2). Western blotting and real-time
polymerase chain reaction (qRT-PCR) were carried out using the methods outlined in Section 2.10
and Section 2.9, respectively. In order to assess the growth of patient cells, 2.0x104 cells/mL were
292
seeded in 25 cm2 flasks and cultured for seven days in media depleted or repleted of pyridoxine.
Cells were counted using the method described in Section 2.7.2.
7.3 results and discussion
7.3.1 Method development of UPLC-MS/MS method for B6 vitamer quantitation
Patients with suspected PNPO deficiency are often on PN or PLP supplementation, therefore
it can be difficult to determine the pathogenicity of novel sequence variants within PNPO by
measuring plasma vitamer profiles. We therefore aimed to directly quantify PNPO enzyme
activity from patient fibroblasts and subsequently use this method to determine the differences in
vitamer profiles between disorders affecting vitamin B6 metabolism. The UPLC-MS/MS method
described in this chapter for the analysis of B6 vitamers was adapted from that already published
for the quantitation of these analytes in plasma by Footitt et al. (2013). In addition to enabling
the examination of fibroblasts, in vitro conditions can be modified to gain greater insights into
disease pathogenesis. The method described by Footitt et al. (2013) has a limit of detection of 1
nM for all vitamers, which was not deemed sensitive enough for these purposes. The method was
transferred to an Acquity Ultra Performance LC system linked to a triple quadrupole Xevo TQ-S
instrument. Cone and collision energies were varied to provide optimal sensitivity and deuterated
pyridoxamine (d3-PM) was added as an additional internal standard to increase the accuracy of
endogenous PM quantitation. The run time and injection volumes were reduced from 25 minutes
and 25 µL to 5 minutes and 15 µL, respectively. Details of the parameters that were optimised
are given below.
7.3.1.1 Mobile phase
The successful retention and separation of the B6 vitamers is dependent on the mobile phase
composition. In order to accurately determine the concentrations of any analyte using mass
spectrometry, the compound must produce a single, reproducible peak without cross-talk between
channels. An Acquity UPLC HSS T3 column (1.8 µm x 2.1 mm x 50 mm) fitted with a HSS T3
VanGuard guard column (Waters) was used for analysis as it was functionally analogous to the HS
F5 column used by Footitt et al. (2013). This column consists of a trifunctional C18 alkyl phase
bonded at a density that promotes the retention and separation of small, water-soluble polar
compounds. The phase is also tolerant of the low pH’s and highly aqueous mobile phases needed
to retain the B6 vitamers on the column. All LC-MS/MS methods analysing the B6 vitamers
use 3.7% acetic acid with variable concentrations of the ion-pairing reagent, heptafluorobutyric
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acid (HFBA) as the aqueous phase, with either acetonitrile or methanol as the solvent phase
(Midttun et al., 2005; Footitt et al., 2013; Albersen et al., 2015). Methanol was determined to
produce a better peak shape and sensitivity for the majority of vitamers when compared to
acetonitrile (Figure 7.3.1a). The concentration of HFBA required within the aqueous phase was
also investigated over a range of 0 - 0.1% (Figure 7.3.1c). An increase in HFBA concentration was
found to improve the chromatography of the phosphorylated vitamers whilst having a deleterious
effect on the unphosphorylated species. A composition of 3.7% acetic acid containing 0.01%
HFBA was determined to be the best compromise achieving acceptable sensitivity for all analytes.
A flow rate of 0.8 mL/min was examined as is the standard methodology in our laboratory
(Manwaring et al., 2013); however, the vitamers were not well-retained on the column with
all eluting within 0.5 minutes. Reducing the flow rate to 0.4 mL/min increased the retention
times of the vitamers to between 0.69 - 1.42 minutes without compromising the chromatography
(transitions and mobile phase gradient detailed in Table 2.11.3 and Table 2.11.2, respectively).
7.3.1.2 Transitions
The B6 vitamers and 4-pyridoxic acid were detected using multiple reaction monitoring (MRM)
mode. The transitions (i.e. the precursor/product ions) and the cone/collision voltages used to
generate them were optimised by infusion of each analyte within the mobile phase composition at
the time of elution of the analyte from the column. Several possible transitions were identified for
each vitamer and one was then selected for the final method based on those which gave superior
response (final conditions in Table 2.11.3). The mass spectrometer was operated in positive ion
mode and a scan segment of 3.6 minutes from 0.4 to 4.0 minutes. The total sample run time was
5 minutes, including time for column re-equilibration. All analytes could be differentiated based
on both their transitions (m/z ratios) and retention times, without cross-talk between ion pairs
originating from different vitamers.
7.3.1.3 Linearity
The linear range of each vitamer using three different mobile phase compositions (i) 3.7% acetic
acid [0.02% HFBA] + acetonitrile, (ii) 3.7% acetic acid [0.01% HFBA] + methanol and (iii) 3.7%
acetic acid [0.01% HFBA] + methanol was investigated. The latter provided the greatest linearity
and sensitivity not only for PMP (Figure 7.3.1b), but also for all other vitamers. Calibration
curves were constructed for each B6 analyte in both water and a pooled mixture of fibroblast cell
lysates. A range from 0 - 200 nmol/L was chosen because it is comparable to previous vitamer
measurements in cell lines such as Chinese hamster ovary cells (Fargue et al., 2013). Values of r2
equal to 0.99 were achieved for each vitamer using linear regression. All vitamers had a linear
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Figure 7.3.1: Optimisation of the parameters required for the quantitation of the B6 vitamers
in fibroblasts. (a) The effect of acetonitrile and methanol as mobile phase B on the
chromatography and sensitivity of vitamer detection. (b) Linearity of the response for
pyridoxamine 5’-phosphate (PMP) using an injection volume of 15 µL and different mobile
phase compositions. (c) Different concentrations of heptafluorobutyric acid (HFBA) were
added to mobile phase A [3.7% acetic acid] in order to improve chromatographic peak shape.
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response up to 200 nmol/L, with the exception of PLP which remained linear up to 100 nmol/L.
The limits of detection for this assay were determined to be 10 pmol/L for PA, PM, PN and
PL, 100 pmol/L for PLP and 1 nmol/L for PMP. The final method for the quantitation of the
endogenous B6 vitamers in fibroblasts is described in Section 2.11.
Figure 7.3.2: Calibration curves of B6 analytes. Curves were generated in water (black)
and cell lysate (red).
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7.3.2 Examining vitamin B6 metabolism and homoeostasis in patients with B6-responsive seizure
disorders
7.3.2.1 Enzymatic assay of PNPO activity in control fibroblasts
A diagnosis of PNPO can be suspected on the basis of a severe early-onset seizure disorder
which shows a clinical response (in the form of a reduction or cessation of seizures) to either
PN or PLP. However, the clinical response can be difficult to interpret as patients are typically
receiving treatment with multiple AEDs concurrently and may be affected by other sequelae (e.g.
complications of prematurity). A low concentration of PLP in the CSF prior to commencing
treatment is also indicative but often not measured. The identification of two sequence variants
in the PNPO gene is also strong evidence but their pathogenicity must be determined if the
variants are novel and not known to be disease-causing. To date, no method has been described
which facilitates the quantitation of PNPO activity in patient cells to confirm the diagnosis of
PNPO deficiency and the pathogenicity of any sequence variants identified in PNPO. Therefore,
the UPLC-MS/MS method described in Section 2.13 was established to facilitate the analysis of
PNPO activity directly rather than indirectly (i.e. scrutinising subtle differences in B6 vitamer
profiles). The assay described in this chapter is a coupled assay of both pyridoxal kinase (PK) and
PNPO enzyme activity (Figure 7.3.3), therefore the experimental conditions needed to facilitate
the activity of both enzymes in vivo. The pH optimum of PNPO is between 9.0 - 10.0 (Wada
and Snell, 1961), whereas that for PK is 6.0 (Neary and Diven, 1970). Flavin mononucleotide
is also an essential cofactor for PNPO activity (Musayev et al., 2003). Similarly, human PK
requires monovalent (K+) and divalent cations (Mg2+) for its activation and ATP to donate the
phosphate group required for phosphorylation (Musayev et al., 2007).
Initial studies had been performed previously (unpublished data; Dr Philippa Mills, ICH, UK)
which demonstrated that potassium phosphate buffered at pH 7.6 provided adequate activity
for both enzymes. This buffer also contributed sufficient K+ ions for optimal PK activity. In
addition, the presence of phosphate ions inhibits the action of phosphatases present in the
fibroblast lysate that otherwise function to dephosphorylate the deuterated B6 vitamers. The
chosen concentrations of FMN, MgCl2 and ATP were based on those previously described (Wada
and Snell, 1961; Neary and Diven, 1970; Musayev et al., 2003, 2007).
In control fibroblast lysates, once exogenous d2-PN is added it is converted to d2-PNP
by PK with almost complete disappearance of the substrate within a two hour period. This
d2-PNP accumulates linearly over the first 60 minutes before reaching a plateau and is then
converted to d2-PLP by PNPO. The increase in d2-PLP concentration is linear between 30 - 60
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Figure 7.3.3: Conversion of deuterated vitamers measured during the coupled
PNPO enzyme assay. Graphical representation of the conversion of (a) d2-
pyridoxine (d2PN), to (b) d2-pyridoxine 5’-phosphate (d2-PNP) and then to (c)
d2-pyridoxal 5’-phosphate (d2-PLP). Black, control; blue, PROSC-deficient, red;
PNPO-deficient.
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minutes following an initial lag phase (Figure 7.3.3). PNPO activity was therefore quantified
by measuring the increase in d2-PLP concentration over this time period and was expressed
in terms of pmol/hr/mg protein. Control PNPO activity ranged from 50 - 300 pmol/hr/mg
protein (Figure 7.3.6). The findings in patients with PNPO, antiquitin and PROSC deficiency
are discussed in Sections 7.3.3, 7.3.5 and 7.3.7, respectively.
7.3.2.2 B6 vitamer profiles in control fibroblasts
After having established a direct method for the analysis of PNPO enzyme activity, this mass
spectrometry-based assay was adapted to quantitate the endogenous B6 vitamers in the fibroblasts
of patients with PNPO, antiquitin and PROSC deficiency and determine the correlation with
published findings in plasma. Initial experiments were carried out with cells that had been
cultured in standard media containing 971 nM pyridoxine hydrochloride (Figure 7.3.4). The major
vitameric species in control cells were PL (4 - 20 nmol/g cell protein), PLP (8 - 15 nmol/g cell
protein) and PMP (5 - 35 nmol/g cell protein) whereas the concentrations of PM, PN and PNP
were less than 1 nmol/g cell protein. Experiments were then performed to investigate the effect of
variable concentrations of PN in the culture media on the cellular B6 vitamer composition (Figure
7.3.5). In control fibroblasts, the levels of all vitamers remained unchanged, with the exception
of PMP which showed an approximate 5-fold increase, upon culturing in media deficient in PN.
This likely reflects an increase in the recycling of PMP from apoenzymes when no exogenous
source of vitamin B6 is present. The B6 vitamer profiles of fibroblasts derived from patients with
PNPO, antiquitin and PROSC deficiency cultured in conditions of PN depletion and repletion
are discussed in Sections 7.3.3, 7.3.5 and 7.3.7, respectively.
7.3.3 Differences between PN- and PLP-responsive patients with PNPO deficiency
To date, more than twenty disease-causing mutations in PNPO have been identified with nine
having been associated with PN-responsiveness in twenty patients (Mills et al., 2014; Plecko et al.,
2014; Jaeger et al., 2016). Some, such as the p.Arg225His mutation present in the patient we
have examined (PNPO 3), are associated exclusively with a response to PN with a switch to PLP
resulting in status epilepticus in some patients (Plecko et al., 2014). This mutation is commonly
present as at least one of the pathogenic alleles in PN-responsive patients and affects a highly
conserved region within the active site of PNPO (Musayev et al., 2009). Indeed, the mutated
residue is conserved across multiple species between humans and E. coli. Whilst residual activity
associated with this mutation has been measured as being between 8% and undetectable, both
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used artificial systems that may have underestimated activity due to the potential stabilisation
of the mutant protein in vivo (Mills et al., 2014; Plecko et al., 2014).
The observed PN-response suggests that the p.Arg225His mutation does allow for some
residual enzyme activity. Indeed, examinations of patient fibroblasts provided some evidence to
support this hypothesis (Figure 7.3.4 and Figure 7.3.5). When grown in conditions of B6 repletion,
the PNPO-deficient fibroblasts did not show any significant differences in the concentrations of
PL, PM or PMP compared to control cells. The latter was at first sight somewhat unexpected
given that PM and PMP have been reported in plasma and CSF samples from patients with
PNPO deficiency (Footitt et al., 2013; Jaeger et al., 2016). However, it can be explained by
the fact that PN is the sole vitamin B6 source within the cell culture medium. Indeed, all
PNPO-deficient cell lines showed a significant increase in the concentrations of PN and PNP. The
PN concentrations were elevated to the same extent in both the PLP- and PN-reponsive cells
(2.5 - 15 nmol/g cell protein). However, the accumulation of PNP occurred to a greater extent in
the PLP-responsive fibroblasts (PNPO 1 and 2; 20 - 50 AU/g cell protein) compared to those
derived from the PN-responsive patient (PNPO 3; 4 - 11 AU/g cell protein). In these conditions
of B6 repletion, only the two PLP-responsive cell lines (PNPO 1 and 2) demonstrated a deficiency
of PLP. This greater degree of PNP accumulation and the presence of PLP deficiency despite
supplementation with concentrations of PN in excess of those required for growth indicates a
greater dysfunction of the PNPO enzyme in the patients with PLP-responsive seizures (PNPO 1
and 2). These findings suggest that the p.Arg225His mutation allows for some flux through the
pathway, in agreement with the findings published by (Mills et al., 2014).
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Figure 7.3.4: Comparison of the B6 vitamer profiles of patient fibroblasts with that
of controls grown in standard media. Media contains 971 nM pyridoxine
hydrochloride. Each point represents the mean vitamer concentration of one
flask of cells analysed in triplicate within one quantitation experiment. A quality
control (QC) cell line was analysed in every experiment in order to confirm
correct instrument functioning and sample preparation. The treatment response
of each PNPO-deficient patient is shown in brackets. Error bars represent ±
standard deviation. (a) PLP, pyridoxal 5’-phosphate; (b) PL, pyridoxal; (c)
PNP, pyridoxine 5’-phosphate; (d) PN, pyridoxine; (e) PMP, pyridoxamine
5’-phosphate; (f) PM, pyridoxamine. * p < 0.05, ** p < 0.01, *** p < 0.001.
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When fibroblasts were cultured in media depleted of vitamin B6, the cells from PLP-responsive
patients still had elevated levels of PN and PNP although concentrations were reduced between
6 - to 10-fold and 4- to 6-fold, respectively. However the accumulation of PN and PNP seen in
PNPO 3 (PN-reponsive) under conditions of B6 repletion was ameliorated when the fibroblasts
were depleted of vitamin B6. Under conditions of extreme vitamin B6 deficiency, PNPO not
only functions to generate sufficient PLP through the metabolism of PNP and PMP, but also
to recycle the cofactor from PMP released by degraded apoenzymes (Musayev et al., 2003).
Fibroblasts from all patients showed an increase in PMP concentrations compared to the same
cell lines grown in media supplemented with PN, indicative of increased recycling of PMP from
apoenzymes when no exogenous B6 source is present. However, in the PLP-responsive cell lines,
the accumulation of PMP was more marked compared to the PNPO 3 (PN-reponsive) cell line
indicating an impairment of this function. PM levels also appeared to be elevated in some
patients (PNPO 2) but reduced in others (PNPO 3); this is likely due to analytical variability
when measuring these extremely low analyte concentrations. Finally, compared to the control
fibroblasts (6 - 16 nmol/g cell protein) the PLP concentrations in the PNPO-deficient cell lines
were below (PNPO 2; 3 nmol/g cell protein) or at the lower boundary of the control range (PNPO
1 and 3; 6 nmol/g cell protein).
Direct quantitation of PNPO enzyme activity also provided evidence that the p.Arg225His
mutation results in a higher residual enzyme activity than the mutations harboured by the two
PLP-responsive PNPO patients (Figure 7.3.6). Fibroblasts from all three PNPO-deficient patients
showed an identical reduction in d2-PN concentration but a marginally increased accumulation
of d2-PNP relative to controls due to the action of PK and the lack of active PNPO to convert
it into d2-PLP, although this was not statistically significant. Control PNPO activity ranged
from 50 - 300 pmol/hr/mg protein. The residual enzyme activity in the PN-responsive cells
(11 pmol/hr/mg protein) was 6.7% of the mean activity detectable in controls and 20% that of
the control cell line with the lowest activity, whereas it was undetectable in the cells from the
PLP-responsive PNPO-deficient patients (Figure 7.3.6).
Although a degree of residual enzymatic function would account for the therapeutic response
to PN, the reasons underlying the intolerance to PLP therapy remain unknown. PNPO is known
to be strongly inhibited by free cellular PLP due to the toxic effects of its cellular accumulation
(Choi et al., 1987). Given that the p.Arg225His mutation is located within a site that can bind
PLP, the mutant protein may suffer complete inhibition by the administration of PLP. It is
possible that supplementation of these patients with much lower doses of PLP than conventionally
required to treat patients with PNPO deficiency may be sufficient to correct the pathogenic
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Figure 7.3.5: Comparison of the B6 vitamer profiles of patient fibroblasts with that
of controls grown in standard media and media depleted of pyridoxine.
Dark green, standard media; light green, media depleted of pyridoxine. The
treatment response of each PNPO-deficient patient is shown in brackets. The
results of one experiment are shown where each patient was analysed in triplicate.
Error bars represent ± standard deviation. (a) PLP, pyridoxal 5’-phosphate; (b)
PL, pyridoxal; (c) PNP, pyridoxine 5’-phosphate; (d) PN, pyridoxine; (e) PMP,
pyridoxamine 5’-phosphate; (f) PM, pyridoxamine.
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Figure 7.3.6: PNPO enzyme activity quantitation in patient fibroblasts. All cells from
PNPO-deficient patients showed a significant (p < 0.001) reduction in enzyme
activity.
deficiency of the active vitamer without encountering enzymatic inhibition. Further in vivo
studies are required to investigate these possibilities.
Additional questions that remain include why some patients with identical mutations respond
to PN and others do not and why there appears to be little correlation between in vitro residual
activity and response to either PN or PLP. For example p.Arg225Cys (9% activity), p.Arg225His
(8% activity) and p.Asp33Val (44% activity) are predominantly PN-responsive genotypes, whereas
patients harbouring the p.Arg229Trp mutation (15% activity) have been predominantly treated
with PLP (Mills et al., 2014). The latter may be due to variability amongst assay methodologies
as already noted (Mills et al., 2014; Plecko et al., 2014). In addition, in vitro measurements may
not be representative of the interactions occurring in vivo. Environmental factors affecting the
levels of PLP within the brain as well as the clinical condition of the affected neonate are also
likely to influence the therapeutic response. These include polymorphisms within the ALPL gene
encoding tissue non-specific alkaline phosphatase, dietary intake of vitamin B6 and riboflavin,
prematurity, breast feeding, age at the time of each treatment trial and the degree of any previous
insults (e.g. poor condition requiring intubation at birth or prolonged status epilepticus) (Mills
et al., 2014). As well as influencing treatment response, these factors likely play a role in the
overall clinical outcome of each patient making further research into these areas critical.
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7.3.4 Confirmation of PNPO deficiency in the background of only partially informative genetic
analyses
One of the patients examined in this study (PNPO 2) was clinically diagnosed as having
PNPO deficiency due to her severe epilepsy beginning at five hours of life which was completely
unresponsive to conventional antiepileptic drugs and pyridoxine, but a therapeutic breakthrough
was achieved when PLP was administered at 20 days of age. A case report describing her clinical
history has been published (Raimondi et al., 2015). Whilst standard Sanger sequencing of the
PNPO gene identified a single heterozygous frameshift mutation resulting in a premature stop
codon (p.Val215Glyfs*14), it was not possible to identify a second mutation despite isolating
mRNA from patient fibroblasts to analyse cDNA. A tentative diagnosis of PNPO deficiency could
therefore only be given (Dr Philippa Mills, ICH).
Mass spectrometry-based analysis revealed that this patient not only had negligible PNPO
enzyme activity (Figure 7.3.6), but also showed the characteristic deficiency of PLP, accumulation
of both PN and PNP under conditions of B6 depletion and repletion and accumulation of
PMP under conditions of stress (Figure 7.3.4 and Figure 7.3.5). Indeed, in PNPO 2 these B6
abnormalities were evident to a much greater extent than in PNPO 1 (the other PLP-responsive
patient), potentially suggesting an even more severe functional impairment of PNPO which
would be inconsistent with heterozygote mutation status. Thus, these investigations confirm the
diagnosis of PNPO deficiency in this patient. Given that cDNA analysis was unremarkable and
the wild-type allele could be visualised when the frameshift mutation was identified by Sanger
sequencing, the possibility of an exonic or whole gene deletion could be excluded. Instead, the
second pathogenic mutation is likely to reside in an intronic or regulatory genomic region.
7.3.5 Abnormalities in a patient with antiquitin deficiency
The B6 vitamer profile of one patient with genetically confirmed antiquitin deficiency was
examined (Figure 7.3.4 and Figure 7.3.5). Concentrations of PL, PNP and PMP were found
to be within the control range. A mildly elevated concentration of PM was identified in cells
supplemented with PN, however, similarly to the cell lines from other patients, this finding was
not recapitulated in fibroblasts grown in depleted media. This variability observed across these
experiments is likely due to analytical variability when measuring these extremely low analyte
concentrations. In contrast to fibroblasts from patients with PNPO deficiency who had PLP
levels comparable to or below that of controls, these cells showed elevated PLP levels under
conditions of PN supplementation. These levels were 3-fold higher than those seen in control cells
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and comparable to those identified in PROSC-deficient patients (discussed further in Section
7.3.7). The concentration of PN was also elevated 55-fold relative to control cells, similar to
the accumulation observed in PNPO-deficient cells (22- to 145-fold elevated above controls).
However, when the antiquitin-deficient cells were cultured in media depleted of B6, no vitamer
abnormalities were detected.
Studies examining the concentrations of the B6 vitamers in the plasma of patients with
PDE whilst on PN supplementation have revealed that levels of PLP, PL and pyridoxic acid
(PA) are strongly elevated in the vast majority of cases (Footitt et al., 2013; Mathis et al.,
2016). Concentrations of PN have also been documented as markedly elevated in a sub-group
(71%) of patients (Mathis et al., 2016). However, the vitamer profiles in these patients did
not differ from those of other patients on PN-treatment, including those affected by epileptic
encephalopathy or hypophosphatasia. Therefore, these findings have been suggested to reflect
the intake of supra-physiological doses of vitamin B6. Similarly, the variability in PN levels has
been postulated to be due to the interval between sampling and the intake of the last PN dose.
PA is not detectable in fibroblasts as the enzymes which function to convert PL to PA for
urinary excretion (aldehyde oxidase or β-NAD dehydrogenase) are not expressed in these cells.
PL is also not elevated in the fibroblasts, likely due to differences in the identity, distribution
and activity of phosphatases that acts to dephosphorylate PLP to from PL between plasma and
fibroblasts. In contrast, the elevated PLP and PN reported in plasma was recapitulated in the
fibroblasts from PDE 1. As suggested by Mathis et al. (2016), the elevated PN may simply be
due to a shorter interval between the last media change (containing excess PN) and harvesting
the fibroblasts. Alternatively, the PDE cells may increase the uptake of PN from the media to
correct for the physiological deficiency of PLP and to maintain adequate function of B6-dependent
enzymes.
As discussed in Section 7.1.2, endogenous PLP undergoes a Knoevenagel condensation reaction
with the ∆1-piperideine-6-carboxylic acid (P6C) that accumulates in patients with antiquitin
deficiency (Figure 7.3.7a) (Mills et al., 2006). This chemical reaction consists of the nucleophilic
addition of a carbanion molecule to a carbonyl group followed by a dehydration reaction in which
a molecule of water is lost. It could also be hypothesised that PLP may react with the equilibrium
partner α-aminoadipic semialdehyde (α-AASA) through a Schiff base interaction (Figure 7.3.7b).
It is known that PLP forms a Schiff base with lysine residues within proteins (Toney, 2005).
Therefore, given the structural similarities between lysine and α-AASA, it is possible that the
latter could partake in a similar interaction with PLP. Indeed, as part of the study identifying
the pathogenic aetiology of PDE (Mills et al., 2006), urine samples from patients were analysed
for the presence of this complex. The complex was not identified (unpublished data; Dr Philippa
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Mills, ICH, UK), however the conditions used to prepare the urine samples were different to those
used in this chapter. Schiff bases are known to be hydrolysed under acidic conditions; indeed,
these conditions are used for the measurement of total PLP in biofluids (Albersen et al., 2015;
Footitt et al., 2013). However, bonds formed by Knoevenagel condensations are less labile and
unlikely to be broken by acid hydrolysis. Thus, the increased PLP may be derived from the
accumulated PLP-AASA and/or PLP-P6C complexes. An alternative hypothesis is that the
physiological deficiency of PLP in PDE cells resulted in a compensatory upregulation of PNPO
enzyme activity resulting in apparently greater concentrations of PLP upon TCA precipitation
of the samples. However, this hypothesis was not supported by the direct quantitation of PNPO
enzyme activity in PDE cells, which was found to be within the control range (Figure 7.3.6).
Finally, it is important to note that these cells were only analysed on one occasion and thus
statistical analysis could not be performed. Indeed, these results only represent the findings in one
patient with antiquitin deficiency and caution should be taken when drawing conclusions. Further
work analysing a larger cohort of patients would be beneficial to investigate the hypotheses
presented above.
Figure 7.3.7: Undesired reactions of PLP in patients with antiquitin deficiency. (a)
PLP (red) can react with P6C (black) by a Knoevenagel condensation reaction.
(b) One hypothesis is that PLP (red) may also react with α-AASA (black)
forming a Schiff base.
7.3.6 Investigation of the effects of mutations in PROSC on protein transcription and translation
Three patients with genetically confirmed PROSC-deficiency, a novel disorder of vitamin B6
metabolism, were examined; one patient had a homozygous missense mutation (PROSC 1;
p.Leu175Pro), one was compound heterozygous for two splice site mutations (PROSC 2;
c.207+1G>A and c.320-2A>G) and one had a homozygous nonsense mutation (PROSC 3;
p.Ser78*) (Table 7.2.1). The effect of each mutation on transcription and translation of the
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PROSC gene product were characterised as were the effects of the two splice site mutations in
PROSC 2 on the cDNA product.
cDNA was generated from RNA extracted from fibroblasts and the PROSC gene was subse-
quently amplified and sequenced (Section 2.8). A housekeeping gene, hypoxanthine phosphoribo-
syltransferase 1 (HPRT1 ), was also amplified to check the integrity of the RNA and corresponding
cDNA. A single fragment corresponding to the size expected for the region of HPRT1 amplified
was identified in all samples, indicating that the reverse-transcription of total RNA to generate
cDNA had been successful. cDNA amplification of PROSC from control cells resulted in a 846
bp fragment which corresponds to the predicted size of the wildtype PROSC gene in control
fibroblasts. In contrast, three DNA fragments of different sizes were identified in PROSC 2
(Figure 7.3.8). In order to investigate these further, each fragment was excised and cloned into the
TOPO 2.1 vector prior to Sanger sequencing (Sections 2.16.11 and 2.16.8). Real-time polymerase
chain reaction (qRT-PCR) (Section 2.9) and Western blotting (Section 2.10) were also carried out
to investigate the effects of mutations on gene expression and protein translation (Figures 7.3.9
and 7.3.10). Taken together, these investigations revealed some intuitive and some unexpected
findings.
Figure 7.3.8: cDNA generated from RNA extracted from fibroblasts. (a) PROSC
and (b) HPRT1 cDNA amplified from total RNA extracted from fibroblasts.
Firstly, the presence of the nonsense mutation (p.Ser78*) in PROSC 3 would be expected
to result in nonsense-mediated decay and indeed a significant, approximately 5-fold, reduction
in PROSC mRNA expression was demonstrated (Figures 7.3.9). PROSC protein was also
undetectable (Figure 7.3.10). As expected as a carrier of this mutation, the mother of this patient
showed intermediate levels of mRNA and protein expression.
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Figure 7.3.9: qRT-PCR of PROSC mRNA in fibroblasts. Fibroblasts were grown in
standard media containing 971 nM pyridoxine hydrochloride. Relative quantita-
tion was carried out using the comparative CT (2−∆∆CT ) method with β-actin and
GAPDH as reference genes and analysed in quadruplicate. Statistical analysis was
performed using Welch’s unequal variances t-test. Data is presented as means ±
s.d. All patient cells showed a significant (p<0.0001) reduction in PROSC mRNA
expression, with PROSC het cells having an intermediate reduction (p=0.0110).
Controls, n=8; patients, n=3.
Analysis of cDNA extracted from PROSC2 revealed that c.207+1G>A and c.320-2A>G
affect DNA splicing and result in decreased mRNA expression (Figures 7.3.9). The c.207+1G>A
mutation was found to cause not only the inclusion of the second intron which would be
predicted to result in nonsense-mediated decay due to the introduction of a premature stop
codon (p.Val70Ilefs*6; 923bp cDNA fragment), but also the skipping of the second exon and
an in-frame deletion of 36 amino acids (p.Asp34_Tyr69del; 816bp cDNA fragment) which
corresponds to a protein approximately 26 kDa in size (Figure 7.3.10). Western blotting was
carried out using the HPA023646 antibody (Sigma) which binds to a stretch of 75 amino acids
encompassing exon five and approximately half of exon six of the PROSC gene (Section 2.10). A
protein product corresponding to the p.Val70Ilefs*6 mutation was not detected as the protein
is truncated upstream of the antibody binding site (Figure 7.3.10). Indeed, if this mutation
results in nonsense-mediated decay as predicted, this protein product would not be detectable
using Western blotting regardless of the antibody epitope. Splice site mutations can lead to exon
skipping, intron retention and insertions or deletions of variable size due to the use of cryptic
splice sites. In the classic model of spliceosome assembly, only a single intron was thought to be
removed at a time in a progressive 5’ to 3’ direction along the mRNA (Lang and Spritz, 1983). If
this was the case, it would be expected that mutations of the 5’ splice donor site would result
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Figure 7.3.10: Western blot of the PROSC protein in patient fibroblast lysates.
(a) Western blot of PROSC protein alongside a β-actin loading control.
(b) Densitometry quantification of the PROSC protein was carried out us-
ing ImageJ software. A detailed description of the method used can be
found at www.lukemiller.org/index.php/2010/11/analyzing-gels-and-western-
blots-with-image-j/.
exclusively in retention of the following intron. However, this is now known not to be the case;
indeed many mutations of the canonical +1G residue have been reported to causing skipping
of the preceding exon in other disorders including sialidosis, congenital afibrinogenemia and
phenylketonuria (Penzel et al., 2001; Attanasio et al., 2003; Marvit et al., 1987). This impact
on transcription is determined by many factors including the size of the mutated intron, the
order of intron removal within each specific gene and surrounding genomic elements (Takahara
et al., 2002). Although most splice site mutations only produce a single outcome, there are many
reports of a single mutation generating multiple products. This can be attributed to "major" and
"minor" splicing pathways in which the order that exons are removed differs (Schwarze et al.,
1999).
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Sequencing of the transcript corresponding to the c.320-2A>G mutation also revealed some-
what unexpected results. Instead of causing the skipping of exon five, only the first ten exonic
amino acids are deleted due to the use of a cryptic splice site (p.Ala107_Thr116del; 827bp cDNA
framgent). A protein product corresponding to the p.Ala107_Thr116 mutation was not detected
due to the deletion’s location within the antibody binding site (Figure 7.3.10). Western blotting
using an alternative antibody binding to a stretch of 16 amino acids within exon two was also
performed (SAB1105316, Sigma), however a specific band could not be obtained (data not shown).
These cDNA and protein findings illustrate the importance of experimental confirmation of the
effects of mutations predicted to affect correct splicing and caution against the over-reliance on
in silico prediction tools (Baralle and Baralle, 2005).
The missense mutation (p.Leu175Pro) identified in a homozygous state in PROSC 1 affects a
residue conserved across mammalian species, but also in Yggs (bacterial homolog) and YBL036C
(yeast ortholog). It also lies within the predicted PLP-binding barrel domain similar to that at
the N-terminus of bacterial alanine racemase and eukaryotic ornithine decarboxylase (Ito et al.,
2013). Unexpectedly, the p.Leu175Pro mutation significantly decreases PROSC mRNA expression
(Figures 7.3.9) and results in no detectable PROSC protein in patient fibroblasts (Figure 7.3.10).
Although the immunogen sequence of the antibody encompasses the mutated residue, this would
not necessarily be expected to affect antibody binding. The binding affinity of an antibody for
its corresponding epitope can be variable (Saper, 2009). Indeed, polyclonal antibodies such as
the one utilised in this study, are more tolerant of minor antigen changes such as polymorphisms
or missense mutations than monoclonal antibodies (Lipman et al., 2005). Furthermore, the
protein findings were mirrored at the mRNA level, suggesting that this decreased expression
of PROSC is not an artefact of the experimental methodology. Although unusual, missense
mutations have been reported to reduce mRNA expression (Nguyen et al., 2011). Since point
mutations are unlikely to induce a dramatic reduction in mRNA stability and result in reduced
levels, another possible explanation is that the mutation increases the affinity for the binding
of a microRNA (miRNA) or creates an miRNA binding site which causes RNA degredation.
MicroRNAs are small non-coding regulatory RNA molecules which function to regulate the
expression of complementary mRNAs. miRNAs typically silence mRNA molecules by either (i)
cleavage of mRNA strands, (ii) destabilising the mRNA by shortening the poly(A) tail or (iii)
reducing translation efficiency by ribosomes (Fabian et al., 2010). The p.Leu175Pro mutation lies
within a predicted binding site of hsa-miR-202-5p miRNA (Paraskevopoulou et al., 2013). Very
little is known about this miRNA except that it is highly expressed in Sertoli cells and plays a
role in testis development (Wainwright et al., 2013). The significance of this is uncertain but it is
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possible that the missense mutation present in PROSC 1 affects mRNA stability through the
modification of miRNA binding.
An additional factor to consider at the protein level is the known propensity of the introduction
of proline residues to disrupt correct secondary and tertiary structure formation, particularly
within cytoplasmic proteins (Li et al., 1996). JPred4, a tool for secondary structure prediction
(Drozdetskiy et al., 2015), suggests that the p.Leu175 residue is located immediately prior to a
β-sheet motif, at the end of a sequence of five amino acids connecting it to a preceding α-helix.
Proline disfavours the β-sheet structure due to its incompatible dihedral angle and lack of one
potential hydrogen bond donor (Li et al., 1996). Perhaps more importantly, because of its
cyclic structure, proline induces a turn or bend in the structure; this often functions to bring
α-helices and β-sheets into close proximity to allow for the formation of more complex tertiary
and quaternary conformations. Within this sequence of five amino acids, a proline residue is
already present two amino acids upstream of our mutated leucine. Therefore, it may be expected
that the two proline residues in close proximity result in a marked instability of the encoded
protein due to an aberrant tertiary structural conformation.
7.3.7 PROSC deficiency affects PLP homeostasis
The analyses described above demonstrated that all mutations present in the three PROSC-
deficient patients cause decreased expression of each mutant mRNA and protein. The most
consistent phenotypic feature in these patients was an early-onset seizure disorder which responded
to treatment with either PN or PLP. To exclude PNPO deficiency, the enzyme activity of PNPO
in fibroblasts from the PROSC-deficient patients was quantified (Figure 7.3.6). PROSC 1 and
PROSC 2 had activity of 310 and 367 pmol/hr/mg protein, respectively. These values were
marginally above the reference range of 50 - 300 pmol/hr/mg protein, although the increase was
not statistically significant and likely reflects the relatively small number of control fibroblast
lines available for analysis. The PNPO activity in PROSC 3 and PROSC het cells was within
the control range.
In addition, as part of their diagnostic work-up, three patients had their B6 vitamers analysed
in plasma whilst receiving supplementation. Whilst these patients had high levels of PLP, unlike
patients with PNPO deficiency (Footitt et al., 2013), they do not accumulate PN, PM, PNP
and PMP in plasma (unpublished data; Dr Philippa Mills, ICH, UK). Although not as high as
those seen in patients with hypophosphatasia due to mutations in tissue non-specific alkaline
phosphatase (Whyte et al., 1988), PLP levels were 4 - 15 times higher than those reported for
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PNPO and PDE patients receiving comparable supraphysiological doses of vitamin B6 (Table
7.3.1).
Table 7.3.1: Plasma PLP levels in patients with vitamin B6-responsive disorders
being treated with variable doses of either pyridoxine (PN) or pyridoxal
5’-phosphate (PLP). * Data taken from Footitt et al. (2013).
Patient Vitamer dosage Plasma PLP levels
(nmol/L)
Control range None 46 - 321
Treatment with pyridoxine (PN)
Pyridoxine-dependent epilepsy (PDE)* 100 mg twice a day 11 - 604
Undiagnosed seizure disorder* 100 mg twice a day 877
PROSC deficiency 200 mg twice a day 2600
Treatment with pyridoxal phosphate (PLP)
PNPO deficiency* 30 mg/kg/day 580 - 633
PLP-responsive seizures* 30 mg/kg/day 710
Partially PLP-responsive seizures* 30 mg/kg/day 478
PROSC deficiency 45 mg/kg/day 2166
PROSC deficiency 20 mg/kg/day 2750
B6 vitamer analysis was then carried out in patient fibroblasts to determine whether the
findings in biofluids (i.e. plasma) would be recapitulated intracellularly. Similarly to the profiles
in plasma, elevated levels of PLP were identified in all PROSC-deficient fibroblasts when cultured
in media containing excess concentrations of PN (Figure 7.3.4). However, the accumulation
was not as striking as that observed in plasma, only being between 2- and 3-fold higher than
control fibroblasts cultured under identical conditions. The PLP concentrations in the PROSC
het cells which harbour the p.Ser78* mutation in a heterozygous state (15 - 18 nmol/g cell
protein) were approximately half of those in the PROSC 3 cells which are homozygous for the
same mutation (30 - 50 nmol/g cell protein). These intermediate concentrations support the
hypothesis that dysfunction of the PROSC protein results in dysregulation of intracellular PLP
concentrations. The concentration of PL was also marginally higher in patient cells and, whilst
not statistically significant, it likely reflects endogenous phosphatase activity on elevated PLP
levels. All other vitamer concentrations remained within control ranges, mirroring the findings in
plasma. However, when cells were cultured under conditions of B6 depletion, levels of PLP were
maintained between 4 - 6 nmol/g cell protein similar to those seen in control cells (Figure 7.3.5).
This, along with the normalisation of the PLP deficiency in PNPO-deficient cells (Section 7.3.3)
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suggests that mechanisms exist to tightly regulate PLP in conditions where vitamin B6 is scarce.
Indeed, no other vitamer abnormalities were identified under these conditions.
In addition to the plasma samples that had been analysed previously (unpublished data; Dr
Philippa Mills, ICH, UK) and the cultured fibroblasts from the three patients described above,
two cerebrospinal fluid (CSF) samples from PROSC 2 (c.207+1G>A and c.320-2A>G) whilst
off-treatment were available for analysis. In order to check the validity of the UPLC-MS/MS
method (Section 2.11) for the quantitation of the B6 vitamers CSF, seven samples from the
Neurometabolic Unit, National Hospital for Neurology and Neurosurgery where PLP had been
measured were analysed (Table 7.3.2). The results for PLP were found to agree with those from
the previous analyses. The concentrations of the other vitamers were compared to the reference
ranges reported by Albersen et al. (2015), which is the only study to report reference ranges for
all vitamers (with the exception of PNP) in children.
PROSC 2 was receiving 40 mg/kg/day of PLP for seizure control but underwent a withdrawal
trial at 17 months of age. The dosage was tapered over a two week period and two CSF samples
were taken 48 hours after this cessation. PL concentrations were slightly below the reference
range reported by (Albersen et al., 2015). In contrast, PLP levels were markedly decreased in
both samples at 5.5 and 6.0 nmol/L (ref: 11 - 34) (Table 7.3.2). Combined with the patients’
dramatic seizure resolution in response to vitamin B6 treatment, this suggests a cerebral PLP
deficiency and supports the hypothesis that PROSC is involved in vitamin B6 homeostasis.
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Table 7.3.2: CSF B6 vitamer profiles of a PROSC patient (not on B6 supplementation) and of patients who have been investigated for
possible PLP deficiency or neurotransmitter abnormalities. All concentrations are expressed in nmol/L with the exception of PNP which
is stated in "concentration units". * Albersen et al. (2015), ** Patient was receiving 40 mg/kg/day which was then tapered and eventually stopped
over a two week period, CSF was taken 48 hours after this cessation. 1, the patients on PN supplementation all had PL concentrations that were
greater than the 200 nmol/L upper limit of quantitation. n/a, not applicable; nd, not detected; nm, not measured; PLP, pyridoxal 5’-phosphate; PL,
pyridoxal; PA, 4-pyridoxic acid; PN, pyridoxine; PNP, pyridoxine 5’-phosphate; PMP, pyridoxamine 5’-phosphate; PM, pyridoxamine; 5-HIAA;
5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate.
Patient Age Supplementation Neurotransmitter
phenotype
Clinical phenotype PLP PL PA PN PNP PMP PM
Reference
range*
1y - 18y None n/a n/a 11 - 34 16 - 56 <0.09 - 3 nd nm nd 0.3 - 0.9
PROSC 2 17m 48h after PLP
cessation**
nd Neonatal-onset seizures 6.0, 5.5 15.1, 14.9 nd 0.05, 0.08 0.92, 0.82 0.88, 1.05 0.13, 0.18
C8 13m None Marginally raised
5-HIAA, PLP within
ref range
Near respiratory arrest,
dysmorphic features,
global developmental
delay
20.9 28.2 nd 0.04 1.52 1.05 0.20
C3 15m None Neurotransmitters and
PLP within ref ranges
Developmental
impairment
23.3 23.5 nd 0.05 0.84 0.88 0.21
C6 17m None Elevated 5-HIAA and
PLP within ref range
Acute-on-chronic
neurodegeneration
25.6 41.1 nd 0.08 0.56 0.53 0.27
A8 17m PN Low 5-MTHF, high
PLP, interfering peak
on PLP chromatogram
Seizures, cardiac arrest 81.2 > 2001 nd 5.87 1.00 1.58 0.66
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A2 16m PN Elevated PLP Pyridoxine-dependent
epilepsy
82.9  2001 nd 41.53 0.98 1.41 2.22
A7 14m None Undetectable PLP,
marginally raised
5-HIAA
Seizures,
developmental delay
1.06 91.8 nd 0.22 0.66 1.05 0.44
A1 18m PN Elevated PLP B6-dependent epilepsy 75.7  2001 nd  200 0.98 1.05 4.92
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7.3.8 Characterisation of potential pathogenic mechanisms underlying PROSC deficiency
The elevated PLP concentrations observed in the plasma of patients on vitamin B6 supple-
mentation and in fibroblasts grown in conditions of PN excess, combined with the CSF PLP
deficiency observed in PROSC 2 prior to treatment initiation suggested that pathogenesis in
PROSC deficiency could be due to abnormal transport of PLP into the brain or dysfunction
of PLP homeostasis. PROSC is a soluble cytoplasmic protein and has a binding site which
binds PLP through a Schiff base linkage but does not affect the quaternary structure of the
protein upon binding (Prunetti et al., 2016). Its structural properties would therefore not be
consistent with a transmembrane protein which functions to facilitate the transport of PLP into
the brain. In addition, the lack of a conformational change upon the binding of PLP does not
support a catalytic function of PROSC; rather, it suggests that the protein may simply bind
PLP and act as a carrier protein. Indeed, it is possible that the normal function of PROSC is to
carry newly-synthesised PLP from pyridoxal kinase and PNPO to the B6-dependent enzymes
that require it as a cofactor, thereby protecting PLP from unwanted reactions in the cytosol.
Dysfunction of PROSC may then be expected to result in uncontrolled reactions of PLP with
proteins, amino acids and metabolites such as cysteine (Terzuoli et al., 1998) and carnosine
(Vistoli et al., 2013), thus rendering it inactive as a cofactor. If this was indeed the case, it would
be expected that PLP would not be preferentially bound to proteins or metabolites. In order
to investigate whether this was the case, cell lysates were fractionated using a 3 kDa cut-off
filter. Each fraction containing proteins (> 3 kDa) and metabolites (< 3 kDa) was then prepared
and analysed. The method developed in this chapter uses trichloroacetic acid to precipitate the
proteins within the matrix being analysed. However, this also functions to break any Schiff bonds
binding PLP to proteins or other molecules. Therefore, although it was possible to discriminate
between protein- and metabolite-bound PLP, the determination of the proportion of free PLP
within cells was not possible and was included in the < 3kDa fraction (Figure 7.3.11).
As observed in the whole cell lysate vitamer analysis (Section 7.3.7), all PROSC-deficient
cell lines showed an accumulation of PLP when compared to controls (Figure 7.3.12a). The
concentration of PLP in the < 3 kDa and > 3 kDa fractions should equate to the total concentration
in the unfiltered sample. However, as illustrated in Figure 7.3.12a this was not the case. This
was because each fraction could not be corrected for the protein concentration in the respective
fraction as no protein was detectable in the < 3 kDa solution. Therefore, correction of the PLP
concentration in these samples for a negligible amount of cell protein would result in an extremely
elevated artefactual quantification. To negate this problem, the PLP concentrations in each
fraction were corrected for the total protein concentration in the unfiltered sample (Figure 7.3.11);
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Figure 7.3.11: Preparation of cell lysate fractions from control and PROSC-deficient
fibroblasts. Fibroblasts were harvested, lysed and the protein concentration
of the unfiltered lysate was determined using a protein assay. The unfiltered, <
3 kDa and > 3 kDa fractions were analysed using UPLC-MS/MS before being
corrected for the protein concentration of the unfiltered sample.
this allowed each patient to be directly compared. The concentrations of PLP within both the <
3 kDa and > 3 kDa fractions were significantly increased in all PROSC-deficient cell lines (p <
0.001) when compared to that of control fibroblasts (Figure 7.3.12a-c). When considering the
uncorrected PLP concentrations, approximately 60% of the vitamer was detected in the > 3kDa
fraction suggesting that it was bound to proteins and other large molecules (Figure 7.3.12d).
This distribution in the PROSC-deficient fibroblasts was similar to that seen in control cells.
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Figure 7.3.12: Distribution of PLP in fibroblast cell lysate fractions from PROSC patients and controls. (a) Concentrations of PLP in each
fraction corrected for the protein concentration of the unfiltered sample. (b) and (c) Concentration of PLP in each patient compared to controls
in the < 3kDa and >3kDa fraction, respectively. (d) Distribution of PLP between > 3kDa and < 3kDa fractions.All patients had significantly
increased PLP concentrations (p < 0.001) relative to controls (n=3).
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The fact that PLP concentrations were found to be elevated in both low and high molecular
weight fractions, suggests that the supra-physiological cellular concentrations of PLP react non-
specifically with a range of intracellular molecules. One of the molecules that PLP is known
to spontaneously react with is cysteine, forming a PLP-cysteine thiazolidine molecule (Buell
and Hansen, 1960; Liu et al., 2013). In order to investigate whether this was occurring in
patients with PROSC deficiency, mass spectrometry-based methods were established to detect
this molecule in fibroblasts. The formation of this thiazolidine complex has been reported to
occur rapidly upon the incubation of a solution containing PLP and cysteine, being completed
within 30 minutes at room temperature and 10 minutes at 45◦C (Głowacki et al., 2016). However,
various factors affect the efficiency of the reaction including molar ratio of PLP:cysteine, pH
and temperature. A solution of the PLP-cysteine thiazolidine complex was prepared (Section
7.2) and analysed before being spiked into a matrix of fibroblast cell lysate. The retention time
and peak shape of the thiazolidine compound was very different in an aqueous solution, where
a broad peak was eluted between 4 - 6 minutes, compared to that spiked into a matrix of cell
lysate where a single sharp peak was observed with a retention time of 4.12 minutes (Figure
7.3.13a). Indeed, similar differences in chromatography were also observed dependent on whether
PLP or cysteine was in excess within the reaction mix, with conditions of PLP excess resulting
in superior chromatography (Figure 7.3.13b).
320
Figure 7.3.13: Experiments investigating the presence of PLP-cysteine conjugates within patient fibroblasts. (a) Chromatography of the PLP-
cysteine conjugate in water and spiked into fibroblast cell lysate. (b) Differing chromatographic peak shape depending on the ratio of PLP:cysteine
in solution. (c) Endogenous PLP-cysteine in fibroblasts show co-eluting peaks when the cells are precipitated with acid, as for the B6 vitamer
method (Section 2.11). (d) Concentration of PLP-cysteine in fibroblasts precipitated using methanol with an injection volume of 2 µL. (e)
Decreasing PLP-cysteine response over time. (f) Samples were run twice sequentially. Graphs illustrate the decrease in response from the first
injection (red) to the second (orange).
321
Despite this variability, fibroblasts from control and PROSC-deficient patients were analysed
to determine whether any endogenous PLP-cysteine could be detected. The cell lysates were
prepared using the same methodology as for the quantitation of the B6 vitamers, with the
exception that 50 µL of cell lysate supernatant was used to generate a more concentrated solution
for analysis. Several peaks that shared the same parent/daughter ions and had similar retention
times were detected; presumably isomeric forms of the PLP-cysteine conjugate. It has been shown
that the thiazolidine exists as two diastereoisomers differing in the orientation of the carboxyl
group, which are in equilibrium via the Schiff base (Ponticelli et al., 1983; Terzuoli et al., 1998)
(Figure 7.3.14). The interconversion of the two diastereoisomers at a neutral pH of 6.4 occurs so
rapidly that distinct nuclear magnetic resonsance signals from the two diastereoisomers cannot
be discerned, however at much lower pH’s (∼ pH 3.0) similar to the solutions used for sample
preparation and the mobile phase for the mass spectrometry analysis, this interconversion is
significantly slower. If the reaction also shows first order kinetics, the rate of interconversion via
the Schiff base will occur faster at higher concentrations. Therefore, the peaks could correspond
to a mixture of the two diastereoisomers and the Schiff base (Figure 7.3.13c), given the low
physiological concentrations of the thiazolidine complex in fibroblasts and low pH generated by
the protein precipitation using 0.3N trichloroacetic acid and 3.7% acetic acid used as a component
of the mobile phase.
Given the effects of assay conditions such as pH on the stability of PLP-cysteine, fibroblast
samples were also prepared by using methanol precipitation (method described in Section 2.12).
Analysis using this method resulted in a single peak and demonstrated an apparent increase in
the concentration of the thiazolidine in PROSC-deficient cells (Figure 7.3.13d). However, upon
greater scrutiny is was apparent that the response corresponding to the PLP-cysteine thiazolidine
was decreasing over time (Figure 7.3.13e). This instability has also been documented by others
(Buell and Hansen, 1960). Given that the PROSC-deficient cells were analysed first, it is unknown
whether or not the increased concentrations identified in these fibroblasts were an artefact of
the instability of the analyte. All samples were analysed twice with approximately five hours
between each analysis (Figure 7.3.13f). Despite being kept in the dark at 4◦C between analyses,
PLP concentrations were comparably reduced in all samples. In contrast, the PLP-cysteine
concentrations were reduced in the PROSC samples but not in control samples. The significance
of these findings, if any, are uncertain. Therefore the development of novel, more robust analytical
methods is warranted to further investigate the hypothesis that pathogenesis in PROSC deficiency
is caused by uncontrolled reactions of PLP with proteins and small molecules such as cysteine
and carnosine (Vistoli et al., 2013). Indeed, very recently a novel method using hydrophilic
interaction liquid chromatography followed by ultra-violet detection has been described using
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Figure 7.3.14: Formation of the PLP-cysteine thiazoldine complex. Firstly, PLP and
cysteine react via a condensation reaction with the loss of water to form an
addition compound which is in equilibrium with the Schiff base. This imine
molecule then cyclises to form the thiazolidine complex.
PLP as a derivatising agent for the analysis of cysteine and homocysteine, which may be adapted
and utilised to analyse endogenous concentrations of the PLP-cysteine thiazolidine complex
(Głowacki et al., 2016).
Finally, in order to further investigate the apparent inability of patients with PROSC deficiency
to appropriately regulate PLP homeostasis, the growth of control and PROSC-deficient fibroblasts
in standard media (repleted) and media depleted of PN was examined. Fibroblasts were seeded
at the same density and allowed to grow for seven days before counting the cells (Section 7.2).
In standard media which contains 971 nM pyridoxine hydrochloride, the PROSC-deficient cells
showed a 2.5- to 10-fold reduction in growth compared to control cells. Furthermore, PROSC het
(p.Ser78*, heterozygous) fibroblasts demonstrated an intermediate reduction in growth compared
to PROSC 3 cells (p.Ser78*, homozygous) despite the growth rate of the PROSC het cells being
2-fold reduced when compared to control levels.
However, when control fibroblasts were cultured in media depleted of a source of vitamin B6,
growth was reduced by approximately 70%. This is intuitive as the sub-optimal functioning of
cellular B6-dependent enzymes would be expected to result in a deficiency of metabolites essential
for growth and cell division. This trend was also reflected in the PROSC-deficient and PROSC
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Figure 7.3.15: Fibroblast growth in media repleted and depleted of vitamin B6. Con-
trols, n=3; patients, n=1.
het fibroblasts with growth being reduced by between 63% and 74% in conditions of B6 depletion
compared to repletion. Indeed, the trends observed in repleted media were also recapitulated
in depleted media, with PROSC 2 cells showing the most severe growth impairment followed
by PROSC 3 and PROSC 1. This growth deficiency in all patients with PROSC mutations,
independent of mutation type, suggests that under conditions which usually promote cell viability,
these cells experience PN toxicity which may be caused by an accumulation of toxic PLP-reacted
molecules and inefficient functioning of PLP-dependent apoenzymes.
7.3.9 Current hypotheses regarding PROSC deficiency
The most consistent finding amongst patients with PROSC deficiency was an apparent inability
to regulate PLP levels. In one patient, CSF PLP deficiency was identified prior to the initiation of
vitamin B6 supplementation. Combined with the patients’ universal dramatic seizure resolution in
response to supplementation with PN or PLP, this suggested a cerebral PLP deficiency. However,
when these patients were treated with doses of PN or PLP typically used for the treatment of
PNPO deficiency or pyridoxine-dependent epilepsy, abnormally high concentrations of PLP where
detected in plasma. Indeed, this abnormality was also identified in patient-derived fibroblasts
grown in conditions of PN excess. Further investigation revealed that these supra-physiological
cellular concentrations of PLP react non-specifically with a range of intracellular molecules
including proteins and metabolites. Finally, PROSC-deficient fibroblasts exhibited reduced
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growth rates under conditions that usually promote cell viability, suggesting a susceptibility to
PN-toxicity. Taken together, these results suggest that PROSC plays a role in cellular homeostasis
of PLP in humans.
In eukaryotic cells, the concentration of free PLP is tightly controlled at approximately 1 µM;
however, this is not high enough to meet the demand of the multiple B6-dependent apoenzymes
(di Salvo et al., 2011). Thus, the question of how cells supply sufficient PLP with high enough
specificity to avoid non-specific attack on nucleophilic molecules remains. As touched on in
Section 7.1.5, several mechanisms have been proposed related to how cells ensure that PLP is
guided to apoenzymes whilst preventing damaging accumulation of the free vitamer. These
include:
1. Significant substrate inhibition of pyridoxal kinase and PNPO by PLP prevents its accumu-
lation (Zhao and Winkler, 1995; Safo et al., 2006).
2. Free cellular PLP is dephosphorylated by phosphatases to form PL, which is subsequently
converted to 4-pyridoxic acid by aldehyde oxidase and NAD-dependent dehydrogenases for
urinary excretion.
3. Circulating PLP is protected from hydrolysis by phosphatases through protein binding.
In plasma, in excess of 95% of circulating PLP is bound to the Lys190 residue of human
serum albumin (Bohney et al., 1992). PLP also binds to the N-terminal amino acid of the
β-chain of deoxygenated haemoglobin in erythrocytes which decreases its affinity for oxygen
(Benesch et al., 1982).
4. It has been proposed that amino acids may carry PLP to apoenzymes and function to
provide a pool of bioavailable PLP. Each PLP-amino acid aldimine would react with a
corresponding apoenzyme whose substrate has a similar structure to allow for PLP transfer
within the active site. This hypothesis is largely based on the observation that, similarly to
our molecular weight cut-off experiments, a significant proportion of cellular PLP in E. coli
cells is "free" (i.e. not protein-bound) (Fu et al., 2001).
5. Both pyridoxal kinase and PNPO have also been proposed to have a channelling capacity,
protecting PLP from the cytosolic environment and interacting with each apoenzyme.
Structural and in vitro solution studies have revealed that one PLP molecule binds at a non-
catalytic site within a surface cleft of each PNPO monomer (Safo et al., 2005). This site lies
approximately 11 angstroms from the active site with a putative tunnel connecting the two,
allowing the spatial transfer of PLP without contacting the solvent. Indeed, crystallographic
studies have illustrated that a series of conformational changes occur following PNP binding
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at the active site that enlarge the putative channel to such an extent that PLP could pass
through (Safo et al., 2005). Studies have shown that more efficient conversion of certain
apoenzymes to holoenzymes occurs when PLP bound to the non-catalytic site of PNPO
was introduced to the cell extract when compared to free PLP (Yang and Schirch, 2000).
It has also been demonstrated that pyridoxal kinase can form complexes with multiple
B6-dependent enzymes including aspartate aminotransferase, alanine aminotransferase and
glutamate decarboxylase accompanied by the transfer of PLP (Kim et al., 1988; Cheung
et al., 2003). However, this hypothesis remains somewhat controversial as it requires that
these two structurally dissimilar proteins are able to recognise and bind to over 100 different
enzymes, encompassing many different topological folds.
It is highly unlikely that these mechanisms (if they indeed occur in vivo) are mutually exclusive.
Rather, the predominance of each is likely to be specific to each apoenzyme and determined by
its cellular location. Whilst the exact mechanisms underlying this function remain unknown, we
propose that PROSC is a PLP-carrier protein which protects PLP from endogenous phosphatase
activity as well as preventing unwanted side-reactions and ensuring a sufficient reservoir for
PLP-dependent apoenzymes.
One possible mechanism that we propose is that, once pyridoxal has entered the cell and
been phosphorylated by pyridoxal kinase, the PLP is transferred to the PLP binding site within
the β-barrel motif of PROSC. Thereby ensuring that the concentration of free cellular PLP is
maintained at low enough levels to prevent inappropriate reactions with other reactive molecules
(including amino acids, peptides and proteins) and also its dephosphorylation to pyridoxal by
endogenous phosphatases. When required, the PLP is then transferred from PROSC to B6-
dependent apoenzymes where it forms a Schiff base with specific lysine residues within their
active sites. Following catalysis PMP may be formed which can be recycled by PNPO back to
PLP and transferred again to PROSC (Figure 7.3.16).
As the results described in this chapter show, mutations in PROSC affect the homeostasis
of vitamin B6. This is likely due to the inability of the mutant protein to protect PLP (Figure
7.3.16). This not only results in the cofactor being dephosphorylated to pyridoxal, but due to
the highly reactive nature of PLP, the vitamer reacts with small molecules such as cysteine and
carnosine as well as the N-terminal amine of peptides and proteins. Whilst the total amount
of PLP (both bound and unbound) in patient cells and biofluids is high when supplemented
with supra-physiological concentrations of vitamin B6, under normal conditions the amount of
bioavailable PLP is insufficient in these patients. This results in decreased activity of enzymes
requiring PLP for effective catalysis and an increase in the concentration of their substrates. In
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Figure 7.3.16: Schematic illustrating the hypothesised function of PROSC and the
implications of its deficiency. Steps involving the interconversion/chemical
alteration of the B6 vitamer are shown as solid arrows. Those that simply involve
vitamer transfer between enzymes are shown as dashed arrows. The implications
of a deficiency or dysfunction of PROSC are depicted in the right-hand pathway
(red arrows). PL, pyridoxal; PLP, pyridoxal 5’-phosphate; PMP, pyridoxamine
5’-phosphate.
patients carrying these mutations this presents as an epilepsy that responds to treatment with
vitamin B6.
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7.3.10 Evaluation of the UPLC-MS/MS methods developed in this chapter
7.3.10.1 Effect of cell culture conditions on the quantitation of endogenous B6 vitamer concen-
trations
Whilst the method described in this chapter consistently identified trends in B6 vitamer profiles
between disease groups and individual patients, a degree of variability was noted in the absolute
vitamer concentrations (Figure 7.3.4). It is likely that a significant proportion of this variability
arose as a result of differences in passage number as each cell line was received at different times
throughout this project. Endeavours were made to control for this parameter, although the
passage number between patients varied by up to five. Reports have shown that increased time
in serial sub-culture results in increased cellular senescence, apoptosis, decreased fidelity of DNA
polymerase activity and alterations in metabolism including mitochondrial function (Mammone
et al., 2006; Linn et al., 1976; Shmookler Reis and Goldstein, 1983). To date, there have been
no reports describing the effects of passage number on vitamin B6 metabolism. However, this
metabolic pathway is facilitated by the action of multiple enzymes including pyridoxal kinase,
PNPO and intracellular phosphatases (Figure 7.1.1) and it is possible that the activity of these
enzymes may be affected by the time each cell line has spent in sub-culture, thereby changing the
vitamer profile. In addition to variations in the age of each fibroblast line, cellular metabolism
can be affected by culture conditions. For example, the turnover rate of proteins within cultured
cells has been estimated to be 1% per hour (Eagle et al., 1959). The degradation and turnover of
B6-dependent holoenzymes would be expected to result in the release of PMP which subsequently
is recycled using the salvage pathway to form PLP. In addition, small variations in factors such
as the confluence of each culture, time between media changes and media volume will affect
the amount of PN taken up by each cell. Although this would not be expected to affect the
intracellular vitamer composition, the absolute concentrations of each vitamer could be altered.
7.3.10.2 Advantages of the direct quantitation of PNPO activity in patient fibroblasts
Current published methods for investigating the pathogenicity of variants in PNPO have necessi-
tated the overexpression of each mutant protein in an artificial system (Mills et al., 2014; Plecko
et al., 2014). This requires various molecular techniques including site-directed mutagenesis,
cloning and transfection which are both costly and time-consuming. In addition, these methods
may not accurately recapitulate endogenous post-translational modifications, dimerisation and
folding; they also do not take into account the genetic background of each patient. Whilst, the
method we have described requires the patient to undergo a skin biopsy, once the fibroblast
cell line has been established the pathogenicity of sequence variants in PNPO can be rapidly
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determined. Furthermore, as a coupled assay, it is possible to not only measure PNPO activity
but also that of pyridoxal kinase, for which mutations have yet to be described. In addition,
supplementation of different compounds including B6 vitamers (e.g PN, PLP and PM) and
cofactors (e.g. flavin mononucleotide) can be trialled in vitro to provide optimal enzyme function
and potentially improve treatments for patients.
7.4 summary
In summary, methods have been developed to enable the functional assessment of patients
with known or suspected abnormalities of vitamin B6 metabolism with a view to providing
personalised medicine and a greater understanding of pathogenic mechanisms. These methods
have enabled the confirmation of a diagnosis of PNPO deficiency in the background of only
partially informative genetic analyses and provided evidence to suggest that PROSC is a protein
essential for intracellular PLP homoeostasis in humans. Supplementary B6 vitamer data should
be gathered from additional PNPO-deficient patients to further explore the reasons underlying
differences in treatment response. Finally, additional research should be undertaken to better
understand the function of PROSC and its deficiency. Generation of a knock-out animal model
followed by in-depth disease characterisation would be a valuable endeavour.
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8
CONCLUS IONS AND FUTURE WORK
This thesis has utilised next-generation sequencing technology and novel mass spectrometry-based
techniques to determine the cellular and molecular aetiologies for the clinical phenotypes observed
in patients with undiagnosed neurometabolic disorders (NMD). Inborn errors of metabolism
(IEM), of which NMD constitute a large sub-group, affect up to 1 in 500 newborns and account
for a significant proportion of morbidity and mortality both in childhood and the neonatal
period (Chiaratti de Oliveira et al., 2001). Indeed, defects in more than 600 genes are known
to cause these disorders. However, extreme genetic and phenotypic heterogeneity amongst IEM
often results in diagnostic delays, with potential consequential adverse neurological outcomes.
Ultimately it is hoped that research within these groups of patients will impact upon children and
their families by improving diagnosis and treatment options, thereby having a positive impact on
quality of life.
The work presented in Chapter 3 demonstrates the utility of an extended gene panel sequencing
approach to improve the diagnosis of patients with undiagnosed suspected NMD in clinical practice.
Indeed, this study highlighted findings that may have important implications not only for the
diagnosis of patients with complex NMD, but also the interpretation of routine biochemical tests
in wider patient populations. These include the propensity for patients to present with atypical or
wide-ranging clinical features, blended phenotypes resulting from more than one single-gene defect
or harbour mutations in genes causing disorders that are extremely rare or recently described.
However, the difficulties in predicting the functional consequences of novel sequence variants
were also emphasised. As noted by others (Walters-Sen et al., 2015), in silico prediction tools
were unable to consistently correctly assign pathogenicity. Future work is warranted to consider
the advantage and practicality of techniques such as computational protein structural analysis to
improve diagnostic specificity in situations where there is no scope for definitive in vitro assays.
This thesis also explores whole exome sequencing for the examination of patients in which
extensive genetic and biochemical testing has not identified a diagnosis, and molecular biology
techniques to explore their underlying aetiology. Chapter 5 presents the cases of five children
from two unrelated families affected by a severe developmental disorder accompanied by, in the
majority of cases early-onset seizures, who were found to have mutations in SLC25A22. Despite
being known to function as a mitochondrial glutamate transporter, no biochemical abnormalities
had been identified in any of the nine patients described in the literature. In contrast, multiple
abnormalities including hyperprolinaemia, low CSF glutamate and cellular lipid accumulation
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were observed in these cases. Taken together, these features indicated that SLC25A22 may
also function in vivo as a mitochondrial glutamate γ-semialdehyde transporter. In order to
substantiate this hypothesis, SLC25A22 should be reconstituted into liposomes as described by
Molinari et al. (2005) to determine whether this mitochondrial protein can indeed catalyse the
transport or exchange of this intermediate of proline metabolism.
Unlike the previous section in which novel phenotypes led to the proposition of alternative
protein functions, Chapter 6 aimed to determine whether sequence variants in CCBL1, a gene that
has not been previously associated with disease, were pathogenic in a patient with a movement
disorder and hyperlysinaemia. These variants were deemed to be good candidates due to the
known role of this protein in the homeostasis of kynurenic acid in the brain and postulated
function in lysine metabolism. Mass spectrometry-based studies revealed that the variants had
no effect on enzyme activity towards kynurenine but, despite trying several different approaches
in earnest, the possibility of CCBL1 playing a role in lysine metabolism has not been excluded.
Indeed, further studies to interrogate the crystal structure of this protein for possible binding
sites of lysine would be beneficial. In addition, evaluation of the effect of these sequence variants
on the other biological functions of CCBL1, including the metabolism of the cysteine conjugates
of certain halogenated alkenes and alkanes may reveal additional insights (Han et al., 2009b).
Much of this thesis focusses on the metabolism of vitamin B6 and the implications of genetic
defects affecting the homeostasis of these vitameric species. These disorders are a well known group
of NMD typically presenting with seizures which are intractable to treatment with conventional
antiepileptic drugs but respond to high-dose vitamin B6 therapy. Novel mass spectrometry-based
assays identified subtle differences in vitamer concentrations between patients with pyridox(am)ine
5’-phosphate oxidase (PNPO) deficiency depending on their response to treatment. This not
only paves the way for personalised medicine in these groups of patients to optimise the efficacy
and minimise the systemic toxicity of treatment, but also furthers the understanding of the
mechanisms underlying these differing therapeutic outcomes. Ongoing research to address the
latter would be best performed using larger patient cohorts and each assay should be adapted to
enable the analysis of dried blood spots for ease of patient sampling.
Nevertheless, as presented and discussed in Chapters 4 and 7, many patients present to
clinicians with seizures that are responsive to vitamin B6 but do not have PNPO or antiquitin
deficiency. In the former, the diagnosis of an apparently-responsive patient with a potassium
channelopathy required the detailed consideration of mechanisms underlying the anticonvulsant
effect of B6 vitamers in the wider epileptic population. The reasons behind this clinical response
are likely multi-factorial including the requirement of pyridoxal 5’-phosphate (PLP) as a cofactor
in the synthesis of GABA (the major inhibitory neurotransmitter in the brain), the ability
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of B6 vitamers to quench the reactive oxygen species released due to unregulated neuronal
firing, and the inhibited activation of P2X7 receptors which in turn reduces excitotoxicity and
neuroinflammation (Henshall et al., 2013). These hypotheses suggest that further research into
these mechanisms using patch clamping in cell-based systems or by assessing the neuropathological
effects of vitamin B6 treatment in an established epileptic mouse model (Löscher, 2011), may
lay the foundation for novel treatment protocols for intractable seizures. In contrast, Chapter
7 includes the investigation of the pathogenic mechanism underlying a novel inborn error of
vitamin B6 metabolism, PROSC deficiency. Patients with this disorder were found to have an
inability to regulate their cellular PLP levels, suggesting that the PROSC protein functions to
chaperone PLP to the enzymes which require it as an essential cofactor. The severe seizures
affecting these patients are hypothesised to be propagated by the uncontrolled reactions of PLP
with proteins and metabolites, not only resulting in a physiological PLP deficiency but also of
small molecules (e.g. cysteine) and the impaired function of attacked enzymes. The detection
of stable complexes of PLP with other metabolites in order to provide evidence to support this
theory proved to be technically challenging. However, the adaptation of novel methods that use
hydrophillic interaction liquid chromatography and ultra-violet detection for the quantitation of
physiochemically similar molecules would be a valuable endeavour (Głowacki et al., 2016).
The work contained within this thesis has provided a genetic diagnosis for more than twenty
patients who, despite extensive genetic and often invasive biochemical testing over many years,
remained undiagnosed. It has also expanded the genotypic and phenotypic spectrum of many
neurometabolic disorders and resulted in the implementation of comprehensive clinical genetic
analysis for inborn errors of metabolism, which it is hoped will benefit many children in the
future. However, nine patients remained undiagnosed following gene panel sequencing and whole
exome sequencing failed to identify a diagnosis in six families. In these cases, a whole genome
sequencing approach should be employed as disease may be due to mutations in genes that have
not been associated with disease previously or are not amenable to targeted capture methodologies.
Indeed, the underlying aetiology of disease may be due to a mutation that, due to a lack of
supporting bioinformatic and functional evidence, are currently classified as variants of uncertain
significance. As the number of individuals who have had their exome or genome sequenced
rapidly increases, databases containing population frequency data will become more populated,
which will aid in the interpretation of patient data. However, there is a need for the development
of high-throughput functional assays to assess the potential pathogenicity of variants that have
not been associated with disease previously. Indeed, as healthcare shifts towards a paradigm of
"personalised medicine" (i.e. using each individual’s genetic profile to guide decisions made in
regard to the prevention, diagnosis and treatment of disease), the complexity of unravelling the
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relationship between genotype and phenotype of both rare and common disorders will remain at
the forefront.
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APPENDICES
9.1 confirmation of gene panel findings by sanger sequencing
Table 9.1.1: Primers and conditions used to amplify and sequence gene panel find-
ings. Primers to amplify TPP1 are not listed because confirmatory Sanger
sequencing was performed on a clinical basis at North East Thames Regional
Genetic Service, GOSH, UK.
Gene Sequence 5’ → 3’ Tm
(◦C)
MgCl2
(mM)
Product
size (bp)
POMGNT1
(splice F)
GTCCATGTCTGCCAGCTCT 64 1.5 250
POMGNT1
(splice R)
CCCAAGGTTACATGGCTAGC
POMGNT1
(missense F)
TGTTTCAAGCAGCTGGTGTT 58 1.5 232
POMGNT1
(missense R)
ACTTCTGGTGAGTTGGTGTCA
ACSF3 (F) CTGGCATAGCTGTTTCTCCG 62 1.5 389
ACSF3 (R) GACTCATCTGCAGTCGTCTAA
PEX6 (F) TGCCAACTCTGTTTCTTCCTG 60 1 293
PEX6 (R) CCTCAAACTCCTGGGCTCAA
AFG3L2 (F) TGTTCTACCATAGCTCAGATGTT 60 1.5 370
AFG3L2 (R) AGGGCCATCTCTAGCAAGTG
SERAC1 (F) CCCATTCGGCCTCTTTCAGT 62 1.5 383
SERAC1 (R) TACAGCGCTTGAAGGGAGAA
PGAP2 (F) AATTACCTGCCCTCGGTGAG 60 1.5 534
PGAP2 (R) TTTTCTTCTGGGCTGCCTTG
DPYS (F) TCCGGATTTGCAGCCTGA 64 1 583
DPYS (R) GACCCCAGCGAAGAGAATCT
GALE (F) GCATTGCCAAGGACTAAAACC 64 1.5 201
GALE (R) CTAGTGTCTGTGCCCTGTCC
ALDOB (F) GGTCTTCTCCCTGGAACAC 62 1.5 500
ALDOB (R) GATGGAAAAGGGTGAGAAGAGA
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1.      Disorders of amino acid and peptide metabolism
1.1.        Urea cycle disorders and inherited hyperammonaemias
1.1.1.         Carbamoylphosphate synthetase I deficiency CPS1
1.1.2.         N-Acetylglutamate synthetase deficiency NAGS
1.1.3.         Ornithine transcarbamylase deficiency OTC
1.1.4.         Citrullinaemia type1 ASS1
1.1.5.         Argininosuccinic aciduria ASL
1.1.6.         Argininaemia ARG1
1.1.7.         HHH syndrome SLC25A15
1.1.8.         Citrullinemia Type 2 SLC25A13
1.1.9.         Hyperinsulinemic hypoglycemia and hyperammonemia GLUD1
1.1.10.        Hyperammonemia CA5A
1.2.        Organic acidurias
1.2.1.         Glutaric aciduria
1.2.1.1.           Glutaric aciduria type I GCDH
1.2.1.2.           Glutaric aciduria type III C7orf10
PCCA
PCCB
1.2.3.         Methylmalonic aciduria
1.2.3.1.           Methylmalonyl-CoA mutase deficiency MUT
1.2.3.2.           Methylmalonyl-CoA epimerase deficiency MCEE
1.2.4.         Isovaleric aciduria IVD
1.2.5.         Methylcrotonylglycinuria MCCC1
MCCC2
1.2.6.         Methylglutaconic aciduria
1.2.6.1.           Methylglutaconic aciduria type I AUH
1.2.6.2.           Methylglutaconic aciduria type II, Barth syndrome TAZ
1.2.6.3.           Methylglutaconic aciduria type III, Costeff syndrome OPA3
1.2.6.4.           Methylglutaconic aciduria type IV
1.2.6.5.           Methylglutaconic aciduria type V DNAJC19
1.2.6.6.           Methylglutaconic aciduria with deafness, encephalopathy 
and Leigh-like syndrome (MEGDEL)
SERAC1
1.2.7.         3-Hydroxy-3-methyl-glutaric aciduria HMGCL
1.2.8.         2-Methylbutyric aciduria ACADSB
1.2.9.         2-Methyl-3-hydroxybutyric aciduria, HSD10 disease HSD17B10
1.2.10.     3-Oxothiolase deficiency ACAT1
1.2.11.     Isobutyric aciduria ACAD8
1.2.12.     Methacrylic aciduria HIBCH
1.2.13.     3-Hydroxyisobutyric aciduria ALDH6A1
1.2.14.     Methylmalonate semialdehyde dehydrogenase deficiency ALDH6A1
1.2.15.     L-2-hydroxyglutaric aciduria L2HGDH
1.2.16.     D-2-hydroxyglutaric aciduria
1.2.16.1.       D-2-hydroxyglutarate dehydrogenase deficiency D2HGDH
1.2.16.2.       Mitochondrial isocitrate dehydrogenase deficiency IDH2
Disease group / disease
1.2.2.         Propionic aciduria
Gene name
9.2 list of genes included in iem gene panel grouped by disease class
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1.2.17.     Aminoacylase deficiency
1.2.17.1.       Aminoacylase 1 deficiency ACY1
1.2.17.2.       Aminoacylase 2 deficiency ASPA
1.2.18.     Methylmalonate semialdehyde dehydrogenase deficiency ALDH6A1
1.2.19.     Combined methylmalonic and malonic aciduria ACSF3
1.2.20.     Malonyl-CoA decarboxylase deficiency MLYCD
1.3.        Disorders of the metabolism of branched-chain amino acids not 
classified as organic acidurias
1.3.1.         Branched-chain amino acid transferase BCAT1
BCAT2
1.3.2.         Maple syrup urine disease
1.3.2.1.           BCKD E1 alpha subunit of deficiency BCKDHA
1.3.2.2.           BCKD E1 beta subunit of deficiency BCKDHB
1.3.2.3.           Dihydrolipoamide branched chain transacylase deficiency DBT
1.4.        Disorders of phenylalanine or tyrosine metabolism
1.4.1.         Phenylalanine hydroxylase deficiency PAH
1.4.2.         Tyrosinaemia type II TAT
1.4.3.         4-hydroxyphenylpyruvate dioxygenase deficiency HPD
S       Tyrosinaemia type III
S       Hawkinsinuria
1.4.4.         Alkaptonuria HGD
1.4.5.         Tyrosinaemia type I FAH
1.5.        Disorders of the metabolism of sulphur amino acids
1.5.1.         Methionine adenosyltransferase I/III deficiency MAT1A
1.5.2.         Glycine N-methyltransferase deficiency GNMT
1.5.3.         S-adenosylhomocysteine hydrolase deficiency AHCY
1.5.4.         Cystathionine beta-synthase deficiency CBS
1.5.5.         Cystathionase deficiency CTH
1.5.6.         Isolated sulfite oxidase deficiency SUOX
1.5.7.         Methionine synthase deficiency-cblG MTR
1.5.8.         Methionine synthase reductase deficiency-cblE MTRR
1.6.        Disorders of histidine, tryptophan or lysine metabolism
1.6.1.         Histidinaemia HAL
1.6.2.         Urocanase deficiency UROC1
1.6.3.         Glutamate formiminotransferase deficiency FTCD
1.6.4.         Tryptophanaemia TDO2
1.6.5.         Hyperlysinaemia AASS
PTPRZ1
1.6.6.         2-Aminoadipic aciduria DHTKD1
1.6.7.         2-Oxoadipic aciduria DHTKD1
1.6.8.         Hydroxykynureninuria KYNU
1.6.9.         Hydroxylysinuria AGPHD1
AGXT2L2
1.7.        Disorders of serine, glycine or glycerate metabolism
1.7.1.         Phosphoglycerate dehydrogenase deficiency PHGDH
1.7.2.         Phosphoserine phosphatase deficiency PSPH
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1.7.3.         Phosphoserine aminotransferase deficiency PSAT1
1.7.4.         Nonketotic hyperglycinaemia
1.7.4.1.           P protein deficiency GLDC
1.7.4.2.           T protein deficiency AMT
1.7.4.3.           H protein deficiency GCSH
1.7.5.         Sarcosinaemia SARDH
1.7.6.         D-glyceric aciduria GLYCTK
1.8.        Disorders of ornithine or proline metabolism
1.8.1.         Ornithine aminotransferase deficiency OAT
1.8.2.         Hyperprolinaemia type I PRODH
1.8.3.         Hyperprolinaemia type II ALDH4A1
1.8.4.         Hypoprolinaemia, Cutis laxa, autosomal recessive, type IIIa ALDH18A1
1.9.        Disorders of amino acid transport
1.9.1.         Lysinuric protein intolerance SLC7A7
SLC3A1
SLC7A9
1.9.3.         Cystinuria-hypotonia syndrome (contiguous gene defect)
1.9.4.         Hartnup disease SLC6A19
1.9.5.         Iminoglycinuria SLC36A2
1.9.6.         Lowe syndrome OCRL
1.9.7.         Hypotonia-cystinuria syndrome SLC3A1
1.9.8.         Hypotonia-cystinuria syndrome PREPL
1.10.     Other disorders of amino acid metabolism
1.10.1.     Glutamine deficiency, congenital GLUL
1.11.     Disorders of the gamma-glutamyl cycle
1.11.1.     Glutathionuria GGT1
1.11.2.     Cysteinylglycinase deficiency DPEP1
1.11.3.     Oxoprolinuria OPLAH
1.11.4.     Gamma-glutamylcysteine synthetase deficiency GCLC
1.11.5.     Glutathione synthetase deficiency GSS
1.12.     Other disorders of peptide metabolism
1.12.1.     Prolidase deficiency PEPD
1.12.2.     Carnosinaemia CNDP1
1.12.3.     Homocarnosinosis
1.13.     Other disorders of amino acid and protein metabolism
2.      Disorders of carbohydrate metabolism
2.1.        Disorders of galactose metabolism
2.1.1.         Classical galactosaemia GALT
2.1.2.         Galactokinase deficiency GALK1
2.1.3.         Uridine diphosphate galactose-4-epimerase deficiency GALE
2.2.        Disorders of fructose metabolism
2.2.1.         Essential fructosuria KHK
2.2.2.         Hereditary fructose intolerance ALDOB
1.8.5.         Cutis laxa, autosomal recessive, type IIb/IIIb PYCR1
1.9.2.         Cystinuria
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2.3.        Disorders of pentose metabolism
2.3.1.         Essential pentosuria DCXR
2.3.2.         Ribose-5-phosphate isomerase deficiency RPIA
2.3.3.         Transaldolase deficiency TALDO1
2.4.        Disorders of glycerol metabolism
2.4.1.         Glycerol kinase deficiency GK
2.4.2.         Complex glycerol kinase deficiency due to contiguous gene deletion
2.5.        Disorders of glyoxylate metabolism
2.5.1.         Primary hyperoxaluria type I AGXT
2.5.2.         Primary hyperoxaluria type II GRHPR
2.6.        Disorders of glucose transport
2.6.1.         Glucose transporter 1 deficiency (blood-brain barrier) SLC2A1
2.6.2.         Glucose transporter 2 deficiency SLC2A2
S       Fanconi-Bickel syndrome
2.6.3.         Glucose/galactose malabsorption SLC5A1
2.7.        Disorders of gluconeogenesis
2.7.1.         Fructose-1,6-bisphosphatase deficiency FBP1
2.7.2.         Pyruvate carboxylase deficiency PC
2.7.3.         Phosphoenolpyruvate carboxykinase deficiency PCK1
2.8.        Glycogen storage disorders
2.8.1.         Glycogen storage disease type 1a, von Gierke G6PC
2.8.2.         Glycogen storage disease type 1b, von Gierke SLC37A4
2.8.3.         Glycogen storage disease type II, Pompe GAA
2.8.4.         Glycogen storage disease type III, Cori AGL
2.8.5.         Glycogen storage disease type IV, Andersen GBE1
2.8.6.         Glycogen storage disease type V, McArdle PYGM
2.8.7.         Glycogen storage disease type VI, Hers PYGL
2.8.8.         Glycogen storage disease type VII, Tarui PFKM
2.8.9.         Glycogen storage disease type IX
2.8.9.1.           Hepatic phosphorylase kinase deficiency PHKA2
2.8.9.2.           Hepatic and muscle phosphorylase kinase deficiency PHKB
2.8.9.3.           Hepatic phosphorylase kinase deficiency with cirrhosis PHKG2
2.8.9.4.           Muscle phosphorylase kinase deficiency PHKA1
2.8.9.5.           Cardiac muscle phosphorylase kinase deficiency PRKAG2
2.8.10.     Glycogen storage disease type X PGAM2
2.8.11.     Glycogen storage disease type XI SLC2A2
2.8.12.     Glycogen storage disease type XIV PGM1
2.8.13.     Glycogen storage disease type XV GYG1
2.8.14.     Glycogen storage disease type 0a, liver GYS2
2.8.15.     Glycogen storage disease type 0b, muscle GYS1
2.8.16.     Other glycogen storage disease
2.8.16.1.       Muscle LDH deficiency LDHA
2.8.16.2.       Aldolase A deficiency ALDOA
2.8.16.3.       Beta-enolase deficiency ENO3
2.8.16.4.       Phosphoglycerate kinase deficiency PGK1
2.8.17.     Unspecified glycogen storage disease
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2.9.        Other carbohydrate disorders 
2.9.1.         Lactose intolerance LCT
2.9.2.         Disaccharide intolerance 1 SI
2.9.3.         Trehalase deficiency TREH
3.      Disorders of fatty acid and ketone body metabolism
3.1.        Disorders of lipolysis
3.1.1.         Neutral lipid storage disease ABHD5
3.2.        Disorders of carnitine transport and the carnitine cycle
3.2.1.         Carnitine transporter deficiency SLC22A5
3.2.2.         Carnitine palmitoyltransferase I (CPTI) deficiency CPT1A
3.2.3.         Carnitine acylcarnitine translocase deficiency SLC25A20
3.2.4.         Carnitine palmitoyltransferase II (CPTII) deficiency CPT2
3.3.        Disorders of mitochondrial fatty acid oxidation
3.3.1.         Very long - chain acyl CoA dehydrogenase deficiency ACADVL
HADHA
HADHB
3.3.3.         Medium - chain acyl CoA dehydrogenase deficiency ACADM
3.3.4.         Short - chain acyl CoA dehydrogenase deficiency ACADS
3.3.5.         3-alpha-hydroxyacyl- CoA dehydrogenase deficiency HADH
3.3.6.         Multiple acyl-CoA dehydrogenase deficiency
3.3.6.1.           Electron transfer flavoprotein deficiency, alpha chain ETFA
3.3.6.2.           Electron transfer flavoprotein deficiency, beta chain ETFB
3.3.6.3.           ETF-ubiquinone oxidoreductase deficiency ETFDH
3.4.        Disorders of ketone body metabolism
3.4.1.         3-Hydroxy-3-Methylglutaryl-CoA synthase deficieny HMGCS2
3.4.2.         Succinyl-CoA:3-Oxoacid-CoA transferase (SCOT) deficiency OXCT1
3.4.3.         Cytosolic acetoacetyl-CoA thiolase deficiency ACAT1
3.5.        Other disorders of fatty acid and ketone body metabolism
3.5.1.         Malonyl CoA decarboxylase deficiency MLYCD
4.      Disorders of energy metabolism
4.1.        Disorders of pyruvate metabolism
4.1.1.         Pyruvate dehydrogenase complex deficiency
4.1.1.1.           Pyruvate dehydrogenase E1α subunit deficiency PDHA1
4.1.1.2.           Pyruvate dehydrogenase E1β subunit deficiency PDHB
4.1.1.3.           Dihydrolipoyl transacetylase deficiency DLAT
4.1.1.4.           Dihydrolipoyl dehydrogenase deficiency DLD
4.1.1.5.           Pyruvate dehydrogenase E3 binding protein deficiency PDHX
4.1.1.6.           Pyruvate dehydrogenase kinase deficiency PDK1
PDK2
PDK3
PDK4
4.1.1.7.           Pyruvate dehydrogenase phosphatase deficiency PDP1
PDP2
PDPR
3.3.2.         Mitochondrial trifunctional protein deficiency
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4.1.1.8.           Pyruvate dehydrogenase deficiency, unspecified
4.2.        Disorders of the citric acid cycle
OGDH
DLST
4.2.2.         Fumarase deficiency FH
4.3.        Mitochondrial respiratory chain disorders (caused by nuclear 
mutations only)
4.3.1.         OXPHOS structural subunits
4.3.1.1.           Complex I NDUFS1
NDUFS2
NDUFS3
NDUFS4
NDUFS6
NDUFS7
NDUFS8
NDUFV1
NDUFV2
NDUFA1
NDUFA2
NDUFA9 
NDUFA10 
NDUFA11
NDUFA12
NDUFB3
NDUFB9
4.3.1.2.           Complex II SDHA
SDHB
SDHC
SDHD
4.3.1.3.           Complex III UQCRB
UQCRQ
4.3.1.4.           Complex IV COX4I2
COX6B1
COX7B
4.3.1.4.           Complex V ATP5E
ATP5A1
4.3.2.         OXPHOS assembly factors
4.3.2.1.           Complex I NDUFAF1
NDUFAF2
NDUFAF3
NDUFAF4
NDUFAF6
NDUFAF5
NUBPL
FOXRED1
ACAD9
4.2.1.         2-Oxoglutarate dehydrogenase deficiency
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4.3.2.2.           Complex II SDHAF1
SDHAF2
4.3.2.3.           Complex III BCS1L
HCCS
TTC19
4.3.2.4.           Complex IV SURF1
SCO2
SCO1
COX10
COX15
LRPPRC 
FASTKD2
ETHE1 
TACO1
COA5
COX14
COX20
4.3.2.5.           Complex V ATPAF2
TMEM70
4.3.3.         Required for mtDNA maintenance POLG
POLG2
C10orf2
SLC25A4
TYMP
DGUOK
TK2
SUCLA2
SUCLG1
MPV17
RRM2B
4.3.4.         Required for mitochondrial gene expression PUS1
MTO1 
MRPS16
MRPS22
MRPL3 
GFM1
TSFM
TUFM
AARS2 
DARS2
EARS2 
FARS2 
HARS2 
IARS2
LARS2
MARS2
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RARS2
SARS2 
YARS2
TRMU
MTFMT 
MTPAP 
C12orf65
RMND1
4.3.5.         Defective Fe-S/lipoic acid biosynthesis ISCU 
FXN
NFU1
BOLA3
LIAS
ABCB7
GLRX5
4.3.6.         Disorders of CoQ10 biosynthesis PDSS1
PDSS2
COQ2
ADCK3
COQ9
COQ6
COQ4
4.3.7.         Secondary CoQ10 deficiency APTX
SETX
ETFDH
4.3.8.         Disorders of mitochondrial solute import SLC25A3
SLC25A12
SLC25A22
SLC25A38
4.3.9.         Disorders of mitochondrial protein import TIMM8A
DNAJC19
GFER
PNPT1
4.3.10.         Disorders of mitochondrial membrane lipids TAZ
AGK
SERAC1
4.3.11.         Disorders of mitochondrial dynamics, fusion and fission MFN2
OPA1
DNM1L
MFF
4.3.12.         Miscellaneous disorders/unknown function AIFM1
TMEM126A
SPG7
HSPD1
AFG3L2
4.3.12.1.           Hyperoxaluria Type III HOGA1
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4.3.12.1.           Charcot-Marie-Tooth disease, recessive intermediate, B 
(Lysyl-tRNA synthetase mutations) KARS
4.3.12.1.           Spinocerebellar ataxia-7 ATXN7
4.3.12.1.           Succinyl CoA:3-oxoacid CoA transferase deficiency OXCT1
4.3.12.1.           Parkinson disease 6, early onset PINK1
4.3.12.1.           Hypotonia-cystinuria syndrome PPM1B
4.3.12.1.           Wolfram syndrome 1 WFS1
4.3.12.1.           Wolfram syndrome 2 CISD2
4.3.13.         Disorders of creatinine metabolism
4.3.13.1.           Creatine transporter deficiency SLC6A8
4.3.13.2.           Guanidinoacetate methyltransferase deficiency GAMT
4.3.13.3.           Arginine:glycine amidinotransferase deficiency GATM
5.      Disorders in the metabolism of purines, pyrimidines and nucleotides
5.1.        Disorders of purine metabolism
5.1.1.         Primary idiopathic gout ABCG2
5.1.2.         Familial juvenile hyperuricaemic nephropathy UMOD
5.1.3.         Adenylosuccinate lyase deficiency ADSL
5.1.4.         AICAR transformylase deficiency ATIC
5.1.5.         Adenosine deaminase deficiency ADA
5.1.6.         Deoxyguanosine kinase deficiency DGUOK
5.1.7.         Myoadenylate deaminase deficiency AMPD1
5.1.8.         Lesch-Nyhan syndrome HPRT1
5.1.9.         Adenine phosphoribosyl transferase deficiency APRT
5.1.10.     Phosphoribosyl pyrophosphate synthetase 1 defects PRPS1
5.1.11.     Inosine triphosphatase deficiency ITPA
5.1.12.     Adenosine deaminase superactivity
5.1.13.     Purine nucleoside phosphorylase deficiency PNP
5.1.14.     Mitochondrial Ribonucelotide Reductase subunit 2 deficiency RRM2B
5.1.15.     Xanthinuria type I XDH
5.1.16.     Xanthinuria type II XDH
AOX1
5.1.17.      Thiopurine S-methyltransferase deficiency TPMT
5.2.        Disorders of pyrimidine metabolism
5.2.1.         Orotic aciduria UMPS
5.2.2.         Pyrimidine - 5 - nucleotidase deficiency NT5C
5.2.3.         Dihydroorotate dehydrogenase deficiency DHODH
5.2.4.         Uridine-5’-monophosphate hydrolase superactivity NT5C3
5.2.5.         Thymidine phosphorylase deficiency TYMP
5.2.6.         Thymidine kinase 2 deficiency TK2
5.2.7.         Dihydropyrimidine dehydrogenase deficiency DPYD
5.2.8.         Dihydropyrimidinase deficiency DPYS
5.2.9.         Beta-ureidopropionase deficiency UPB1
5.2.10.     Hyper-beta-alaninaemia
5.2.11.     Beta-aminoisobutyrate-pyruvate transaminase deficiency
5.3.        Disorders of nucleotide metabolism
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5.3.1.         Aicardi-Goutières Syndrome (AGS)
5.3.1.1.           AGS1 TREX1
5.3.1.2.           AGS2 RNASEH2B
5.3.1.3.           AGS3 RNASEH2C
5.3.1.4.           AGS4 RNASEH2A
5.3.1.5.           AGS5 SAMHD1
5.3.1.6.       AGS6 ADAR
5.3.2.         RNASET2-deficient cystic leukoencephalopathy RNASET2
6.      Disorders of the metabolism of sterols
6.1.        Disorders of sterol biosynthesis
6.1.1.         Mevalonate kinase deficiency MVK
6.1.2.         Smith - Lemli - Opitz syndrome DHCR7
6.1.3.         X-linked dominant chondrodysplasia punctata 2 EBP
6.1.4.         Congenital hemidysplasia with ichtyosiform erythroderma and limb 
defects 
NSDHL
6.1.5.         Desmosterolosis DHCR24
6.1.6.         Lathosterolosis SC5DL
6.1.7.         Greenberg skeletal dysplasia LBR
6.1.8.         Antley-Bixler syndrome
6.1.8.1.           Antley-Bixler syndrome with disordered steroidogenesis POR
6.1.8.2.           Antley-Bixler syndrome type without disordered 
steroidogenesis
FGFR2
6.1.9.         Sterol-C4-methyl oxidase deficiency MSMO1
6.2.        Disorders of bile acid biosynthesis
6.2.1.         3- β-hydroxysterol  Δ5-oxidoreductase/isomerase deficiency HSD3B7
6.2.2.          Δ4-3-oxysterol 5β-reductase deficiency AKR1D1
6.2.3.         Oxysterol 7-alpha-hydroxylase deficiency CYP7B1
6.2.4.         Cholesterol 7-alpha-hydroxylase deficiency CYP7A1
6.2.5.         Cerebrotendinous xanthomatosis CYP27A1
6.2.6.         Bile acid amidation defect BAAT
6.2.7.      Bile acid CoA ligase deficiency SLC27A5
6.3.        Disorders of bile acid metabolism and transport
6.3.1.         Bilirubin UDP-glucuronosyltransferase 1 deficiency UGT1A1
6.3.2.         Byler disease ATP8B1
6.3.3.         Progressive familial intrahepatic cholestasis type 2 ABCB11
6.3.4.         Progressive familial intrahepatic cholestasis type 3 ABCB4
6.4.        Other disorders in the metabolism of sterols
6.4.1.         X-linked ichthyosis STS
7.      Disorders of porphyrin and haem metabolism
7.1.1.         Acute neuropathic porphyrias
7.1.1.1.           Acute intermittent porphyria HMBS
7.1.1.2.           Variegate porphyria PPOX
7.1.1.3.           Hereditary coproporphyria CPOX
7.1.1.4.           Acute hepatic porphyria ALAD
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7.1.2.         Porphyrias with erosive photodermatosis
7.1.2.1.           Porphyria cutanea tarda UROD
7.1.2.2.           Congenital erythropoietic porphyria UROS
7.1.3.         Porphyrias with acute painful photosensitivity
7.1.3.1.           Erythropoietic protoporphyria FECH
7.1.3.2.           X-linked dominant protoporphyria ALAS2
7.1.3.3.           X-linked sideroblastic anaemia (XLSA) ALAS2
8.      Disorders of lipid and lipoprotein metabolism
8.1.        Inherited hypercholesterolaemias
8.1.1.         Disorder of low density lipoprotein receptor LDLR
ABCG5
ABCG8
8.2.1.         Autosomal dominant hypercholesterolemia-3 PCSK9
8.2.1.         Autosomal recessive hypercholesterolemia LDLRAP1
8.2.        Inherited hypertriglyceridaemias
8.2.1.         Familial chylomicronaemia 
8.2.1.1.           Familial lipoprotein lipase deficiency LPL
8.2.1.2.           Familial apolipoprotein C - II deficiency APOC2
APOA5
LIPI
8.3.        Inherited mixed hyperlipidaemias
8.3.1.         Familial dysbetalipoproteinaemia APOE
8.3.2.         Familial combined hyperlipoproteinaemia USF1
8.3.3.         Hepatic lipase deficiency LIPC
8.4.        Disorders of high density lipoprotein metabolism
8.4.1.         Apolipoprotein A-I deficiency APOA1
8.4.2.         Tangier disease ABCA1
8.4.3.         Lecithin cholesterol acyltransferase deficiency LCAT
8.4.3.1.           Fish-eye disease
8.4.3.2.           Norum disease
8.4.4.         Familial hyperalphalipoproteinaemia CETP
8.5.        Inherited hypolipidaemias
8.5.1.         Familial abetalipoproteinaemia MTTP
8.5.2.         Familial hypobetalipoproteinaemia APOB
8.5.3.         Anderson disease SAR1B
8.5.3.         Scavenger receptor class B type I deficiency  SCARB1
8.6.        Other disorders of lipid and lipoprotein metabolism
8.6.1.1.           Sjøgren - Larsson syndrome ALDH3A2
8.6.1.2.           Pancreatic triacylglycerol lipase deficiency PNLIP
8.6.1.3.           Pancreatic colipase deficiency CLPS
8.7.        Unspecified disorders of lipid and lipoprotein metabolism
8.8.        Disorders of complex lipid synthesis
8.8.1.     Serine palmitoyl transferase deficiency SPTLC1
8.8.2.     Serine palmitoyl transferase deficiency SPTLC2
8.8.3.     Fatty acid 2-hydroxylase deficiency FA2H
8.1.2.         Sitosterolaemia
8.2.2.         Familial hypertriglyceridaemia
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8.8.4.     Phosphatidate phosphatase deficiency LPIN1
8.8.5.     Phospholipase A2 deficiency PLA2G6
8.8.6.     PHARC syndrome ABHD12
8.8.7.     Choline kinase deficiency  CHKB
8.8.8.     GM3 synthase deficiency ST3GAL5
8.8.9.     Acylglycerol kinase deficiency (Senger syndrome) AGK
9.      Congenital disorders of glycosylation and other disorders of protein 
modification
S       CDG
9.1.        Disorders of protein N-glycosylation
9.1.1.         Phosphomannomutase 2 deficiency PMM2
9.1.2.         Phosphomannose isomerase deficiency MPI
9.1.3.         Glucosyltransferase 1 deficiency ALG6
9.1.4.         Mannosyltransferase 6 deficiency ALG3
9.1.5.         Mannosyltransferase 8 deficiency ALG12
9.1.6.         Glucosyltransferase 2 deficiency ALG8
9.1.7.         Mannosyltransferase 2 deficiency ALG2
9.1.8.         UDP-GlcNAc:Dol-P-GlcNac-P transferase deficiency DPAGT1
9.1.9.         Mannosyltransferase 1 deficiency ALG1
9.1.10.     Mannosyltransferase 7-9 deficiency ALG9
9.1.11.     Flippase of Man5GlcNAc2-PP-Dol deficiency RFT1
9.1.12.     N-acetylglucosaminyltransferase deficiency MGAT2
9.1.13.     Glucosidase 1 deficiency GLS
9.1.14.     TUSC3-CDG TUSC3
9.1.15.     SRD5A3-CDG SRD5A3
9.1.16.     Mannosyltransferase 1 deficiency ALG1
9.1.17.     Congenital myasthenic sydrome ALG14
9.1.17.     Congenital myasthenic sydrome GFPT1
9.1.17.     ALG13-CDG ALG13
9.1.17.     ALG11-CDG ALG11
9.1.17.     ALG3-CDG ALG3
9.1.17.     ALG9-CDG ALG9
9.1.17.     IAP-CDG MAGT1
9.1.17.     MOGS-CDG MOGS
9.1.17.     MAN1B1-CDG MAN1B1
9.1.17.     ST3GAL3-CDG ST3GAL3
9.2.        Disorders of protein O-glycosylation
9.2.1.         O-xylosylglycan synthesis deficiencies
9.2.1.1.           Multiple exostoses type I EXT1
9.2.1.2.           Multiple exostoses type II EXT2
9.2.1.3.            Beta-1,4-galactosyltransferase 7 deficiency B4GALT7
9.2.2.         O-N-acetylgalactosaminylglycan synthesis deficiencies
9.2.2.1.           Polypeptide N-acetylgalactosaminyl transferase deficiency GALNT3
9.2.2.2.           GALNT12-CDG GALNT12
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9.2.2.3.           COSMC-CDG C1GALT1C1
9.2.3.         O-xylosyl/N-acetylgalactosaminylglycan synthesis deficiencies SLC35D1
9.2.4.         O-mannosylglycan synthesis deficiencies
9.2.4.1.           Protein-O-mannosyltransferase 1 deficiency POMT1
9.2.4.2.           Protein-O-mannosyltransferase 2 deficiency POMT2
9.2.4.3.           Protein-O-mannose beta-1,2-N-
acetyglucosaminyltransferase deficiency
POMGNT1
9.2.4.4.           Fukutin deficiency FKTN
9.2.4.5.           Fukutin-related protein deficiency FKRP
9.2.4.6.           N-acetylglucosaminyltransferase-like protein deficiency LARGE
9.2.4.7.           O-fucose-specific beta-1,3-N-acetylglucosaminyltransferase 
deficiency
LFNG
9.2.4.8.           O-fucose-specific beta-1,3-N-glucosyltransferase deficiency B3GALTL
9.2.4.8.               LFNG-CDG LFNG
9.2.4.8.           B4GALT7-CDG B4GALT7
9.2.4.8.           B3GAT3-CDG B3GAT3
9.2.4.8.           CHSY1-CDG CHSY1
9.2.4.8.           CHST3-CDG CHST3
9.2.4.8.           CHST14-CDG CHST14
9.2.4.8.           CHST6-CDG CHST6
9.3.        Disorders of glycosphingolipid and glycosylphosphatidylinositol 
anchor glycosylation
9.3.1.1.           Lactosylceramide alpha-2,3-sialyltransferase deficiency ST3GAL5
9.3.1.2.           Phosphatidylinositolglycan, class M deficiency PIGM
9.3.1.3.           Hyperphosphatasia PIGV
9.3.1.4.           Hyperphosphatasia PIGO
9.3.1.4.           PIGA-CDG PIGA
9.3.1.4.           PIGL-CDG PIGL
9.3.1.4.           PIGN-CDG PIGN
9.3.1.4.           PGAP2-CDG PGAP2
9.4.        Disorders of multiple glycosylation and other glycosylation 
pathways
9.4.1.          GDP-Man:Dol-P mannosyltransferase deficiency DPM1
9.4.2.          Lec35 deficiency MPDU1
9.4.3.         Beta-1,4-galactosyltransferase 1 deficiency B4GALT1
9.4.4.         UDP-GlcNAc epimerase/kinase deficiency GNE
9.4.5.          CMP-sialic acid transporter deficiency SLC35A1
9.4.6.          GDP-fucose transporter deficiency SLC35C1
9.4.7.         Dolichol pathway deficiencies
9.4.7.1.           Dolichol kinase deficiency DOLK
9.4.8.         Conserved oligomeric Golgi (COG) complex deficiency
9.4.8.1.            Component of COG complex 7 deficiency COG7
9.4.8.2.           Component of COG complex 1 deficiency COG1
9.4.8.3.           Component of COG complex 8 deficiency COG8
9.4.8.3.           Component of COG complex 4 deficiency COG4
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9.4.8.3.           Component of COG complex 5 deficiency COG5
9.4.8.3.           Component of COG complex 6 deficiency COG6
9.4.9.         V-ATPase deficiencies
9.4.9.1.            V0 subunit A2 of vesicular H(+)-ATPase deficiency ATP6V0A2
9.4.9.2.           COPII component SEC23B SEC23B
9.5.        Disorders of protein ubiquitinylation
9.6.        Other disorders of protein modification
9.6.        Other CDGs
9.6.1.          SLC35A2-CDG SLC35A2
9.6.1.          G6PC3-CDG G6PC3
9.6.1.          CDG2K TMEM165
9.6.1.          Retinitis pigmentosa DHDDS
9.6.1.          DMP3-CDG DPM3
10.  Lysosomal disorders
10.1.     Mucopolysaccharidoses
10.1.1.     MPS I, Hurler, Scheie disease IDUA
10.1.2.     MPS II, Hunter disease IDS
10.1.3.     MPS III, Sanfilippo disease
10.1.3.1.       MPS IIIA, Sanfilippo A disease SGSH
10.1.3.2.       MPS IIIB, Sanfilippo B disease NAGLU
10.1.3.3.       MPS IIIC, Sanfilippo C disease HGSNAT
10.1.3.4.       MPS IIID, Sanfilippo D disease GNS
10.1.4.     MPS IV, Morquio disease
10.1.4.1.       MPS IVA, Morquio A disease GALNS
10.1.4.2.       MPS IVB, Morquio B disease GLB1
10.1.5.      MPS VI, Maroteaux - Lamy disease ARSB
10.1.6.      MPS VII, Sly disease GUSB
10.1.7.     MPS IX, Natowicz HYAL1
10.2.     Oligosaccharidoses 
10.2.1.     Alpha - D – mannosidosis MAN2B1
10.2.2.     Beta - D – mannosidosis MANBA
10.2.3.     Sialidosis NEU1
10.2.4.     Aspartylglucosaminuria AGA
10.2.5.     Fucosidosis FUCA1
10.2.6.     Schindler disease NAGA
10.3.     Sphingolipidoses
10.3.1.     GM1-gangliosidosis GLB1
10.3.2.     GM2-gangliosidosis
10.3.2.1.       GM2-gangliosidosis 0-variant, Sandhoff disease HEXB
10.3.2.2.       GM2-gangliosidosis B-variant, Tay-Sachs disease HEXA
10.3.2.3.       GM2-gangliosidosis AB-variant GM2A
10.3.3.     Gaucher disease GBA
10.3.4.     Krabbe disease GALC
10.3.5.     Metachromatic leukodystrophy ARSA
10.3.6.     Prosaposin deficiency PSAP
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10.3.6.1.       Saposin A deficiency
10.3.6.2.       Saposin B deficiency
10.3.6.3.       Saposin C deficiency
10.3.6.4.       Saposin D deficiency
10.3.7.     Fabry disease GLA
10.3.8.     Farber disease ASAH1
10.3.9.     Niemann-Pick disease type A or B SMPD1
10.3.10.  Niemann-Pick disease type C
10.3.10.1.    Niemann-Pick disease type C1 NPC1
10.3.10.2.    Niemann-Pick disease type C2 NPC2
10.4.     Ceroid lipfuscinoses, neuronal (CLN)
10.4.1.     CLN1, Santavuori-Haltia disease PPT1
10.4.2.     CLN2, Jansky-Bielschowsky disease TPP1
10.4.3.     CLN3, Batten Spielmeyer-Vogt disease CLN3
10.4.4.     CLN4A, Kufs disease recessive type CLN6
10.4.5.     CLN4B Kufs disease dominant type DNAJC5
10.4.6.     CLN5 Finnish variant CLN5
10.4.7.     CLN6 CLN6
10.4.8.     CLN7 MFSD8
10.4.9.     CLN8, Northern epilepsy type CLN8
10.4.10.  CLN9
10.4.11.  CLN10 CTSD
10.5.     Lysosomal export disorders
10.5.1.     Cystinosis CTNS
10.5.2.     Salla disease/infantile sialic acid storage disease SLC17A5
10.6.     Other lysosomal disorders
10.6.1.     Mucolipidosis II, I-cell disease GNPTAB
10.6.2.     Mucolipidosis III, Pseudo-Hurler polydystrophy GNPTG
10.6.3.     Mucolipidosis IV MCOLN1
10.6.4.     Multiple sulphatase deficiency SUMF1
10.6.5.     Wolman/cholesterol ester storage disease LIPA
10.6.6.     Pompe disease, GSD type II GAA
10.6.7.     Sialuria GNE
10.6.8.     Danon disease LAMP2
10.6.9.     Cathepsin-related disorders
10.6.9.1.       Galactosialidosis CTSA
10.6.9.2.       Papillon-Lefèvre  syndrome CTSC
10.6.9.3.       Pycnodysostosis CTSK
10.6.10.  Hermansky-Pudlak Syndrome HPS1
11.  Peroxisomal disorders
PEX1
PEX2
PEX3
PEX5
PEX6
11.1.     Disorders of peroxisome biogenesis
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PEX10
PEX12
PEX13
PEX14
PEX16
PEX19
PEX26
11.2.     Rhizomelic chondrodysplasia punctata
11.2.1.     Rhizomelic chondrodysplasia punctata type 1 PEX7
11.2.2.     Rhizomelic chondrodysplasia punctata type 2 GNPAT
11.2.3.     Rhizomelic chondrodysplasia punctata type 3 AGPS
11.3.     Disorders of peroxisomal alpha-, beta and omega-oxidation
11.3.1.     X-linked adrenoleukodystrophy ABCD1
11.3.2.     Peroxisomal acyl-CoA oxidase 1 deficiency ACOX1
11.3.3.     Peroxisomal D-bifunctional protein deficiency HSD17B4
11.3.4.     Sterol carrier protein deficiency SCP2
11.3.5.     Alpha-methylacyl-CoA racemase deficiency AMACR
11.3.6.     Refsum  disease PHYH
11.4.     Other peroxisomal disorders
11.4.1.     Primary hyperoxaluria type I AGXT
11.4.2.     Acatalasaemia CAT
11.4.3.     Mulibrey nanism TRIM37
12.  Disorders of neurotransmitter metabolism
12.1.     Disorders in the metabolism of biogenic amines
12.1.1.     Tyrosine hydroxylase deficiency TH
12.1.2.     Aromatic L-amino acid decarboxylase deficiency DDC
12.1.3.     Dopamine beta-hydroxylase deficiency DBH
12.1.4.     Monoamine oxidase MAOA
12.2.     Disorders in the metabolism of gamma-aminobutyrate
12.2.1.     Succinic semialdehyde dehydrogenase deficiency ALDH5A1
12.2.2.     GABA transaminase deficiency ABAT
12.3.     Other disorders of neurotransmitter metabolism
12.3.1.     Dopamine transporter deficiency syndrome SLC6A3
12.3.1.     Brain Dopamine–Serotonin Vesicular Transport Disease SLC18A2
13.  Disorders in the metabolism of vitamins and (non-protein) cofactors
13.1.     Disorders of folate metabolism and transport
13.1.1.     Hereditary folate malabsorption SLC46A1
13.1.2.     Cerebral folate deficiency due to FOLR1 deficiency FOLR1
13.1.3.     Dihydrofolate reductase deficiency DHFR
13.1.4.     Methylenetetrahydrofolate reductase deficiency MTHFR
13.2.     Disorders of cobalamin absorption, transport and metabolism  
13.2.1.     Intrinsic factor deficiency GIF
13.2.2.     Enterocyte intrinsic factor receptor deficiency
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13.2.2.1.       Intrinsic factor receptor deficiency due to CUBN  mutations CUBN
13.2.2.2.       Intrinsic factor receptor deficiency due to AMN mutations AMN
13.2.3.     Haptocorrin deficiency TCN1
13.2.4.     Transcobalamin II deficiency TCN2
13.2.5.     Defect in adenosylcobalamin synthesis-cbl A MMAA
13.2.6.     Defect in adenosylcobalamin synthesis-cbl B MMAB
13.2.7.     Combined defect in adenosylcobalamin and methylcobalamin synthesis-
cblC
MMACHC
13.2.8.     Defect in adenosylcobalamin and/or methylcobalamin synthesis-cblD MMADHC
13.2.9.     Combined defect in adenosylcobalamin and methylcobalamin synthesis-
cblF
LMBRD1
13.2.10.   Transcobalamin receptor (TCblR/CD320) defect CD320
13.2.10.   cbl-J ABCD4
13.3.     Disorders of pterin metabolism
13.3.1.     Guanosine 5 triphosphate cyclohydrolase I deficiency GCH1
13.3.2.     6-Pyruvoyl-tetrahydropterin synthase deficiency PTS
13.3.3.     Sepiapterin reductase deficiency SPR
13.3.4.     Quinoid dihydropteridine reductase deficiency QDPR
13.3.5.     Pterin 4 carbinolamine dehydratase deficiency PCBD1
13.4.     Disorders of vitamin D metabolism and transport
13.5.     Disorders of biotin metabolism
13.5.1.     Biotinidase deficiency BTD
13.5.2.     Holocarboxylase synthetase deficiency HLCS
13.6.     Disorders of pyridoxine metabolism
13.6.1.     Pyridoxine-dependent seizures ALDH7A1
13.6.2.     Pyridoxamine 5´-oxidase deficiency PNPO
13.6.3.     Hypophosphatasia ALPL
13.6.3.     Pryridoxal kinase deficiency PDXK
13.7.     Disorders of thiamine metabolism
13.7.1.     Thiamine-responsive megaloblastic anemia syndrome SLC19A2
13.7.2.     Biotin-responsive basal ganglia disease SLC19A3
13.7.3.     Microcephaly, Amish type SLC25A19
13.8.     Disorders of molybdenum cofactor metabolism
13.8.1.     Molybdenum cofactor deficiency
13.8.1.1.       Mo cofactor deficiency, complementation group A MOCS1
13.8.1.2.       Mo cofactor deficiency, complementation group B MOCS2
13.8.1.3.       Mo cofactor deficiency, complementation group C GPHN
13.9.     Other disorders of vitamins and cofactors
13.9.1.     TTP1 deficiency TTPA
13.9.2.     Vitamin K epoxide reductase deficiency VKORC1
13.9.3.     Retinol binding protein deficiency RBP4
13.9.4.     Pantothenate kinases deficiency PANK2
13.10.     Disorders of riboflavin transport and metabolism
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13.10.1.     Riboflavin transporter deficiency SLC25A1
13.10.1.     Riboflavin transporter deficiency SLC25A2
13.10.1.     Riboflavin transporter deficiency SLC25A3
14.  Disorders in the metabolism of trace elements and metals
14.1.     Disorder of copper metabolism
14.1.1.     Menkes syndrome ATP7A
14.1.1.1.       Occipital horn syndrome
14.1.2.     Wilson disease ATP7B
14.2.     Disorder of iron metabolism
14.2.1.     Hereditary haemochromatosis
14.2.1.1.       Hereditary haemochromatosis Type 1 HFE
14.2.1.2.       Hereditary haemochromatosis Type 2 HFE2
HAMP
14.2.1.3.       Hereditary haemochromatosis Type 3 TFR2
14.2.1.4.       Hereditary haemochromatosis Type 4 SLC40A1
14.2.2.     Acoeruloplasminaemia CP
14.2.3.     Neurodegeneration with brain iron accumulation (NBIA) PANK2
PLA2G6
C19orf12
FA2H
WDR45
ATP13A2
14.3.     Disorder of zinc metabolism
14.3.1.     Acrodermatitis enteropathica SLC39A4
14.3.2.     Hyperzincemia and hypercalprotectinemia
14.4.     Disorder of phosphate, calcium and vitamin D metabolism
14.5.     Disorder of magnesium metabolism
14.5.1.     Hypermagnesaemia
14.5.1.1.       Hypermanganesemia with dystonia, polycythemia, and 
cirrhosis
SLC30A10
14.5.2.     Primary hypomagnesaemia
14.5.2.1.       Hypomagnesaemia type 1, intestinal TRPM6
14.5.2.2.       Hypomagnesaemia type 2, renal FXYD2
14.5.2.3.       Hypomagnesaemia type 3, renal CLDN16
14.5.2.4.       Hypomagnesaemia type 4, renal EGF
14.5.2.5.       Hypomagnesaemia type 5, renal with ocular involvement CLDN19
14.5.2.6.       Hypomagnesaemia type 6, renal CNNM2
14.5.2.7.       Gitelman syndrome SLC12A3
14.5.3.     Secondary hypomagnesaemia
14.5.4.     Hypomagnesaemic tetany
14.5.5.     Hypomagnesaemia with cerebellar atrophy, hypotonia, strabismus, 
developmental delay, short stature, mild skeletal dysplasia, and connective 
tissue abnormalities
SLC39A8
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14.6.     Disorders in the metabolism of other trace elements and metals
15.  Disorders and variants in the metabolism of xenobiotics
15.1.     Disorders and variants of cytochrome P450-mediated oxidation 
15.2.     Disorders and variants of other enzymes that oxidise xenobiotics
15.2.1.     Trimethylaminuria FMO3
15.2.2.     Dimethylglycinuria DMGDH
15.3.     Disorders and variants of xenobiotics conjugation
15.4.     Disorders and variants of xenobiotics transport
16.  Other disorders
16.1.       Infantile striatal necrosis NUP62
16.2.     Myoclonic epilepsy of Unverricht and Lundborg CSTB
16.3.     Myoclonic epilepsy of Lafora EPM2A
NHLRC1
16.4.     Succinyl-CoA synthetase deficiency SUCLG2
16.5.     ARC Syndrome VPS33B
VIPAS39
16.6.     Sedoheptulokinase deficiency SHPK
16.7.     Trichohepatoenteric syndrome 1 TTC37
16.8.     Trichohepatoenteric syndrome 2 SKIV2L
16.8.     Acute necrotizing encephalopathy RANBP2
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9.3 details of 23 patients with kcnq2 mutations treated with vitamin b6
Figure 9.3.1: Literature review of reports indexed in PubMed detailing patients with autosomal dominant KCNQ2 mutations that had been
trialled either transiently or on a long-term basis with pyridoxine or pyridoxal 5’-phosphate. ACTH, adrenocorticotropic hormone;
B6, vitamin B6 (not stated whether PN or PLP); DZP, diazepam; CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; KD, ketogenic diet;
FA, folinic acid; LEV, levetiracetam; LZP, lorazepam; MDZ, midazolam; NZP, nitrazepam; PB, phenobarbital; PHT, phenytoin; PLP, pyridoxal
5’-phosphate; PN, pyridoxine; TPM, topiramate; VGB, vigabatrin; VPA, valproate; ZNS, zonisamide.
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9.4 slc25a22 primer sequences and pcr conditions
Table 9.4.1: Primers and conditions used to amplify and sequence SLC25A22. The
first set of primers used for the nested PCR amplification of exons 4 and 6 are
indicated by a *.
Exon Sequence 5’ → 3’ Tm
(◦C)
MgCl2
(mM)
Product size
(bp)
1 - 2 F CTCAAGGCCTCCTCCACC 64 1.5 420
AGCTAAGCGCGAGAAGGC
1 - 2 R CCGTTTCCCTTCTGTCAAAC
GCTTTACCGCTCAACCGTT
3 F TGAGGACTTGGCCTCTTCTATC 66 1.5 280
3 R ACGTCCACGCTCACACAC
4* F CAGGAGGCAAGTCCTGG 50 1.5 279
AGCTAAGCGCGAGAAGGC
4* R AAGGGGCTGAAGACAGGC
GCTTTACCGCTCAACCGTT
4 F CTCCCCACTCAGGCCAC 62 2.0 208
4 R GGGTGGACCCATCCTTTATC
5 F CCCCACAGGCCTGCATCT 64 1.5 374
AGCTAAGCGCGAGAAGGC
5 R AGGCTGCTGTCTCCTCTTC
GCTTTACCGCTCAACCGTT
6* F GAAGAGGTGAGGGCGAGG 50 1.5 393
AGCTAAGCGCGAGAAGGC
6* R CACCACAGAGAAGGGGACAT
GCTTTACCGCTCAACCGTT
6 F CCTGCCCAGTTCGCACAG 62 1.0 280
6 R TGGGGTGGGCAGGCC
7 F ACGCTGCTCAGGTAGGAGG 66 1.5 495
7 R CTGTGGAGGAAGGACGAAAG
8 F TCAACCCCTGTGATGGTCAG 62 1.5 247
AGCTAAGCGCGAGAAGGC
8 R TGGAGGAAGGACGAAAGGG
GCTTTACCGCTCAACCGTT
9 F CTCTGGGATCCTGGACTGTG 66 1.5 345
9 R GAGGGGTCTTCCCTTGCTC
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9.5 ccbl1 primers and pcr conditions
Table 9.5.1: Primers and conditions used to amplify and sequence CCBL1. All exons
were amplified using a Tm of 64◦C, 1.5 mM MgCl2 and 5% DMSO. All primers are
tailed at the 5’ end (forward primers: AGCTAAGCGCGAGAAGGC and reverse
primers: GCTTTACCGCTCAACCGTT).
Gene Sequence 5’ → 3’ Tm (◦C) MgCl2 (mM) Product size (bp)
1 F TAGGAACGGGAGAGTGTGTG 64 1.5 322
1 R GTCACCTCTCGAAACCCACT
2 F GCCCCGGAAGTGACGTCA 64 1.5 292
2 R GTTAGCCGACCCTCCCAG
4 F CACTTGGTGCTATTCCTGGC 64 1.5 408
4 R GCTGCAGTTAAAGAGGGCTC
5 F CTAGTGAGAGTGCAGTGGGA 64 1.5 309
5 R CCAAGATCGTGCCAGCCA
6 F TGCTGGAGTCAAGAGGAACC 64 1.5 395
6 R TGGAATCTGGCAGTCTGTGT
7 F TCTAAACAGGCCGAAGTCCA 64 1.5 293
7 R GCTGTGTGGGCTTGAAGTC
8 F GGAGGAGGTGACACTTAAACC 64 1.5 389
8 R AGTGAGCCGTGATCATGTCA
9 F AGGAGTTTGAGGCCAGTGC 64 1.5 249
9 R GCCACCATACCCAGCTTTTG
10 F AGGTGCTAGAATTGCCTGGA 64 1.5 480
10 R TCCTTTTCCAACTCCCAGGG
11 F AAGGTGGGGATAGATGCTGG 64 1.5 348
11 R AGTCTTGGTCCTCAGTGCTC
12 F TGACCTCCAGTGTTCCGC 64 1.5 399
12 R ATCTGCAGGGCTCCATAACC
13 F CTATGCGTGTCCCCTGGG 64 1.5 487
13 R GGGCAGATGGACACACAGAT
14 F CAGAGCCAGGTGAAGAGGG 64 1.5 679
14 R CCTGGGCAAGAGTGAGACT
15 F GAACCTCTCTGTCCCCTCC 64 1.5 700
15 R GCCAGGGAAGGTGAGGTTAT
16 F TCTAGGTTGGGGAAGATGCT 64 1.5 678
16 R CAGGAGGTGGAGGTTGCAAT
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Accession number Protein name
A0A024QZX5 Serpin B6 
A0A024R4E5 High density lipoprotein binding protein (Vigilin), isoform CRA_a 
A0A024R571 EH domain-containing protein 1 
A0A075B752 Annexin 
A0A087WSW2 Zinc finger protein 43 
A0A087WSW9 Thioredoxin reductase 1, cytoplasmic 
A0A087WSY9 Thioredoxin reductase 1, cytoplasmic 
A0A087WTT1 Polyadenylate-binding protein 
A0A087WUD7 Sec1 family domain-containing protein 2 
A0A087WUL0 Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing) 
A0A087WUL2 Proteasome subunit beta type-3 (Fragment) 
A0A087WUS0 40S ribosomal protein S24 
A0A087WV23 SH3 domain-binding glutamic acid-rich-like protein 3 
A0A087WV47 Ig gamma-1 chain C region 
A0A087WV48 Uncharacterized protein 
A0A087WV55 Complement C1q tumor necrosis factor-related protein 8 
A0A087WV77 Ubiquitin-40S ribosomal protein S27a 
A0A087WVN4 Farnesyl pyrophosphate synthase (Fragment) 
A0A087WVQ6 Clathrin heavy chain 
A0A087WW66 26S proteasome non-ATPase regulatory subunit 1 
A0A087WWU8 Tropomyosin alpha-3 chain 
A0A087WXM6 60S ribosomal protein L17 (Fragment) 
A0A087WY61 Nuclear mitotic apparatus protein 1 
A0A087WYR3 Tumor protein D54 
A0A087WYT3 Prostaglandin E synthase 3 
A0A087WZ27 Zinc finger protein 90 
A0A087WZ65 Ankyrin-3 (Fragment) 
A0A087WZV1 Heterogeneous nuclear ribonucleoprotein A/B 
A0A087X0N0 Trafficking kinesin-binding protein 1 
A0A087X0X3 Heterogeneous nuclear ribonucleoprotein M 
A0A087X1I3 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 
A0A087X1S2 Nuclease-sensitive element-binding protein 1 
A0A087X1X7 Elongation factor 1-delta 
A0A087X1Z3 Proteasome activator complex subunit 2 
A0A087X2D0 Serine/arginine-rich-splicing factor 3 
A0A087X2G1 ATP-dependent RNA helicase DDX1 
A0A087X2I1 26S protease regulatory subunit 10B 
A0A0A0MQW3 Serpin B13 
A0A0A0MR45 Calpastatin 
A0A0A0MR47 Neurotrophin receptor-interacting factor homolog 
A0A0A0MRI6 Regulator of G-protein-signaling 7 
A0A0A0MRK8 Fucose mutarotase 
A0A0A0MRM2 Nebulin-related-anchoring protein 
A0A0A0MSI0 Peroxiredoxin-1 (Fragment) 
A0A0A0MSN4 Angiotensin-converting enzyme 
A0A0A0MSN9 Negative elongation factor E (Fragment) 
A0A0A0MSQ0 Plastin-3 
A0A0A0MSR7 Protein TBATA 
A0A0A0MSS8 Aldo-keto reductase family 1 member C3 
A0A0A0MSW4 Phosphatidylinositol transfer protein beta isoform 
A0A0A0MTN3 Glutathione S-transferase Mu 3 
A0A0A0MTS2 Glucose-6-phosphate isomerase (Fragment) 
A0A0A6YYG9 Protein ARPC4-TTLL3 
A0A0B4J1Z1 Serine/arginine-rich-splicing factor 7 
A0A0B4J2A4 3-ketoacyl-CoA thiolase, mitochondrial 
A0A0B4J2B4 40S ribosomal protein S15 
A0A0B4J2C3 Translationally-controlled tumor protein 
A0A0B4J2F2 Protein LOC102724428 
A5A3E0 POTE ankyrin domain family member F 
A6NCQ0 ADP-sugar pyrophosphatase 
A6NI03 Putative tripartite motif-containing protein 64B 
A6NLN1 Polypyrimidine tract binding protein 1, isoform CRA_b 
A6NM15 Putative COBW domain-containing protein 7 
A6ZIE3 MUC1 isoform M9 
A8MU27 Small ubiquitin-related modifier 3 
A8MU58 Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 
A8MUS3 60S ribosomal protein L23a 
9.6 list of proteins identified through qtof analysis of the ivt kit
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A8MXH2 Nucleosome assembly protein 1-like 4 (Fragment) 
A8MXP9 Matrin-3 
A8MZ26 EF-hand calcium-binding domain-containing protein 9 
B0QY89 Eukaryotic translation initiation factor 3 subunit L 
B0QYC2 Interleukin-2 receptor subunit beta (Fragment) 
B0QZ18 Copine-1 
B1AK85 F-actin-capping protein subunit beta 
B1AKR6 Dynein light chain roadblock-type 1 
B1ALD0 AP complex subunit beta 
B1ANR0 Polyadenylate-binding protein 
B3KNJ4 SUMO-1 activating enzyme subunit 1, isoform CRA_a 
B3KQ25 Proteasome activator complex subunit 3 
B4DQU5 Ras-related protein Rab-11A 
B4DUR8 T-complex protein 1 subunit gamma 
B4DXD0 Translin-associated factor X-interacting protein 1 
B4DXW1 Actin-related protein 3 
B5MCI0 Smoothelin 
B5MCX3 Septin-2 
B5MDF5 GTP-binding nuclear protein Ran 
B5ME19 Eukaryotic translation initiation factor 3 subunit C-like protein 
B7Z4W5 Cysteine conjugate-beta lyase cytoplasmic (Glutamine transaminase K, kyneurenine aminotransferase), isoform CRA_b 
B7Z574 Calpastatin 
B7Z645 Heterogeneous nuclear ribonucleoprotein Q 
B7Z6Z4 Myosin light polypeptide 6 
B7Z7P8 Eukaryotic peptide chain release factor subunit 1 
B8ZZ45 Glycosyltransferase-like domain-containing protein 1 
B8ZZA1 Prothymosin alpha 
B8ZZL8 10 kDa heat shock protein, mitochondrial 
B9A041 Malate dehydrogenase, cytoplasmic 
B9ZVP7 60S ribosomal protein L23 
C9IYI6 Tyrosine-protein phosphatase non-receptor type 7 (Fragment) 
C9J0D1 Histone H2A 
C9J0K6 Sorcin 
C9J0Q5 Nuclear receptor corepressor 2 
C9J1T2 Transforming protein RhoA (Fragment) 
C9J1V9 HCG2043275 
C9J1Z8 ADP-ribosylation factor 5 (Fragment) 
C9J4W5 Eukaryotic translation initiation factor 5A (Fragment) 
C9J6D1 Nucleosome assembly protein 1-like 4 (Fragment) 
C9J6G3 Geranylgeranyl pyrophosphate synthase (Fragment) 
C9J9K3 40S ribosomal protein SA (Fragment) 
C9J9W2 LIM and SH3 domain protein 1 (Fragment) 
C9JA08 60S ribosomal export protein NMD3 
C9JIF9 Acylamino-acid-releasing enzyme 
C9JJ34 Ran-specific GTPase-activating protein (Fragment) 
C9JNW5 60S ribosomal protein L24 
C9JY79 Non-erythrocytic beta-spectrin 4 
C9JZI7 Nucleosome assembly protein 1-like 4 (Fragment) 
D3DSM8 Formimidoyltransferase-cyclodeaminase 
D3DVN5 Transmembrane protein 175 
D3YTB1 60S ribosomal protein L32 (Fragment) 
D6R967 Inorganic pyrophosphatase 2, mitochondrial (Fragment) 
D6RA82 Annexin 
D6RAF8 Heterogeneous nuclear ribonucleoprotein D0 (Fragment) 
D6RAN4 60S ribosomal protein L9 (Fragment) 
D6RDG3 Transcription factor BTF3 (Fragment) 
D6RFW5 UDP-glucuronosyltransferase 2A1 
D6RG13 40S ribosomal protein S3a (Fragment) 
D6RJC3 Type II inositol 3,4-bisphosphate 4-phosphatase (Fragment) 
E5RFP0 NudC domain-containing protein 2 
E5RHG6 Tubulin-specific chaperone A 
E5RI99 60S ribosomal protein L30 (Fragment) 
E5RIT6 60S ribosomal protein L26-like 1 (Fragment) 
E5RJH5 Beta-enolase 
E5RJR5 S-phase kinase-associated protein 1 
E7ENH0 Pregnancy-specific beta-1-glycoprotein 8 
E7EPB3 60S ribosomal protein L14 
E7EPB6 Cystic fibrosis transmembrane conductance regulator (Fragment) 
E7EQG2 Eukaryotic initiation factor 4A-II 
E7EQL5 Cytoplasmic dynein 1 intermediate chain 2 (Fragment) 
E7EQV9 Ribosomal protein L15 (Fragment) 
E7ERU0 Dystonin 
E7ERW8 Protein diaphanous homolog 1 
E7EUU4 Eukaryotic translation initiation factor 4 gamma 1 
E7EVA0 Microtubule-associated protein 
E9PAV3 Nascent polypeptide-associated complex subunit alpha, muscle-specific form 
E9PB90 Hexokinase 
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E9PCP0 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 
E9PCY7 Heterogeneous nuclear ribonucleoprotein H 
E9PDE8 Heat shock 70 kDa protein 4L 
E9PEZ3 Protein diaphanous homolog 1 
E9PHA6 DNA mismatch repair protein Msh2 
E9PIY6 ADP-ribosylation factor GTPase-activating protein 2 (Fragment) 
E9PIZ5 Thioredoxin reductase 1, cytoplasmic (Fragment) 
E9PJD9 60S ribosomal protein L27a 
E9PJK5 FTS and Hook-interacting protein 
E9PK25 Cofilin-1 
E9PKD5 26S protease regulatory subunit 6A (Fragment) 
E9PKG1 Protein arginine N-methyltransferase 1 
E9PKW4 Sulfotransferase 
E9PKZ0 60S ribosomal protein L8 (Fragment) 
E9PLG2 26S protease regulatory subunit 6A (Fragment) 
E9PLH9 GDP-L-fucose synthase (Fragment) 
E9PLI6 Probable RNA-binding protein EIF1AD (Fragment) 
E9PLK3 Puromycin-sensitive aminopeptidase 
E9PM95 Apolipoprotein L2 (Fragment) 
E9PMI6 Methylosome subunit pICln 
E9PNW8 Fatty acyl-CoA reductase 1 (Fragment) 
E9PPP3 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (Fragment) 
E9PPV6 Serpin H1 
E9PR30 40S ribosomal protein S30 
E9PR53 Protein FAM212B 
E9PRQ5 Puromycin-sensitive aminopeptidase (Fragment) 
E9PRQ7 UBX domain-containing protein 1 
E9PRY8 Elongation factor 1-delta 
F2Z2V0 Copine-1 (Fragment) 
F2Z2Y4 Pyridoxal kinase 
F2Z388 60S ribosomal protein L35 
F2Z393 Transaldolase 
F5GY55 DNA damage-binding protein 1 
F5GYZ6 LIM domain only protein 3 (Fragment) 
F5H039 Gephyrin 
F5H126 Synaptotagmin-7 
F5H4R6 Nucleosome assembly protein 1-like 1 
F5H5G6 Fanconi anemia-associated protein of 100 kDa (Fragment) 
F5H6X6 Neutral alpha-glucosidase AB 
F5H7S3 Tropomyosin alpha-1 chain 
F5H7Y1 T-complex protein 1 subunit alpha (Fragment) 
F6U211 40S ribosomal protein S10 
F6X3S4 Uncharacterized protein 
F8VPD4 CAD protein 
F8VRK7 60S acidic ribosomal protein P0 
F8VTQ5 Heterogeneous nuclear ribonucleoprotein A1 (Fragment) 
F8VXH9 Poly(rC)-binding protein 2 (Fragment) 
F8VXI9 ARF GTPase-activating protein GIT2 
F8VY02 Endoplasmic reticulum resident protein 29 
F8VZ49 Heterogeneous nuclear ribonucleoprotein A1 (Fragment) 
F8VZX2 Poly(rC)-binding protein 2 
F8W1A4 Adenylate kinase 2, mitochondrial 
F8W1R7 Myosin light polypeptide 6 
F8W6G6 Leukocyte immunoglobulin-like receptor subfamily B member 3 
F8W775 Neuronal cell adhesion molecule 
F8W9U3 Alpha/beta hydrolase domain-containing protein 14B 
F8W9U4 Microtubule-associated protein 
F8WBD4 Zinc finger protein with KRAB and SCAN domains 5 
G3V1C5 Interleukin 18 binding protein, isoform CRA_a 
G3V203 60S ribosomal protein L18 
G3V295 Proteasome subunit alpha type 
G3V3G9 DDB1- and CUL4-associated factor 8 
G3V483 G2/M phase-specific E3 ubiquitin-protein ligase 
G3V5F4 Mitochondrial basic amino acids transporter (Fragment) 
G5E9C7 Dual-specificity mitogen-activated protein kinase kinase 2 
G5E9G0 60S ribosomal protein L3 
G8JLD5 Dynamin-1-like protein 
H0Y2S9 Myosin phosphatase Rho-interacting protein (Fragment) 
H0Y325 Nesprin-1 (Fragment) 
H0Y586 Proteasome subunit alpha type-7 (Fragment) 
H0Y5B4 60S ribosomal protein L36a 
H0Y5H9 Serpin B4 (Fragment) 
H0Y8C6 Importin-5 (Fragment) 
H0YAK9 Nephronectin (Fragment) 
H0YCQ8 Eukaryotic translation initiation factor 3 subunit M (Fragment) 
H0YEM1 Poly(U)-binding-splicing factor PUF60 (Fragment) 
H0YFX9 Histone H2A (Fragment) 
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H0YGI8 Stress-induced-phosphoprotein 1 (Fragment) 
H0YI98 Dynactin subunit 2 (Fragment) 
H0YIV4 Nucleosome assembly protein 1-like 1 (Fragment) 
H0YJC0 26S protease regulatory subunit 10B (Fragment) 
H0YKC5 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial (Fragment) 
H0YKN4 Annexin A2 
H0YL52 Tropomyosin alpha-1 chain (Fragment) 
H0YL69 Proteasome subunit alpha type (Fragment) 
H0YL80 Tropomyosin alpha-1 chain (Fragment) 
H0YLA4 Sorbitol dehydrogenase 
H0YN26 Acidic leucine-rich nuclear phosphoprotein 32 family member A 
H0YNG5 Alpha-mannosidase 
H3BPS8 Fructose-bisphosphate aldolase (Fragment) 
H3BQI1 Dynein light chain roadblock-type 2 
H3BQZ9 Adenine phosphoribosyltransferase 
H3BR35 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (Fragment) 
H7BXP1 NF-kappa-B inhibitor-interacting Ras-like protein 2 
H7C084 Bifunctional purine biosynthesis protein PURH (Fragment) 
H7C0A3 Protein ARPC4-TTLL3 (Fragment) 
H7C144 Alpha-actinin-4 (Fragment) 
H7C307 Ubiquitin carboxyl-terminal hydrolase 40 (Fragment) 
I3L0K2 Thioredoxin domain-containing protein 17 
I3L121 Clusterin-associated protein 1 (Fragment) 
I3L1Y9 FLYWCH family member 2 
I3L2F9 Uncharacterized protein 
I3L397 Eukaryotic translation initiation factor 5A (Fragment) 
I6L894 Ankyrin-2 
I6L9D5 FAM114A2 protein 
J3KN39 NACHT, LRR and PYD domains-containing protein 2 
J3KNQ3 26S proteasome non-ATPase regulatory subunit 13 
J3KPE3 Guanine nucleotide-binding protein subunit beta-2-like 1 
J3KQ18 D-dopachrome decarboxylase 
J3KQ32 Obg-like ATPase 1 
J3KQG3 EPH receptor A10, isoform CRA_b 
J3KR24 Isoleucine--tRNA ligase, cytoplasmic 
J3KRH3 Hexosaminidase D (Fragment) 
J3KRP9 Protein TANC2 (Fragment) 
J3KSD5 Lethal(2) giant larvae protein homolog 2 (Fragment) 
J3KSH8 Hematological and neurological-expressed 1 protein (Fragment) 
J3KTE4 Ribosomal protein L19 
J3KTF8 Rho GDP-dissociation inhibitor 1 (Fragment) 
J3QLI9 Small nuclear ribonucleoprotein Sm D1 
K7EJ78 40S ribosomal protein S15 
K7EJR3 26S proteasome non-ATPase regulatory subunit 8 (Fragment) 
K7ELJ7 Calpain small subunit 1 
K7ELL7 Glucosidase 2 subunit beta 
K7EMW4 Nicalin 
K7EP46 Thimet oligopeptidase 
K7EPC4 Histone acetyltransferase KAT2A (Fragment) 
K7EQA9 Hsp90 co-chaperone Cdc37 (Fragment) 
K7EQJ8 GTPase Era, mitochondrial (Fragment) 
K7EQX3 AP-1 complex subunit mu-1 (Fragment) 
K7ESK7 SUMO-activating enzyme subunit 2 (Fragment) 
K7ESP6 Queuine tRNA-ribosyltransferase (Fragment) 
M0QXK4 40S ribosomal protein S19 (Fragment) 
M0QYI7 Protein fuzzy homolog 
M0QZN2 40S ribosomal protein S5 
M0R080 DnaJ homolog subfamily B member 1 (Fragment) 
M0R0E2 Zinc finger protein 432 (Fragment) 
M0R0F0 40S ribosomal protein S5 (Fragment) 
M0R0P7 60S ribosomal protein L18a 
M0R0P8 Unconventional myosin-IXb 
M0R117 60S ribosomal protein L18a 
M0R246 Zinc finger protein 134 
O00148 ATP-dependent RNA helicase DDX39A 
O00170 AH receptor-interacting protein 
O00204 Sulfotransferase family cytosolic 2B member 1 
O00231 26S proteasome non-ATPase regulatory subunit 11 
O00232 26S proteasome non-ATPase regulatory subunit 12 
O00299 Chloride intracellular channel protein 1 
O00303 Eukaryotic translation initiation factor 3 subunit F 
O00429 Dynamin-1-like protein 
O00487 26S proteasome non-ATPase regulatory subunit 14 
O00571 ATP-dependent RNA helicase DDX3X 
O14818 Proteasome subunit alpha type-7 
O14929 Histone acetyltransferase type B catalytic subunit 
O14980 Exportin-1 
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O15031 Plexin-B2 
O15050 TPR and ankyrin repeat-containing protein 1 
O15061 Synemin 
O15067 Phosphoribosylformylglycinamidine synthase 
O15144 Actin-related protein 2/3 complex subunit 2 
O15260 Surfeit locus protein 4 
O15371 Eukaryotic translation initiation factor 3 subunit D 
O43143 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 
O43175 D-3-phosphoglycerate dehydrogenase 
O43182 Rho GTPase-activating protein 6 
O43237 Cytoplasmic dynein 1 light intermediate chain 2 
O43242 26S proteasome non-ATPase regulatory subunit 3 
O43399 Tumor protein D54 
O43432 Eukaryotic translation initiation factor 4 gamma 3 
O43707 Alpha-actinin-4 
O43776 Asparagine--tRNA ligase, cytoplasmic 
O60256 Phosphoribosyl pyrophosphate synthase-associated protein 2 
O60506 Heterogeneous nuclear ribonucleoprotein Q 
O60664 Perilipin-3 
O60701 UDP-glucose 6-dehydrogenase 
O60814 Histone H2B type 1-K 
O60869 Endothelial differentiation-related factor 1 
O60884 DnaJ homolog subfamily A member 2 
O60942 mRNA-capping enzyme 
O75145 Liprin-alpha-3 
O75306 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial 
O75340 Programmed cell death protein 6 
O75369 Filamin-B 
O75531 Barrier-to-autointegration factor 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic 
O76003 Glutaredoxin-3 
O94915 Protein furry homolog-like 
O95336 6-phosphogluconolactonase 
O95373 Importin-7 
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 
O95833 Chloride intracellular channel protein 3 
O96019 Actin-like protein 6A 
P00338 L-lactate dehydrogenase A chain 
P00374 Dihydrofolate reductase 
P00441 Superoxide dismutase [Cu-Zn] 
P00488 Coagulation factor XIII A chain 
P00491 Purine nucleoside phosphorylase 
P00492 Hypoxanthine-guanine phosphoribosyltransferase 
P00558 Phosphoglycerate kinase 1 
P00568 Adenylate kinase isoenzyme 1 
P00966 Argininosuccinate synthase 
P01011 Alpha-1-antichymotrypsin 
P02545 Prelamin-A/C 
P02751 Fibronectin 
P02786 Transferrin receptor protein 1 
P04075 Fructose-bisphosphate aldolase A 
P04080 Cystatin-B 
P04083 Annexin A1 
P04350 Tubulin beta-4A chain 
P04406 Glyceraldehyde-3-phosphate dehydrogenase 
P04792 Heat shock protein beta-1 
P04818 Thymidylate synthase 
P05198 Eukaryotic translation initiation factor 2 subunit 1 
P05386 60S acidic ribosomal protein P1 
P05387 60S acidic ribosomal protein P2 
P05388 60S acidic ribosomal protein P0 
P05455 Lupus La protein 
P06132 Uroporphyrinogen decarboxylase 
P06576 ATP synthase subunit beta, mitochondrial 
P06703 Protein S100-A6 
P06732 Creatine kinase M-type 
P06733 Alpha-enolase 
P06748 Nucleophosmin 
P07195 L-lactate dehydrogenase B chain 
P07237 Protein disulfide-isomerase 
P07355 Annexin A2 
P07437 Tubulin beta chain 
P07737 Profilin-1 
P07741 Adenine phosphoribosyltransferase 
P07814 Bifunctional glutamate/proline--tRNA ligase 
P07900 Heat shock protein HSP 90-alpha 
P07951 Tropomyosin beta chain 
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P07954 Fumarate hydratase, mitochondrial 
P08107 Heat shock 70 kDa protein 1A/1B 
P08238 Heat shock protein HSP 90-beta 
P08243 Asparagine synthetase [glutamine-hydrolyzing] 
P08708 40S ribosomal protein S17 
P08758 Annexin A5 
P09104 Gamma-enolase 
P09960 Leukotriene A-4 hydrolase 
P09972 Fructose-bisphosphate aldolase C 
P0CG38 POTE ankyrin domain family member I 
P10599 Thioredoxin 
P10632 Cytochrome P450 2C8 
P10809 60 kDa heat shock protein, mitochondrial 
P11021 78 kDa glucose-regulated protein 
P11142 Heat shock cognate 71 kDa protein 
P11413 Glucose-6-phosphate 1-dehydrogenase 
P11586 C-1-tetrahydrofolate synthase, cytoplasmic 
P11766 Alcohol dehydrogenase class-3 
P11908 Ribose-phosphate pyrophosphokinase 2 
P11940 Polyadenylate-binding protein 1 
P12004 Proliferating cell nuclear antigen 
P12268 Inosine-5'-monophosphate dehydrogenase 2 
P12814 Alpha-actinin-1 
P12956 X-ray repair cross-complementing protein 6 
P13010 X-ray repair cross-complementing protein 5 
P13489 Ribonuclease inhibitor 
P13639 Elongation factor 2 
P13667 Protein disulfide-isomerase A4 
P13804 Electron transfer flavoprotein subunit alpha, mitochondrial 
P13929 Beta-enolase 
P14174 Macrophage migration inhibitory factor 
P14618 Pyruvate kinase PKM 
P14625 Endoplasmin 
P14868 Aspartate--tRNA ligase, cytoplasmic 
P15085 Carboxypeptidase A1 
P15121 Aldose reductase 
P15311 Ezrin 
P15531 Nucleoside diphosphate kinase A 
P15880 40S ribosomal protein S2 
P15927 Replication protein A 32 kDa subunit 
P16152 Carbonyl reductase [NADPH] 1 
P17066 Heat shock 70 kDa protein 6 
P17174 Aspartate aminotransferase, cytoplasmic 
P17655 Calpain-2 catalytic subunit 
P17812 CTP synthase 1 
P17844 Probable ATP-dependent RNA helicase DDX5 
P17858 ATP-dependent 6-phosphofructokinase, liver type 
P17980 26S protease regulatory subunit 6A 
P17987 T-complex protein 1 subunit alpha 
P18124 60S ribosomal protein L7 
P18206 Vinculin 
P18669 Phosphoglycerate mutase 1 
P19338 Nucleolin 
P20042 Eukaryotic translation initiation factor 2 subunit 2 
P20073 Annexin A7 
P20290 Transcription factor BTF3 
P20618 Proteasome subunit beta type-1 
P20848 Putative alpha-1-antitrypsin-related protein 
P20929 Nebulin 
P21333 Filamin-A 
P21980 Protein-glutamine gamma-glutamyltransferase 2 
P22102 Trifunctional purine biosynthetic protein adenosine-3 
P22234 Multifunctional protein ADE2 
P22314 Ubiquitin-like modifier-activating enzyme 1 
P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 
P23025 DNA repair protein complementing XP-A cells 
P23258 Tubulin gamma-1 chain 
P23284 Peptidyl-prolyl cis-trans isomerase B 
P23378 Glycine dehydrogenase (decarboxylating), mitochondrial 
P23381 Tryptophan--tRNA ligase, cytoplasmic 
P23396 40S ribosomal protein S3 
P23526 Adenosylhomocysteinase 
P23921 Ribonucleoside-diphosphate reductase large subunit 
P24534 Elongation factor 1-beta 
P24666 Low molecular weight phosphotyrosine protein phosphatase 
P25705 ATP synthase subunit alpha, mitochondrial 
P25786 Proteasome subunit alpha type-1 
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P25787 Proteasome subunit alpha type-2 
P25788 Proteasome subunit alpha type-3 
P25815 Protein S100-P 
P26038 Moesin 
P26373 60S ribosomal protein L13 
P26447 Protein S100-A4 
P26639 Threonine--tRNA ligase, cytoplasmic 
P26640 Valine--tRNA ligase 
P26641 Elongation factor 1-gamma 
P27348 14-3-3 protein theta 
P27635 60S ribosomal protein L10 
P27695 DNA-(apurinic or apyrimidinic site) lyase 
P27797 Calreticulin 
P28065 Proteasome subunit beta type-9 
P28066 Proteasome subunit alpha type-5 
P28070 Proteasome subunit beta type-4 
P28074 Proteasome subunit beta type-5 
P29350 Tyrosine-protein phosphatase non-receptor type 6 
P29401 Transketolase 
P29508 Serpin B3 
P30041 Peroxiredoxin-6 
P30043 Flavin reductase (NADPH) 
P30044 Peroxiredoxin-5, mitochondrial 
P30046 D-dopachrome decarboxylase 
P30048 Thioredoxin-dependent peroxide reductase, mitochondrial 
P30050 60S ribosomal protein L12 
P30084 Enoyl-CoA hydratase, mitochondrial 
P30085 UMP-CMP kinase 
P30086 Phosphatidylethanolamine-binding protein 1 
P30101 Protein disulfide-isomerase A3 
P30153 Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 
P30740 Leukocyte elastase inhibitor 
P31150 Rab GDP dissociation inhibitor alpha 
P31327 Carbamoyl-phosphate synthase [ammonia], mitochondrial 
P31689 DnaJ homolog subfamily A member 1 
P31939 Bifunctional purine biosynthesis protein PURH 
P31946 14-3-3 protein beta/alpha 
P31947 14-3-3 protein sigma 
P31948 Stress-induced-phosphoprotein 1 
P31949 Protein S100-A11 
P32119 Peroxiredoxin-2 
P32320 Cytidine deaminase 
P32942 Intercellular adhesion molecule 3 
P32969 60S ribosomal protein L9 
P33991 DNA replication licensing factor MCM4 
P33993 DNA replication licensing factor MCM7 
P34897 Serine hydroxymethyltransferase, mitochondrial 
P34931 Heat shock 70 kDa protein 1-like 
P34932 Heat shock 70 kDa protein 4 
P35221 Catenin alpha-1 
P35241 Radixin 
P35268 60S ribosomal protein L22 
P35270 Sepiapterin reductase 
P35520 Cystathionine beta-synthase 
P35579 Myosin-9 
P35580 Myosin-10 
P35913 Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta 
P35998 26S protease regulatory subunit 7 
P36578 60S ribosomal protein L4 
P36871 Phosphoglucomutase-1 
P36952 Serpin B5 
P37108 Signal recognition particle 14 kDa protein 
P37802 Transgelin-2 
P38117 Electron transfer flavoprotein subunit beta 
P38606 V-type proton ATPase catalytic subunit A 
P38646 Stress-70 protein, mitochondrial 
P38919 Eukaryotic initiation factor 4A-III 
P39019 40S ribosomal protein S19 
P39023 60S ribosomal protein L3 
P39748 Flap endonuclease 1 
P40121 Macrophage-capping protein 
P40227 T-complex protein 1 subunit zeta 
P40426 Pre-B-cell leukemia transcription factor 3 
P40763 Signal transducer and activator of transcription 3 
P40925 Malate dehydrogenase, cytoplasmic 
P40926 Malate dehydrogenase, mitochondrial 
P41091 Eukaryotic translation initiation factor 2 subunit 3 
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P41250 Glycine--tRNA ligase 
P41252 Isoleucine--tRNA ligase, cytoplasmic 
P42338 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 
P42695 Condensin-2 complex subunit D3 
P43121 Cell surface glycoprotein MUC18 
P43490 Nicotinamide phosphoribosyltransferase 
P43626 Killer cell immunoglobulin-like receptor 2DL1 
P43686 26S protease regulatory subunit 6B 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 
P46777 60S ribosomal protein L5 
P46778 60S ribosomal protein L21 
P46779 60S ribosomal protein L28 
P46781 40S ribosomal protein S9 
P46940 Ras GTPase-activating-like protein IQGAP1 
P47712 Cytosolic phospholipase A2 
P47897 Glutamine--tRNA ligase 
P47914 60S ribosomal protein L29 
P48357 Leptin receptor 
P48643 T-complex protein 1 subunit epsilon 
P48741 Putative heat shock 70 kDa protein 7 
P49189 4-trimethylaminobutyraldehyde dehydrogenase 
P49321 Nuclear autoantigenic sperm protein 
P49327 Fatty acid synthase 
P49368 T-complex protein 1 subunit gamma 
P49411 Elongation factor Tu, mitochondrial 
P49588 Alanine--tRNA ligase, cytoplasmic 
P49721 Proteasome subunit beta type-2 
P49756 RNA-binding protein 25 
P49773 Histidine triad nucleotide-binding protein 1 
P49915 GMP synthase [glutamine-hydrolyzing] 
P50395 Rab GDP dissociation inhibitor beta 
P50454 Serpin H1 
P50747 Biotin--protein ligase 
P50990 T-complex protein 1 subunit theta 
P50991 T-complex protein 1 subunit delta 
P51665 26S proteasome non-ATPase regulatory subunit 7 
P51858 Hepatoma-derived growth factor 
P52209 6-phosphogluconate dehydrogenase, decarboxylating 
P52597 Heterogeneous nuclear ribonucleoprotein F 
P52788 Spermine synthase 
P52888 Thimet oligopeptidase 
P52907 F-actin-capping protein subunit alpha-1 
P53396 ATP-citrate synthase 
P53675 Clathrin heavy chain 2 
P53814 Smoothelin 
P53999 Activated RNA polymerase II transcriptional coactivator p15 
P54136 Arginine--tRNA ligase, cytoplasmic 
P54577 Tyrosine--tRNA ligase, cytoplasmic 
P54652 Heat shock-related 70 kDa protein 2 
P54725 UV excision repair protein RAD23 homolog A 
P54727 UV excision repair protein RAD23 homolog B 
P55010 Eukaryotic translation initiation factor 5 
P55060 Exportin-2 
P55072 Transitional endoplasmic reticulum ATPase 
P55795 Heterogeneous nuclear ribonucleoprotein H2 
P55884 Eukaryotic translation initiation factor 3 subunit B 
P56192 Methionine--tRNA ligase, cytoplasmic 
P56211 cAMP-regulated phosphoprotein 19 
P56537 Eukaryotic translation initiation factor 6 
P57077 MAP3K7 C-terminal-like protein 
P57737 Coronin-7 
P60174 Triosephosphate isomerase 
P60228 Eukaryotic translation initiation factor 3 subunit E 
P60709 Actin, cytoplasmic 1 
P60842 Eukaryotic initiation factor 4A-I 
P60866 40S ribosomal protein S20 
P60891 Ribose-phosphate pyrophosphokinase 1 
P60900 Proteasome subunit alpha type-6 
P60903 Protein S100-A10 
P60953 Cell division control protein 42 homolog 
P61006 Ras-related protein Rab-8A 
P61088 Ubiquitin-conjugating enzyme E2 N 
P61160 Actin-related protein 2 
P61163 Alpha-centractin 
P61204 ADP-ribosylation factor 3 
P61221 ATP-binding cassette sub-family E member 1 
P61247 40S ribosomal protein S3a 
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P61353 60S ribosomal protein L27 
P61604 10 kDa heat shock protein, mitochondrial 
P61758 Prefoldin subunit 3 
P61970 Nuclear transport factor 2 
P61978 Heterogeneous nuclear ribonucleoprotein K 
P61981 14-3-3 protein gamma 
P62081 40S ribosomal protein S7 
P62136 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 
P62191 26S protease regulatory subunit 4 
P62195 26S protease regulatory subunit 8 
P62241 40S ribosomal protein S8 
P62244 40S ribosomal protein S15a 
P62249 40S ribosomal protein S16 
P62258 14-3-3 protein epsilon 
P62263 40S ribosomal protein S14 
P62266 40S ribosomal protein S23 
P62269 40S ribosomal protein S18 
P62277 40S ribosomal protein S13 
P62280 40S ribosomal protein S11 
P62304 Small nuclear ribonucleoprotein E 
P62306 Small nuclear ribonucleoprotein F 
P62318 Small nuclear ribonucleoprotein Sm D3 
P62328 Thymosin beta-4 
P62424 60S ribosomal protein L7a 
P62701 40S ribosomal protein S4, X isoform 
P62714 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform 
P62753 40S ribosomal protein S6 
P62829 60S ribosomal protein L23 
P62851 40S ribosomal protein S25 
P62854 40S ribosomal protein S26 
P62857 40S ribosomal protein S28 
P62899 60S ribosomal protein L31 
P62906 60S ribosomal protein L10a 
P62913 60S ribosomal protein L11 
P62937 Peptidyl-prolyl cis-trans isomerase A 
P62942 Peptidyl-prolyl cis-trans isomerase FKBP1A 
P62979 Ubiquitin-40S ribosomal protein S27a 
P63104 14-3-3 protein zeta/delta 
P63151 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform 
P63220 40S ribosomal protein S21 
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 
P63267 Actin, gamma-enteric smooth muscle 
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform 
P67809 Nuclease-sensitive element-binding protein 1 
P67936 Tropomyosin alpha-4 chain 
P68036 Ubiquitin-conjugating enzyme E2 L3 
P68104 Elongation factor 1-alpha 1 
P68363 Tubulin alpha-1B chain 
P68366 Tubulin alpha-4A chain 
P68371 Tubulin beta-4B chain 
P78371 T-complex protein 1 subunit beta 
P78417 Glutathione S-transferase omega-1 
P78527 DNA-dependent protein kinase catalytic subunit 
P80723 Brain acid soluble protein 1 
P82970 High mobility group nucleosome-binding domain-containing protein 5 
Q00526 Cyclin-dependent kinase 3 
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 
Q00796 Sorbitol dehydrogenase 
Q00839 Heterogeneous nuclear ribonucleoprotein U 
Q00889 Pregnancy-specific beta-1-glycoprotein 6 
Q01105 Protein SET 
Q01469 Fatty acid-binding protein, epidermal 
Q01518 Adenylyl cyclase-associated protein 1 
Q01813 ATP-dependent 6-phosphofructokinase, platelet type 
Q02750 Dual specificity mitogen-activated protein kinase kinase 1 
Q02790 Peptidyl-prolyl cis-trans isomerase FKBP4 
Q02878 60S ribosomal protein L6 
Q04446 1,4-alpha-glucan-branching enzyme 
Q04760 Lactoylglutathione lyase 
Q04828 Aldo-keto reductase family 1 member C1 
Q04917 14-3-3 protein eta 
Q04941 Proteolipid protein 2 
Q05586 Glutamate receptor ionotropic, NMDA 1 
Q05639 Elongation factor 1-alpha 2 
Q05BV3 Echinoderm microtubule-associated protein-like 5 
Q06323 Proteasome activator complex subunit 1 
Q06830 Peroxiredoxin-1 
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Q08J23 tRNA (cytosine(34)-C(5))-methyltransferase 
Q12774 Rho guanine nucleotide exchange factor 5 
Q12931 Heat shock protein 75 kDa, mitochondrial 
Q12955 Ankyrin-3 
Q12965 Unconventional myosin-Ie 
Q13057 Bifunctional coenzyme A synthase 
Q13136 Liprin-alpha-1 
Q13162 Peroxiredoxin-4 
Q13200 26S proteasome non-ATPase regulatory subunit 2 
Q13263 Transcription intermediary factor 1-beta 
Q13283 Ras GTPase-activating protein-binding protein 1 
Q13315 Serine-protein kinase ATM 
Q13347 Eukaryotic translation initiation factor 3 subunit I 
Q13409 Cytoplasmic dynein 1 intermediate chain 2 
Q13509 Tubulin beta-3 chain 
Q13541 Eukaryotic translation initiation factor 4E-binding protein 1 
Q13885 Tubulin beta-2A chain 
Q14005 Pro-interleukin-16 
Q14011 Cold-inducible RNA-binding protein 
Q14019 Coactosin-like protein 
Q14116 Interleukin-18 
Q14152 Eukaryotic translation initiation factor 3 subunit A 
Q14195 Dihydropyrimidinase-related protein 3 
Q14204 Cytoplasmic dynein 1 heavy chain 1 
Q14240 Eukaryotic initiation factor 4A-II 
Q14258 E3 ubiquitin/ISG15 ligase TRIM25 
Q14315 Filamin-C 
Q14376 UDP-glucose 4-epimerase 
Q14444 Caprin-1 
Q14568 Putative heat shock protein HSP 90-alpha A2 
Q14669 E3 ubiquitin-protein ligase TRIP12 
Q14674 Separin 
Q14687 Genetic suppressor element 1 
Q14764 Major vault protein 
Q14774 H2.0-like homeobox protein 
Q14974 Importin subunit beta-1 
Q15021 Condensin complex subunit 1 
Q15029 116 kDa U5 small nuclear ribonucleoprotein component 
Q15046 Lysine--tRNA ligase 
Q15056 Eukaryotic translation initiation factor 4H 
Q15084 Protein disulfide-isomerase A6 
Q15181 Inorganic pyrophosphatase 
Q15365 Poly(rC)-binding protein 1 
Q15366 Poly(rC)-binding protein 2 
Q15691 Microtubule-associated protein RP/EB family member 1 
Q15843 NEDD8 
Q16543 Hsp90 co-chaperone Cdc37 
Q16555 Dihydropyrimidinase-related protein 2 
Q16576 Histone-binding protein RBBP7 
Q16658 Fascin 
Q16719 Kynureninase 
Q2VPJ9 Leucine-rich repeat-containing protein 75B 
Q32Q12 Nucleoside diphosphate kinase 
Q3V6T2 Girdin 
Q3ZCM7 Tubulin beta-8 chain 
Q4VXU2 Polyadenylate-binding protein 1-like 
Q53EL6 Programmed cell death protein 4 
Q53SF7 Cordon-bleu protein-like 1 
Q562R1 Beta-actin-like protein 2 
Q58FF7 Putative heat shock protein HSP 90-beta-3 
Q58FF8 Putative heat shock protein HSP 90-beta 2 
Q58FG0 Putative heat shock protein HSP 90-alpha A5 
Q5H907 Melanoma antigen family D, 2, isoform CRA_d 
Q5JQF8 Polyadenylate-binding protein 1-like 2 
Q5JXB2 Putative ubiquitin-conjugating enzyme E2 N-like 
Q5SR53 Putative uncharacterized protein PIK3CD-AS1 
Q5T4S7 E3 ubiquitin-protein ligase UBR4 
Q5T6H7 Xaa-Pro aminopeptidase 1 
Q5TBR0 Sialic acid synthase (Fragment) 
Q5TFE4 5'-nucleotidase domain-containing protein 1 
Q5TIA1 Meiosis inhibitor protein 1 
Q5TID7 Coiled-coil domain-containing protein 181 
Q68CZ2 Tensin-3 
Q6AWC2 Protein WWC2 
Q6DN14 Multiple C2 and transmembrane domain-containing protein 1 
Q6FI81 Anamorsin 
Q6GQQ9 OTU domain-containing protein 7B 
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Q6IN84 rRNA methyltransferase 1, mitochondrial 
Q6P2Q9 Pre-mRNA-processing-splicing factor 8 
Q6P575 Putative inactive beta-glucuronidase protein GUSBP11 
Q6PGP7 Tetratricopeptide repeat protein 37 
Q6PKG0 La-related protein 1 
Q6S8J3 POTE ankyrin domain family member E 
Q6TGC4 Protein-arginine deiminase type-6 
Q6ZMR3 L-lactate dehydrogenase A-like 6A 
Q6ZP82 Coiled-coil domain-containing protein 141 
Q6ZSI9 Calpain-12 
Q71U36 Tubulin alpha-1A chain 
Q7KZF4 Staphylococcal nuclease domain-containing protein 1 
Q7L2H7 Eukaryotic translation initiation factor 3 subunit M 
Q7Z406 Myosin-14 
Q7Z692 Carcinoembryonic antigen-related cell adhesion molecule 19 
Q7Z6J0 E3 ubiquitin-protein ligase SH3RF1 
Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1 
Q7Z794 Keratin, type II cytoskeletal 1b 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 
Q86VS8 Protein Hook homolog 3 
Q86W92 Liprin-beta-1 
Q86WI1 Fibrocystin-L 
Q86YR6 POTE ankyrin domain family member D 
Q8IZF4 Probable G-protein coupled receptor 114 
Q8IZS6 Tctex1 domain-containing protein 3 
Q8IZT9 Protein FAM9C 
Q8N163 Cell cycle and apoptosis regulator protein 2 
Q8N1D0 Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene B protein 
Q8N1L9 Basic leucine zipper transcriptional factor ATF-like 2 
Q8N3C0 Activating signal cointegrator 1 complex subunit 3 
Q8N5J2 Protein FAM63A 
Q8N7S5 Phosphoinositide phospholipase C 
Q8N9F8 Zinc finger protein 454 
Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein 
Q8NGP4 Olfactory receptor 5M3 
Q8TF72 Protein Shroom3 
Q8WUM4 Programmed cell death 6-interacting protein 
Q8WVJ2 NudC domain-containing protein 2 
Q8WW27 Putative C->U-editing enzyme APOBEC-4
Q8WXA9 Splicing regulatory glutamine/lysine-rich protein 1 
Q8WXG6 MAP kinase-activating death domain protein 
Q8WXG9 G-protein coupled receptor 98 
Q92466 DNA damage-binding protein 2 
Q92526 T-complex protein 1 subunit zeta-2 
Q92538 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 
Q92688 Acidic leucine-rich nuclear phosphoprotein 32 family member B 
Q92841 Probable ATP-dependent RNA helicase DDX17 
Q92878 DNA repair protein RAD50 
Q92905 COP9 signalosome complex subunit 5 
Q92928 Putative Ras-related protein Rab-1C 
Q92973 Transportin-1 
Q96A99 Pentraxin-4 
Q96BD8 Spindle and kinetochore-associated protein 1 
Q96DG6 Carboxymethylenebutenolidase homolog 
Q96F86 Enhancer of mRNA-decapping protein 3 
Q96FQ6 Protein S100-A16 
Q96HE9 Proline-rich protein 11 
Q96LR5 Ubiquitin-conjugating enzyme E2 E2 
Q96NW4 Ankyrin repeat domain-containing protein 27 
Q96P64 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 4 
Q96PY6 Serine/threonine-protein kinase Nek1 
Q96R06 Sperm-associated antigen 5 
Q96S07 Proline-rich protein 25 
Q96TA1 Niban-like protein 1 
Q99426 Tubulin-folding cofactor B 
Q99436 Proteasome subunit beta type-7 
Q99497 Protein deglycase DJ-1 
Q99523 Sortilin 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 
Q99829 Copine-1 
Q99832 T-complex protein 1 subunit eta 
Q9BPU6 Dihydropyrimidinase-related protein 5 
Q9BPZ3 Polyadenylate-binding protein-interacting protein 2 
Q9BQE3 Tubulin alpha-1C chain 
Q9BR76 Coronin-1B 
Q9BRP8 Partner of Y14 and mago 
Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 family member E 
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Q9BUF5 Tubulin beta-6 chain 
Q9BVA1 Tubulin beta-2B chain 
Q9BVG4 Protein PBDC1 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic 
Q9BWT3 Poly(A) polymerase gamma 
Q9BYX7 Putative beta-actin-like protein 3 
Q9BZ29 Dedicator of cytokinesis protein 9 
Q9H082 Ras-related protein Rab-33B 
Q9H0J4 Glutamine-rich protein 2 
Q9H1A4 Anaphase-promoting complex subunit 1 
Q9H2P9 Diphthine synthase 
Q9H361 Polyadenylate-binding protein 3 
Q9H5J0 Zinc finger and BTB domain-containing protein 3 
Q9H6Y2 WD repeat-containing protein 55 
Q9HB71 Calcyclin-binding protein 
Q9HBG6 Intraflagellar transport protein 122 homolog 
Q9HC52 Chromobox protein homolog 8 
Q9HCK5 Protein argonaute-4 
Q9NPA0 ER membrane protein complex subunit 7 
Q9NQI0 Probable ATP-dependent RNA helicase DDX4 
Q9NQW7 Xaa-Pro aminopeptidase 1 
Q9NR45 Sialic acid synthase 
Q9NR48 Histone-lysine N-methyltransferase ASH1L 
Q9NSC5 Homer protein homolog 3 
Q9NTI7 Protein FAM212B 
Q9NVE5 Ubiquitin carboxyl-terminal hydrolase 40 
Q9NVI1 Fanconi anemia group I protein 
Q9NXD2 Myotubularin-related protein 10 
Q9NYL9 Tropomodulin-3 
Q9NZA1 Chloride intracellular channel protein 5 
Q9NZL4 Hsp70-binding protein 1 
Q9P258 Protein RCC2 
Q9P2H3 Intraflagellar transport protein 80 homolog 
Q9P2J5 Leucine--tRNA ligase, cytoplasmic 
Q9UBT2 SUMO-activating enzyme subunit 2 
Q9UHV9 Prefoldin subunit 2 
Q9UI15 Transgelin-3 
Q9UKX2 Myosin-2 
Q9UKY7 Protein CDV3 homolog 
Q9ULV0 Unconventional myosin-Vb 
Q9UMS4 Pre-mRNA-processing factor 19 
Q9UMX0 Ubiquilin-1 
Q9UQ80 Proliferation-associated protein 2G4 
Q9Y230 RuvB-like 2 
Q9Y265 RuvB-like 1 
Q9Y266 Nuclear migration protein nudC 
Q9Y281 Cofilin-2 
Q9Y2T7 Y-box-binding protein 2 
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog 
Q9Y3I0 tRNA-splicing ligase RtcB homolog 
Q9Y3L3 SH3 domain-binding protein 1 
Q9Y3U8 60S ribosomal protein L36 
Q9Y490 Talin-1 
Q9Y4Y9 U6 snRNA-associated Sm-like protein LSm5 
Q9Y536 Peptidyl-prolyl cis-trans isomerase A-like 4A/B/C 
Q9Y570 Protein phosphatase methylesterase 1 
Q9Y617 Phosphoserine aminotransferase 
Q9Y6N3 Calcium-activated chloride channel regulator family member 3 
Q9Y6U3 Adseverin 
S4R435 Protein RPS10-NUDT3 (Fragment) 
377
9.7 prosc internal cdna sequencing primers
Table 9.7.1: Primer sequences used to sequence across the whole PROSC cDNA.
Primer Sequence
1F GCTAGTGGCGGTCAGCAAAACC
2F GGTTAAAGGTTATGGTCCAGAT
3F GGACAAGTGCGCAGCAGACGTGAA
1R GGGCTGGATGGCTGGGAGATCC
2R AGCATGAAGAGATTGGGGACAGCC
3R CATGCCCATGCTCAGCTCAACC
4R CCATTGCCTGAAGCAAGCTTCC
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